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Phase III study of adjuvant encorafenib plus binimetinib

12 weeks of negative SLNB staging, no other signs of metastases,

versus placebo in fully resected stage IIB/C BRAFV600-mutated

fully recovered from surgery, ECOG 0/1, adequate hematologic, hep-

melanoma: COLUMBUS-AD study design

atic, cardiac, coagulation and renal functions. Molecular screening to
confirm BRAFV600E/K -mutant status will be performed by a central lab-

Victoria G. Atkinson1 , Axel Hauschild2 , Georgina V. Long3 , Mario

oratory. Eligible patients are randomised 1:1 to receive encorafenib

Mandala4 , Michal Kicinski5 , Anne-Sophie Govaerts5 , Isabelle Klauck6 ,

450 mg once daily + binimetinib 45 mg twice daily or matching place-

Monia Ouali6 , Paul C. Lorigan7 , Alexander M. M. Eggermont8 ,

bos. The primary endpoint is RFS. Secondary endpoints include DMFS,

Alexander C. J. van Akkooi9

OS, QoL, safety and tolerability between the two arms, and PK data.

1 University

The first patient was screened in May 2022, and accrual is anticipated

of Queensland, Princess Alexandra & Greenslopes Private

Hospital, Brisbane, QLD, Australia

to be completed by mid-2025.

2 Department of Dermatology, University Hospital (UKSH), Kiel, Germany

Conclusion: COLUMBUS-AD is the first phase 3 randomised trial to

3 Melanoma

evaluate adjuvant BRAFi/MEKi in stage IIB/C melanoma.

Institute Australia, the University of Sydney, and Mater and

Royal North Shore Hospitals, Sydney, NSW, Australia
4 University

of Perugia, Ospedale Santa Maria Della Misericordia, Perugia,
181

Italy

Colorectal cancer stem cells and hypoxia

5 EORTC Headquarters, Brussels, Belgium
6 Pierre Fabre, France

Reem Alhulais1 , Stephen Ralph1

7 Christie NHS Foundation Trust, Manchester, United Kingdom

1 School

8 University Medical Center Utrecht, Utrecht, The Netherlands

Queensland, Griffith University, GoldCoast, QLD, Australia

9 Melanoma

of Pharmacy and Medical Sciences, Menzies Health Institute

Institute Australia, the Faculty of Medicine and Health, the

University of Sydney, Royal Prince Alfred Hospital, Sydney, NSW, Australia

Publish consent withheld

Background: COLUMBUS demonstrated the safety and efficacy
of encorafenib + binimetinib for BRAFV600E/K -mutant advanced
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melanoma. Stage IIB/C melanoma has ≥ risk of recurrence and mor-

screening programs

Facilitators for participation in mail-out bowel cancer

tality versus stage IIIA/B, for which there are multiple treatments
available. Until recently, standard of care for stage II melanoma

Laura E. Anderson1 , Larry Myers1,2 , Michael J. Ireland2,3 , Bianca

was surveillance post-resection, and there is currently only one

Viljoen1,3,4 , Belinda C. Goodwin1,3

IO approved globally in this setting. Thus, there is need for more

1 Cancer Council Queensland, Fortitude Valley, QLD, Australia

treatment options for BRAF-mut stage II disease. Here we report the

2 School

rationale and design of COLUMBUS-AD (NCT05270044).

Springfield, Queensland, Australia

Trial design: COLUMBUS-AD is a worldwide, multicenter, placebo-

3 Centre

controlled, randomised, triple-blind Phase 3 study evaluating adjuvant

field, Queensland

encorafenib + binimetinib treatment versus double matched place-

4 School

bos in patients with fully resected stage IIB/C BRAFV600 -mutant

Toowoomba, Queensland

of Psychology and Wellbeing, University of Southern Queensland,
for Health Research, University of Southern Queensland, Springof Nursing and Midwifery, University of Southern Queensland,

melanoma. Approximately 2200 patients will be screened to enrol 815.
More than 170 sites in ≤26 countries will participate in the study

Aims: Participation in population-wide bowel cancer screening pro-

conducted in collaboration with the EORTC. Patients will receive treat-

grams saves lives through early cancer detection. However, only 44%

ment for 12 months, or until disease recurrence. Participants will

of eligible Australians participate in the National Bowel Cancer Screen-

be followed monthly during treatment, every 3 months for 3 years,

ing Program (NBCSP). Most non-participants intend to participate in

then regularly for 10 years. Inclusion criteria include adult patients

the program but fail to do so because they forget or procrastinate.

(≥18 years), fully resected stage IIB/C cutaneous melanoma within

Therefore, the present study sought to identify targets for planning

Editorial material and organization © 2022 John Wiley & Sons Australia. Copyright of individual abstracts remains with the authors.
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interventions, as they have the potential to overcome these barriers

chi-square model to examine differences between patients working

and greatly increase screening participation.

versus not working.

Methods: Two semi-structured interviews were conducted (recruit-

Results: 61% of patients were working and 27% not working at time

ment ceased upon data saturation). Twenty NBCSP participants iden-

of visit. Statistical difference was found in the fatigue severity (FACIT-

tified planning strategies they employed to prompt kit return. These

Fatigue Subscale) scores (N = 397) of patients working (39.43 ± 10.34)

were presented to a sample of people who had not completed their

compared to patients not working (33.33 ± 14.29) (p < 0.001); as well

most recent NBCSP kit to assess if these strategies would help them

as patients quality of life (FACT-BMT) (N = 379; 112.08 ± 26.60 ver-

not procrastinate or forget to return their next screening kit. Data were

sus 106.38 ± 34.24 (p < 0.001)) and their depression (HADS) (N = 429,

analysed using thematic analysis.

3.27 ± 3.10 versus 5.09 ± 4.09 (p < 0.001))

Results: Kit-completers identified that placing the kit in highly visible

Conclusion: ALLOSCT survivors who are working are still suffering

location, using reminders, and planning to complete the kit around time

from fatigue but are reporting better quality of life and mood compared

at home were key strategies used to prevent procrastination and for-

to those who are not working. Returning to work remains an important

getting. People who had not completed their most recent kit tended

indicator of quality of life for these patients. Further investigation into

to endorse the idea of planning to complete the kit around a time at

why people return to work, and the level of interference of their fatigue

home, however, there was great variability about most strategies. For

is required to determine an appropriate intervention model.

example, there was strong division regarding utility and engagement in
a suggestion to place the kit in a highly visible location.
Conclusions: Planning interventions must consider individual differ-
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ences when suggesting strategies to reduce forgetting and procrasti-

application to gain understanding on Victorian cancer incidence,

nation. A multifaceted planning intervention with a range of planning

mortality, survival and prevalence

VCR data explorer – A public-facing user-friendly

strategies is likely to be most effective as this will allow people to
choose the planning strategy that is best suited to them. Future inter-

Luc te Marvelde1 , Yachna Shethia2 , Ryan Andrianto3 , Cuong Lam4 ,

ventions to increase screening participation should consider the most

Richard Muntz4 , Sue M. Evans1,5

effective, broad-reaching combination of planning strategies to facil-

1 Victorian

itate the invitee’s transition from having screening intentions into

tralia

screening participation.

2 Bendigo Health, Bendigo, VIC, Australia

Cancer Registry, Cancer Council Victoria, Melbourne, VIC, Aus-

3 Corporate Services, Cancer Council Victoria, Melbourne, VIC, Australia
4 Brand,
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Physical, psychological, and quality of life outcomes in

Communications and Marketing, Cancer Council Victoria, Mel-

bourne, VIC, Australia

adults post allogeneic stem cell transplantation: A prospective

5 Cancer

cohort study

Medicine, Monash University, Melbourne, VIC, Australia

Celia K. Marston2,1 , Yvonne Panek-Hudson2 , Toni Withiel1 ,

Aim: Develop an easy to use and understand platform to gain specific

Dominique Shreeve1

cancer information in Victoria for a wide range of users

1 Royal Melbourne Hospital, Melbourne, VIC, Australia

Methods: Evidence-based Human-Centred Design approach were

2 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

undertaken including stakeholder interviews and testing to identify

Research Program, School of Public Health and Preventive

and validate Victorian cancer data presentation and articulation. A
Background: Returning to work is a vital indicator of recovery among

prototype application was designed, and user acceptance testing was

cancer survivors. Allogeneic stem cell transplant (ALLOSCT) recipients

performed. The final data visualisation suite was built using PowerBI.

are more vulnerable to long-term physical and psychosocial adverse

Results: Stakeholders were most interested (trends in) cancer inci-

outcomes compared to other cancer survivors. The increasing propor-

dence, mortality, survival and prevalence, including disparities in each

tion of working-age ALLOSCT survivors means that a comprehensive

of the measures according to sex, socio-economic position, Aborig-

evaluation of outcomes is required; to improve care pathways for these

inality and geography. User experience testing led to an updated

patients and address their work-related goals.

design. A single R-script was coded to create all input data for the

Aim: Describe the physical, psychological, and quality of life outcomes

application. A PowerBI application was built focussing on stakeholder

of ALLOSCT patients that have returned to work compared to those

needs, user experience, as well as transparency in methodology and

who have not returned to work.

interpretability of the results.

Methods: Prospective cohort study of post ALLOSCT patients at their

Conclusions: The VCR Data Explorer is available now on the VCR

first clinic visit between April 2014 and June 2021 was conducted.

homepage https://www.cancervic.org.au/research/vcr. This version

Data was collected using patient questionnaires measuring symptom

will be the base on which we will build updates. We aim to include spa-

burden, quality of life, vocational/work status and functional perfor-

tial patterns and well as prevalence as an outcome measure in the next

mance. Data were analysed using descriptive statistics and a Pearson

update. Continuous post-publishing study is being conducted to ensure
continuous improvement of the Data Explorer.
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cycles) + chemotherapy (paclitaxel 175 mg/m2 +cisplatin 50 mg/m2 or

Pembrolizumab plus chemotherapy in persistent,

recurrent, or metastatic cervical cancer: A KEYNOTE-826

carboplatin AUC 5) ± bevacizumab 15 mg/kg. Dual primary endpoints

subgroup analysis

were PFS by investigator (RECIST v1.1) and OS in patients with PD-L1

Sally Baron-Hay1 , Krishnansu S. Tewari2 , Nicoletta Colombo3 , Bradley

groups defined by bevacizumab use, histology, platinum use, and prior

J. Monk4 , Coraline Dubot5 , M. Valeria Cáceres6 , Kosei Hasegawa7 ,

chemoradiation therapy (CRT).

Ronnie Shapira-Frommer8 , Pamela Salman9 , Eduardo Yañez10 ,

Results: 617 patients were randomized (pembrolizumab + chemother-

Mahmut Gümüş11 , Mivael Olivera Hurtado de Mendoza12 , Vanessa

apy ± bevacizumab, n = 308; placebo + chemotherapy ± bevacizumab,

Samouëlian13 , Vincent Castonguay14 , Alexander Arkhipov15 , Sophia

n = 309). At data cutoff (May 3, 2021), median follow-up was 22

Frentzas16 , Cumhur Tekin17 , Kan Li17 , Sarper Toker17 , Stephen M.

months. In all comers, pembrolizumab + chemotherapy ± bevacizumab

Keefe17 , Domenica Lorusso18

prolonged PFS and OS versus placebo + chemotherapy ± beva-

1 Northern

cizumab in all subgroups. In bevacizumab-treated patients, PFS HR

CPS ≥1, all comers, and CPS ≥10. Results were examined in sub-

Sydney Cancer Center, Royal North Shore Hospital, St Leonards,

NSW, Australia

(95% CI) was 0.61 (0.47–0.79) and OS HR was 0.63 (0.47–0.87); with-

2 Obstetrics & Gynecology, University of California, Irvine, Orange, CA, USA

out bevacizumab, 0.74 (0.54–1.01) and 0.74 (0.53–1.04). For squamous

3 Gynecologic Oncology, European

histology, PFS HR was 0.63 (0.50–0.80) and OS HR was 0.61 (0.47–

Institute of Oncology IRCCS and Univer-

sità degli Studi di Milano Bicocca, Milan, Italy

0.80); for nonsquamous, 0.66 (0.43–1.00) and 0.76 (0.47–1.23). For

4 Gynecologic

carboplatin-treated patients, PFS HR was 0.69 (0.55–0.86) and OS HR

Oncology, University of Arizona College of Medicine,

Creighton University School of Medicine, Phoenix, AZ, USA

was 0.69 (0.54–0.89); with cisplatin, 0.47 (0.28–0.77) and 0.59 (0.32–

5 Oncologie Médicale, Institut Curie Saint Cloud, and GINECO, Paris, France

1.09). For patients with prior CRT, PFS HR was 0.62 (0.45–0.86) and

6 Medical

OS HR was 0.64 (0.45–0.91). Similar benefits of pembrolizumab +

Oncology, Instituto de Oncologia Angel H. Roffo, Buenos Aires,

chemotherapy ± bevacizumab were seen in the CPS ≥1 and CPS ≥10

Argentina
7 Gynecologic

Oncology, Saitama Medical University International Medical

populations.

Center, Hidaka, Japan

Conclusions: Pembrolizumab + chemotherapy ± bevacizumab pro-

8 Ella

longed PFS and OS versus placebo + chemotherapy ± bevacizumab

Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center,

Ramat Gan, Israel

in key subgroups and provided clinically meaningful benefits similar

9 Medical Oncology, Oncovida Cancer Center, Providencia, Santiago, Chile

to the broader population with persistent, recurrent, or metastatic

10 Medical Oncology, Universidad de la Frontera, Temuco, Chile

cervical cancer.

11 Istanbul

Medeniyet University, Prof. Dr. Suleyman Yalcin City Hospital,

Istanbul, Turkey
12 Medical

Oncology, Instituto Nacional de Enfermedades Neoplásicas,

189

Neoadjuvant pembrolizumab + chemotherapy versus

placebo + chemotherapy, followed by adjuvant pembrolizumab

Lima, Peru
13 Gynecologic

Oncology, Centre Hospitalier de l’Université de Montréal

(CHUM), Centre de Recherche de l’Université de Montréal (CRCHUM),

versus placebo for early-stage TNBC: Event-free survival
sensitivity and subgroup analyses from KEYNOTE-522

Université de Montréal, Montreal, QC, Canada
14 Medical Oncology, Centre Hospitalier Universitaire de Québec, Université

Peter Schmid1 , Javier Cortes2 , Rebecca Dent3 , Lajos Pusztai4 ,

Laval, Quebec City, QC, Canada

Heather McArthur5 , Sherko Kümmel6 , Jonas Bergh7 , Carsten

15 Oncology and Chemical Therapy, Medical Rehabilitation Center under the

Denkert8 , Yeon Hee Park9 , Rina Hui10 , Nadia Harbeck11 , Masato

Ministry of Health of Russian Federation, Moscow, Russian Federation

Takahashi12 , Michael Untch13 , Peter A. Fasching14 , Fatima Cardoso15 ,

16 Monash Health, Monash Medical Centre, Clayton, VIC, Australia

Jay Andersen16 , Debra Patt17 , Michael Danso18 , Marta Ferreira19 ,

17 Oncology, Merck & Co., Inc., Kenilworth, NJ, USA

Marie-Ange Mouret-Reynier20 , Seock-Ah Im21 , Jin Hee Ahn22 , Maria

18 Gynaecology

Gion23 , Sally Baron-Hay24 , Jean-Francois Boileau25 , Yalin Zhu26 ,

Oncology Unit, Fondazione Policlinico Universitario A

Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy

Wilbur Pan26 , Konstantinos Tryfonidis26 , Vassiliki Karantza26 , Joyce

Aims:

1 Barts Cancer Institute, Queen Mary University London, London, UK

O’Shaughnessy27
In

KEYNOTE-826

(NCT03635567),

pem-

brolizumab + chemotherapy ± bevacizumab provided statistically

2 International

significant, clinically meaningful PFS and OS improvements in persis-

Institute of Oncology (VHIO), Madrid & Barcelona, Spain and Universidad

tent, recurrent, or metastatic cervical cancer. We present outcomes in

Europea de Madrid, Faculty of Biomedical and Health Sciences, Department

key subgroups.

of Medicine, Madrid, Spain

Methods: Eligible adults had persistent, recurrent, or metastatic cer-

3 National Cancer Center Singapore, Duke-NUS Medical School, Singapore

vical cancer not previously treated with chemotherapy nor amenable

4 Yale School of Medicine, Yale Cancer Center, New Haven, CT, USA

to curative treatment; measurable disease (RECIST v1.1); ECOG PS

5 University of Texas Southwestern Medical Center, Dallas, TX, USA

0–1; and a tumour sample for PD-L1 assessment. Patients were ran-

6 Kliniken

domized 1:1 to pembrolizumab 200 mg Q3W or placebo (up to 35

Berlin, Department of Gynecology with Breast Center, Berlin, Germany

Breast Cancer Center, Quironsalud Group, Vall d,Hebron

Essen-Mitte, Essen, Germany and Charité – Universitätsmedizin
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7 Department of Oncology-Pathology, Karolinska Institutet and Breast Can-

Results: One Thousand one hundred and seventy-four patients were

cer Centre, Cancer Theme, Karolinska University Hospital, Solna, Sweden

randomized (pembrolizumab + chemotherapy, n = 784; placebo +

8 Institute

chemotherapy, n = 390). At data cutoff (March 23, 2021), median

of Pathology, Philipps-University Marburg and University Hospi-

tal Marburg (UKGM), Marburg, Germany

follow-up was 39.1 months. EFS HRs (95% CIs) for neoadjuvant pem-

9 Samsung

brolizumab + chemotherapy followed by adjuvant pembrolizumab

Medical Center, Sungkyunkwan University School of Medicine,

Seoul, Republic of Korea

versus neoadjuvant chemotherapy alone were, for sensitivity anal-

10 Department

yses using alternative censoring rules: 0.64 (0.48‒0.84); and using

of Medical Oncology, Crown Princess Mary Cancer Centre,

Westmead Hospital, Westmead, NSW, Australia

modified EFS definitions: ‘new anticancer therapy for metastatic dis-

11 Breast

ease’ considered EFS event, 0.63 (0.48‒0.82); ‘positive margin at last

Center, Department of Obstetrics and Gynecology and CCC

Munich, LMU University Hospital, Munich, Germany

surgery’ removed, 0.65 (0.50‒0.85); ‘positive margin at last surgery’

12 Hokkaido Cancer Center, Sapporo, Japan

and ‘second primary malignancy’ removed, 0.63 (0.48‒0.84); ‘second

13 Breast

breast malignancy’ included, 0.63 (0.48‒0.82). EFS HRs (95% CIs)

Cancer Center, HELIOS Klinikum Berlin-Buch GmbH, Berlin, Ger-

for subgroups: nodal involvement positive, 0.65 (0.46‒0.91) or nega-

many
14 University

Hospital Erlangen, Department of Gynecology and Obstetrics,

tive, 0.58 (0.37‒0.91); disease stage II, 0.60 (0.42‒0.86]) or III, 0.68

Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany

(0.45‒1.03); pre-menopausal, 0.62 (0.42‒0.91) or post-menopausal,

15 Breast

0.64 (0.44‒0.93); HER2 status 2+ by IHC but FISH-, 0.73 (0.43‒1.24)

Unit, Champalimaud Clinical Center/Champalimaud Foundation,

Lisbon, Portugal

or 0-1+ by IHC, 0.60 (0.44‒0.82); and LDH >ULN, 0.65 (0.37‒1.12) or

16 Compass Oncology, The US Oncology Network, Portland, OR, USA

≤ULN, 0.63 (0.46‒0.86).

17 Texas Oncology, The US Oncology Network, Austin, TX, USA

Conclusions: EFS sensitivity analyses showed robust treatment benefit

18 Virginia

of neoadjuvant pembrolizumab + chemotherapy followed by adjuvant

Oncology Associates, The US Oncology Network, Norfolk, VA,

pembrolizumab for previously untreated non-metastatic TNBC, which

USA
19 Instituto

Português de Oncologia do Porto Francisco Gentil (IPO-Porto),

was generally consistent across patient subgroups evaluated.
Schmid P, et al. N Engl J Med 2022;386:556–67.

Porto, Portugal
20 Centre Jean-Perrin, Clermont-Ferrand, France
21 Seoul National University, Seoul, Republic of Korea
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22 Asan

oesophageal and gastric adenocarcinoma

Medical Center, University of Ulsan College of Medicine, Seoul,

The prognostic significance of nutritional status in

Republic of Korea
23 Ramon y Cajal University Hospital, Madrid, Spain

Tamara Bosward1

24 Royal North Shore Hospital, St. Leonards, NSW, Australia

1 The University of Wollongong, Wollongong, NSW, Australia

25 McGill University, Jewish General Hospital Segal Cancer Centre, Montréal,

Québec, Canada

Background: Oesophageal and gastric cancer is associated with the

26 Merck & Co., Inc., Rahway, NJ, USA

highest rates of malnutrition amongst all types of malignancies. Prelim-

27 Baylor

inary research indicates that nutritional status is predictive of overall

University Medical Center, Texas Oncology, The US Oncology

Network, Dallas, TX, USA

survival in patients with upper gastrointestinal cancer. The aim of this
study is to investigate the prognostic significance of malnutrition and

Aims: The phase 3 KEYNOTE-522 (NCT03036488) study primary

inflammatory markers on overall survival (OS) and progression-free

analysis showed significantly longer event-free survival (EFS) with

survival (PFS).

neoadjuvant pembrolizumab + chemotherapy followed by adjuvant

Methods: We performed a retrospective cohort study of 127 partici-

pembrolizumab versus neoadjuvant chemotherapy alone in patients

pants with oesophageal and gastric adenocarcinoma who underwent

with early-stage TNBC (HR, 0.63 [95% CI, 0.48‒0.82]; P < 0.001).1 We

treatment in the Illawarra Shoalhaven Local Health District between

present

August 2013 and September 2021. The Patient Generated Subjective

prespecified

sensitivity

and

subgroup

analyses

for

EFS.

Global Assessment (PG-SGA) was used to assess malnutrition before

Methods: Patients with previously untreated, non-metastatic TNBC

and after surgery. The Prognostic Nutritional Index (PNI) was calcu-

(stage T1c N1-2 or T2-4 N0-2 per AJCC) were randomized 2:1

lated from preoperative serum albumin and total lymphocyte count.

to pembrolizumab 200 mg Q3W or placebo, both given with four

OS and PFS were evaluated with Kaplan Meier and Cox proportional

cycles of paclitaxel + carboplatin, then with four cycles of doxoru-

hazards model.

bicin or epirubicin + cyclophosphamide (neoadjuvant). After definitive

Results: The prevalence of malnutrition significantly increased from

surgery, patients received pembrolizumab or placebo for nine cycles or

56.5% preoperatively to 84.5% postoperatively (p = 0.003). Preop-

until recurrence/unacceptable toxicity (adjuvant). Dual primary end-

erative tube feeding was significantly associated with improvement

points: pCR rate and EFS. Five prespecified sensitivity analyses for

or maintenance of PG-SGA score (p = 0.015). The variables inde-

EFS were performed and treatment effects on EFS were examined in

pendently associated with OS in the multivariable analysis were

prespecified patient subgroups.

postoperative malnutrition (Hazard Ratio [HR] 7.79, 95% confidence
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interval [CI] 1.03–59.08, p = 0.047) and PNI score (HR 0.91, 95% CI

192

0.85–0.98, p = 0.008). PFS was not associated with PG-SGA or PNI

recommendations: A Delphi consensus study

Development of psycho-oncology telehealth

score.
Conclusion: Postoperative malnutrition and a low preoperative PNI

Claire Cooper1 , Jemma Gilchrist2 , Lisa Beatty3 , Laura Kirsten4 , Louise

score are associated with shorter survival time in oesophageal and

Sharpe5 , Nienke Zomerdijk6 , Maree Grier7 , Jane Turner8 , Kim Hobbs9 ,

gastric cancer. Preoperative nutritional intervention is warranted to

Helen Haydon10 , Haryana Dhillon11 , Brian Kelly12 , Joanne Shaw1

preserve nutritional status and prevent postoperative malnutrition.

1 Psycho-oncology

Cooperative Research Group (PoCoG), University of

Sydney, Camperdown, NSW, Australia
2 Western Sydney Local Health District, Sydney, NSW, Australia

191

Impacts and outcomes of COVID-19 infection in medical

oncology patients in a Western Australian tertiary centre

3 College

of Education, Psychology and Social Work, Flinders University,

Adelaide, SA, Australia
4 Nepean Cancer Care Centre, Nepean Blue Mountains Local Health District,

Sowmya Cheruvu1 , Claire Tay1 , Hilary Martin1

Kingswood, NSW, Australia

1 Fiona Stanley Hospital, Murdoch, Western Australia, Australia

5 School of Psychology, The University of Sydney
6 Melbourne School of Psychological Sciences, The University of Melbourne,

Aim: Assessing impacts of Covid-19 infection in Medical Oncology

Melbourne, VIC, Australia

patients in a highly vaccinated population at a Western Australian

7 Psychology Department, Royal Brisbane and Women’s Hospital, Brisbane,

hospital post opening of state borders.

QLD, Australia

Methods: Patients with Covid-19 RAT positivity were prospectively

8 Faculty

identified between March and May 2022 by treating clinicians. Elec-

tralia

tronic case notes and pathology records were reviewed for data

9 Westmead

collection. Outcomes assessed included treatment delays and mortal-

Australia

ity.

10 Centre

Results: Thirty-six patients were identified with solid organ malignancy

University of Queensland, Brisbane, QLD, Australia

and RAT positive Covid-19 infection of whom 64% (23) were female.

11 Centre

The median age was 57.5 years. 81% (29) had metastatic disease and

University of Sydney, Sydney, NSW, Australia

the most predominant subtype was breast cancer (42%). 81% (29)

12 Faculty

were on active therapy with 55% on chemotherapy (31% chemother-

NSW, Australia

of Medicine, The University of Queensland, Brisbane, QLD, AusHospital, Western Sydney Local Health District, Sydney, NSW,

for Online Health, Centre for Health Services Research, The
for Medical Psychology & Evidence-Based Decision Making, The
of Health and Medicine, University of Newcastle, Newcastle,

apy alone). 78% of the patients had received at least two doses of
Covid-19 vaccination, with 53% having had at least one booster. 8%

Aim: The COVID-19 pandemic triggered rapid implementation of tele-

were unvaccinated. 78% were community acquired infections versus

health (telephone and videoconference) in Australia. Psycho-oncology

22% acquired during a hospital admission. 67% (24) patients were

clinicians report a need for greater guidance on adapting in person

symptomatic at detection, with symptom severity ranging from mild

psycho-oncology therapies to telehealth. We aimed to establish con-

to moderate, with 8% patients needing oxygen for desaturation. 64%

sensus on elements of psycho-oncology therapy that can be adapted

were managed as outpatients. A total of 58% received antiviral ther-

for telehealth for inclusion in an educational resource incorporating

apy (14% IV Remdesevir and 86% oral with Molnupiravir (44%) and

clinical practice recommendations.

Paxlovid (50%)) of which 90% completed their course. 90% of those

Methods: Draft recommendations were developed based on exist-

receiving antivirals were on active therapy.

ing literature, reviews and guidelines. These were refined using a

Treatment delays were observed in 83% (24/29) of patients with

co-design process involving expert consultation (n = 13) with psycho-

a median delay of 2 weeks. Two deaths were partially attributed

oncology clinicians and researchers. This process identified some

to Covid-19 infection in inpatients with disease progression and

uncertainty around key recommendations. A two round Delphi con-

concurrent bacterial sepsis. Both these patients were double vac-

sensus process was conducted to confirm the relative importance and

cinated and on chemotherapy. No deaths were solely attributed to

therapeutic appropriateness of content for inclusion in clinical practice

Covid-19.

recommendations. Participants included psycho-oncology clinicians

Conclusion: The overall outcomes in this population of WA Oncology

with telehealth experience. Respondents rated their level of agree-

patients from Covid-19 infection remained favourable with low mor-

ment with each statement on a 5-point Likert scale. Consensus was

tality despite symptomatic infection requiring antiviral therapy and

defined as >80% of respondents scoring within two points on the Likert

treatment delays.

scale.
Results: The co-design approach identified key topics for inclusion in the recommendations: (1) preparation for telehealth (e.g.,
privacy, security, technical considerations); (2) clinical and cultural
considerations (e.g., safety considerations, therapeutic alliance, vulnerable/underserved communities); (3) adaptations to therapeutic
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assessment and intervention; (4) specific client considerations (e.g.,

intake at the end of RT (g) with GI toxicity (P = 0.149) and quality of life

clients in palliative care). 32 clinicians participated in Delphi Round

(P = 0.083), however improving trends in the functional subset were

1, where thirteen recommendations were presented and consen-

identified. Results may be confounded by the sample size resulting

sus reached for nine. Recommendations where consensus was not

from limited eligibility (n = 14) and high attrition rate (n = 4).

reached were re-presented in Round 2. We will present the consensus

Conclusion: The majority of participants successfully increased their

recommendations based on the Delphi.

fibre intake throughout treatment, with no significant adverse events

Conclusion and clinical implication: The clinical practice recommen-

noted for radiation treatment delivery accuracy. This study highlighted

dations will provide a robust expert-endorsed educational resource to

challenges in participant recruitment and retention. Further research is

guide psycho-oncology clinicians tailoring their practice to telehealth.

required to inform the efficacy of a high fibre diet in this cohort. These

This will support delivery of evidence-based treatments to people liv-

results provide preliminary data to calculate the sample size required

ing with cancer, increasing the sustainability of, and confidence in,

to produce meaningful effect sizes.

psycho-oncology telehealth.
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Dietary counselling to increase soluble fibre in patients

Circulating-tumour DNA (ctDNA) detection using an

ultra-sensitive next generation sequencing (NGS)-based assay in

with gynaecological cancers undergoing pelvic radiotherapy: A

patients with resected colorectal cancer (CRC) in the phase III

feasibility study

ASCOLT trial

Emilie Croisier1,2 , Teresa Brown2 , Alice Grigg3 , Philip Chan4 , Judy

Daphne Day1 , Anna Starus2 , Oliver Sieber3 , Daniela Prasse4 , Agathe

Bauer5

Lamik4 , Johannes Fredebohm4 , John Simes5 , Fiona Day6 , Mark

1 School of Human Movement Nutrition Sciences, University of Queensland,

Jeffery7 , Robert Zielinski8 , Madhu Singh9 , Geoffrey Chong10 , Li

Brisbane, Queensland, Australia

Shan3 , Dmitri Mouradov3 , John WK Chia11 , Raghib Ali12 , Han Chong

2 Nutrition

and Dietetics, Royal Brisbane and Women’s Hospital, Brisbane,

Toh11 , Frederick Jones2 , Eva Segelov1

Queensland, Australia

1 Department

3 Radiation Therapy, Royal Brisbane and Women’s Hospital, Brisbane, QLD,

Melbourne, VIC, Australia

Australia

2 Sysmex Inostics Inc., Baltimore, Maryland, USA

4 Radiation Oncology, Royal Brisbane and Women’s Hospital, Brisbane, QLD,

3 Walter and Eliza Hall Institute, Melbourne, VIC, Australia

Australia

4 Sysmex Inostics GmbH, Hamburg, Germany

5 Nutrition,

Dietetics and Food, Monash University, Melbourne, Victoria,

Australia

of Oncology, Monash Health and Department of Medicine,

5 University of Sydney NHMRC Clinical Trials Centre, Sydney
6 Calvary Mater Newcastle, Newcastle, NSW, Australia
7 Christchurch Hospital, Christchurch, New Zealand

Aim: To determine if increasing soluble fibre intake via dietary coun-

8 Orange Health Service, Orange, NSW, Australia

selling is feasible and improves patient outcomes (gastrointestinal

9 Barwon Health Andrew Love Cancer Centre, Geelong, VIC, Australia

toxicity (GI) and quality of life (QOL)) in patients with gynaecological

10 Ballarat Regional Integrated Cancer Centre, Ballarat, VIC, Australia

cancers undergoing pelvic radiotherapy without adverse conse-

11 Division

of Medical Oncology, National Cancer Centre Singapore, Singa-

quences on radiation treatment (RT) delivery accuracy.

pore

Methods: A single-arm, single-centre intervention feasibility trial

12 New York University, Abu Dhabi, United Arab Emirates

included patients with gynaecological cancers undergoing pelvic
RT ± chemotherapy at a tertiary hospital. Participants were provided

Aims: Detection of ctDNA can identify patients with minimal residual

weekly dietary counselling to increase soluble fibre intake incremen-

disease (MRD) in curatively-treated CRC. Highly sensitive NGS-based

tally each week during treatment. GI toxicity and QOL scores were

assays can have comparable sensitivity to digital PCR, with broader

assessed using the Inflammatory Bowel Disease questionnaire and the

coverage and no requirement for prior tumour sequencing. The ASpirin

European Organisation for Research and Treatment of Cancer Qual-

for Dukes C and high-risk Dukes B COLorecTal cancer trial (ASCOLT,

ity of Life questionnaire. Results were analysed using Mann-Whitney U

NCT00565708) is a randomised, double-blinded, phase III fully accrued

tests.

study investigating adjuvant aspirin benefit. In the Australian and New

Results: In total, nine of 14 eligible patients participated (55 years

Zealand cohort, serial plasma samples were prospectively collected at

old (SD 13.2), diagnosis: three cervical, five endometrial/uterine, one

study enrolment, 6 and 12 months (m), along with baseline tumour tis-

vagina), with the majority categorised as low fibre consumers at base-

sue. In this pilot, we evaluated the utility of an ultra-sensitive ctDNA

line (n = 6). The median soluble fibre baseline intake was 3 g (1–6.5

NGS assay (SafeSEQ, Sysmex Inostics).

g) and on average, increased by 150% throughout treatment. There

Methods: Extracted cell-free DNA was analysed using a SafeSEQ CRC

were no adverse events or major adjustments required for radiation

MRD 14-gene assay: AKT1, APC, BRAF, CTNNB1, ERBB3, FBXW7, KRAS,

treatment delivery. There were no significant differences between low

NRAS, PIK3CA, POLE, PPP2R1A, RNF43, SMAD4 and TP53. Tumour

and moderate/high fibre consumers in fibre change (%) or with fibre
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sequencing used an amplicon-based 59-gene custom panel. ctDNA was

to understand the potential to prevent or delay resistance through

correlated with tumour sequencing and recurrence data.

immune-modulation.

Results: Twenty-nine plasma samples (median 3.6 ml) from the first 10

Methods: CELEBRATE is an investigator-initiated, phase 1b dose-

patients were analysed (median age 65; 2 stage II, 8 III). All received

escalation and dose-expansion study to determine the maximum tol-

adjuvant 5-Fluorouracil-based chemotherapy. Median follow-up was

erated dose, dose-limiting toxicities (DLT), and recommended phase 2

59.9 m, with three known recurrences. Two of these patients had

dose of palbociclib in combination with encorafenib and binimetinib

detectable ctDNA: 1 at 6 m (KRAS G12V, lung metastases) and the

for patients with BRAFV600 -mutant metastatic melanoma. Treatment-

other at 12 m (KRAS G13D/ SMAD4 L540P, lung and nodal metas-

naïve patients and patients resistant to BRAF/MEKi and/or checkpoint

tases). Cancer recurrence was detected by CT 16.5 m after and

inhibitors are eligible for dose-escalation. A minimum of 10 patients in

within 1 m, respectively, of ctDNA positivity. Both plasma muta-

dose-expansion will undergo paired biopsy for pharmacodynamic eval-

tion profiles were concordant with tumour analysis. A third patient

uation, with a focus on immune-modulation. Key secondary endpoints

recurred 59.2 m after commencement (peritoneal metastases) without

are overall response rate, progression-free survival and pharmacody-

detectable ctDNA. CEA did not predict recurrence in any of the three

namic changes in the tumour microenvironment on treatment and at

patients.

progression.

Conclusions: In this pilot cohort, two of three patients who recurred

Results: Thirteen patients have been enrolled in dose-escalation and

had detectable ctDNA using a SafeSEQ assay (concordant with tumour

received at least one dose of encorafenib, binimetinib and palbociclib;

sequencing results). A third patient with late recurrence did not

nine patients are evaluable for DLTs. One of six evaluable patients

have detectable ctDNA. Analyses in the larger cohort (n = 368) are

experienced DLT at dose level 1 (grade 3 hyponatraemia) and one

underway.

of three evaluable patients experienced DLT at dose level 2 (grade 3
alanine aminotransferase increase). Dose-escalation is ongoing.
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CELEBRATE: A phase 1b study to evaluate the safety,

tolerability and preliminary efficacy of the Combination of

196

Encorafenib, Binimetinib and Palbociclib in patients with

(ARs) in patients with advanced renal cell carcinoma (aRCC)

BRAF-mutant metastatic melanoma (The CELEBRATE study)

receiving lenvatinib + pembrolizumab (CLEAR study)

Julia R Dixon-Douglas1 , Jennifer Soon1 , Alison Weppler1 , Chloe

Robert Motzer1 , Saby George2 , Jaime R. Merchan3 , Thomas E.

Bailey1 , Phillip Parente2 , Mark Shackleton3 , Damien Kee1,4 , Grant A

Hutson4,5 , Xun Song6 , Rodolfo F. Perini6 , Ran Xie7 , Urmi Bapat7 ,

Characterization and management of adverse reactions

McArthur1,5

Basant Ebaid8 , Javier Puente9

1 Peter MacCallum Cancer Centre, Parkville, VIC, Australia

1 Department

2 Department

York, NY, USA

of Medical Oncology, Eastern Health, Monash University,

of Medicine, Memorial Sloan Kettering Cancer Center, New

Melbourne, VIC, Australia

2 Department

3 Department of Medical Oncology, Alfred Health, Melbourne, VIC, Australia

Buffalo, NY, USA

4 Department

3 Department

of Medical Oncology, Olivia Newton John Cancer and Well-

of Medicine, Roswell Park Comprehensive Cancer Center,
of Medicine, University of Miami Sylvester Comprehensive

ness Centre, Austin Health, Melbourne, VIC, Australia

Cancer Center, Miami, FL, USA

5 Sir

4 Department

Peter MacCallum Department of Medical Oncology, University of

Melbourne, Parkville, VIC, Australia

of Medical Oncology, Texas Oncology-Baylor Charles A. Sam-

mons Cancer Center, Dallas, TX, USA
5 Texas A&M HSC College of Medicine, Bryan, TX, USA

Background: BRAF and MEK inhibitors (BRAF/MEKi) significantly
improve survival in patients with

BRAFV600 -mutant

metastatic

6 Merck & Co., Inc., Rahway, NJ, USA
7 Eisai Inc., Nutley, NJ, USA

melanoma. However, resistance to MAPK pathway blockade is com-

8 Eisai Australia Pty Ltd., Melbourne, Australia

mon and novel strategies are required to overcome this. Up to 90% of

9 Department

melanomas exhibit dysregulation of the Cyclin D pathway, providing

Carlos, Madrid, Spain

of Medical Oncology, Hospital Clinico Universitario San

the opportunity for dual blockade of the convergent MAPK and Cyclin
D pathways. Immune exhaustion is a feature of treatment resistance

Aims: In the CLEAR study, lenvatinib + pembrolizumab significantly

in BRAF-mutant melanoma and both BRAF/MEKi and CDK4/6i have

improved efficacy outcomes versus sunitinib in first-line treatment

been shown to be immunomodulatory, providing further rationale for

of aRCC. Herein, we characterize key ARs (grouped preferred terms

this combination. Combined BRAF/MEKi and CDK4/6i demonstrated

per the US prescribing information) in patients with aRCC treated

cell cycle arrest and cell death in vitro, with rapid and sustained tumour

with lenvatinib + pembrolizumab; we also discuss AR management

regression in human tumour xenograft models. Recently, mouse

strategies.

models have shown immunogenic synergy between these agents.

Methods: Patients were randomized (1:1:1) to lenvatinib 20 mg QD PO

This combination requires further clinical evaluation to determine

+ pembrolizumab 200 mg IV Q3W (n = 355); lenvatinib 18 mg QD PO +

the optimal dosing schedule and preliminary clinical activity, and

everolimus 5 mg QD PO (n = 357); or sunitinib 50 mg QD PO (4 weeks
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on/2 weeks off) (n = 357). Key ARs in patients treated with lenvatinib

5 Department

+ pembrolizumab are characterized.

Republic

Results: Median times (weeks) to first onset of key ARs (any grade,

6 Department

incidence >30%) with lenvatinib + pembrolizumab were: decreased

Alberta, Edmonton, AB, Canada

of Oncology, Thomayer University Hospital, Prague, Czech
of Medical Oncology, Cross Cancer Institute, University of

appetite (14.6), diarrhoea (20.0), fatigue (4.4), hypertension (3.0),

7 Department

hypothyroidism (14.3), musculoskeletal pain (6.4), nausea (14.4), rash

Maimonides Institute for Biomedical Research of Córdoba, Córdoba, Spain

(11.4), and stomatitis (6.6).

8 Department

Key ARs resulting in dose modifications/discontinuations are shown

National Medical Research Center for Oncology, Ministry of Health of the

of Medical Oncology, Hospital Universitario Reina Sofía,
of Clinical Pharmacology and Chemotherapy, N.N. Blokhin

(Table). The time to onset of grade ≥3 ARs and AR management

Russian Federation, Moscow, Russian Federation

strategies will be reported.

9 Division

Conclusions: ARs due to lenvatinib + pembrolizumab were generally

Medical Center, Sungkyunkwan University School of Medicine, Seoul,

consistent with known safety profiles. As will be presented, clini-

Republic of South Korea

cians play a critical role in prompt identification and AR-directed

10 Department of Oncology, Palacký University Medical School and Teaching

of Hematology/Oncology, Department of Medicine, Samsung

management; such management may potentially reduce treatment

Hospital, Olomouc, Czech Republic

interruption(s) and/or lenvatinib dose reduction.

11 Department

Table. Lenvatinib + Pembrolizumab (n = 352)a

Sammons Cancer Center, Dallas, TX, USA

of Medical Oncology, Texas Oncology-Baylor Charles A.

12 Texas A&M HSC College of Medicine, Bryan, TX, USA

Lenvatinib
interruption

AR,b %
Decreased appetite

Lenvatinib
reduction

Pembrolizumab
interruption

Lenvatinib
discontinuation

Pembrolizumab
Discontinuation

4.5

7.7

2.6

0.3

0.3

Diarrhoea

17.6

16.2

10.2

1.4

1.1

Fatigue

11.1

9.7

7.4

0.6

0.3

9.1

11.9

3.1

0.9

0.3

Hypothyroidism

1.7

1.1

1.4

0.3

0.6

Musculoskeletal pain

6.0

2.6

3.4

0.3

0.6

Nausea

4.3

5.1

1.4

0.3

0.3

Rash

5.7

4.0

2.8

1.4

2.3

Stomatitis

5.1

4.5

1.1

0.3

0

Hypertension

a

All safety analyses included patients who received at least one dose of any study drug.
Key ARs include those with >30% incidence (all grades).1. Clinical trial information: NCT02811861 Funding: This study was sponsored by Eisai Inc., Nutley,
NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Medical writing support was provided by Oxford PharmaGenesis
Inc., Newtown, PA, USA, with funding by Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
b
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Updated efficacy of lenvatinib (LEN) + pembrolizumab

(PEMBRO) versus sunitinib (SUN) in patients with advanced renal
cell carcinoma (aRCC) in the CLEAR study
Camillo G. Porta1 , Masatoshi Eto2 , Robert J. Motzer3 , Ugo De Giorgi4 ,
Tomas Buchler5 , Naveen S. Basappa6 , Maria Jose Mendez Vidal7 ,
Sergei Tjulandin8 , Se Hoon Park9 , Bohuslav Melichar10 , Thomas
Hutson11,12 , Carlos Alemany13 , Bradley McGregor14 , Cixin Steven
He15 , Rodolfo Perini16 , Kalgi Mody15 , Jodi McKenzie15 , Basant
Ebaid17 , Toni Choueiri14
1 Interdisciplinary Department of Medicine, University of Bari ‘A. Moro’, Bari,

Italy
2 Department of Urology, Kyushu University, Fukuoka, Japan
3 Department

of Medicine, Memorial Sloan Kettering Cancer Center, New

York, NY, USA
4 Department

of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio

dei Tumouri (IRST) Dino Amadori, Meldola, Italy

13 Department

of Hematology and Oncology, Advent Health Cancer Insti-

tute, Orlando, FL, USA
14 Department

of Medical Oncology, Dana-Farber Cancer Institute, Boston,

MA, USA
15 Eisai Inc., Nutley, NJ, USA
16 Merck & Co., Inc., Rahway, NJ, USA
17 Eisai Australia Pty Ltd, Melbourne, Australia

Aims: The phase 3 CLEAR study showed statistically significant PFS
(primary endpoint) and OS benefits, and improved ORR with LEN +
PEMBRO versus SUN in 1 L aRCC. We report updated efficacy and
describe patients who completed 2 years of PEMBRO and continued
on LEN monotherapy.
Methods: Patients with aRCC and no prior systemic therapy were randomized (1:1:1) to LEN 20 mg PO QD+PEMBRO 200 mg IV Q3W; LEN
18 mg + EVE 5 mg PO QD; or SUN 50 mg PO QD (4 weeks on/2 weeks
off). In this descriptive follow-up analysis (data-cutoff: 31st March
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2021), we report updated PFS, ORR, and duration of response (DOR)

exercise may overcome the aforementioned barriers and augment

by independent imaging review per RECIST v1.1 for LEN+PEMBRO

immunotherapy.

and SUN, as well as an exploratory analysis of patients who completed

Methods: A systematic of the available literature was conducted

2 years of PEMBRO per protocol and continued LEN.

according to the Preferred Reporting Items for Systematic reviews and

Results: Median (m) survival follow-up was 33.7 and 33.4 months

Meta Analyses (PRISMA) of all studies on physical activity/exercise

in the LEN+PEMBRO (N = 355) and SUN (N = 357) arms, respec-

for people on immunotherapy were evaluated. The quality of the

tively. Updated efficacy results continued to be improved with

included studies was evaluated using the MONDOS scale. Further

LEN+PEMBRO versus SUN (Table). Of patients who completed 2 years

exploration of pre-clinical, epidemiological, and other relevant papers

of PEMBRO (n = 101/355), most (n = 65) had IMDC intermediate/poor

were narratively reviewed.

risk disease; fewer (n = 36) had favourable risk disease, consis-

Results: Only two studies met the inclusion criteria (n = 44). Both stud-

tent with the intention-to-treat population. PEMBRO completers had

ies found high satisfaction with programs, reduction in fatigue and high

a 36-month OS-rate of 94.5%; 69 (68.3%) of these patients had

adherence to exercise protocols. Pre-clinical evidence demonstrated

treatment-related AEs (TRAEs).

that exercise could inhibit tumour growth, increase vascularisation

Conclusions: With longer follow-up, LEN+PEMBRO continued to

and perfusion, number tumour infiltrating lymphocytes and increase

show clinically meaningful benefit versus SUN, consistent with prior

immune checkpoint expression thus increase the effectiveness of

results of CLEAR. A large proportion of patients treated with

immunotherapy.

LEN+PEMBRO completed 2 years of PEMBRO and continued LEN

Conclusions: Whilst the evidence in human trials remains limited to

monotherapy with ongoing clinical benefit. The results further support

its ability to improve quality of life and reduce risk of recurrence.

LEN+PEMBRO as a standard of care in 1 L aRCC.

Pre-clinical and epidemiological evidence suggests exercise has the
capacity to inhibit tumour growth, progression, and/or metastasis
for those undergoing immunotherapy treatment. Future studies are

LEN+PEMBRO (N = 355) SUN (N = 357)
mPFS, months (95%CI)
HR (95%CI)

23.3 (20.8–27.7)

9.2 (6.0–11.0)

0.42 (0.34–0.52)

mOS, months (95%CI)a
HR (95%CI)

required to confirm the pre-clinical evidence in human clinical trials.

a

NE (41.5-NE)

NE (38.4-NE)

patients with PD-L1+, locally advanced/metastatic, nonsquamous

0.72 (0.55–0.93)

ORR, % (95%CI)

71.0 (66.3–75.7)

36.1 (31.2–41.1)

Relative risk, % (95%CI) 1.97 (1.69–2.29)
CR, %

17.2

mDOR, months (95%CI)

26.0 (22.2–41.4)

Safety and efficacy of sitravatinib + tislelizumab in

199
NSCLC

Bo Gao1 , Jun Zhao2 , Jingxun Wu3 , Lifeng Wang4 , Meili Sun5 , Zhiyong
4.2

Ma6 , Yunpeng Liu7 , Zhehai Wang8 , Xin Li9 , Hui Li10 , Juan Zhang9 ,

14.7 (9.4–16.8)

a
Previously reported.1. Previously presented at ESMO Congress 2022, FPN
(Final Publication Number): 1449MO, Camillo Porta et al. - Reused with
permission ClinicalTrials.gov number: NCT02811861 Funding source: This
study was sponsored by Eisai Inc., Nutley, NJ, USA, and Merck Sharp &
Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Medical
writing support was provided by Irene Minkina, PhD, of Oxford PharmaGenesis Inc., Newtown, PA, USA, with funding by Eisai Inc., Nutley, NJ, USA,
and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway,
NJ, USA.

Jingchao Sun9 , Yanyan Peng10 , Yi-Long Wu11
1 Blacktown Cancer and Haematology Centre, Blacktown, NSW, Australia
2 Key

Laboratory of Carcinogenesis and Translational Research (Ministry

of Education/Beijing), Department of Thoracic Oncology, Peking University
Cancer Hospital and Institute, Beijing, China
3 The First Affiliated Hospital of Xiamen University, Xiamen, China
4 Nanjing Drum Tower Hospital, Nanjing, China
5 Jinan Central Hospital, Jinan, China
6 The

Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer

Hospital, Zhengzhou, China
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Exercise and immunotherapy: A systematic and narrative

review

8 Shandong Cancer Hospital & Institute, Jinan, China
9 BeiGene (Beijing) Co., Ltd., Beijing, China
10 BeiGene (Shanghai) Co., Ltd., Shanghai, China

Morgan J. Farley1
1 School of Human Movement and Nutrition Sciences, University of Queens-

land, Brisbane, QLD, Australia
Introduction:

7 The First Hospital of China Medical University, Shenyang, China

Clinicians

have

had

increasing

success

using

immunotherapy to treat various cancers. However, effective
immunotherapy requires a functioning immune system, an immunogenic tumour, tumour infiltrating lymphocytes, and the treatment must
be tolerated by the patients. The aim of this review is to explore how

11 Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospi-

tal and Guangdong Academy of Medical Sciences, Guangzhou, China
Aims: Sitravatinib, an investigational and selective tyrosine kinase
inhibitor, reduces the number of myeloid-derived suppressor cells,
which promotes expansion of antitumour cytotoxic T cells and
increases the ratio of M1/M2-polarized macrophages. Tislelizumab is
a clinical-stage anti-PD-1 antibody engineered to minimize binding to
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FcγR on macrophages that has shown clinical activity in patients with

6 Tongji Hospital, Wuhan, China

advanced solid tumours.

7 The First Hospital of China Medical University, Shenyang, China

Methods: In SAFFRON-103 Cohort H (NCT03666143), patients with

8 Shandong Cancer Hospital & Institute, Jinan, China

PD-L1+, locally advanced/metastatic nonsquamous NSCLC without

9 BeiGene (Beijing) Co., Ltd., Beijing, China

prior systemic treatment in the metastatic setting were enrolled;

10 BeiGene (Shanghai) Co., Ltd., Shanghai, China

PD-L1+ was defined as PD-L1 staining on ≥1% of tumour cells (VEN-

11 Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospi-

TANA SP263 immunohistochemistry assay). Patients with documented

tal and Guangdong Academy of Medical Sciences, Guangzhou, China

EGFR mutation, ALK/ROS1 rearrangement, or BRAF mutation were
not eligible. Patients received sitravatinib 120 mg orally QD plus

Aims: Sitravatinib, an investigational selective tyrosine kinase inhibitor,

tislelizumab 200 mg intravenously Q3W until unacceptable toxicity,

reduces the number of myeloid-derived suppressor cells, which pro-

withdrawal, or death. The primary endpoint was safety/tolerability;

motes expansion of antitumour cytotoxic T cells and increases the

other endpoints included investigator-assessed ORR, DCR, PFS, and

ratio of M1/M2-polarized macrophages. Tislelizumab, a clinical-stage

OS.

anti-PD-1 antibody engineered to minimize binding to FcγR on

Results: Between 7th November 2019 and 23rd December 2020, 22

macrophages, has shown clinical activity in patients with advanced

patients were enrolled (median age 60.5 years [range: 41–78]; 68.2%

solid tumours.

male). Median study follow-up was 11.8 months (range: 0.9–17.9). At

Methods: In SAFFRON-103 Cohort I (NCT03666143), patients with

the data cut-off (8th November 2021), AEs were reported in 100.0%

PD-L1+, locally advanced/metastatic squamous NSCLC without prior

(any grade) and 59.1% (grade ≥3) of patients. Treatment-related AEs

systemic treatment in the metastatic setting were enrolled; PD-L1+

(TRAEs) of any grade or grade ≥3 were observed in 95.5% and 50.0%

was defined as PD-L1 staining on ≥1% of tumour cells (VENTANA

of patients, respectively; the most common grade ≥3 TRAE was hyper-

SP263 immunohistochemistry assay). Patients with documented EGFR

tension (13.6%). Serious AEs were reported in 45.5% of patients; two

mutation, ALK/ROS1 rearrangement, or BRAF mutation were not eligi-

patients experienced TRAEs leading to death (death, n = 1; pneumoni-

ble. Patients received sitravatinib 120 mg orally QD plus tislelizumab

tis, n = 1). Confirmed ORR was 57.1% (95% CI: 34.0, 78.2), with all

200 mg intravenously Q3W until unacceptable toxicity, withdrawal,

12 patients achieving partial response; DCR was 85.7% (95% CI: 63.7,

or death. Primary endpoint was safety/tolerability; other endpoints

97.0). Median PFS was 11.1 months (95% CI: 5.5, not estimable [NE])

included investigator-assessed ORR, DCR, PFS, and OS.

and median OS was 17.4 months (95% CI: 11.8, NE).

Results: Between 12th May 2020 and 10th February 2021, 24 patients

Conclusions: Sitravatinib plus tislelizumab demonstrated a manage-

were enrolled (median age 65.0 years [range: 56–71]; 91.7% male).

able safety/tolerability profile and antitumour activity in systemic

Median study follow-up was 9.4 months (range: 0.4–16.2). At the data

therapy-naïve patients with PD-L1+, locally advanced/metastatic non-

cut-off (08th November 2021), AEs were reported in 100% (any grade)

squamous NSCLC.

and 66.7% (grade ≥3) of patients. Treatment-related AEs (TRAEs) of

Acknowledgments: This study was sponsored by BeiGene, Ltd. Med-

any grade or grade ≥3 were observed in 95.8% and 58.3% of patients,
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8.6), while median OS was not reached (95% CI: 6.7, not estimable).

Safety and efficacy of sitravatinib + tislelizumab in
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Conclusions: Sitravatinib plus tislelizumab demonstrated a manage-

patients with PD-L1+, locally advanced/metastatic, squamous

able safety/tolerability profile and antitumour activity in systemic

NSCLC
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Pharmacogenetic testing for fluoropyrimidine (DPYD) and

tive treatment settings. Research data, education, and implementation

irinotecan (UGT1A1) based chemotherapies in routine clinical

studies may overcome clinicians’ hesitancy to reduce dosing for cura-

care: Perspectives of medical oncologists and oncology

tive intent treatments and barriers to routine clinical implementation.

pharmacists
Sarah Glewis1,2 , Senthil Lingaratnam1,2 , Mei Krishnasamy2,3,4 ,
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Jennifer Martin5 , Jeanne Tie2,6,7 , Marliese Alexander1,2 , Michael

backgrounds after cancer treatment: A qualitative study

Supporting women from Chinese, Vietnamese and Arabic

Michael2,6
1 Department

of Pharmacy, Peter MacCallum Cancer Centre, Melbourne,

Suzanne J. Grant1 , Carolyn Ee1 , Cannas Kwok1 , Sheetal Challam2 ,

VIC, Australia

Tinashe Dune1 , Elisabeth Elder3 , Ashanya Malalasekera4 , Jolyn

2 Sir

Hersch5 , Nema Hayba1 , Judith Lacey6 , Joel Rhee7 , Eric Yueng8 , Kristi

Peter MacCallum Department of Oncology, University of Melbourne,

Parkville, VIC, Australia

Milley9

3 Academic Nursing Unit, Peter MacCallum Cancer Centre, Melbourne, VIC,

1 Western Sydney University, Sydney, NSW, Australia

Australia

2 Cancer Institute NSW, Sydney, NSW, Australia

4 VCCC Alliance, Parkville, VIC, Australia

3 Westmead Breast Cancer Institute, Westmead, NSW, Australia

5 School of Medicine and Public Health, University of Newcastle, Callaghan,

4 Sydney Local Health District, Sydney, NSW, Australia

NSW, Australia

5 University of Sydney, Sydney, NSW, Australia

6 Department

6 Chris O’Brien Lifehouse, Sydney, NSW, Australia

of Medical Oncology, Peter MacCallum Cancer Centre, Mel-

bourne, VIC, Australia

7 University of Wollongong, Wollongong, NSW, Australia

7 Personalised Oncology Division, Walter and Eliza Hall Institute of Medical

8 CanRevive, Haymarket, NSW, Australia

Research, Parkville, VIC, Australia

9 PC4, Melbourne, Victoria, Australia

Background and Aims: Despite international guidelines and robust

Cancer survivors face physical, psychological and financial challenges,

evidence to support pharmacogenetic (PGx) testing prior to adminis-

which may prevent or delay return to work and other life roles

tration of fluoropyrimidine (FP) and irinotecan-based chemotherapy,

(1–2). Outcomes are compounded for culturally diverse women, as

integration into practice has been limited. This study aimed to explore

both information and supportive care are usually directed at English-

clinicians’ views and experiences of pre-treatment DPYD and UGT1A1

speaking, Caucasian women (3). Despite the need for culturally respon-

gene testing and barriers to and enablers of routine clinical implemen-

sive programs to support patients with cancer from culturally and

tation.

linguistically diverse (CALD) backgrounds (4) there remains a paucity

Methods: A study-specific survey consisting of 17 questions was

of research dedicated to serving ethnic minorities in Australia.

emailed (1st February–12th April 2022) to health care professionals

Our objective was to understand women’s concerns and preferences

(HCPs) from Clinical Oncology Society of Australia (COSA), Medical

for content, format and delivery of supportive care after cancer

Oncology Group of Australia (MOGA), and the International Soci-

treatment; and to understand facilitators and barriers to accessing sup-

ety of Oncology Pharmacy Practitioners (ISOPP). Data from survey

portive care after cancer to assist women surviving cancer from Arabic,

responses were collated and descriptive statistics were utilised to

Vietnamese, and Chinese backgrounds.

analyse and report outcomes.

Methods: This was a qualitative study using focus groups and semi-

Results: One hundred and fifty-six HCPs responded (78% medical

structured individual interviews (according to participant preference)

oncologists, 22% oncology pharmacists). Only 21% reported routinely

with women from Arabic, Vietnamese, and Chinese backgrounds, and

test for pre-treatment DPYD and 1% for UGT1A1. For patients having

healthcare professionals who have worked in cancer survivorship

treatments with curative or palliative intent, clinicians reported intent

programs with women from CALD backgrounds.

to implement genotype-guided dosing by reducing FP dose for peo-

Results: Two focus groups were conducted with women from Chi-

ple classified as DPYD intermediate metabolisers (79% curative intent

nese speaking backgrounds (Mandarin and Cantonese), two with

versus 94% palliative intent), avoiding FP for DPYD poor metabolisers

Vietnamese women and one with Arabic women. Further data were

(68% curative intent versus 90% palliative intent), and reducing irinote-

collected via six one-on-one interviews. The majority of women from all

can dose for UGT1A1 poor metabolisers in palliative setting (84%).

three cancer survivor groups preferred a program that has ‘in language

Barriers to implementation included: lack of financial reimbursements

support’, and is culturally reflective. For Chinese women (Mandarin and

(82%) and perceived lengthy test turnaround time (76%). Enablers

Cantonese), supportive cancer care organisations such as CanRevive

to implementation included: a dedicated program coordinator i.e.,

was an integral part of supportive cancer care. For women from Ara-

PGx pharmacist (74%), availability of resources for education/training

bic and Vietnamese backgrounds there was very limited support. There

(74%) and access to centralised testing services (74%).

were distinct cultural nuances in the supportive care preferences of the

Conclusion: PGx testing prior to the administration of FP and irinote-

different groups of women.

can is not routinely practiced despite robust evidence demonstrating

We interviewed 12 healthcare professionals (HCPs) including oncol-

its impact on clinical decision making in both the curative and pallia-

ogists, community program providers, allied health, and nurses. The
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results of the thematic analysis of both groups will be presented in full

Cohen8 , Lillian Siu9 , Danny Rischin10 , Lisa Licitra11 , Jan Vermorken12 ,

at the conference.

Quynh Le13 , Makoto Tahara14 , Jean-Pascal Machiels15 , Karen
O’Hara16 , Kumudu Pathiraja17 , Burak Gumuscu17 , Behzad Bidadi17 ,
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A single centre review of contemporary systemic therapy

in in-transit melanoma (ITM)

Barbara Burtness18 , Elani Bowers19
1 Institute

of Cancer Research and The Royal Marsden NHS Foundation

Trust, National Institute for Health and Care Research Biomedical Research
Amy Griffin1 , Geoffrey Peters2 , Rebecca Read3

Centre, London, United Kingdom

1 Australian National University, Watson, ACT, Australia

2 Yonsei

2 Medical Oncology, The Canberra Hospital, Canberra, ACT, Australia

Korea

3 General Surgery, Calvary Public Hospital Bruce, Canberra, ACT, Australia

3 CHU Timone, Marseille, France

Cancer Center, Yonsei University College of Medicine, Seoul, South

4 Institut Català d’Oncologia, Barcelona, Spain

Aims: In-transit melanoma (ITM) occur in 5%–10% of patients and has

5 The Christie NHS Foundation Trust, Manchester, United Kingdom

poor prognosis. Numerous lesions can limit surgical options and the

6 Rigshospitalet, Copenhagen, Denmark

role of systemic therapies is not well defined. We investigated the clin-

7 Seoul National University Bundang Hospital, Seongnam, South Korea

ical outcomes of those treated with systemic therapies in a tertiary

8 UC San Diego Health Moores Cancer Center, La Jolla, CA, USA

centre.

9 Princess Margaret Cancer Centre, University Health Network, Toronto, ON,

Methods: A retrospective case series of 23 patients with ITM between

Canada

2016 and 2021 at the Canberra Hospital. Patients with stage IV dis-

10 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

ease at diagnosis of ITM were excluded leaving 20 eligible patients.

11 Fondazione IRCCS Istituto Nazionale dei Tumouri and University of Milan,

Patient demographics, primary and ITM clinicopathologic characteris-

Milan, Italy

tics, treatment regimens and outcomes were analysed.

12 Antwerp University Hospital, Edegem, Belgium

Results: Patients were predominantly male (70%), with mean age

13 Stanford University, Stanford, CA, USA

61.8 years (SD = 14.44). Primary melanomas were on lower limbs in
70% with mean Breslow thickness 2.96 mm (SD = 1.82) and 31.25%

14 National Cancer Center Hospital East, Kashiwa, Japan
15 Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium

were ulcerated. BRAF V600E mutation was present in five patients.

16 Eisai Inc., Nutley, NJ, USA

Patients developed their first episode of ITM on average 28.99 months

17 Merck & Co., Inc., Rahway, NJ, USA

(SD = 29.40) post diagnosis of their primary with 30% of patients
presenting with innumerable ITM.

18 Yale Cancer Center, New Haven, CT, USA
19 MSD, Melbourne, VIC, Australia

Treatment data was available for 19 of 20 eligible patients. Eighteen
patients received immunotherapy as first-line management. Complete

Aims: The open-label, phase 2 LEAP-009 (NCT04428151) study is

response (one clinical, 10 PET-CT) to first-line therapy was observed

designed to evaluate the safety and efficacy of Lenvatinib + pem-

in 11 patients (one targeted, 10 immunotherapy). Immunotherapy was

brolizumab or Lenvatinib monotherapy versus chemotherapy in R/M

offered as second, third- and fourth-line treatment to four (n = 6),

HNSCC after progression on platinum-based therapy and a PD-1/PD-

three (n = 4) and one (n = 3) patient respectively. At least one grade

L1 inhibitor.

three toxicity was experienced by 31.58% of patients comparable

Methods: Approximately 400 adults with locally incurable, histologi-

to other studies. Patients also underwent isolated limb infusion (3),

cally confirmed R/M HNSCC (of the oral cavity, oropharynx, hypophar-

radiotherapy (3), diphencyprone (2) and clinical trials (2).

ynx, and/or larynx) will be randomly assigned 3:3:2 to Lenvatinib 20

Complete response was seen in 63.2% with complete response deter-

mg PO QD + pembrolizumab 200 mg IV Q3W (≤35 pembrolizumab

mined by PET-CT. In this group, there were two melanoma-related

cycles), standard-of-care chemotherapy (investigator’s choice of doc-

deaths occurring 24.53 and 14.07 months after initiation of systemic

etaxel, paclitaxel, cetuximab, or capecitabine), or Lenvatinib monother-

therapy.

apy 24 mg PO QD. Patients must have an ECOG PS of 0 or 1, no

Conclusions: Complete response was observed in 63% of patients con-

ulceration and/or fungation of disease on skin, disease progression

firming the utility of contemporary systemic therapy in ITM. Toxicity

on or after platinum-based therapy (±cetuximab) and PD-1/PD-L1

was similar to other published studies.

inhibitor (progression ≤12 weeks from last dose; received ≥2 doses).
Treatment continues until centrally verified disease progression, unac-
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LEAP-009: Phase 2 study of lenvatinib with or without

pembrolizumab vs chemotherapy for the treatment of recurrent
or metastatic (R/M) head and neck squamous cell carcinoma
(HNSCC) upon progression after platinum and immunotherapy
(PD-1/PD-L1 inhibition)
Kevin J. Harrington1 , Hye Ryun Kim2 , Sebastien Salas3 , Marc Oliva4 ,
Robert Metcalf5 , Mogens Bernsdorf6 , Ji-Won Kim7 , Ezra E. W.

ceptable toxicity, or withdrawal. Participants who experience centrally
verified disease progression in chemotherapy or Lenvatinib monotherapy arms can cross over to Lenvatinib + pembrolizumab at time of
disease progression with sponsor consultation. Stratification factors
are PD-L1 tumour proportion score (<50% vs ≥50%) and ECOG PS
(0 vs 1). Imaging will be performed Q6W through year 1 and Q9W
thereafter. Response will be assessed per RECIST v1.1 by blinded
independent central review. Safety will be monitored until 30 days fol-
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lowing treatment end (90 days for serious AEs). The primary end point

13% (two partial responses) in EC7. Kaplan-Meier estimate of median

is objective response rate. Secondary end points are progression-free

progression-free survival was 14.2 (95% CI: 5.6–not estimated) months

survival, duration of response, overall survival, and safety.

in EC6 and 1.4 (95% CI: 1.3–7.7) months in EC7. Median duration of

Results: LEAP-009 is enrolling patients in North America, Europe, Asia,

response was not reached in EC6 or EC7.

and Australia. Recruitment is currently underway.

Conclusion: Fianlimab plus cemiplimab in advanced melanoma had

Conclusion: Results of LEAP-009 will provide clarification on the

a similar safety profile to anti–PD-1 monotherapies. Clinical activ-

efficacy and safety of Lenvatinib with or without pembrolizumab vs

ity in anti–PD-(L)1–naive patients appeared higher than previously

chemotherapy for patients with R/M HNSCC upon progression after

reported for anti–PD-1 monotherapy or anti–LAG-3 plus anti–PD-1. A

platinum and immunotherapy.

Phase 3 trial (NCT05352672) investigating fianlimab plus cemiplimab

Clinical trial registration: NCT04428151

in advanced melanoma is ongoing.
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Phase 1 study of fianlimab, a human lymphocyte

Efficacy and tolerability of docetaxel chemotherapy in

activation gene-3 (LAG-3) monoclonal antibody, plus cemiplimab

‘real-world’ patients with metastatic hormone-sensitive prostate

in advanced melanoma

cancer (mHSPC)

Omid Hamid1 , Amy Weise2 , Tae Min Kim3 , Meredith McKean4 , Nehal

May Tun Hla Maw1 , Laeeq Malik1

J. Lakhani5 , John Kaczmar6 , Kyriakos P. Papadopoulos7 , Shuquan

1 Department

Chen8 , Jayakumar Mani8 , Vladimir Jankovic8 , Glenn Kroog8 , Tasha

Australia

of Medical Oncology, The Canberra Hospital, Garran, ACT,

Sims8 , Israel Lowy8 , Giuseppe Gullo8
1 The

Angeles Clinical and Research Institute, a Cedars-Sinai Affiliate, Los

Background: Recent clinical trials have demonstrated improved sur-

Angeles, CA, USA

vival of young and fit patients with metastatic hormone sensi-

2 Henry Ford Hospital, Detroit, MI, USA

tive prostate cancer treated with upfront docetaxel chemotherapy.

3 Seoul National University Hospital, Seoul, South Korea

Prostate cancer patients in ‘real world’ are elderly with multiple comor-

4 Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, TN,

bidities. The efficacy and tolerability of docetaxel in these patients is

USA

unknown.

5 START Midwest, Grand Rapids, MI, USA

Methodology: We conducted a retrospective observational study of

6 MUSC Hollings Cancer Center, North Charleston, SC, USA

patients with newly diagnosed hormone-sensitive de novo or recurrent

7 START San Antonio, San Antonio, TX, USA

(metastatic) prostate cancer (mHSPC) who were treated with upfront

8 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

docetaxel within three months of starting androgen deprivation therapy at Canberra Region Cancer Centre. We collected demographic and

Background: Concurrent LAG-3 blockade may enhance efficacy of

the relevant medical information from the medical records.

anti–program cell death-1 (PD-1) therapies such as cemiplimab. We

Results: There were 38 patients in our study with a median age of 65

present updated safety and clinical activity data from patients with

years (range 46–77 years). The median PSA at the start of chemother-

advanced melanoma treated concurrently with cemiplimab and fian-

apy was 63.5. The sites of metastases included bone (82% of patients),

limab (NCT03005782).

lymph nodes (79%) lung (21%) and liver (8%). 26 patients had de

Methods: Patients were included with unresectable or metastatic

novo disease, 10 patients had recurrent disease, and two patients had

melanoma (excluding uveal melanoma) who were anti–PD-ligand (L) 1

missing data.

treatment naive (expansion cohort [EC] 6) or anti–PD-(L)1 experienced

After a median follow up of 28 months, 24 patients were still alive.

within 3 months of screening (EC7). Patients received fianlimab 1600

The 12-month and 24-month survival rates were 84% and 66%,

mg + cemiplimab 350 mg intravenously every 3 weeks for 12 months

respectively. About five patients (13%) experienced grade ≥3 toxicities

(optional extra 12 months if clinically indicated). Tumours were mea-

including fatigue, peripheral neuropathy, mucositis, infusion reaction,

sured every 6 weeks for 24 weeks, then every 9 weeks. In EC6 (n = 40)

and palmar plantar erythrodysesthesia.

and EC7 (n = 15), respectively (data cutoff 9th February 2022), median

Conclusion: In this small retrospective study with a short follow up, we

age was 69.5 and 59.0 years, and median treatment duration was 37.1

found that docetaxel was tolerable in ‘real world’ patients with mHSPC

and 9.0 weeks.

with a low grade ≥3 toxicity rate. Longer follow-up is needed to assess

Results: In EC6 and EC7, respectively, incidence of Grade ≥3

efficacy outcomes.

treatment-emergent adverse events (TEAEs) were 38% and 47%, incidence of serious TEAEs was 33% and 33%, and 18% and 13% of
patients discontinued treatment due to a TEAE. Adrenal insufficiency

207

rate was 13% and 7% in EC6 and EC7, respectively; no instances led to

advanced cancers: Retrospective analysis in a regional centre

Immunotherapy efficacy and concomitant antibiotic use in

treatment discontinuation. Investigator-assessed objective response
rate was 63% (six complete responses; 19 partial responses) in EC6 and

Saw Htut1 , Megan Lyle2 , James Flectcher3
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1 Liverpool Hospital, Liverpool, NSW, Australia

ogy patients. Hazards include falls, increased hospitalisation rates,

2 Cairns and Hinterland Hospital and Health Services, Cairns, QLD, Australia

morbidity and increased mortality. This study aimed to determine

3 James Cook University, Cairns, QLD, Australia

baseline polypharmacy, incident polypharmacy, prescribing practices,
and associated characteristics that may influence the older oncology

Background: Immune checkpoint inhibitors (ICI) have changed treat-

population.

ment paradigm in advanced cancer management. Factors affect-

Methods: This retrospective cohort study analysed clinical and demo-

ing survival in patients managed with ICI are not fully under-

graphic details of a randomly selected group of patients with solid

stood. Concomiitant use of antibiotics early in the treatment phase

organ malignancies through individually reviewed electronic medical

is a factor being investigated. This study aims to compare sur-

records. We examined the cohort from their first oncology review to

vival differences in two groups of patients treated with ICI for

three months post initial review. Collected information included age,

advanced cancers with or without antibiotics use in the first 4 weeks

comorbidities, baseline medication burden, cancer variables, includ-

of treatment. CHHHS services 250,000 population in Far North

ing stage, and prescribing practices. The primary aim was to examine

Queensland.

prescribing practices over three months, and to assess the classes of

Methods: Retrospective single-site study at a regional centre in

medications that were added or removed. Additionally, we looked for

Queensland investigating patients receiving ICI without chemother-

possible drug-drug interactions and adverse events from medications.

apy for advanced cancers (melanoma, non-small cell lung cancer,

Results: At the time of publication, 107 patients had been analysed out

head and neck squamous cell carcinoma, urothelial cancer, renal cell

of a planned 300. The median age was 73 (range 65–89). 70% had base-

carcinoma, mesothelioma) from 2015 to 2019. Baseline demograph-

line polypharmacy, with the average number of medications being four

ics and prognostic factors data including age, ECOG performance

(range 3–15). Baseline medications represented pre-existing comor-

score, comorbidities, number of metastatic sites and presence of brain

bidities (including chronic cardiovascular, respiratory and endocrine

metastasis were collected. Antibiotics use within 4 weeks after ICI

disease). At first review, no deprescription occurred in any patients.

commencement was examined. Cox proportional hazard model and

71% of patients were on or planned to commence cancer-related ther-

Kaplan-Meier analysis was used to examined median progression free

apy shortly. The average medication number prescribed after 3 months

survival (PFS) and median overall survival (OS) in two cohorts with and

was six, with 14 patients taking over 10 medications.

without antibiotics treatment.

Conclusion: Our research confirms high baseline polypharmacy and a

Results: One hundred and eighty-four patients were treated with ICI

tendency to prescribe rather than deprescribe. The extra medications

in this study. Thirty-nine patients (21%) received antibiotics within

administered were primarily anti-cancer treatments and supportive

first 4 week of ICI treatment and 145 patients (79%) did not. Patient

medications. Further research into clinician prescribing, documenta-

who did not receive antibiotics had median PFS of 9.4 months com-

tion and stakeholder engagement is needed to minimise the risks

pared with 4.3 months for those who did (HR of 2.018, P = 0.001).

associated with polypharmacy.

median OS was 38.2 months compared with 10.5 months (HR of 2.351,
P = 0.001)
Conclusion: This study demonstrated statistically significant trend

209

toward shorter survival times in patients with concomitant antibi-

malignancy: A systematic review

Prevalence of fatigue in patients with haematological

otics use. Further research with multivariate analysis correcting for
covariates such as age, comorbidities, ECOG performance status, num-

Tegan Ilsley1,2,3 , Geerthika Galister2 , Arwel Jones1 , Erin Howden1,3 ,

ber of metastatic sites is in progress and will be presented in future

Anne E. Holland1,2

publications.

1 Monash University, Melbourne, Victoria, Australia
2 Alfred Health, Melbourne, Victoria, Australia
3 Baker Heart and Diabetes Institute, Melbourne, Victoria

208

Polypharmacy and prescription practices in the older

oncology population at The Kinghorn Cancer Centre: A single

Background: Cancer-related fatigue (CRF) is distressing for patients

site, retrospective audit

and can manifest across the cancer journey, from diagnosis, through
treatment and into survivorship. CRF impacts daily activities, mood,

Joshua Hurwitz1,2 , Annabelle Robinson2 , Michael Krasovitsky1,2,3

social relationships, and work, and is associated with decreased qual-

1 St Vincent’s Clinical School, University of New South Wales, Sydney, NSW,

ity of life. However, no systematic review has been conducted to

Australia

analyse the prevalence of CRF specifically in patients with haemato-

2 The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia

logical malignancies. Understanding the prevalence of CRF amongst

3 Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia

patients with haematological cancer may help guide assessment and
management of this distressing symptom.

Background: Polypharmacy is over-represented in the over 65 cohort.

Aim: To determine the prevalence of CRF in patients with haematolog-

Around 65.5% of new cancers in men and 55% in women are diagnosed

ical malignancy.

in those 65 and older.

Polypharmacy is a risk for older oncol-
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Methods: The review protocol was registered with PROSPERO

Results: Eighty-four patients who had selected irAEs and needed sys-

(2021 CRD42021258752). Medline, Embase, PyscINFO and CINAHL

tems steroids were identified (44 prior to clinic and 40 managed in

databases were searched from inception to July 2021. Studies pub-

clinic). There was a numerical reduction in total days admitted with a

lished in English that utilised quantitative measures of fatigue and

mean of 3.23 days in the clinic group vs 8.07 in the non-clinic group

reporting prevalence data on fatigue in adult patients with any subtype

(p = 0.108). The time taken to taper was also numerically lower at 48

and any stage of haematological malignancy were eligible, including

days compared to 62 days (p = 0.881). There was a significant increase

new diagnosis, refractory and relapsed disease.

in the documentation of steroid side effects in the clinic patients at

Results: Eleven thousand six hundred and twenty-five articles were

60.5% vs 33.3% (p = 0.011). There was no difference in the rates of

screened with 83 meeting the inclusion criteria, involving 31,932

major steroid side effects.

patients and sample sizes ranging from 18 to 5306 participants. The

Conclusion: The study was underpowered to comment on the signif-

prevalence of CRF in individual studies varied from 15% to 95%.

icance of the difference of total admitted days but was numerically

Random-effects meta-analysis determined the pooled prevalence of

lower in the clinic managed group. There was a statistically significant

fatigue to be 59% (95% CI: 51%–67%, 50 studies, n = 14,775), however

increase in the documentation rates of steroid complications, thereby

heterogeneity was high (I2 = 99%). Subgroup analysis showed pooled

facilitating proactive management. The time to event curves were sim-

CRF prevalence of 71% in patients with Leukaemia (95% CI: 58%–81%,

ilar for time to taper steroids. Further study is needed to assess for

n = 2754, I2 = 97%), 33% in those with Lymphoma (95% CI: 28%–39%,

financial benefit.

n = 4546, I2 = 92%), 59% in those with Myeloma (95%CI: 31%–
82%, n = 728, I2 = 97) and 85% in patients with a Myeloproliferative
Neoplasm (95% CI: 70%–93%, n = 3913, I2

= 98%).

Conclusion: This systematic review highlights that fatigue is common
amongst patients with haematological malignancy. Due to the known
association of high CRF and low QOL, management of CRF should be
prioritised across the survivorship continuum.

1. Brahmer, J.R., et al., Management of Immune-Related Adverse
Events in Patients Treated with Immune Checkpoint Inhibitor
Therapy: American Society of Clinical Oncology Clinical Practice
Guideline. J Clin Oncol. 2018;36(17):p. 1714-1768.
2. Haanen, J., et al., Management of toxicities from immunotherapy:
ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 2017;28(suppl_4): p. iv119-iv142.
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Implementation of an immunotherapy toxicity

management clinic
Haakan A. Jakobsson1,2 , Oluwaseun Kolade3 , Marcin Dzienis2,4 ,
Jasotha Sanmugarajah2,4 , Robert Mason2,4
1 Princess Alexandra Hospital, Woolloongaba, QLD, Australia
2 Medical

Oncology, Gold Coast University Hospital, Gold Coast, QLD,

Australia
3 Gold Coast University Hospital, Gold Coast, QLD, Australia
4 Griffith University, Gold Coast, QLD, Australia

Objectives: Immune check-point inhibitors (ICIs) can have significant
immune related adverse events (irAE) that may require high dose corticosteroids and inpatient management.1,2 This study investigated if
a specialised clinic could reduce the total days of admission, time
to taper steroids and improve detection of steroid complications in
patients with select irAE needing systemic corticosteroids. The primary
outcomes were time admitted and to taper steroids (<10 mg/day prednisone). Secondary outcomes were documented steroid complications,
steroid sparing agent use and clinic completion.
Methods: An observational study at a tertiary centre in Queensland Australia was conducted. Data was collected prospectively for
patients with select irAE requiring steroids managed in a specialist
immunotherapy toxicity clinic and retrospectively prior to clinic implementation. The select toxicities were hepatitis, colitis, pneumonitis,
nephritis, and dermatological. Patients were excluded if they did not
require systemic steroids.
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CDK4/6 Inhibitors (CKD4/6i) in advanced

hormone-receptor-positive (HR+) HER2-negative (HER2-) breast
cancer: Prescribing practices and outcomes in a real-world,
Australian cohort
Anadil Javaid1 , Sheau Wen Lok2 , Vanessa Wong2,3 , Sally Baron-Hay4 ,
Fran Boyle5 , Ian Collins6 , Katharine Cuff7 , Richard de Boer8 , Lucy
Gately9 , Chloe Georgiou10 , Sally Greenberg11 , Bhaskar Karki12 ,
Michelle Nottage13 , Natalie Rainey14 , Javier Torres15 , Belinda Yeo16 ,
Bianca Devitt1,17 , Peter Gibbs2 , Angelyn Anton1,17
1 Eastern Health, Melbourne, Victoria, Australia
2 Personalised Oncology Division, Walter and Eliza Hall Institute of Medical

Research, Melbourne, Victoria, Australia
3 Ballarat Health Services, Ballarat, Victoria, Australia
4 Northern Cancer Institute, Sydney, New South Wales, Australia
5 Mater North Sydney Hospital, Sydney, New South Wales, Australia
6 South West HealthCare, Warrnambool, Victoria, Australia
7 Princess Alexandra Hospital, Brisbane, Queensland, Australia
8 St Vincent’s Private Hospital, Melbourne, Victoria, Australia
9 Alfred Hospital, Melbourne, Victoria, Australia
10 Bendigo Health, Bendigo, Victoria, Australia
11 Western Health, Melbourne, Victoria, Australia
12 Toowoomba Hospital, Toowoomba, Queensland, Australia
13 Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia
14 Cairns Hospital, Cairns, Queensland, Australia
15 Goulburn Valley Health, Shepparton, Victoria, Australia
16 Austin Health, Melbourne, Victoria, Australia
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17 Eastern

Clinical Research Unit, Monash University, Melbourne, Victoria,

Australia

Background: Cancer survivorship is characterised by increasing complexity of impairments related to disease and treatment. Inpatient
rehabilitation of patients with cancer aims to improve functional out-

Aims: To examine treatment trends, efficacy and toxicity in advanced

comes and independence. We aimed to describe patients referred for

HR+/HER2- breast cancer in a real-world, Australian cohort.

rehabilitation at Nepean Hospital, a tertiary-level acute facility, and

Methods: Data was extracted from the Advanced Hormone Receptor

ascertain any association with overall survival (OS).

Positive Breast Cancer Registry in Australia (ARORA), a prospective

Methods: Retrospective review of adults referred to rehabilitation

registry, including 15 sites. Patients had inoperable or metastatic

with solid-organ malignancies. Primary endpoints included: OS, change

HR+/HER2- breast cancer diagnosed after January 1st 2020. Patient

in Functional Independence Measure (FIM) score and FIM efficiency.

and disease characteristics, treatment, progression-free survival (PFS)

Multivariate analysis using Cox proportional hazards with OS as the

and adverse events (AEs) were extracted. Data analysis used descrip-

dependent variable was undertaken. Updated analysis with expanded

tive statistics. This Research Collaboration was supported by Novartis.

data is reported.

Results: Two hundred and one patients were enrolled; six were

Results: One hundred and forty-four patients were referred for reha-

excluded due to incomplete data; median age 63 years (29–89

bilitation between January 1, 2018 and December 31, 2020. Median

years); median follow-up 12.8 months. Sixty-seven (34%) had de novo

age was 70 years; 95 (66%) were male, 117 (81%) had Stage IV

metastatic disease. Of 128 patients with relapsed disease, 107 (84%)

disease and 121 (84%) were ECOG 3-4. Urogenital, lung and gastroin-

received adjuvant therapy, 98 (77%) endocrine therapy (ET) and 69

testinal cancers accounted for 64%. Thirty-two (22%) patients had

(54%) chemotherapy. Seventeen (13%) received no adjuvant therapy.

curative treatment planned, whilst 31 (22%) were for supportive care

Four (3%) were unknown. One hundred and forty-seven (75%) received

only. Median Charlson Comorbidity Index was 4. One hundred and

CDK4/6i+ET in the first-line metastatic setting, 25 (13%) received ET

eight patients were accepted for inpatient rehabilitation (84 within

alone, 13 (7%) received chemotherapy and nine (5%) received no treat-

Nepean Hospital). Median follow-up was 5.4 months. Median OS was

ment. In the CDK4/6i+ET group, 83 (56%) received Palbociclib, 58

6.2 months (95%CI: 5.0–9.9). Acceptance to rehabilitation correlated

(39%) Ribociclib and 12 (8%) Abemaciclib. CDK4/6i was combined with

with OS (HR 0.48, 95%CI 0.30–0.78, p = 0.003) after adjustment for

an aromatase inhibitor in 121 (82%) and with fulvestrant in 27 (18%).

age, treatment intent, ECOG, co-morbidities and stage. Secondary end-

Sixty-seven (46%) in the CDK4/6i+ET group had visceral metastases,

points included: re-admission within 30 days of discharge (22, 20%),

compared to nine (69%) in the chemotherapy group. At reporting,

transfer back to acute care (21, 19%) and death in hospital after reha-

55 (27%) had progressed on first-line treatment; of these 43% had

bilitation (16, 15%). Of patients accepted at Nepean Hospital: median

relapsed on or within 6 months of adjuvant ET and 27% had de novo

rehabilitation duration was 16 days with 57 (72%) discharged home,

metastatic disease. Twelve-month PFS was 83% for CDK4/6i+ET.

median FIM change was 16 points, median FIM efficiency of 0.83

PFS and OS data is immature. The most common AEs associated with

points/day, 17 patients (22%) had concurrent anti-cancer treatment.

CDK4/6i+ET were neutropenia (27%), nausea/vomiting (14%) and

FIM score >80 on discharge (p = 0.0071), FIM change (p < 0.001) and

diarrhoea (5%).

FIM efficiency (p = 0.020) correlated with better survival.

Conclusions: Real-world Australian data of advanced HR+/HER2-

Conclusions: Patients with cancer selected for rehabilitation have

breast cancer demonstrates significant uptake of CDK4/6i+ET in the

improved function and may experience longer survival.

first-line setting. Toxicity is consistent with previous reports. Longer
follow up will allow analysis of efficacy and subgroups.
213

Effective selection of patients with solid-organ

malignancies for in-patient rehabilitation: Analysis of cancer
212

Survival of patients with solid-organ malignancies

referred to Nepean Hospital Rehabilitation services between

patients referred to Nepean Rehabilitation services between
2018 and 2020

2018 and 2020
Vikram Joshi1 , Michael Que2 , Sharon Wong1 , Laurence Chu1 , Deme
Vikram Joshi1 , Michael Que2 , Sharon Wong1 , Laurence Chu1 , Deme

Karikios2,3 , Alexander Murphy3

Karikios3,2 , Alexander Murphy3

1 Department

1 Department

Blue Mountains Local Health District, Kingswood, New South Wales,

of Rehabilitation Medicine, Nepean Hospital, Nepean and

Blue Mountains Local Health District, Kingswood, New South Wales,

Australia

Australia

2 Nepean

2 Nepean

Clinical School, Faculty of Medicine and Health, University of

of Rehabilitation Medicine, Nepean Hospital, Nepean and

Clinical School, Faculty of Medicine and Health, University of

Sydney, Kingswood, NSW, Australia

Sydney, Kingswood, New South Wales, Australia

3 Nepean

3 Nepean

District, Kingswood, New South Wales, Australia

Cancer & Wellness Centre, Nepean Blue Mountains Local Health

Cancer & Wellness Centre, Nepean Blue Mountains Local Health

District, Kingswood, New South Wales, Australia
Background: Cancer survivorship is characterised by increasing complexity of impairments related to disease and treatment side effects.
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Access to inpatient rehabilitation resources remains limited. We evalu-

tions product information for paclitaxel and cabazitaxel recommends

ated clinical factors that may help prognosticate successful rehabilita-

the use of an antihistamine, corticosteroid and H2-antagonist pre-

tion outcomes.

treatment.

Methods: Retrospective review of adult patients referred to rehabili-

In September 2019, ranitidine became unavailable due to possible con-

tation at Nepean Hospital with solid-organ malignancies. Primary end-

tamination. Prior to routine availability of alternate H2-antagonists

points included: change in Functional Independence Measure (FIM),

our unit administered taxane chemotherapy without H2-antagonists.

FIM efficiency (FIM change/length of stay), rehabilitation failure and

This practice has continued for weekly paclitaxel and cabazitaxel

discharge FIM above 80.1 We performed t tests and Chi-squared tests

protocols.

to establish differences between cohorts.

This project aimed to determine if the rate or severity of tax-

Results: One hundred and eight patients were accepted for rehabil-

ane infusion reactions changed following removal of ranitidine as

itation over 36 months, with 24 discharged to an external facility.

a standard pre-medication in our cancer centre from September

Thirty-six were declined, with presence of central line (p = 0.011),

2019.

infection/ collection (p = 0.012) and prescription of anti-psychotics

Method: A retrospective audit of case notes was conducted of all

(p = 0.008) significantly higher. Of the 84 patients rehabilitated at

patients who received weekly paclitaxel or 3-weekly cabazitaxel

Nepean, median FIM at admission (69) and discharge (87) demon-

for 1 year preceding unavailability of ranitidine (August 2018–

strated significant improvement (p < 0.001); mostly in motor domains

August 2019) and 1 year post unavailability (October 2019–October

(FIM: 41–63).

2020). Case notes were reviewed for the first three cycles of all

We reported elsewhere increased survival for cancer patients with

patients who received weekly paclitaxel (as ranitidine is typically

a discharge FIM over 80. Clinical variables associated with achiev-

ceased post cycle three) and all cycles for patients who received

ing a FIM score above 80 included: curative cancer treatment intent

cabazitaxel.

(p = 0.047), urinary and bowel continence (p = 0.027), nil or one per-

Results: To date, 175 patients have been reviewed, receiving a total

son transfer assistance (p = 0.004), ambulation with up to one person

of 541 infusions (79 patients receiving 234 infusions with ranitidine,

assisting (p = 0.029) and having a higher FIM at the start of rehabilita-

and 96 patients receiving 307 infusions without ranitidine). Current

tion (p < 0.001). Poorer outcomes (discharge to an acute team, death

analysis indicates no difference in infusion reactions, with 10 infu-

in hospital and return to hospital within 30 days) were experienced by

sion reactions experienced (4.3% of infusions) amongst those receiving

those with a discharge FIM <80 (p < 0.001), cancer diagnosed more

ranitidine compared with seven infusion reactions (2.3% of infusions)

than 1 year ago (p = 0.026) and those who had emergency surgery

amongst those without ranitidine, p = 0.2. No patient experienced

during admission (p = 0.005).

multiple reactions. All patients who experienced an infusion reaction

Recent anti-cancer treatment, selected nursing measures, biochem-

received paclitaxel. Data collection is ongoing and expected to be

istry/haematology data, surgical complications and medications, did

completed by end of August 2022.

not reliably predict FIM change or efficiency prior to Rehabilitation

Conclusion: We observed no increase in the rate of infusion reactions

consultation.

with weekly paclitaxel and 3-weekly cabazitaxel despite cessation of

Conclusions: The determinants of effective selection of patients with

routine H2-antagonists administration. Our audit suggests patients

cancer to inpatient rehabilitation remain heterogenous; encouraging a

may be able to safely receive these treatments without routine H2-

considered and collaborative approach.

antagonist.

1. Saotome et al. 2015. Cancer rehabilitation: A barometer for survival? Support Care Cancer, 23:3033–3041.
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Is there a relationship between frequency of port-care

maintenance and related complications in patients with cancer?
214

H2-antagonists for prevention of taxane infusion

reactions: Are these required?

Tali Lang1 , Sarah Jaboury1 , Alexander West1 , Jo O’Sullivan2 , Kirsten
Seletto3 , Lucy Wilson3 , Gleisner Elizabeth3 , Gary Richardson1,4
1 Cabrini Research, Malvern, VIC, Australia

Kimberley-Ann Kerr1,2,3 , Huda Binte Ryaz Patel4 , Angela Shum5 ,

2 Cabrini Health, Brighton, Victoria, Australia

Kirsty Tait1,2,5 , Chen-Yao Hung1,2 , Christopher Hocking1,4

3 Cabrini Health, Malvern, Victoria, Australia

1 Lyell McEwin Hospital, Greenwith, SA, Australia

4 Oncology Clinics Victoria, Brighton, Victoria, Australia

2 SA Pharmacy, Adelaide
3 Digital Health SA, Adelaide

Background: Totally implantable ports require regular maintenance

4 University of Adelaide, Adelaide

to prevent port-related complications. Manufacturers recommend

5 University of South Australia, Adelaide

monthly maintenance port flushes for patients for the life of the port.
Previous studies show that extending intervals between maintenance

Aim: Taxane-based chemotherapy is used in the treatment of mul-

port flushes up to 16 weeks does not increase incidence of port-related

tiple malignancies. Due to the high risk of hypersensitivity reac-

complications. To date, no prospective study has been conducted to
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evaluate the medical safety of extending flush intervals from monthly

11 Hubei

Cancer Hospital (Affiliated Cancer Hospital of Tongji Medical

to every 12 weeks within a heterogeneous disease cohort.

College, Huazhong University of Science and Technology), Wuhan, China

Aim: To determine is it feasible and medically safe to extend intervals

12 Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

between maintenance port flushes to every 12 weeks in patients with

13 Chongqing

cancer not on active treatment?

Chongqing, China

Methods: This study enrolled oncology and haematology patients who

14 The

University Cancer Hospital (Chongqing Cancer Hospital),

First Affiliated Hospital of Wenzhou Medical University, Wenzhou,

had retained their port following completion of anticancer treatment.

China

Clinical data were extracted for 1059 participants. The primary end

15 Cancer Hospital of China Medical University (Liaoning Cancer Hospital &

points of this study were the overall number of ports removed and inci-

Institute), Shenyang, China

dence of port-related complications reported between cohorts 1 and 2

16 Women’s

Hospital School of Medicine Zhejiang University, Hangzhou,

(flushes every 4–8 weeks), and cohort 3 (flushes every 12 weeks).

China

Results: Data were allocated into three study cohorts on the basis of

17 Cancer

year and duration between port flushes. No difference was observed in

Fuzhou, China

the overall percentage of ports removed because of physician-reported

18 Harbin Medical University Cancer Hospital, Harbin, China

complications across all cohorts (25%–30%). No change in the inci-

19 Cancer Center, Union Hospital, Tongji Medical College, Huazhong Univer-

Hospital of Fujian Medical University (Fujian Cancer Hospital),

dence of port-related complications including suspected infection and

sity of Science and Technology, Wuhan, China

malfunction was observed between cohorts 1 and 2 (8%), or cohort 3

20 Tianjin Central Hospital of Gynecology Obstetrics, Tianjin

(5%).

21 The

Third Affiliated Hospital of Kunming Medical University (Yunnan

Conclusion: Our findings show that extending maintenance port flush

Cancer Hospital), Kunming, China

intervals to 12 weeks does not increase the incidence of port-related

22 Zai Lab (US) LLC, Boston, USA

adverse events and is medically safe.

23 Zai Lab (Shanghai) Co., Ltd, Shanghai, China
24 GSK, Melbourne, Australia
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Efficacy and safety of niraparib as maintenance treatment

Aims: The PRIME study (NCT03709316) evaluated the efficacy and

in patients with newly diagnosed advanced ovarian cancer using

safety of niraparib using an individualized starting dose as mainte-

an individualized starting dose (PRIME Study): A randomized,

nance treatment following complete or partial response (CR/PR) to

double-blind, placebo-controlled, phase 3 trial

first-line (1 L) platinum-based chemotherapy (CT) in Chinese patients
with advanced ovarian cancer (OC).

Ning Li1 , Jianqing Zhu2 , Rutie Yin3 , Jing Wang4 , Lingya Pan5 , Beihua

Methods: In this double-blind, placebo-controlled, phase three study,

Kong6 , Hong Zheng7 , Jihong Liu8 , Xiaohua Wu9 , Li Wang10 , Yi

patients with newly diagnosed, advanced (stage III–IV) OC were ran-

Huang11 , Ke Wang12 , Dongling Zou13 , Hongqin Zhao14 , Chunyan

domized 2:1 to niraparib or placebo after CR/PR to 1 L CT. The study

Wang15 , Weiguo Lu16 , An Lin17 , Ge Lou18 , Guiling Li19 , Pengpeng

aimed to recruit 381 patients. Patients in the niraparib arm received

Qu20 , Hongying Yang21 , Xiaoa Zhen22 , Wenzhao Hang23 , Jianmei

200 mg once daily, except patients with baseline body weight ≥77

Hou23 , Ashish Banerjee24 , Lingying Wu1

kg and platelet count ≥150,000/μl who received 300 mg once daily.

1 National

Cancer Center/National Clinical Research Center for Can-

Patients were stratified by germline BRCA (gBRCA) status, tumour

cer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking

homologous recombination deficiency/proficiency (HRd/HRp) status,

Union Medical College, Beijing, China

neoadjuvant chemotherapy, and best response to 1 L CT. Primary

2 Cancer hospital of the University of Chinese Academy of Sciences (Zhejiang

endpoint was progression-free survival (PFS); secondary endpoint

Cancer Hospital), Hangzhou, China

included overall survival (OS). All efficacy outcomes were analysed

3 West

based on the intention-to-treat population.

China Second University Hospital, Key Laboratory of Birth Defects

and Related Diseases of Women and Children, Ministry of Education,

Results: Of 384 randomized patients (niraparib, n = 255; placebo,

Sichuan University, Chengdu, China

n = 129), 125 (32.6%) were gBRCA-mutated and 257 (66.9%) were

4 Hunan

HRd. Median follow-up was 27.5 months. Median PFS was signifi-

Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School

of Medicine, Central South University, Changsha, China

cantly longer in patients receiving niraparib compared with placebo

5 Peking

(24.8 vs 8.3 months; HR 0.45; 95% CI 0.34–0.60; P < 0.001).

Union Medical College Hospital, Chinese Academy of Medical

Sciences and Peking Union Medical College, Beijing, China

Treatment benefit was demonstrated in HRd-subgroup (HR 0.48;

6 Qilu Hospital of Shandong University, Jinan, China

95% CI 0.34–0.68; P < 0.001) and HRp-subgroup (HR 0.41; 95%

7 Peking University Cancer Hospital & Institute, Beijing, China

CI 0.25–0.65; P < 0.001) subgroups. OS data was immature (HR

8 Sun Yat-sen University Cancer Center, Guangzhou, China

0.63; 95% CI 0.38–1.03; P = 0.061). The most common grade

9 Fudan University Shanghai Cancer Center, Shanghai, China

≥3 adverse events in the niraparib arm were anaemia (18.0%),

10 Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospi-

neutrophil count decreased (17.3%) and platelet count decreased

tal), Zhengzhou, China

(14.1%).
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Conclusions: This phase 3 study is the first to confirm the efficacy and

15 Merck & Co., Inc., Rahway, NJ, USA

safety of niraparib in Chinese patients with advanced OC. Niraparib

16 Barts Cancer Institute, Centre for Experimental Cancer Medicine, London,

resulted in a clinically meaningful and significant PFS improvement

UK

over placebo, regardless of biomarker status. Niraparib was well

17 International

tolerated, and no new safety signals were identified.

Barcelona, Spain and Vall d’Hebron Institute of Oncology, Barcelona, Spain,

Breast Cancer Center (IBCC), Quiron Group, Madrid and

Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences,
1. This work was previously presented at Society of Gynaecologic

Department of Medicine, Madrid, Spain

Oncology, March 2022; submitted with permission and on behalf of
the original authors. The study was funded Zai Lab (Shanghai) Co.

Aims: In the phase 3 KEYNOTE-355 trial (NCT02819518),

Ltd. This work was also partially supported by the National Major

pembrolizumab+chemotherapy significantly improved OS and PFS

Scientific and Technological Special Project for ‘Significant New

versus placebo+chemotherapy in patients with previously untreated

Drugs Development’ in 2020, China [grant number 2020ZX09101

locally recurrent inoperable/metastatic TNBC with PD-L1 combined

014]. ClinicalTrials.gov identifier: NCT03709316 Third-party med-

positive score (CPS) ≥10.1,2 There were no significant differences

ical writing support: Writing and editorial support, funded by

between treatment groups in the CPS ≥1 population, and significance

GlaxoSmithKline and coordinated by Rebecca Crawford, PhD, of

was not tested in the ITT population due to the prespecified testing

GlaxoSmithKline, was provided by Sanuji Gajamange, PhD, and

strategy. Here, we compare outcomes in subgroups of patients by

Joyce Lee, PhD, of Meditech Media (Sydney, Australia), part of

additional CPS cut-offs to the primary results of KEYNOTE-355.

Nucleus Global.

Methods: Eligible patients with measurable disease per RECIST
v1.1, ECOG PS 0‒1, and ≥6-month disease-free interval were randomized 2:1 to pembrolizumab+chemotherapy (nab-paclitaxel; pacli-
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Pembrolizumab+Chemotherapy vs

taxel; or gemcitabine+carboplatin) or placebo+chemotherapy for up

Placebo+Chemotherapy by PD-L1 Combined Positive Scores 1–9,

to 35 administrations of pembrolizumab/placebo or until progres-

10–19, and ≥20 for Previously Untreated Locally Recurrent

sion/intolerable toxicity. Dual primary endpoints were OS and PFS

Inoperable or Metastatic Triple-Negative Breast Cancer:

(RECIST v1.1, BICR) in patients with PD-L1–positive tumours (CPS ≥10

KEYNOTE-355 Subgroup Analysis

and ≥1) and in the ITT population.
Results: Eight hundred and forty-seven patients were randomized.

Sherene Loi1 , David W. Cescon2 , Hope S. Rugo3 , Zbigniew Nowecki4 ,

Median time from randomization to data cutoff (15th June 2021) was

Seock-Ah Im5 , Mastura Md Yusof6 , Carlos Gallardo7 , Oleg Lipatov8 ,

44 months. Baseline characteristics of the CPS 1‒9, 10‒19, and ≥20

Carlos Henrique Barrios9 , Jose Perez-Garcia10 , Hiroji Iwata11 ,

subgroups were generally similar to those of the ITT population. In

Norikazu Masuda12 , Marco Torregroza Otero13 , Erhan Gokmen14 ,

the primary analyses, HRs (95% CI) for OS were 0.73 (0.55‒0.95) in

Zifang Guo15 , Xuan Zhou15 , Vassiliki Karantza15 , Wilbur Pan15 , Peter

the CPS ≥10 subgroup, 0.86 (0.72‒1.04) in the CPS ≥1 subgroup, and

Schmid16 , Javier Cortes17 , Julia Douglas

0.89 (0.76‒1.05) in the ITT population; HRs (95% CI) for PFS were

1 Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne,

0.66 (0.50‒0.88), 0.75 (0.62‒0.91), and 0.82 (0.70‒0.98), respectively.

Australia; The Sir Peter MacCallum Department of Medical Oncology,

HRs (95% CI) for the additional CPS subgroups were, for OS: CPS

University of Melbourne, Parkville, Australia

1‒9, 1.09 (0.85‒1.40); CPS 10‒19, 0.71 (0.46‒1.09); and CPS ≥20, 0.72

2 Princess

(0.51‒1.01); and for PFS: CPS 1‒9, 0.85 (0.65‒1.11); CPS 10‒19, 0.70

Margaret Cancer Centre, University of Toronto, Toronto, Ontario,

(0.44‒1.09); and CPS ≥20, and 0.62 (0.44‒0.88).

Canada
3 University

of California San Francisco Comprehensive Cancer Center, San

Conclusions: These results provide support that CPS ≥10 is a

Francisco, CA, USA

reasonable cut-off to define the population of patients with

4 Maria

metastatic TNBC expected to derive treatment benefit from

Sklodowska-Curie Memorial Cancer Centre and Institute of Oncol-

ogy, Warsaw, Poland

pembrolizumab+chemotherapy.

5 Seoul National University Hospital, Seoul, Republic of Korea
6 Cancer Center at Pantai Hospital, Kuala Lumpur, Malaysia
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7 Arturo Lopez Perez Foundation, Santiago, Chile
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8 Republican
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Russian Federation

218
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10 International

(dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the

Breast Cancer Center (IBCC), Quiron Group, Barcelona,
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11 Department
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Max Shub12 , Jon Emery1,2
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1 Centre for Cancer Research, University of Melbourne, Melbourne, Victoria,

14 GSK, Waltham, Massachusetts, USA
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16 Department
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of Medicine, British Columbia Cancer, Vancouver Centre,

University of British Columbia, Vancouver, Canada

3 Melbourne

of General Practice, University of Melbourne, Melbourne,

School of Population and Global Health, University of Mel-

bourne, Melbourne, Victoria, Australia
Aims: Dostarlimab is a PD-1 inhibitor approved provisionally in Aus-

4 Colorectal

tralia as monotherapy for patients with dMMR A/R EC that has

bourne, Victoria, Australia

progressed on/after a platinum-containing regimen. Efficacy and safety

5 Murdoch Children’s Research Institute, Melbourne, Victoria, Australia

in two expansion cohorts of the multicenter, open-label, single-arm

6 School of Population Health, University of New South Wales, Sydney, New

Phase I GARNET trial are reported (third interim analysis).

South Wales, Australia

Methods: Patients with A/R EC were assigned to Cohort A1

7 Wolfson

(dMMR/MSI-H) or A2 (MMRp/MSS); receiving dostarlimab 500

London, United Kingdom

mg IV Q3W X4, then 1000 mg Q6W until disease progression, discon-

8 Primary Health Care, School of Public Health, University of Sydney, Sydney,

tinuation, or withdrawal. Primary endpoints were ORR and DOR by

NSW, Australia

blinded independent central review (RECIST v1.1).

9 Early Detection and Immunisation, Prevention Department, Cancer Coun-

Results: One hundred and fifty-three dMMR/MSI-H and 161

cil Victoria, Melbourne, Victoria, Australia

MMRp/MSS patients were enrolled/dosed; 143 and 156 patients

10 Cancer Institute of New South Wales, Sydney, New South Wales, Australia

were in the efficacy-evaluable population, respectively (measurable

11 Belmore Road Medical Centre, Melbourne, Victoria, Australia

disease at baseline; ≥6 months follow-up). ORRs (95% CI) were 45.5%

12 PC4

(37.1–54.0; dMMR/MSI-H) and 15.4% (10.1–22.0; MMRp/MSS).

bourne, Victoria, Australia

Medicine and Genetics, The Royal Melbourne Hospital, Mel-

Institute of Population Health, Queen Mary London University,

Joint Community Advisory Group, University of Melbourne, Mel-

Median (m) DOR (95% CI) was not reached (NR) (1.18+ to 47.21+;
dMMR/MSI-H) and 19.4 months (2.80–47.18+; MMRp/MSS). 6-, 9-,

Background: Australian guidelines recommend that all people aged

and 12-month PFS was 49.5%, 48.0%, and 46.4% in dMMR/MSI-H

50–70 years old consider taking aspirin for 2.5–5 years to reduce their

EC and 35.8%, 31.3%, and 29.4% in MMRp/MSS EC, respectively.

risk of colorectal cancer (CRC). (1) This trial, SITA, is a randomised
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controlled trial with general practice patients that aims to test the effi-

and pre-surgery time points. Univariate and multivariate analyses were

cacy of a health consultation and use of a sex-specific decision aid, to

performed to determine the influence of these parameters on overall

present the benefits and harms of taking low dose aspirin, on two co-

survival (OS), recurrence free survival (RFS) and rates of pathological

primary outcomes including informed decision-making at one-month

complete response (pCR).

and uptake of aspirin at 6 months.

Ninety-five patients were included, with median age of 68. Baseline

Methods: Patients who weren’t currently taking aspirin were invited

NLR of ≥2 was associated with reduced RFS (HR 3.72, 95% CI 1.31–

to participate in the trial. Participants were talked through either a

10.5, p < 0.01) and OS (HR 2.28, 95% CI 1.02–5.13, p = 0.04). For

decision aid or the control brochure before their GP appointments.

patients who had a pCR, the mean baseline NLR was 2.1 compared

We used multiple imputation to handle the missing trial data for the

to 3.1 in those without a pCR (p < 0.01). A sustained NLR of ≥2 after

co-primary outcomes and present the complete case analysis as a

neoadjuvant treatment was associated with reduced OS (HR 1.4, 95%

sensitivity analysis.

CI 1.01–2.05, p = 0.04) and trended towards association with reduced

Results: Two hundred and sixty-one participants (87% of eligible

RFS (HR 1.4, 95%CI 0.99–2.13, p = 0.051). Baseline and post-treatment

patients) were randomised (129 intervention, 132 control). Baseline

PLR, albumin and BMI as well as their dynamic changes were not

characteristics were balanced between the control and intervention

associated with RFS or OS.

groups. For informed choice at one-month the odds were 2.42 (0.92–

We have demonstrated that a baseline NLR ≥2 is associated with worse

6.36) p = 0.040. There was a 10.9% absolute increase in informed

RFS, OS and response. PLR, albumin and BMI or their post-treatment

choice at 1 month in the intervention group for the complete case

changes were not shown to predict survival outcomes.

analysis [OR 2.76 (1.03–7.42) p = 0.021], (113 intervention, 118 control). The odds were 0.72 (0.29–1.77) p = 0.408, for aspirin uptake at 6
months. A -4.1% difference between the groups for the complete case

221

Incidence of NTRK fusions in non-small cell lung cancer

analysis [OR 0.71 (0.29–1.77) p = 0.417], (intervention 118, control
Jared Mathai1 , Abdelaziz Sammour1 , Khashayar Asadi1 , Sagun

116).
Conclusion: A decision aid, presenting the aspirin guidelines increased

Parakh1

informed choice but there was no difference in aspirin uptake between

1 Austin Health, Heidelberg, VIC, Australia

the intervention and control groups. As participants in both study
groups were taking aspirin over time, there was contamination as this

Introduction: Treatments targeting oncogenic drivers have demon-

was an individually randomised trial and the control group was an

strated high response rates and improved outcomes in a variety of

active control.

tumour types. Neurotrophic tropomyosin receptor kinase (NTRK) rearrangements have been described in most solid tumours however, the
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Haematological and nutritional prognostic markers for

patients receiving CROSS
Nicholas McNamee1 , Udit Nindra2 , Adel Shahnam1 , Robert Yoon2 ,
Ray Asghari3 , Weng Ng2 , Deme Karikios4 , Mark Wong1
1 Westmead Hospital, Sydney, NSW, Australia
2 Liverpool Hospital, Sydney, NSW, Australia
3 Bankstown-Lidcombe Hospital, Sydney, NSW, Australia
4 Nepean Hospital, Sydney, NSW, Australia

Neoadjuvant carboplatin and paclitaxel with radiotherapy (CROSS) is
widely used for gastro-oesophageal junction (GOJ) and oesophageal
cancers (OC), but validated prognostic markers are lacking. Dynamic
haematological and nutritional markers have been evaluated for their
predictive value. This study evaluates dynamic neutrophil-lymphocyte
ratios (NLR), platelet-lymphocyte ratios (PLR), albumin and body mass
index (BMI) as predictors of survival outcomes and response.
In this multi-centre retrospective observational study across five hospitals in Sydney, patients treated with CROSS were identified from
2015 to 2021. Haematological results and BMI were recorded prior to
treatment and pre-operatively. An NLR of ≥2 and a PLR of ≥200 was
used to stratify patients into high and low groups. Sustained NLR or
PLR was defined as patients who had high values at both pre-treatment

frequency in non-small cell lung cancer (NSCLC) is not well established.
Methods: This is a retrospective, single-site study in which archival
tissue from histologically diagnosed NSCLC between 2018 and 2020
was screened by immunohistochemistry (IHC) for NTRK rearrangements using the VENTANA® pan-TRK (EPR17341) assay. IHC-positive
or equivocal cases were confirmed by Fluorescent in-situ Hybridisation
(FISH). Correlative clinicopathologic parameters were also collected.
Results: Analysis of 289 samples was undertaken. For the entire
cohort, the median age was 70.9 years (range 35–93 years) with 42%
female and 77% smokers. Majority of patients had stage IV disease
(83%) and tumours of adenocarcinoma histology (69%). Of the 289
samples analysed, nine (3%) samples were IHC-positive and sent for
FISH analysis. Of the nine cases the median age of patients was 74.9
years (range 44–88 years), 33% female and 71% smokers. Six (75%)
cases had adenocarcinoma histology, and one each were of squamous
cell carcinoma, large-cell neuroendocrine and NOS histologies respectively. PDL1 expression was <50% in 78% (7/9) cases. Concurrent
mutations were detected in 44% (4/9) cases, including EGFR mutations
and MET amplification. In 8/9 cases staining was cytoplasmic, with one
case demonstrating paranuclear dot-like staining. Confirmatory FISH
analysis is underway.
Conclusion: NTRK fusions were not uncommon and detected in all
NSCLC histologies as well as with concurrent mutations.
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Checkpoint inhibitor immunotherapy-induced radiation

recall pneumonitis: A case series

1 Macarthur Cancer Therapy Centre, Campbelltown, NSW, Australia
2 Macquarie University, North Ryde, NSW, Australia
3 Royal Hobart Hospital, Hobart, Tasmania, Australia

Andrew O. Parsonson2,1 , John J. Park2,3 , Deme Karikios3,4 , Annette

4 Crown Princess Mary Cancer Centre, Westmead, NS , Australia

Tognela1,5 , Howard Gurney2,6 , Tim Wang4,6 , Dhanusha Sabanathan2,3

5 University of Sydney, Camperdown, NSW, Australia

1 Department

6 Nepean Cancer Care Centre, Penrith, NSW, Australia

of Medical Oncology, Macarthur Cancer Therapy Centre,

Campbelltown, NSW, Australia
2 Clinical

Trials Unit, Macquarie University Hospital, Macquarie University,

Background: Using estimated scenarios for survival to explain life

NSW, Australia

expectancy to patients conveys more meaning and hope than single

3 Department

point estimates of the median overall survival.1

of Medical Oncology, Nepean Cancer Care Centre, Penrith,

NSW, Australia

Aim: To assess whether using simple multiples of median survival

4 University of Sydney, Camperdown, NSW, Australia

could accurately assess scenarios for survival for patients with oestro-

5 Western Sydney University, Campbelltown, NSW, Australia

gen receptor (ER) positive, metastatic breast cancer (MBC) starting

6 Crown Princess Mary Cancer Centre, Westmead, NSW, Australia

endocrine therapy (ET).
Methods: We systematically searched for randomised trials of ET for

Introduction: Radiation Recall Pneumonitis (RRP) is a clinical syn-

ER positive MBC. We then recorded the following percentiles (repre-

drome that describes the development of focal pneumonitis in a

sentative scenarios) from each overall survival (OS) curve: 90th (worst-

previously irradiated field, triggered by systemic therapy months after

case), 75th (lower-typical), 50th (median) 25th (upper-typical), and

completion of radiation therapy. We present three cases of checkpoint

10th (best-case). The accuracy of estimating these percentiles for each

inhibitor immunotherapy-induced RRP.

OS curve was assessed by multiplying its median by four simple multi-

Case presentations: Our first patient, diagnosed with metastatic

ples: 0.25 (to estimate the 90th percentile), 0.5 (75th), 2 (25th) and 3

non-small cell carcinoma, received palliative radiation therapy to his

(10th). Estimates were deemed accurate if within 0.75–1.33 times the

lung and thoracic spine. He developed RRP after seven cycles of

actual value.

pembrolizumab, approximately six months after completing palliative

Results: We identified 24 trials with 10,068 patients. The median

radiation therapy. Our second patient with metastatic triple nega-

OS (interquartile range [IQR]) was: 61.3 months (53.4–64.8) for first-

tive breast cancer developed RRP following two cycles of treatment

line ET with cyclin-dependant kinase 4/6 inhibitors (CDK4/6i) (four

with pembrolizumab, nab-paclitaxel and a novel ILT3 inhibitor. She had

treatment groups); 42.6 months (40.9–50.4) for first-line ET alone (22

received palliative radiotherapy to an axillary lymph node recurrence

treatment groups) and 29.2 months (24.8–33.4) for subsequent line

two months prior to commencing systemic therapy. Our third patient

ET (21 treatment groups). The median OS (IQR) for each scenario for

was diagnosed with metastatic Hurtle cell thyroid carcinoma and had

first-line ET with CDK4/6i was: worst-case 17.4 months (13.8–20.7);

received palliative radiotherapy to a left rib metastasis, two months

lower-typical 32.5 months (29.3–34.9); upper-typical and best-case

prior to commencing a novel PD-L1 checkpoint inhibitor. All three

percentiles were not available. Simple multiples of the median OS

patients were treated by temporarily withholding treatment and a

accurately estimated the 90th percentile in 79%; 75th percentile

course of oral corticosteroids, with clinical resolution of RRP and were

in 93%; and 25th percentile in 76% of curves. The 10th percentile

able to be rechallenged with checkpoint inhibitor immunotherapy.

was only available for four OS curves and could not be accurately

Discussion: RRP is a distinct clinical phenomenon that can occur with

assessed.

palliative doses of radiotherapy and small treated lung volumes, that

Conclusion: Using simple multiples of the median OS to estimate and

are normally associated with a low risk of radiation induced lung injury.

explain survival times to patients with MBC starting ET, is accurate

Immunotherapy-induced RRP conforms to the prior radiation field and

and meaningful. Longer follow-up of trials is required to help clinicians

must be differentiated from diffuse checkpoint inhibitor immunother-

estimate the best-case scenario for these patients.

apy induced pneumonitis, as well as local processes such as pneumonia. As indications for the use checkpoint inhibitor immunotherapy

1. Kiely BE, McCaughan G, Christodoulou S, et al. Using scenarios

increase in cancer care, it is likely that immunotherapy-induced RRP

to explain life expectancy in advanced cancer: attitudes of people

will increase in incidence. Early diagnosis and management may allow

with a cancer experience. Support Care Cancer 2013; 21: 369–376.

for the continuation of systemic therapy. Further research is required

2012/06/22. DOI: 10.1007/s00520-012-1526-4.

to understand the mechanisms that lead to this rare form of RRP.
225
223

Beyond the Median: Estimating survival times for patients

starting endocrine therapy for oestrogen receptor positive

Patterns of first site of recurrence in patients treated

with Merkel cell carcinoma: The Westmead hospital experience,
Sydney

metastatic breast cancer
ishaan Pillay1
Andrew O. Parsonson1,2 , Sunit Sarkar3 , Lauren Brown4 , Belinda E.
Kiely1,5 , Anuradha Vasista5,6

1 Radiation Oncology, Westmead Hospital, Westmead, NSW, Australia
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Aims: To investigate patterns of recurrence in Merkel cell carcinoma

tool for randomised trials (RoB 2) was used to assess study risk of

(MCC) to guide future recommendations on surveillance imaging,

bias and overall quality of the evidence was assessed using the GRADE

especially in detecting early asymptomatic distant recurrence.

approach. Meta-analyses were performed to evaluate the effect of

Methods: Review of a prospective database of 267 patients diag-

exercise on pain and pain-associated symptoms. Planned subgroup

nosed with MCC between 1980 and 2019 at Westmead hospital,

analyses were performed to assess the potential for effect modification

Sydney. All patients were treated with curative intent most often with

on exercise-related (mode, intervention duration, degree of supervi-

a combination of surgery and radiotherapy. Data on patient demo-

sion), and patient-related (type of pain, cancer type, stage of treatment)

graphics, clinical details, tumour characteristics was obtained including

features. The protocol for this review was prospectively registered on

tumour size, location, recurrence and treatment. Descriptive analysis

PROSPERO (CRD42021266826).

was performed using SPSS Statistics 25 software.

Results: Sixty studies, with a total of 4908 participants, were included

Results: One hundred and twenty-nine patients (48%) developed

in this review. Most studies were conducted in women with breast

recurrence with a median duration from diagnosis to first recur-

cancer (n = 28 studies), followed by prostate cancer (n = 7 studies).

rence of 7.6 months. The most frequent first site of recurrence was

The meta-analysis of exercise compared to non-exercise or usual care

regional (42%), followed by distant (36%), local (16%), and locoregional

groups at the last follow-up revealed a reduction in pain favouring

(5%). The most common sites of distant recurrence were cutaneous

the exercise group (standardised mean difference (SMD) −0.43; 95%

(29%) and distant (non-regional) lymph nodes (27%). The liver was

confidence interval (CI): −0.60, −0.27), as well as for intensity of neu-

the most frequent site of visceral metastatic disease (20%), and brain

ropathic symptoms (SMD −0.53; 95% CI: −0.98, −0.08) and for pain

and lung metastases were infrequent. Patients with unknown primary

interference (SMD −0.38; 95% CI: −0.66, −0.10). For most of the

had the highest rate of developing distant relapse (69%) as the first

subgroup analyses (96%), the direction of the exercise effect was con-

site of recurrence followed by upper limb primaries (47%). 59% of

sistent and favoured exercise, with effect sizes ranging from small to

immunocompromised patients developed relapse.

large (effect size range: −0.01 to −1.36).

Conclusions: Following treatment MCC can metastasise to any site

Conclusions: Findings support the use of exercise therapy to manage

with certain sites having a greater predilection than others. PET scan

cancer-related pain for the wider cancer population, irrespective of

imaging is considered best practice for detecting early asymptomatic

exercise mode, length of intervention, degree of supervision, stage of

recurrence. Higher risk patients, such as node positive or immuno-

cancer treatment, or type of pain.

suppressed patients, may benefit from more frequent regular follow
imaging. The benefit of initiating systemic immunotherapy in asymptomatic patients with recurrence remains unknown but may improve
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outcome.

carcinoma (UC) who received avelumab first-line (1 L)

Long-term outcomes in patients with advanced urothelial

maintenance with or without second-line (2 L) treatment:
Exploratory analyses from JAVELIN Bladder 100
226

The effect of exercise on cancer-related pain: A

systematic review with meta-analysis

Joaquim Bellmunt1 , Thomas Powles2 , Miguel A. Climent Duran3 ,
Srikala S. Sridhar4 , Howard Gurney5 , David W. Pook6 , Nuno Costa7 ,

Melanie L. Plinsinga1 , Ben Singh2 , Grace L. Rose3 , Briana Clifford3,4 ,

Alessandra di Pietro8 , Bo Huang9 , Shilpa Gupta10 , Petros Grivas11

Tom Bailey3 , Rosa R. Spence1 , Michel W. Coppieters1 , Alexandra L.
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McCarthy3 , Sandi C. Hayes1
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2 Allied
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Health and Human Performance, Alliance for Research in Exer-

cise, Nutrition and Activity, University of South Australia, Adelaide, South

4 Princess

Australia, Australia

Ontario, Canada

3 School

5 Department of Clinical Medicine, Macquarie University, Sydney, New South

of Nursing, Midwifery and Social Work, The University of Queens-

Margaret Cancer Centre, University Health Network, Toronto,

land and Mater Hospitals Brisbane, Brisbane, Queensland, Australia

Wales, Australia

4 School

6 Oncology Department, Monash Health, Melbourne, Victoria, Australia

of Health Sciences, University of New South Wales, Sydney, New

South Wales, Australia

7 Pfizer, Porto Salvo, Portugal
8 Pfizer srl, Milano, Italy

Aims: To evaluate the effect of exercise interventions on cancer-

9 Pfizer, Groton, Connecticut, USA

related pain among people with cancer.

10 Department

Methods: An electronic search was undertaken for exercise stud-

Cleveland, Ohio, USA

ies measuring pain in people with cancer that were published up to

11 University

September 2021. All stages of screening and data extraction were con-

Seattle Cancer Care Alliance, Seattle, Washington, USA

ducted independently by two researchers. The Cochrane risk-of-bias

of Hematology and Medical Oncology, Cleveland Clinic,

of Washington, Fred Hutchinson Cancer Research Center,
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Aims: In the phase 3 JAVELIN Bladder 100 trial (NCT02603432),

2 University

avelumab 1 L maintenance + best supportive care (BSC) signif-

Seattle Cancer Care Alliance, Seattle, Washington, USA

icantly prolonged overall survival (OS) vs BSC alone in patients

3 Gustave Roussy, INSERMU981, Université Paris-Saclay, Villejuif, France

with advanced UC that had not progressed with 1 L platinum-

4 Department

based chemotherapy. Data on outcomes in patients who receive 2

Harvard Medical School, Boston, Massachusetts, USA

L treatment after avelumab 1 L maintenance are limited. We report

5 Oncology Department, Monash Health, Melbourne, Victoria, Australia

exploratory analyses of outcomes in patients enrolled in the avelumab

6 Pfizer, Cambridge, Massachusetts, USA

+ BSC arm of JAVELIN Bladder 100 based on receipt of 2 L treat-

7 Pfizer, New York, USA

ment administered by investigators after discontinuation of study

8 Pfizer srl, Milano, Italy

treatment.

9 Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary

Methods: Eligible patients had unresectable locally advanced or

University of London, St Bartholomew’s Hospital, London, UK

metastatic UC without progression with 4–6 cycles of 1 L platinum-

10 Princess

based chemotherapy. Patients were randomized 1:1 to receive

Ontario, Canada

of Washington, Fred Hutchinson Cancer Research Center,

of Medical Oncology, Beth Israel Deaconess Medical Center,

Margaret Cancer Center, University Health Network, Toronto,

avelumab + BSC or BSC alone.
Results: In the avelumab + BSC arm (n = 350), median follow-up

Aims: In the phase 3 JAVELIN Bladder 100 trial (NCT02603432),

(data cutoff, June 4, 2021) was 38.0 months. One hundred and eighty-

patients with aUC that had not progressed with 1 L platinum-

five patients (52.9%) had discontinued avelumab 1 L maintenance

based chemotherapy had significantly prolonged overall survival and

treatment for any reason and received 2 L treatment, whereas 122

progression-free survival with avelumab 1 L maintenance + best sup-

(34.9%) had discontinued avelumab and did not receive 2 L treatment.

portive care (BSC) compared with BSC alone. Results led to avelumab

Median OS (95% CI) in these subgroups was 19.9 months (18.2–

1 L maintenance being approved worldwide and adopted into inter-

23.0) and 18.2 months (10.0–34.4), respectively. In 43 patients (12.3%)

national treatment guidelines as standard of care. Here, we report

still receiving avelumab, median treatment duration was 154.6 weeks

long-term data from patients with ≥12 months of avelumab 1 L

(range, 106.7–216.0). Among patients who received 2 L treatment,

maintenance treatment as part of the JAVELIN Bladder 100 trial.

median time from end of avelumab 1 L maintenance to start of 2 L

Methods: Eligible patients had unresectable locally advanced or

treatment was 1.35 months (range, 0.3–30.9) and median time from

metastatic UC that had not progressed with 1 L platinum-based

randomization to end of 2 L treatment was 11.7 months (95% CI,

chemotherapy. This analysis included patients randomized to receive

9.7–13.8). 2 L treatment comprised rechallenge with platinum-based

avelumab + BSC. Study treatment continued until confirmed progres-

chemotherapy in 75 patients (21.4%) or other 2 L treatment in 110

sion, unacceptable toxicity, or withdrawal of consent.

(31.4%), including 2 L anti–PD-(L)1 therapy in 11 (3.1%).

Results: After a median follow-up of 38.0 months in the avelumab arm

Conclusions: In this exploratory analysis from JAVELIN Bladder 100

(data cutoff June 4, 2021; ≥2 years in all patients), 118/350 patients

with extended follow-up, 185/307 patients (≈60%) who had discontin-

(33.7%) had received ≥12 months of treatment. Characteristics of

ued avelumab received 2 L treatment. Long-term OS was observed in

these patients were generally similar to those in the overall avelumab

patients who received avelumab 1 L maintenance with or without 2 L

arm. Among all treated patients in the overall avelumab arm (N = 344),

treatment.

grade ≥3 treatment-related adverse events (TRAEs) occurred in 67
(19.5%) and grade ≥3 immune-related AEs (irAEs) occurred in 26

1. This trial was sponsored by Pfizer as part of an alliance between

(7.6%). Among patients treated for ≥12 months (n = 118), grade ≥3

Pfizer and Merck (CrossRef Funder ID: 10.13039/100009945).

TRAEs occurred after ≥12 months in 14 (11.9%) and grade ≥3 irAEs

Medical writing support was provided by Jamie Ratcliffe of Clinical

occurred after ≥12 months in 5 (4.2%). Efficacy outcomes will be

Thinking and was funded by Pfizer and Merck.

presented.

2. © 2022 American Society of Clinical Oncology, Inc. Reused with

Conclusions: In the JAVELIN Bladder 100 trial, prolonged avelumab

permission. This abstract was accepted and previously presented at

1 L maintenance treatment was associated with a safety profile con-

the 2022 ASCO Annual Meeting. All rights reserved.

sistent with prior avelumab monotherapy studies, with no new safety
signals identified with longer treatment duration. These results further support the use of avelumab 1 L maintenance until progression
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Avelumab first-line (1 L) maintenance for advanced

urothelial carcinoma (aUC): Results from patients with ≥12

for patients with aUC that has not progressed with 1 L platinum-based
chemotherapy.

months of treatment in JAVELIN Bladder 100
1. Funding Statement: This trial was sponsored by Pfizer as part
Jeanny B. Aragon-Ching1 , Petros Grivas2 , Yohann Loriot3 , Joaquim

of an alliance between Pfizer and Merck (CrossRef Funder ID:

Bellmunt4 , David W. Pook5 , Jing Wang6 , Elisabete Michelon7 ,

10.13039/100009945). Medical writing support was provided by

Alessandra di Pietro8 , Thomas Powles9 , Srikala S. Sridhar10
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2. Previously presented at ESMO 2022, ‘FPN: 1760P’, ‘Jeanny B.
Aragon-Ching et al.’ – Reused with permission.

subgroup, 0.84 (0.596–1.188). HRs for PFS were: CR subgroup, 0.58
(0.410–0.817); PR subgroup, 0.47 (0.367–0.607); and SD subgroup,
0.59 (0.421–0.816). In the avelumab + BSC vs BSC alone arm, respectively, subsequent second-line anticancer drug therapy was received
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Avelumab first-line (1 L) maintenance for advanced

by: CR subgroup, 50.0% vs 74.2%; PR subgroup, 58.3% vs 71.8%; and

urothelial carcinoma (aUC): long-term outcomes from JAVELIN

SD subgroup, 46.4% vs 70.4%. Long-term safety was consistent across

Bladder 100 in subgroups defined by response to 1 L

subgroups.

chemotherapy

Conclusions: Long-term follow-up from JAVELIN Bladder 100 continues to show prolonged OS and PFS with avelumab + BSC vs BSC alone

Begoña P. Valderrama1 , Thomas Powles2 , Srikala S. Sridhar3 , Claudia

irrespective of response (CR, PR, or SD) to 1 L chemotherapy and

Caserta4 , Yohann Loriot5 , Shilpa Gupta6 , Joaquim Bellmunt7 , Cora N.

despite a higher proportion of patients in the BSC alone arm receiv-

Sternberg8 , David W. Pook9 , Jing Wang10 , Nuno Costa11 , Robert J.

ing subsequent therapy. These findings further support avelumab 1 L

Laliberte12 , Alessandra di Pietro13 , Se Hoon Park14 , Petros Grivas15

maintenance as standard of care for all patients with aUC that has not
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progressed with 1 L platinum-based chemotherapy.
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Chemotherapy response following immunotherapy in

metastatic head and neck cancer; a single-centre experience

9 Oncology Department, Monash Health, Melbourne, Victoria, Australia
10 Pfizer, Cambridge, Massachusetts, USA

Anthony Rodrigues1 , Jia Liu1,2,3 , Jennifer Lim1,4,5 , Venessa Chin1,2,4

11 Pfizer, Porto Salvo, Portugal

1 The

12 Pfizer, Cambridge, Massachusetts, USA

Australia

13 Pfizer srl, Milano, Italy

2 St

14 Sungkyunkwan University Samsung Medical Center, Seoul, Korea

NSW, Australia

15 University

3 The University of Sydney, Camperdown, NSW, Australia

of Washington, Fred Hutchinson Cancer Research Center,

Seattle Cancer Care Alliance, Seattle, Washington, USA

Kinghorn Cancer Centre – St Vincents NSW, Darlinghurst, NSW,

Vincent’s Clinical School, University of New South Wales, Darlinghurst,

4 The Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
5 St George Hospital, Kogarah, NSW, Australia

Aims: In the phase 3 JAVELIN Bladder 100 trial (NCT02603432),
avelumab 1 L maintenance + best supportive care (BSC) significantly

Aim: First-line check point inhibitors alone or in combination with

prolonged overall survival (OS) vs BSC alone in patients with aUC

chemotherapy in advanced head and neck squamous cell can-

that had not progressed with 1 L platinum-based chemotherapy. We

cer (HNSCC) improves OS without PFS benefit compared to

report exploratory analyses in subgroups defined by response to 1

first line chemotherapy with anti-EGFR therapy.1 We hypoth-

L chemotherapy (complete response [CR], partial response [PR], or

esise this may be due to immunotherapy improving responses

stable disease [SD]) after ≥2 years of follow-up.

to later line chemotherapy. The aim of this retrospective study

Methods: Eligible patients had unresectable locally advanced or

is to compare the sequencing of therapy and impact on disease

metastatic UC without progression with 4–6 cycles of 1 L gemcitabine

control rate (DCR) and duration in a cohort of advanced HNSCC

+ cisplatin or carboplatin. Patients were randomized 1:1 to receive

patients.

avelumab + BSC (n = 350) or BSC alone (n = 350), stratified by

Methodology: This single centre retrospective cohort study utilised an

best response to 1 L chemotherapy (CR/PR vs SD) and visceral vs

electronic database of advanced head and neck (HN) patients treated

nonvisceral disease at start of 1 L chemotherapy.

with immunotherapy (including on a clinical trial) from January 2017

Results: At data cutoff (June 4, 2021), median follow-up in both arms

to December 2021 at The Kinghorn Cancer Centre, St Vincent’s Hos-

was ≥38 months. OS and PFS were longer in the avelumab + BSC vs

pital. Salivary gland and paranasal sinus tumours were excluded. Data

BSC alone arm in all subgroups. HRs for OS (95% CI) were: CR sub-

captured included age, sex, tumour location, histology, stage, prior

group, 0.72 (0.482–1.076); PR subgroup, 0.70 (0.541–0.914); and SD

curative treatment, subsequent treatment type, duration of treat-
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ments, and best responses as per clinician. Survival data was analysed

1 Medical

with Kaplan-Meier method and processed with R-software (version

Medical Centre, Bedford Park, SA, Australia

4.2.1)

2 College

Results: From a total 197 head and neck cases, 39 patients were eligi-

SA, Australia

ble for inclusion. Thirty patients with advanced HNSCC were treated

3 Medical Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia

with immunotherapy in any line. Median age was 63 (range 34–73),

4 Gynaecology

85% were male, with mean 2.7 lines of therapy (range 1–7). Thirteen

tralia

patients received chemotherapy following immunotherapy with DCR

5 Gynaecology Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia

62%. This is in contrast historical ORR with first-line chemotherapy of

6 Department

20%–50%2–5 . There were no significant differences in PFS or OS by

SA, Australia

type of therapy in the 1st or 2nd line setting due to the small numbers.

7 Medical Oncology, Lyell McEwin Hospital, Elizabeth Vale, SA, Australia

Oncology, Flinders Centre for Innovation in Cancer, Flinders
of Medicine and Public Health, Flinders University, Bedford Park,

Oncology, Flinders Medical Centre, Bedford Park, SA, Aus-

of Adult Genetics, The Queen Elizabeth Hospital, Woodville,

Conclusion: Responses to chemotherapy after immunotherapy in
advanced HNSCC were higher than expected. The synergism of

Aims: All women with non-mucinous epithelial ovarian cancers should

chemotherapy and immunotherapy, and persistence of immunother-

be referred for genetic testing, particularly for BRCA1/2, to access

apy treatment effect despite discontinuation may influence

this,6

and

targeted therapy, identify those who may benefit from risk-reducing

further translational studies are warranted to explore mechanisms

surgery and predicting familial risks. This retrospective study aimed to

now that first-line immunotherapy is standard of care in advanced

determine the rate of germline and/or somatic BRCA testing in women

HNSCC.1

with high-grade serous ovarian cancer. Secondary outcomes were the
number of women with a germline or somatic only mutation, and to find

1. Burtness B, Harrington KJ, Greil R, et al. 2019. Pembrolizumab

characteristics associated with reduced testing.

alone or with chemotherapy versus cetuximab with chemotherapy

Methods: All adult women with high-grade serous ovarian cancer

for recurrent or metastatic squamous cell carcinoma of the head

discussed at the two South Australian gynaecology-oncology multidis-

and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

ciplinary meetings from January 2020 to June 2021 were included.

Lancet. 2019 Nov 23;394(10212):1915–1928.

Descriptive statistics were used for the primary outcome. Character-

2. Vermorken, J. B., R. Mesia, F. Rivera, et al. 2008. Platinum-based

istics were assessed for significance using chi-square or Fisher’s exact

chemotherapy plus cetuximab in head and neck cancer. N Engl J

test. Significant variables were further analysed with multivariable

Med 359(11):1116–1127.

logistic regression.

3. Forastiere, A. A., B. Metch, D. E. Schuller, et al. 1992. Randomized

Results: Of the 127 women included, 117 (92.1%) had germline test-

comparison of cisplatin plus fluorouracil and carboplatin plus fluo-

ing, 78 (61.4%) had somatic testing and seven (5.5%) had neither. Of

rouracil versus methotrexate in advanced squamous-cell carcinoma

the women who had germline testing, 17 (14.5%) had pathogenic vari-

of the head and neck: a Southwest Oncology Group study. J. Clin

ants and one with a germline mutation did not have a somatic mutation.

Oncol. 10(8):1245–1251.

Of the 103 women who were germline wild-type or were not tested,

4. Ferrari, D., J. Fiore, C. Codeca et al. 2009. A phase II study of car-

60 (58.3%) proceeded to have somatic testing. Of the women who had

boplatin and paclitaxel for recurrent or metastatic head and neck

somatic testing, 15 (19.2%) had pathogenic variants, 7 of which were

cancer. Anticancer Drugs 20(3):185–190.

somatic only mutations. Overall, 24 (18.9%) had either germline or

5. Moosmann, P., F. Egli, R. A. Stahel et al. 2003. Weekly pacli-

somatic pathogenic variants. Women who had surgery (OR 4.32, 95%

taxel and carboplatin combination chemotherapy in patients with

CI 1.15–16.22, p = 0.03) were more likely to have germline testing.

advanced squamous cell carcinoma of the head and neck. Onkologie

No characteristics resulted in statistically significant differences in the

26(6):568–572.

rates of somatic testing.

6. Kacew AJ, Harris EJ, Lorch JH, et al. 2020. Chemotherapy after

Conclusion: Quality improvement measures and a standardised

immune checkpoint blockade in patients with recurrent, metastatic

approach to testing is required to improve the uptake of testing in

squamous cell carcinoma of the head and neck. Oral Oncol. 2020

South Australia. Both somatic and germline testing are important due

Jun;105:104676.

to the risk of false negatives with somatic testing and the chance to
have a somatic only mutation.
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The uptake of germline and somatic BRCA mutation

testing in women with high grade serous ovarian cancer in the

233

public hospital system in South Australia

treated with definitive chemoradiation and durvalumab

Andry Santoso1 , Ganessan Kichenadasse1 , Sudarsha Selva-Nayagam2 ,

Adel Shahnam1 , Udit Nindra2 , Samuel x Stevens3 , Victoria Bray2 , Po

Shahid Ullah3 , Sellvakumaran Paramasivam4 , Emily Stevens4 , Martin

Yee Yip4 , Tamiem Adam5 , Jenny Lee3 , Michael Boyer3 , Steven Kao3 ,

Oehler5 , John Miller5 , Eryn Dow3,6 , Vineet Kwatra7

Patterns of care post progression for NSCLC patients

Adnan Nagrial1
1 Medical Oncology, Westmead Hospital, Sydney, NSW, Australia
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4 Department

3 Medical Oncology, Chris O’Brien Lifehouse, Sydney, NSW, Australia

New South Wales, Sydney, NSW, Australia
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5 Australian
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NSW, Australia

Aims: The standard of care for the treatment of unresectable locally

NSW, Australia

advanced patients with non-small cell lung cancer (NSCLC) is concur-

7 The University of Sydney, Faculty of Medicine and Health, Sydney School of

rent chemoradiotherapy followed by consolidation durvalumab for 12

Public Health, Sydney, NSW, Australia

6 Faculty

of Developmental Disability Neuropsychiatry, University of

Institute of Health Innovation, Macquarie University, Sydney,

of Medicine and Health, University of New South Wales, Sydney,

months. There is a paucity of data investigating the treatments and
outcomes of patients who have progressed post receiving durvalumab

Background: Recent Australian clinical practice guidelines recommend

thus our study aimed to describe the patterns of care in this population

that the assessment of melanoma risk should be integrated into skin

group.

cancer care provision. There is a need for research on how personal

Methods: This retrospective observation study across five cancers

risk information can be incorporated into skin cancer prevention and

centres in Sydney Australia included any patient with locally advanced

surveillance frequency advice.

unresectable NSCLC treated with chemoradiation and who received

Aim: To explore the acceptability and feasibility of personalised

at least one dose of durvalumab between January 2018 and Septem-

melanoma risk assessment and tailored patient education and skin

ber 2021. Progression free survival 1 (PFS1) was defined as the time of

surveillance within routine clinical care in the Melanoma Institute

diagnosis to the date of first progression and PFS2 was defined as date

Australia dermatology clinic.

of relapse to the time of second progression or death whichever came

Methods: This qualitative (semi-structured interviews and observa-

first. PFS was estimated using the Kaplan Meier method.

tions) study was informed by the Theoretical Framework of Accept-

Results: Ninety-nine patients were identified. Median age was 66,

ability (TFA). Personalised, systematic melanoma risk assessment was

majority were male (62%) and had a smoking history (82%). After

implemented at a skin-cancer focused dermatology clinic in February

median follow up of 25.6 month, 43 patients had progression corre-

2021. Observations were performed pre- and post-implementation in

sponding to a median PFS1 of 13.8 months. The most common site

the waiting room and during clinical consultations. Semi-structured

of relapse was thoracic (n = 24), CNS (n = 8), visceral (n = 6) and

interviews with patients and clinic staff explored their experi-

skeletal (n = 4). Of the 43 patients who progressed, 34 received sub-

ences of delivering or receiving personalised melanoma risk scores,

sequent therapy whilst eight were for best supportive care (BSC).

tailored surveillance schedules and skin cancer education. Observa-

Subsequent treatments included surgery (n = 2), radiotherapy (n = 6)

tional and interview data were analysed thematically using the TFA as

and systemic therapy (n = 26). The most utilized systemic therapy

a classifying framework.

was chemotherapy (n = 13) followed by targeted therapy (n = 9),

Results: Pre- and post-implementation observations were performed

immunotherapy (n = 3) and clinical trial (n = 1). The overall median

at the clinic from September 2020 to March 2021 (total of 37 h); 29

PFS2 was 7.2 months. Median PFS2 was 3.9 months for patients with

patients and 12 clinic staff were interviewed. We found that the deliv-

BSC, 5.2 months for patient receiving local therapy and 7.5 months for

ery of personalised melanoma risk scores did not impact on patient

patients treated systemically.

flow through the clinic. Dermatologists reported that the person-

Conclusion: NSCLC patients who progress post durvalumab have lim-

alised risk information enhanced their confidence in recommending

ited treatment options and overall poor prognosis highlighting an area

surveillance schedules and enabled improved identification of high-

of need for future research.

and low-risk groups. Most patients reported that the risk assessment
and tailored information was a beneficial addition to their care. Among
patients whose risk deviated from their expectations some reported

234

Acceptability and feasibility of personalised, systematic

feeling worried, particularly those at low risk who were recommended

melanoma risk assessment from the perspective of patients and

to decrease surveillance frequency.

clinic staff: a qualitative study

Conclusions: It is feasible and acceptable to patients and clinic staff to
calculate and deliver personalised melanoma risk information as part

Amelia K. Smit2,1,3 , Andrea L. Smith1 , Bela I. Laginha4 , Nehal Singh5 ,

of routine clinical care within dermatology clinics.

Frances Rapport5 , Bruna Gallo2 , Jeffrey Braithwaite5 , Linda Martin2,6 ,
Anne E. Cust7,2,1
1 Daffodil

Centre, The University of Sydney, a joint venture with Cancer

Council NSW, The University of Sydney, NSW, Australia
2 Melanoma
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First do no harm: Practical recommendations for harms

reporting in Exercise Oncology
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2 Kirby Institute, University of New South Wales, Sydney, New South Wales,

Aim: Markman’s desensitisation protocol allows successful retreat-

Australia

ment of patients who have significant paclitaxel hypersensitivity

3 Sport

reactions (PHR)1 . We assessed the rates of PHR using a modified Mark-

and Exercise Science, School of Health Science, Western Sydney

University, Sydney, NSW, Australia

man’s protocol in patients with gynaecological malignancies receiving
paclitaxel. By introducing this protocol, we aimed to reduce the risk and

Aims: Over the past two decades, the volume of high-quality evi-

severity of PHR and save time.

dence supporting exercise as being beneficial to cancer survivors has

Methods: We evaluated all patients receiving paclitaxel before

grown exponentially; however, the potential harms of exercise remain

(December 2018–September 2019) and after (October 2019–July

under-studied. Consequently, the trade-off between desirable versus

2020) the implementation of a modified Markman’s protocol. The

undesirable outcomes of engaging in exercise remains unclear to clini-

pre-implementation group received paclitaxel infused with a gradual

cians and survivors. Practical guidance on the collection and reporting

titration rate from 60 ml/h to 180 ml/h. The post-implementation

of harms in exercise oncology is lacking and the direct application of

group received paclitaxel infused via 3 fixed-dose infusion bags (Bag 1:

existing guidelines from other settings (e.g., pharmacological) is inap-

paclitaxel 2 mg in 100 ml saline over 30 min, Bag 2: paclitaxel 10 mg in

propriate. We present the harms reporting protocol developed by

100 ml saline over 30 min, Bag 3: remainder of paclitaxel dose in 500

the ihop research group and refined through exercise-oncology trials

ml saline over 3 h) in the first two cycles. Rates of PHR were compared.

since 2015.

The cost was also compared.

Methods: The ihop exercise-oncology harms protocol was guided by

Results: A total of 426 paclitaxel infusions were administered to 78

national and international guidelines for harms reporting in clinical

patients. Median age was 64 years (range 34–81), and most had ovar-

trials involving therapeutic goods or medical devices, and modified to

ian cancer (49%, n = 38/78). The rate of PHR was 8% (n = 16/195)

ensure applicability to exercise. The protocol has been refined through

versus 9% (n = 20/231) before and after implementation (p = 0.87).

an iterative process of implementation and adjustment through use

Most PHR occurred within the first 30 min in both groups (pre- vs post-

in multiple exercise-oncology trials involving varied cancer types

implementation, 88% [n = 14/16] vs 75% [n = 15/20]; p = 0.45), and

(breast, brain, gynaecological) and stages (I–IV; primary/recurrent

were Grade 2 in severity (pre- vs post-implementation, 81% [n = 13/16]

diagnoses), and heterogeneous exercise intervention character-

vs 75% [n = 15/20]; p = 0.37). There was one Grade 3 PHR in

istics

supervised/unsupervised

pre-implementation group. All patients were successfully rechallenged

exercise).

in the post-implementation group compared to 81% (n = 13/16) in

Results: The ihop harms protocol involves: Step 1 – Monitor occur-

pre-implementation group (p = 0.43). The modified Markman’s pro-

rence of adverse events (AEs) through systematic (i.e., standardised

tocol cost at least $100/cycle more for the first two cycles than the

checklists or tests) and non-systematic (i.e., ‘have you experienced any

pre-implementation protocol.

undesirable events?’) surveillance; Step 2 and 3 – Assess and Record AEs,

Conclusion: The modified Markman’s desensitisation protocol as a pro-

including type (e.g., injury, treatment-related side-effect), causality

phylaxis measure did not reduce the PHR rate although all patients

(relationship of AE with exercise), severity (grade1–5), and impact

were successfully rechallenged.

(face-to-face/telehealth

delivery;

on intervention participation; Step 4 – Review of causality by harms
panel (and revision as necessary); and Step 5 – Analyse and Report,

1. Markman M et al, J Clin Oncol 2000 18:1, 102–102

including frequencies and details of all-cause and exercise-related
AEs.
Conclusions: Future research should refine standardised exercise-
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specific nomenclature, and validate methods of assessing causality.

hepatocellular carcinoma: a single centre real world experience

Atezolizumab and bevacizumab for advanced

Nonetheless, the ihop harms reporting protocol provides a foundation
from which to improve the quality of harms assessment and report-

Pei Ying Tan1 , Samuel Hui2,1 , Paul O’Neill2 , Anouk Dev2,1

ing immediately, while concurrently providing a framework for future

1 School of Clinical Sciences, Monash University, Clayton, Victoria, Australia

refinement.

2 Department of Gastroenterology and Hepatology, Monash Health, Clayton,

Victoria, Australia
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Rates of paclitaxel hypersensitivity reactions using a

modified Markman’s infusion protocol

Background: Atezolizumab, a program-death-ligand-1 inhibitor and
Bevacizumab, a vascular-endothelial-growth-factor inhibitor in combination (A+B), is now the standard first-line treatment for advanced

Rebecca Symons2,1 , Fiona Heath1 , Jennifer Duggan1 , Kim Tam Bui2,1 ,

hepatocellular carcinoma (HCC). The registration trial conducted

Lily Byun1 , Michael Friedlander2,1 , Yeh Chen Lee2,1

internationally reported a median overall-survival (OS) of 10.8-months

1 Royal Hospital for Women, Randwick, NSW, Australia

and a progression-free-survival (PFS) of 7.0-months. We aimed to

2 Prince of Wales Hospital, Randwick, NSW, Australia

document OS and PFS in an Australian population.
Methods: We conducted an observational study of patients with
advanced HCC treated with combination A+B from November 2020
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to August 2022 at a single tertiary centre. Primary outcomes were OS

adjuvant ICI. Seven patients underwent complete resection of radio-

and PFS. Treatment related adverse-events (AEs) including immune-

logically evident disease (of which four remain alive and disease-free)

related adverse-events (irAEs) were secondary outcomes.

and seven underwent systemic therapy. Of those patients who received

Results: Twenty-five patients were included (mean age 65 ± 14 years,

TT, seven experienced recurrences with three of these during adjuvant

males 88%). The median time on treatment was 10-months with the

treatment (42.9%). At a median follow-up of 27.2 months 12- and 24-

longest duration of 18-months. Treatment discontinuation resulted

month survival rates were 92.3 and 72.8% respectively in the overall

from progressive disease (n = 4), death ( = 2), and irAE (n = 2). The

population.

mean Child-Pugh Score was A5. 8% (n = 2) of patients were early-stage

Conclusion: Uptake of adjuvant therapies has been high and outcomes

Barcelona Clinic Liver Cancer (BCLC) A, 36% (n = 9) were intermediate-

in our unselected real-world population were comparable to published

stage (BCLC-B) and 56% (n = 14) were advanced-stage (BCLC-C). 84%

literature. Within the limitation of a small sample size, there was

underwent baseline endoscopic variceal assessment, of whom 40% had

a trend toward improved 24-month RFS with adjuvant ICI than TT,

varices.

though of those with recurrence this was more likely to occur during

At a median follow-up of 10-months, median OS was 10-months and

adjuvant treatment for those receiving ICI.

PFS was 7-months. IrAEs occurred in 36% including rash (16%), thyroiditis (8%), hypophysitis (4%), thrombocytopenia (4%) and colitis
(4%). Additionally, 8% experienced new-onset subclinical hypothy-
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roidism. 28% experienced proteinuria and 84% experienced hyperten-

(SUPER-ED): A stepped wedge cluster randomised controlled trial

sion.

implementing a Model of Care to support earlier diagnosis

Solving unknown primary cancer – Earlier diagnosis

Conclusion: Patients in our real world cohort demonstrated commensurate outcomes to the registration studies. About a third of patients

Penelope Schofield2,1 , Anna Ugalde3 , Richard Tothill4 , Steve Quinn1 ,

experienced irAEs, with 8% resulting in treatment discontinuation.

Hui Li Wong2 , Owen Prall2 , Catherine Mitchell2 , Nilmini

Hypertension and proteinuria were common side effects. Longer term

Wickramasinghe1 , Clare Fedele5 , Louisa Gordon6 , Sarah McLean2 ,

follow up is needed to confirm ongoing benefit.

Cindy Bryant7 , Hyun Ko2,4 , Tim Akhurst2 , Colin Wood2 , Desmond
Yip8 , Christopher Steer9 , Bo Gao10,11 , Nicholas Wilcken10,12 , Narayan
Karanth13 , Anna Kuchel14,15 , Chris S Karapetis16,17 , Louise Nott18 ,
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royal brisbane and women’s hospital
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Background: Both adjuvant targeted therapy (TT) and immune check

6 QIMR Berghofer, Brisbane, QLD, Australia

point inhibitors (ICI) have demonstrated improved recurrence-free

7 Carer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

survival (RFS) in resected melanoma. This study aimed to explore the

8 Canberra Hospital, Canberra, ACT, Australia

real-world impact of these treatments in an unselected population.

9 Border Medical Oncology, Albury, NSW, Australia

Methods: This retrospective cohort study included patients with

10 University of Sydney, Sydney, NSW, Australia

resected stage IIIB-IV melanoma, diagnosed between May 2018 and

11 Westmead Hospital, Sydney, NSW, Australia

December 2021 at Royal Brisbane and Women’s Hospital. Demo-

12 Westmead Hospital, Sydney, NSW, Australia

graphics, adjuvant therapy details, recurrence characteristics and

13 Royal Darwin Hospital, Darwin, NT, Australia

outcomes were recorded.

14 Royal Brisbane Women’s Hospital, Brisbane, QLD, Australia

Results: Sixty-eight patients with resected disease were included (57

15 University of Queensland, Brisbane, QLD, Australia

with stage III and 11 stage IV disease). BRAF mutation was identified

16 Flinders Medical Centre, Adelaide, SA, Australia

in 27 patients (39.7%). The majority received adjuvant ICI (n = 47,

17 Flinders University, Adelaide, SA, Australia

69%), with the remainder receiving TT (n = 16, 24%) or no therapy

18 Royal Hobart Hospital, Hobary, TAS, Australia

(n = 5, 7%). With a median follow-up of 22.1 months the 12- and

19 Launceston General Hospital, Launceston, TAS, Australia

24-month RFS was 70.4% and 53.2% respectively in the overall pop-

20 Southwest Healthcare, Warrnambool, VIC, Australia

ulation. Twenty-four-month RFS rate was higher with ICI (63.7%) than

21 Barwon Health, Geelong, VIC, Australia

TT (39.3%) though this difference did not reach statistical significance,

22 Alfred Health, Melbourne, VIC, Australia

HR 0.61 (95% CI 0.24–1.51, p = 0.30). Sixteen patients treated with

23 Bendigo Health, Bendigo, VIC, Australia

adjuvant ICI experienced recurrence with 12 (75%) recurring during

24 Eastern Health, Melbourne, VIC, Australia
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26 Monash University, Clayton, VIC, Australia

Victoria, Australia

27 Peninsula Health, Frankston, VIC, Australia

7 Department

of Pathology, Peter MacCallum Cancer Centre, Melbourne,
of Clinical Pathology, The University of Melbourne, Parkville,

Victoria, Australia
Background and Aims: Cancer of unknown primary encompasses a
diverse range of cancer types, whereby a metastatic lesion(s) is iden-

Introduction: Primary cutaneous CD4+ small/medium T-cell lympho-

tified but a primary tumour evades clinical detection. Not all patients

proliferative disorder (PCSMLPD) typically manifests as an indolent

with cancer of unknown primary in Australia receive a standardised

head/neck papule, frequently creating cosmetic concerns for patients.

workup and this may lead to prolonged time to diagnosis and poor

Optimal management is uncertain. Herein, we audit patient outcomes

patient experience. This trial, titled Solving Unknown Primary Cancer -

following three more commonly used management strategies: radio-

Earlier Diagnosis (SUPER-ED), aims to (1) standardise a Model of Care

therapy (RT), surgery and watchful-waiting. We also investigate the

that adopts a standardised diagnostic workup adapted from the Opti-

efficacy of ultra-low dose RT, which has not been previously studied in

mal Care Pathways, with an embedded care coordinator, access to a

patients with PCSMLPD.

virtual, national multidisciplinary meeting and an educational website

Methods: Eligibility required diagnosis of PCSMLPD, between 2007

and (2) implement this new Model of Care across a network of oncology

and 2022, confirmed on central pathological review. RT responses

services. This trial is funded from the Medical Research Future Fund.

were assessed: complete response (CR), less than CR, progressive dis-

Method: This is a stepped-wedge cluster randomised trial comparing a

ease (PD). Surgical excisions were classified: complete excision (CE)

control phase (standard practice) with an intervention phase. Fifteen

or incomplete excision (IE) using microscopic margins. Freedom from

sites will be grouped into three health service clusters. People who

relapse (FFR) was compared between modalities.

present with a malignancy of unknown origin, are over 18, are clinically

Results: Of 41 eligible patients, 19 received RT first-line, 17 underwent

appropriate to undergo diagnostic workup and able to consent will be

excision (three received adjuvant RT), and five chose watchful-waiting.

eligible to participate. A total of 288 patients will be enrolled.

Median follow-up was 37 (range 6–167) months.

The intervention is the new Model of Care and the primary end-

Overall, 24 patients received RT: 19 definitive first-line, three adjuvant

point is the time to completion of minimum diagnostic workup. Sec-

first-line, two second-line. RT dose was 4Gy in two fractions in 10 (42%)

ondary endpoints include: the primary tumour type diagnosed, clinical

patients, 20–40 Gy in 14 (58%). Following RT, 100% achieved CR at 6

trial participation rates, patient-reported physical, social and men-

months, with no relapses. No toxicities were reported following 4 Gy.

tal health, uncertainty and understanding. The implementation of the

Patients receiving surgery first-line (n = 14, three with positive mar-

Model of Care will be assessed for acceptability, adoption, feasibility

gins) had CE and IE rates of 65% and 35%, respectively. Four (23.5%)

and fidelity through semi-structured clinician interviews, engage-

patients experienced relapse (two local, two distant) at median 12

ment with the nurse coordinator, diagnostic workup and website

(range, 6–36) months post-excision.

analytics.

Four of five patients managed with watchful-waiting experienced

Progress: Ethical review is underway. This is a 4 year study and the

partial resolution post-biopsy; no complete resolution observed.

recruitment period is August 2023–March 2026.

Three-year FFR was 100% for RT-alone vs 61% for surgery (p = 0.12).
Conclusion: RT is a successful, non-invasive option for PCSMLPD
with 100% CR rate, no relapses, and numerically superior FFR com-
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Exploring treatment options for primary cutaneous CD4+

pared to surgery, in this cohort. Low-dose RT for PCSMLPD (4 Gy in

small/ medium T-cell lymphoproliferative disorder (PCSMLPD) –

two fractions) offers durable control, no acute toxicities and conve-

With particular focus on ultra-low dose radiotherapy

nient 2-day treatment time. For patients without cosmetic concerns,
watchful-waiting is a reasonable management strategy.

Jennifer Ward1 , H. Miles Prince2,3 , Chris McCormack4,5 , Stephen
Lade6 , Odette Buelens2 , Carrie van der Wayden2 , Friyana Bhabha4 ,
Feasibility of DPYD Genotype-guided Personalised

Belinda Campbell3,7,1
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Approximately

10,000

Australians

require

fluoropyrimidine

chemotherapies (FP) for solid organ cancers per annum. Serious
toxicities resulting in hospitalisation and even death can follow
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exposure to FP chemotherapy in ∼10% patients who are deficient in

Hospital who have been started on this combination of immunotherapy

Dihydropyrimidine Dehydrogenase (DPD), the enzyme critical for FP

since PBS approval.

metabolism. Genotyping DPYD, encoding DPD, can identify deficient

Results: Twenty-five patients were on combination immunotherapy at

patients and allow for prospective FP dose adjustment.

our two centres. Compared to CheckMate 214, within the limits of

Aim

and

method:

(TAT)

a small sample size and limited follow up duration (median follow up

for DPYD genotyping. Patients with solid organ cancers (GI, breast,

12.9 months) given recency of PBS approval, our efficacy was lower (12

head and neck) aged 18 and older who were intended to receive, cur-

month OS 61.8% compared with 90%) though with an improved safety

rently receiving or recently completed FP chemotherapy were eligible.

profile (Grade 3/4 events 56% compared with 79%). Our patients had

Blood samples were collected and genotyped at John Hunter Hospital.

higher risk features (number of metastases, percentage of IMDC poor

Samples were genotyped via quantitative Real-Time PCR amplification

risk and histological subtype) and included patients who would have

We

determine

turn-around-time

to identify pre-determined DPYD variants c.1905+1G>A, c.2846A>T,

been excluded from the Checkmate 214.

c.1679T>G and c.1236G>A/HapB3. Genotype-guided dose adjust-

Conclusions: In a real-world population that had higher risk features,

ment is based upon international consortia dose-adjustment guidelines

efficacy was lower though the safety profile was improved, supporting

at clinician discretion.

other real-world data published in other countries since our data col-

Results: Seventy-five patients were recruited across four participating

lection integral to help guide ongoing effective use of the combination

centres in regional NSW. Samples were batched and analysed weekly

in this population.

by a PhD student. Variants were identified in 12/75 patients (16%); 7
c.1236G>A, 3 c.1905+1G>A, 1 c.1679T>G and 1 c.2846A>T. All car-

1. Motzer, R.J., Tannir, N.M., McDermott, D.F., Frontera, O.A., Melichar,

riers were heterozygous for the specified variants. Mean TAT was 6.5

B., Choueiri, T.K., Plimack, E.R., Barthélémy, P., Porta, C., George, S.

days, comparable to European data. TAT could be markedly reduced

and Powles, T., 2018. Nivolumab plus ipilimumab versus sunitinib in

if PCR testing could be offered more than once a week. Prevalence
of DPYD mutations in this cohort was higher than baseline population

advanced renal-cell carcinoma. N Engl J Med.
2. “COMBINATION

IMMUNO-ONCOLOGY
CANCER

data (∼8%), but this explainable by clinician bias in the selection of

FOR

KIDNEY

patients already experiencing toxicities for inclusion in this study.

PBS

FROM

Conclusion: DPYD genotyping provides a functional example of phar-

www.bms.com/assets/bms/australia/documents/press-

macogenomic screening. It is already recommended internationally

releases/Consumer-media-release-PBS-listing-O%2BY-RCC.PDF.
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MARCH

2019.”

AVAILABLE
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28
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2019,

across Europe as a cost-effective means of reducing toxicity rates and
improving toxicity management. This study confirms that results can be
provided to clinicians in a timely manner. Further analyses are needed
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to comprehensively understand the impact of DPYD genotyping within

chemotherapy, which is superior in gastroesophageal

the Australian system.

adenocarcinoma? A retrospective analysis
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Neoadjuvant chemoradiotherapy or peri-operative

Zachary Wilson1 , Gary Tincknell2,3 , Daniel Brungs2,1,4 , Karen Fildes1,4
Real World Outcomes of Ipilimumab and Nivolumab in

patients with advanced renal cell carcinoma

Australia
2 Illawarra

Cancer Care Centre, The Wollongong Hospital, Wollongong,

Sarah Williams1 , Sathya Narayanan 2 , Alexander Guminski2 , Paul

NSW, Australia

Craft1 , Laeeq Malik1

3 School of Chemistry and Molecular Biosciences, University of Wollongong,

1 Medical Oncology, Canberra Hospital, Canberra, ACT, Australia

Wollongong, NSW, Australia

2 Medical

4 Illawarra

Oncology, Royal North Shore Hospital, St Leonards, NSW, Aus-

Health and Medical Research Institute, Wollongong, NSW, Aus-

tralia

tralia

Background: CheckMate 214 demonstrated a significantly higher

Aims: Gastric, gastroesophageal junction, and oesophageal adenocar-

overall survival (OS) and objective response rate with Nivolumab

cinomas (GOCs) have dismal 5-year survival, even when treated with

plus Ipilimumab than with Sunitinib among intermediate and poor

curative intent. In patients with oesophageal and gastroesophageal

risk patients with previously untreated advanced renal cell carcinoma

junction adenocarcinomas, overall survival (OS) was improved by

(RCC).1 Nivolumab with Ipilimumab was subsequently approved on

neoadjuvant chemoradiotherapy (CROSS). In gastric and gastroe-

PBS in Australia from March 2019.2

sophageal junction adenocarcinomas, OS was increased by periopera-

Aims: Our objective was to assess the efficacy and safety of combina-

tive chemotherapy (FLOT/MAGIC). To date, no randomised controlled

tion immunotherapy for RCC in a real-world population as compared to

trials have been attempted between FLOT and CROSS. We aimed

the CheckMate 214 trial.

to compare chemoradiotherapy and chemotherapy for patients with

Methods: This was a retrospective multi-centre observational study

GOC.

assessing patients at The Canberra Hospital and Royal North Shore
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Methods: We performed a retrospective analysis of patients

patient based on their similarity to six different synthetic patients, one

treated for GOCs within the Illawarra Shoalhaven Local Health

for each cancer of interest. The 100 most similar patients each day

District from 2013 to 2022. We included only patients diagnosed

were short-listed and the next ML model made a binary prediction

with GOC adenocarcinoma, excluding other histopathology, who

on patient suitability. The EMR’s of the CogStack short-listed patients

commenced neoadjuvant or peri-operative treatments. Survival

were manually reviewed for suitability.

analysis was performed using Kaplan-Meier method and log-rank

Results: The test case was a complex commercial trial with extensive

tests.

inclusion/exclusion criteria and included multiple cancer types. The

Results: 95 patients were treated with neoadjuvant (n = 64) or

existing method yielded 12/25 suitable patients (precision@k value-

perioperative (n = 31) treatment with the aim for curative surgery.

0.48), identifying the first suitable patient in 84.85 h, and average

Forty-one tumours originated from the distal oesophagus, 36 from the

review time was 5.33 min per-patient.

gastroesophageal junction and 18 from the stomach. There was no dif-

Model 1 short-listed 137 unique patients; yielding 43/137 suitable

ference in median OS between the groups (chemotherapy 52.8 months,

patients (precision@k value-0.31), identifying the first suitable patient

chemoradiotherapy 36.4 months; p = 0.7). Of those located at the

in 2.28 h (97.31% faster) with an average review time of 3.08

gastroesophageal junction, no OS difference was seen between those

min per-patient (42.19% faster); the classification model yielded a

treated with CROSS or FLOT (p = 0.9). Four (6.3%) patients who com-

(weighted-average) F1-score of 55% (precision@k value-0.60).

pleted chemoradiotherapy and 7 (22.6%) who completed chemother-

Conclusions: This CogStack patient recruitment test-case employed

apy did not proceed to surgical resection. Seven patients (7.4%) did

a trial specific solution. Model 1 demonstrated the ability to achieve

not proceed to surgery due to upstaging at pre-operative radiologic

comparable precision with established methods, without requiring

screening or staging laparoscopy, six in chemotherapy and one in

training data. CogStack/ML short-listed more suitable patients, as it

chemoradiotherapy arms. Incomplete resection was seen in three

assessed all hospital presentations and the time saving was signifi-

(4.7%) chemoradiotherapy patients, and four (12.9%) chemotherapy

cant. The classification model results demonstrate that with sufficient

patients.

training data CogStack/ML can out-perform established methods.

Conclusion: There appears to be no demonstratable OS differ-

The benefits are an ‘always-on’ prospective patient-identification and

ence

reduced time-to-trial solution.

between

perioperative

chemotherapy

and

neoadjuvant

chemoradiotherapy for GOCs. Higher rates of incomplete resection and pre-operative upstaging of the disease was seen in

1. Jackson R, Kartoglu I, Stringer C, Gorrell G, Roberts A, Song X, Wu

the chemotherapy group. For those patients where the per-

H, Agrawal A, Lui K, Groza T, Lewsley D. CogStack-experiences of

tinent

deploying integrated information retrieval and extraction services

trials

overlap,

the

two

treatment

regimens

appear

equivocal.

in a large National Health Service Foundation Trust hospital. BMC
medical informatics and decision making. 2018 Dec;18(1):1–3.
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AI-assisted clinical trial recruitment using an open-source

natural language processing workflow

317

Financial toxicity in patients with cancer attending a

public Australian tertiary hospital – A qualitative analysis
Helen Kavnoudias2,1 , Christopher Berry2 , Theo Christian2 , Amy
McKimm2 , Lachlan MacBean2 , Adil Zia2,1 , Adam Morris1 , William

Thivagar Yogaparan1 , Sue-Anne McLachlan1,2 , Luke McLean1,3

Librata2 , Dominic Buensalido2 , Joanna Batstone1 , Meng Law2,1 , Anne

1 St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia

Woollett2 , Stephen Jane2,1 , Helena Teede1

2 The University of Melbourne, Melbourne, Australia

1 Monash University, Melbourne, VIC, Australia

3 Peter MacCallum Cancer Centre, Melbourne, Australia

2 Alfred Health, Melbourne, VIC, Australia

Background: As cancer treatments become more complex, financial
Aims: To evaluate the open-source Natural-Language-Processing tool

toxicity has emerged. This term encompasses direct and indirect costs

‘CogStack’ in conjunction with Machine Learning for oncology clinical

to patients and their families from cancer diagnosis to treatment.1 Our

trial recruitment. Different approaches were explored and compared

group’s recent study of public Australian cancer patients showed a

to existing methods.

substantial proportion experienced financial toxicity and an associated

Methods: A short-list of potential trial patients with hypervascular

poorer quality of life.2 A better understanding is needed of the source

tumours was recorded over five weeks using existing targeted manual

of financial toxicity to allow identification of interventions.

(human) and semi-automated methods. CogStack’s Named-Entity-

Objective: To undertake a comprehensive, exploratory study to under-

Recognition model was employed to review the Electronic-Medical-

stand the source and impact of financial toxicity in Australian public

Record (EMR) of the 21,050 patient presentations during that period

patients receiving anti-cancer therapy in public hospitals. Specifically,

and identify biomedical inclusion/exclusion criteria-based concepts

to explore the spectrum of out-of-pocket costs, restrictions on non-

from the Unified Medical Language System. Each patient output was

health related expenditures, impact of return to work and compliance

used as input into an ensemble of ML models. Model 1 ranked each

with treatment.
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Method: Cross-sectional, qualitative study. Semi-structured telephone

such treatment have not been documented. This research aims to

interviews of patients purposively sampled to demonstrate financial

identify Early phase trial patients’ needs, and provide meaningful rec-

toxicity (COST questionnaire score ≥ 18).2 Interviews were audio-

ommendations and an insight into patients’ journey while receiving

recorded, transcribed, coded using NVivo3 and inductively thematically

novel therapy.

analysed.

Methods: This qualitative research project has recruited Early phase

Results: Twelve patients were interviewed when data saturation

trial participants with advanced or metastatic cancer treated at

was reached. Average age of 54.8 years, 66.7% women. Three key

TKCC/SVH between 2020 and 2022, for whom conventional treat-

themes: (1) increased cancer-related out-of-pocket costs including cost

ment has failed. Participants were audio/video recorded during their

of diagnostic imaging, General Practitioner and specialist follow-up,

interview using semi-structured/relatively unstructured approach.

treatment-related complications such as lymphoedema, parking and

Thematic analysis and narrative inquiry were used to analyse patient

personal expenses (2) reduction in financial resources from loss of

stories and identify unmet needs. Analyses were performed in

employment opportunities and productivity and (3) mitigation strate-

Microsoft 365.

gies including restrictions on non-health related expenditures such as

Results: Nine clinical trial participants (five females, four males) con-

luxuries and travel, access to sickness benefits and use of savings.

sented and completed the in-depth interview between 2020 and 2022.

Conclusion: Cancer patients treated in a universal health care setting

Meaningful recommendations and results, including recurring themes,

face a significant burden of unexpected out-of-pocket costs related to

such as financial toxicity, anxiety/fear of progression, difficulty return-

their diagnosis and therapy. These arise from multiple sources includ-

ing to work, cancer self-blame, coping mechanisms, lack of resources,

ing diagnostic tests, medications, treatment complications, travel and

and isolation will be presented.

income loss. Measures are needed to increase awareness and facilitate

Conclusion: This study will provide practical recommendations on

access to strategies that mitigate financial toxicity. This has implica-

patients’ needs and a management of cancer survivorship. This infor-

tions on adherence to treatment, psychosocial wellbeing and provision

mation will guide development of supportive care interventions to

of holistic care to cancer patients and their families.

assist survivors through Early phase trial treatment.
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Patient experiences of prolonged living with cancer

4 The

Australasian Gastro-Intestinal Cancer Trials Group (AGITG), Sydney,

during early phase trial treatment

NSW, Australia

Oksana Zdanska2,1 , Pavel Zdansky1 , Jia Liu3,4,1 , Anthony M. Joshua4,1 ,

Background: NETs represent a rare group of heterogenous malig-

Melinda Stanners2 , Cath Rogers2

nancies frequently arising in the gastrointestinal system. In addition

1 The

to surgery, targeted therapy and chemotherapy, peptide receptor

Kinghorn Cancer Centre, St Vincent’s Hospital, Darlinghurst, NSW,

Australia

radionuclide therapy (PPRT) with 177 Lu-octreotide showed improved

2 Torrens University, Fortitude Valley, QLD, Australia

PFS in advanced midgut NETs. Access to PPRT in Australia is limited to

3 The University of Sydney, Camperdown, NSW, Australia

clinical trials and specialist centres. Rural/regional NET data on man-

4 St

agement are lacking, especially in the PPRT era. Therefore, aim was to

Vincent’s Clinical School, University of New South Wales, Darlinghurst,

NSW, Australia

evaluate treatment strategies and outcomes of gastrointestinal NETs
in ISLHD over a 5-year period.

Background: Early phase clinical trials represent novel treatment

Methods: Adults diagnosed with NETs between January-2015 and

options that can offer therapeutic effect for cancer patients. With

August-2020 were identified from electronic health records. Gas-

genomic marker-driven approach, lower toxicity profile and increase

trointestinal NETs were assessed for clinicopathological character-

in objective response rates, the demand for access to experimental

istics, treatment strategies and survival. Descriptive analyses were

treatment is significant. While there is substantial research focused on

performed, and survival analysis estimated using Kaplan-Meir method.

treatment outcomes, the patient experiences of those living through
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Results: One hundred and forty-nine patients with NETs were iden-

Results: Phase 1: After full-text screening, 99 studies were included.

tified. Primary analysis included 68 patients with GI NETs. Majority

Thematic analysis elicited six key principles and 30 best-practice

were males (57%) with mean age 70-years (range: 21–90). Most

approaches relevant to co-designing with First Nations peoples. Phase

common primary sites were small bowel (32%) and pancreas (26%).

2: These outcomes were refined and consolidated by 25 stakehold-

49% had metastatic versus localised disease at diagnosis (38%). More

ers in Online Yarning Circles. A final set of six key principles were

had grade 1/2 disease (54%) versus grade 3 (24%). Most frequent

identified: Aboriginal and Torres Strait Islander leadership; Culturally

treatment modality was surgery (50%), followed by somatostatin

grounded approach; Respect; Benefit to community; Inclusive part-

177 Lu-

nerships; and Transparency and evaluation. Thirty-seven best practice

octreotide (10%). Only 50% of metastatic grade 3 disease and 40%

approaches were also identified, which provide guidance for embed-

of metastatic grade 1/2 had chemotherapy. Majority of patients (63%)

ding the principles into practice.

were from rural/regional area, of these 29% had chemotherapy and

Conclusion: This set of principles and approaches offers a constructive

11% had 177 Lu-octreotide. Overall survival was 60% (HR 1.09, 95%CI

foundation to commence a process of co-design with First Nations peo-

0.49–2.40, p = 0.84) for both metropolitan and rural/regional pop-

ples to be integrated into a toolkit for application across cancer policy

ulations with median survival 16.8 months (range: 0.59–54.74) in

and research design.

analogues (34%), chemotherapy (30%), radiation (18%), and

metropolitan versus 10.5 months (range: 0.33–62.52) in rural/regional
population.
Conclusion: This is the first retrospective review of patients in ISLHD
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with gastrointestinal NETs. Chemotherapy and PPRT is underutilized

living with intellectual disability: ScreenEQUAL – An innovative

particularly in rural/regional areas, likely due to limited access to spe-

disability-inclusive study protocol to support equity

Increasing cervical screening participation for people

cialised scans and treatments. Further data is required to identify
underlying causes to improve health outcomes in this population.

Jane Ussher1 , Iva Strnadova2 , Ee-Lin Chang3 , Allison Carter4 , Julie
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1 Translational

Loblinzk2 , Sally Sweeney5 , Deborah Bateson6
Development of evidence-based key principles and best

Health Research Institute, University of Western Sydney,

practice approaches to co-design with First Nations peoples

Sydney, NSW, Australia

applicable to the cancer context in Australia

2 Special Education and Disability Studies, UNSW, Sydney, NSW, Australia
3 Health Promotion Team, Family Planning NSW, Sydney, NSW, Australia

Kate Anderson1 , Tamara Butler1 , Alana Gall1 , Gail Garvey1 , Debra

4 The Kirby Institute, UNSW, Sydney, NSW, Australia

Hector2 , Scott Turnbull2 , Kerri Lucas2 , Caroline Nehill2 , Anna

5 Clinical Services, Family Planning NSW, Sydney, NSW, Australia

Boltong2 , Dorothy Keefe2

6 The

1 School of Public Health, University of Queensland, Herston, QLD, Australia

tralia

Daffodil Centre, The University of Sydney, Camperdown, NSW, Aus-

2 Cancer Australia, Sydney, NSW, Australia

Background: Australia is on track to be the first country to eliminate
Aims: Australia’s social, structural, and political context, together with

cervical cancer but elimination must be achieved equitably. People

the continuing impact of colonisation, perpetuates health care and

with intellectual disability are significantly less likely to engage with

outcome gaps for First Nations peoples, including in cancer. A new

screening than the general population due to social, cultural, economic,

approach is required to overcome these disparities, led by First Nations

physical, sensory and psychological barriers.

peoples. Co-design is emerging as a valued method for First Nations

is developing and evaluating a co-designed and co-produced suite

communities to drive change in health policy and practice to better

of resources to enhance health literacy, support informed decision-

meet their needs and priorities. However, it is critical that a co-design

making and increase participation in the National Cervical Screening

processes and outcomes are culturally safe and effective. This project

Program.

aimed to develop a set of evidence-based key principles and best prac-

Methodology: Supported by the ScreenEQUAL Advisory Group, this 3-

tice approaches to co-design with First Nations peoples applicable to

year mixed-methods study utilises disability-inclusive and integrated

the Australian cancer context.

knowledge translation (iKT) frameworks:

Methods: A First Nations co-led team conducted a two-phase

This NHMRC study

project. In Phase 1, a systematic search was conducted to iden-

∙ Co-designed interviews using novel participatory body-mapping and

tify peer-reviewed and grey literature reporting elements of co-

photovoice methodologies will explore barriers and facilitators to

design by and with First Nations peoples. Thematic analysis was

screening amongst participants (×40) with intellectual disability,

conducted on key findings from the papers to elicit key principles

their careers, disability support workers, GPs and nurses.

and best practice approaches to co-design. In Phase 2, Online Yarn-

∙ Qualitative outcomes will support co-production of a suite of edu-

ing Circles with key stakeholders were utilised to refine Phase 1

cational courses and accessible written and web-based information,

findings.

and a toolkit to support and evaluate informed decision-making and
health literacy attainment.
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∙ People with intellectual disability aged 25–74 years due or overdue

Methods: Secondary analyses were performed on data collected from

for screening (×200) will be invited to participate in a pragmatic clus-

188 caregivers of people with brain cancer who completed a 44 item

ter randomised control trial to evaluate effectiveness and impact of

unmet needs survey (SCNS-P&C) in a randomised controlled trial

the pilot resource packages. Over 6-months, the intervention group

(CARE-IS). Psychometric analyses were conducted to create a brief

will receive supportive resources for people with intellectual disabil-

version of this measure suitable to screen for unmet needs. Items

ity, workshops for family carers, community education for support

were assessed against five psychometric criteria (diagnostic accu-

workers and clinical education for GPs and nurses. Baseline and end-

racy, variance explained, factor score, prevalence and positive/negative

line interviews will be conducted, and resources will be available to

predictive value). Items exceeding pre-specified thresholds for these

all participants at study conclusion.

criteria were considered for inclusion in the final screening measure.
Results: Preliminary results indicate eight items met these criteria and

Implications: Australia’s National Roadmap for Improving the Health

are candidates for inclusion in the final measure. These include infor-

of People with Intellectual Disability (2021–2031) highlights the need

mation needs (two items), health care service needs (two items), work

for improved health literacy, and for education and training for carers

and social needs (two items), and psychological and emotional needs

and healthcare professionals to support autonomy and reduce equity

(two items). Psychometric analyses are ongoing and the final version

gaps. ScreenEQUAL will support policy and practice change across

of this brief screening measure will be presented at the COSA annual

Australia, with implications for achieving the global WHO cervical

scientific meeting.

cancer elimination targets equitably.

Conclusion: This brief screening measure will facilitate identification
of caregiver’s unmet needs in clinical practice and enable timely refer-

1. Carter, A., I. Strnadová, C. Watfern, R. Pebdani, D. Bateson, J.

ral for tailored support. This will help to ensure equitable access to

Loblinzk, R. Guy and C. Newman (2021). "The Sexual and Reproduc-

support services for those caring for people with brain cancer, includ-

tive Health and Rights of Young People with Intellectual Disability:

ing people living in rural or remote regions, potentially contributing to

A Scoping Review." Sexuality Research and Social Policy.

better long-term outcomes for this cohort.

2. Lennox, N., C. Bain, T. Rey-Conde, M. Taylor, F. M. Boyle, D. M. Purdieà and R. S. Ware (2010). "Cluster Randomized-Controlled Trial
of Interventions to Improve Health for Adults with Intellectual Dis-
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ability Who Live in Private Dwellings." Journal of Applied Research

people

Working in partnership to reduce cancer risk for LGBTQ+

in Intellectual Disabilities 23: 303–311.
Rebecca Cerio1 , Kate Reakes1 , Karen Price2 , Scott Walsberger2 , Sarah
McGill1
249

Screening for unmet needs of caregivers of people with

brain cancer: Development of a brief screening measure for use

1 Cancer Institute NSW, St Leonards, NSW, Australia
2 ACON, Sydney, NSW, Australia

in clinical practice
Background: In 2019, Cancer Institute NSW (the Institute) and ACON
Rachel Campbell1,2 , Joanne Shaw1 , Georgia Halkett3 , Mona Faris1 ,

commenced a 5-year partnership to address cancer risks and access

Haryana Dhillon1,2

issues, and improve cancer-related health outcomes for people of

1 University

diverse genders and sexualities. This partnership is important for

of Sydney, Faculty of Science, School of Psychology, Psycho-

oncology Co-operative Research Group (PoCoG), Sydney, NSW, Australia

engaging and empowering LGBTQ+ communities and contributing to

2 University

achieving goals of the NSW Cancer Plan to reduce health inequities of

of Sydney, Faculty of Science, School of Psychology, Centre

for Medical Psychology and Evidence-based Decision-making (CeMPED),

these communities.

Sydney, NSW, Australia

Aim: The partnership aims to increase cancer screening participa-

3 Faculty

tion (bowel, breast and cervical), and reduce preventable cancer risks

of Health Sciences, Curtin School of Nursing, Curtin University,

Perth, Western Australia, Australia

among LGBTQ+ people in NSW through community engagement,
targeted health promotion and training of services.

Introduction: Individuals caring for people with brain cancer have high

Methods: A comprehensive multi-year plan was established including

levels of unmet needs, impacting their capacity to provide support

undertaking formative research, provision of subject matter expertise,

and care, and leading to poorer long-term psychosocial outcomes. As

and communication and training activities. The partnership activity is

part of the Brain cancer Rehabilitation, Assessment, Interventions for

underpinned by evidence, including literature review and formative

survivorship Need (BRAINs) program, we are adapting an existing elec-

research with LGBTQ+ people in NSW who participated in surveys

tronic screening portal to identify the needs of caregivers across the

and focus groups on bowel cancer screening participation, smoking and

brain cancer trajectory to trigger referral for support.

quitting behaviours and alcohol consumption. The co-design, partner-

Aim: Our objective was to develop a brief screening measure to assess

ship approach brings together public health expertise and people with

the unmet needs of caregivers of people with brain cancer feasible for

lived experience of diverse genders and sexualities, who are involved in

use in clinical practice.

all aspects of the work.
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Results: To date, the partnership has delivered targeted bowel cancer

5. Publication of Resources to assist in the care of transgender indi-

screening campaign and smoking cessation campaigns; and developed

viduals referred to a clinical genetics service or familial cancer

a tailored diversity and inclusion e-learning training ‘LGBTQ+ Communities and Cancer’ specifically for BreastScreen NSW, NSW Quitline and
Institute staff, which is now being adapted as a tailored e-learning module for Cancer Services across Australia, accessible in 2022 via eviQ

centre.
6. Gender inclusivity working party planned to commence in late
2022.
7. eviQ Education in collaboration with ACON to progress education

Education.

modules to equip cancer services staff to provide best practice care

Conclusions: This partnership is the first of its kind. The co-design

to sexuality and gender diverse patients and their families.

approach has provided significant value to both organisations. The
partnership is expanding organisational knowledge and capability and

Conclusions: There are significant ongoing opportunities for eviQ and

has influenced research data collection practices and resources for

eviQ Education to work in partnership to deliver improved cancer

consumers and health professionals in cancer control. It is delivering

outcomes for LGBTIQ+ communities.

greater visibility and inclusion of LGBTQ+ people in the Institute’s
programs and campaign activity.

1. https://www.eviq.org.au/
2. https://education.eviq.org.au/
3. https://www.health.nsw.gov.au/lgbtiq-health/Pages/default.aspx
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eviQ and eviQ education opportunities to improve cancer

outcomes for LGBTIQ+ communities

4. https://www.cancer.nsw.gov.au/what-we-do/news/newpartnership-to-improve-lgbtq-cancer-outcomes

Rebecca Cerio1 , Kate Reakes1 , Lisa McLean1 , Aimee Russell1 , Lydia
McGee1 , Philippa Smith1 , Julia Shingleton1 , Aisling Kelly1 , Cynthia
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Cancer risk behaviours among LGBTQ+ people in NSW

Lean1 , Sarah McGill1 , Shelley Rushton1 , Tracey O’Brien1 , Joseph
Lonn2 , Liz Duck-Chong 2 , Scott Walsberger2

Rebecca Cerio1 , Kate Reakes1 , Sarah McGill1 , Colin MacArthur2 ,

1 Cancer Institute NSW, St Leonards, NSW, Australia

Megan Baiocchi3 , Emily Spencer3 , Scott Walsberger3 , Karen Price3

2 ACON, Sydney, NSW, Australia

1 Cancer Institute NSW, St Leonards, NSW, Australia
2 Independent Consultant, Sydney, NSW, Australia

Introduction: eviQ1 and eviQ Education2 are flagship programs of

3 ACON, Sydney, NSW, Australia

the Cancer Institute NSW (CINSW) that provide free online evidencebased information to guide and support the delivery of evidence-based,

Introduction: ACON and Cancer Institute NSW established a 5-year

best practice cancer treatment and care nationally and internation-

partnership to address cancer-related health inequities of LGBTQ+

ally. eviQ provides consensus driven cancer treatment protocols and

people in NSW. Limited evidence shows LGBTQ+ people have higher

information for use at the point of care and eviQ Education pro-

prevalence of smoking and alcohol consumption, and barriers to

vides cancer health professional education. Contributing to the NSW

accessing support services due to a range of factors.

LGBTIQ+ Health Strategy 2022–20273 and the CINSW partnership

Aim: This research explored NSW LGBTQ+ people’s knowl-

with ACON4 , opportunities for eviQ and eviQ Education to improve

edge, beliefs, attitudes, and behaviours around smoking and

cancer outcomes for sexuality and gender diverse communities were

alcohol consumption. Findings inform the partnership’s projects

explored.

and measure outcomes.

Methods: The eviQ and eviQ Education teams consulted with inter-

Methods: A mixed-methods study was conducted including qualita-

nal and external stakeholders involved in delivering the CINSW ACON

tive research with three focus groups and six in-depth interviews (40

partnership4

participants) and a quantitative online survey (n = 781).

to identify opportunities aligned with the NSW LGBTIQ+

Health Strategy 2022–20273 to contribute to improving cancer out-

Results: Mental health is central in the overall health and social con-

comes for LGBTIQ+ communities.

nection of LGBTQ+ people. 85% had experienced stress/anxiety. This

Results: The following initial opportunities were agreed and work

affects access to mainstream health services due to stress/anxiety

commenced:

around ‘coming out’ to healthcare providers and fear of discrimination
and stigma.

1. eviQ collaboration with ACON to review existing eviQ patient
information. Initial work completed includes publication of:
2. Cancer treatment and fertility for people who were assigned female
at birth
3. Cancer treatment and fertility for people who were assigned male
at birth
4. eviQ Cancer Genetics:

Mental health influences the uptake and continuation of smoking
and alcohol consumption. They are perceived coping methods for
stress/anxiety and are engrained in LGBTQ+ social occasions.
80% of people who smoke had previously tried to quit. 58% of current
smokers were seriously considering quitting smoking in the next six
months. Cessation messaging that demonstrates empathy, is encouraging, and highlights the benefits of quitting had the highest perceived
effectiveness and salience.
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Alcohol helped respondents relax and deal with stress/anxiety (49%)

because it was not delivered locally. Total kilometres saved by par-

and gave them a sense of confidence in social situations (47%). On

ticipating in a trial regionally rather than via a tertiary centre will be

average, respondents reported drinking 7.9 standard units of alco-

presented.

hol/week. 61% of survey respondents felt their drinking was not

Conclusions: Actionable mutations in advanced cancer are common,

harmful to their health. A quarter believed their alcohol consumption

and there are many trials available to assess the efficacy of targeted

was harmful. Cancer was the least likely identified potential risk from

treatment. Regional patients benefited from having access to MTP

alcohol.

locally, with 16% commencing a trial, with significant reduction in

Conclusions: There is a need and opportunity for targeted cam-

travel.

paigns to increase awareness of cancer risks and promote culturally
appropriate behaviour change supports among LGBTQ+ people.
Ethics: Sydney University 2020/222 and ACON 2020/08

1. Thavaneswaran et al. 2018. Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking
studies of targeted therapies for rare and neglected cancers. MJA.
209 (8) 354.e1–e6.

253

The utility of molecular tumour profiling for patients with

advanced cancer in a regional Australian setting
255

A call to action: Improve cancer outcomes through

Natalie Chilko2,1 , Ortis Estacio2,1 , Christopher Steer4,3,2,1 , Kerrie

increased research funding awarded for Aboriginal and Torres

Clarke2,1 , Richard Eek4,2,1 , Kim Clark1 , Jacqueline McBurnie1 , David

Strait Islander and culturally diverse communities

Thomas5,6 , Craig Underhill4,3,2,1
1 Border Medical Oncology Research Unit, Albury, NSW, Australia

Tilini Gunatillake1 , Kalinda Griffiths1 , Vijaya Joshi1 , Jennifer Philip1

2 Medical Oncology, Albury-Wodonga Health, Albury-Wodonga, Australia

1 VCCC Alliance, Parkville, VICTORIA, Australia

3 Latrobe University, Wodonga, VIC, Australia
4 UNSW

School of Clinical Medicine, Rural Clinical Campus, Albury, NSW,

Aim: To describe the research funding of Aboriginal and Torres Strait

Australia

Islander and Culturally Diverse Communities and cancer projects

5 Garvan Institute of Medical Research, Sydney, NSW, Australia

relative to overall grant funding.

6 St Vincents Clinical School, University of NSW, Sydney, NSW, Australia

Methods: Major Australian grant funding databases were reviewed
across a 5-year period (2016–2020):

Background: Molecular tumour profiling (MTP) aims to identify
biomarker targets to link to available treatments. The provision of
treatment may be via PBS or clinical trials. The utility of offering
molecular tumour profiling for patients in a regional/rural setting is
unknown.
Aims: This observational study aimed to assess the utility of offering MTP and biomarker testing to patients with advanced cancer in a
regional setting.
Methods: Patients with advanced cancers were consented for MTP

∙ National Health Medical Research Council (NHMRC)
∙ ○Medical Research Future Fund (MRFF)
∙ ○Australian Research Council (ARC)
∙ The following terms were used across the databases to identify
relevant grants (including project grants and fellowships):
∙ ○‘Indigenous’, ‘First Nation’, ‘Aboriginal’, ‘Torres Strait Islander’,
‘CALD’, ‘Culturally and Linguistically Diverse’, ‘Migrant’, ‘Refugee’,
∙ ○‘Cancer’

of their biopsy specimens, organised and conducted by a central
laboratory, as part of the Garvan Research Institute Cancer Molec-

Results: In the 5-year period, 13,078 grants were awarded across the

ular Screening and Therapeutics Program (MoST) research study

three funding agencies. Just 2.9% of NHMRC grants, 5.4% of MRFF

(ACTRN12616000908437). The m is conducted via TruSight Tumour

grants and 0.2% of ARC grants were awarded to projects related to

170 panel (Illumina), plus biomarker assays using immunohistochem-

Aboriginal and Torres Strait Islander communities. Only one grant

istry and fluorescence in situ hybridisation.1 Clinicians received a

(0.1%) from NHMRC and MRFF and no grants from ARC were awarded

report of identified active and actionable mutations and potential clin-

to projects related to culturally and linguistically diverse communities.

ical trials. Available trials, some available locally through the MoST

Further interrogation of those projects specifically related to can-

program, were offered to the patients. The distance from the patient’s

cer revealed that only nine grants overall (0.06%) were awarded to a

postcode to Melbourne in kilometres was used to calculate distance

project related to Aboriginal and Torres Strait Islander people and two

saved by offering trials locally.

grants overall (0.02%) were awarded to projects related to culturally

Results: Fifty patients were included in this study, of whom 49 had

diverse communities.

mutations identified. Of these, 39 had a trial available. Thirteen

Conclusions: There remains persistent inequity in cancer outcomes for

patients (26%) there was had a trial available locally. Eight patients

Aboriginal and Torres Strait Islander and culturally diverse communi-

(16%) commenced a treatment based on their MTP. Barriers to com-

ties in Australia. This review of grant funding highlights this inequity

mencing targeted treatment included waiting for disease progression,

as demonstrated by the paucity of research funding allocated towards

patient choice, poor functional status. Nine patients declined a trial

these communities.
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This study provides the foundation to better understand the drivers

∙ 1.https://www.cancervic.org.au/downloads/cec/cancer-in-

of inequity in the research pipeline and the systems that may perpetuate this inequity. This study raises awareness and promotes the

vic/Cancer-in-Victoria-statistics-and-trends-2020.pdf
∙ 2.https://clinicaltrialsalliance.org.au/resource/acta-clinical-trial-

need for initiatives by research funding bodies to directly address

awareness-and-access-amongst-culturally-and-linguistically-

these inequities in research development targeting cancer outcomes

diverse-cald-populations-environmental-scan/

for Aboriginal and Torres Strait Islander and culturally diverse communities in Australia.
257

Breast cancer: A handbook for aboriginal and torres

strait islander health workers and health practitioners
256

“It’s not me, it’s you”: Taking a systems approach to

health equity

Vivienne Milch1,2 , Donna Moroney1 , Kerri Lucas1 , Caroline Nehill1 ,

Vijaya Joshi1 , Tilini Gunatillake1 , Lisa Somerville1 , Kalinda Griffiths1 ,

1 Cancer Australia, Strawberry Hills, NSW, Australia

Jennifer Philip1

2 The University of Notre Dame Australia, Sydney, NSW, Australia

1 Victorian

3 National

Karl Briscoe3 , Nicole Kilby3 , Jacinta Elston1 , Anna Boltong1,4

Comprehensive Cancer Centre Alliance, Parkville, Victoria, Aus-

tralia

4 Kirby

Health care in Victoria is experienced inequitably; data shows this

Association of Aboriginal and Torres Strait Islander Health

Workers and Health Practitioners, Phillip, ACT, Australia
Institute, UNSW Medicine, The University of New South Wales,

Sydney, NSW, Australia

is overwhelmingly true for those affected by cancer. Regional residents, LGBTIQA+ communities, Aboriginal and Torres Strait Islander

Aims: The National Aboriginal and Torres Strait Islander Cancer Forum

communities, people with low socio-economic status, and those from

in February 2020 identified increasing the knowledge and expertise

culturally, ethnically and linguistically diverse communities all report

of all health professionals involved in cancer prevention and care of

poorer patient outcomes than other population groups. For example,

Aboriginal and Torres Strait islander people as a key priority.

Aboriginal Victorians are nearly 2.5 times more likely to die from can-

Breast Cancer: a handbook for Aboriginal and Torres Strait Islander

cer than other Victorians while 5-year survival is higher for those in

Health Workers and Health Practitioners provides guidance on breast

cities, compared to those residing in regional Victoria.1

cancer detection, diagnosis, treatment and support to help Aborig-

To address inequity we have seen progress through innovative and tar-

inal and Torres Strait Islander Health Workers and Health Practi-

geted work, for example, the development of the Aboriginal and Torres

tioners (Health Workers) provide information and support to their

Strait Islander Optimal Care Pathway, and initiatives to improve the

communities.

participation of culturally, ethnically and linguistically diverse popula-

Methods: A two-phase gap analysis was undertaken to identify prior-

tions in clinical trials. 2 However, these interventions are rarely scalable

ity cancer information needs for Health Workers. Phase 1 comprised

and while they may provide the necessary supports for specific pop-

an environmental scan of existing resources developed from 2014 to

ulations to experience improved access, treatment and care, they do

2020. Phase 2 involved a survey of over 1000 members of the National

not address the underlying disparities within systems of healthcare.

Association of Aboriginal and Torres Strait Islander Health Workers

Moreover, such initiatives are frequently developed with time limited

and Health Practitioners (NAATSIHWP).

funding, leading to challenges with sustainability.

To inform new content and case studies, Cancer Australia focus-

Given the interconnected nature of cancer services and health dis-

tested the handbook with Health Workers through a combination of

parities, equity initiatives must take a systemic view to change the

group online sessions, one-on-one telephone interviews and written

outcomes for all populations. Taking such a view can be risky; it requires

feedback.

equal buy-in from multiple stakeholders, a collective understanding of

Results: An updated breast cancer information resource for Health

the problems, and an appetite for risk and failure.

Workers was launched in August 2022. It comprises updated evidence-

Using a collective impact model, the VCCC Alliance is developing such

based clinical content, a new chapter on supporting optimal social

an approach to health equity. Working across 10 diverse organisations,

and emotional wellbeing and palliative care, and information about

the VCCC Alliance will develop a Cancer Equity Framework that:

breast cancer in men. It is available on the Cancer Australia website and has been distributed to over 1000 Aboriginal and Torres

∙ Builds common understanding around key concepts such as ‘social
determinants of health’ and ‘health equity’

Strait Islander Health Workers, Health Practitioners and other health
professionals.

∙ Identifies examples of good practice across the alliance, suitable for

Conclusion: Breast Cancer: a handbook for Aboriginal and Torres Strait

adaptation and/or scaling; and
∙ Provides practical supports for systems change, drawing focus away

Islander Health Workers and Health Practitioners bridges a gap in the need

from population-specific interventions.

for updated, evidence-based information for Aboriginal and Torres
Strait Islander Health Workers and Health Practitioners.
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Our mob and cancer: Co-designing a national website for

aboriginal and Torres strait islander people affected by cancer

259

A rare cancer diagnosis highlighting ongoing health

inequity for Aboriginal people and Australian’s living rurally

and their health professionals
Sally Magoffin1 , Sally Magoffin1
Candice B. Woods1 , Jane Salisbury1 , Katrina Johnson1,2 , Cassandra

1 North West Hospital and Health Service, Mount Isa, QLD, Australia

Price1 , Hope Cockatoo Collins1 , Krissy Falzon1 , Vivienne Milch1,3 ,
Kerri Lucas1 , Jared Hilliers1 , Jordan Keady1 , Dorothy Keefe1

Introduction: It is well established that Aboriginal and Torres Strait

1 Cancer Australia, Strawberry Hills, NSW, Australia

Islander people, along with others living remotely, face significant

2 Cartymara Consulting, VIC, Australia

health inequity compared to their city counterparts. In this presen-

3 Waminda South Coast Women’s Health & Welfare Aboriginal Corporation,

tation I discuss a unique case of extragonadal choriocarcinoma in a

Nowra, NSW, Australia

14-year-old Aboriginal male. Unfortunately, this case is an example of
the ongoing health inequity that exists in rural and remote areas and it

Aims: Improving knowledge, attitudes and understanding of cancer

highlights the ongoing disparities faced by those living rurally in North

by individuals, families, carers and community members (across the

West Queensland.

continuum) was identified in the National Aboriginal and Torres Strait

Case description and discussion: This presentation describes the

Islander Cancer Framework 2015 and confirmed as a key priority at

journey, and the eventual diagnosis of metastatic extragonadal chorio-

the National Aboriginal and Torres Strait Islander Cancer Forum in

carcinoma, of a 14-year-old Aboriginal male from a remote community

February 2020.

in North West Queensland. This patient presented to his home hos-

Cancer Australia has developed a new national website, Our Mob

pital on four separate occasions with fevers, diarrhoea and abdominal

and Cancer, to provide a central hub of evidence-based, cultur-

pain before being transferred to a level four referral centre for imaging.

ally appropriate and strength-based information about cancer

Upon arrival to this hospital a simple bedside ultrasound raised sus-

for Aboriginal and Torres Strait Islander people and their health

picion for intra-abdominal pathology. A subsequent CT scan revealed

professionals.

a solid rectosigmoid lesion with extensive lymphadenopathy and an

Methods: An all-Indigenous Expert Reference Group was established

enlarged liver filled with irregular hypodensities. Some 11 days after

with national representation members (n = 13) and met on five

this patient’s first contact with the healthcare system he was trans-

occasions during the period 2020–2022.

ferred to the paediatric specialist hospital of the state for further

Cancer Australia’s Leadership Group on Aboriginal and Torres Strait

investigation. Two weeks after initial presentation he underwent biop-

Islander Cancer Control provided strategic overview and monitored

sies and 18 days later came the diagnosis of metastatic extragonadal

the development of the website.

choriocarcinoma.

All contractors engaged to develop, design, build and write con-

Conclusion: The lack of imaging availability in this remote area, coupled

tent for the dedicated website were certified Indigenous owned and

with delayed access to specialist services, likely postponed diagno-

Nation,1

to ensure the website

sis for this patient in a way that a city counterpart would be unlikely

is relevant, culturally appropriate and respectful, engaging, acces-

to experience. Hence, this presentation will use this case as a plat-

sible and user-friendly for Aboriginal and Torres Strait Islander

form for discussion regarding the ongoing health inequity that rural

people.

Australian’s face, with emphasis on the disparities experienced by

Results: Following Indigenous stakeholder recommendations and audi-

Aboriginal people.

operated businesses from Supply

ence research, a suite of videos featuring cancer survivors, Elders and
health professionals covering themes of early detection and screening,
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diagnosis and treatment, and the culturally sensitive topics of Shame

for aboriginal people in NSW

Pilot evaluation of the lung cancer optimal care pathway

and Sorry Business was produced for the website. All content was clinically and culturally reviewed and focus-tested during development and

Alisha McInerney1 , Brooke Stapleton1 , Shelley Rushton1

prior to launch.

1 Cancer Institute NSW, St Leonards, NSW, Australia

A targeted promotional strategy is being implemented to increase
reach and awareness with Aboriginal and Torres Strait people with

Aim: The three Lung Cancer Optimal Care Pathway for Aboriginal People in

cancer and communities.

NSW resources were developed and disseminated to assist health pro-

Conclusion: Guided by an Indigenous Expert Reference Group and

fessionals supporting Aboriginal people affected by lung cancer. A pilot

developed by Indigenous Australians Suppliers, Our Mob and Can-

evaluation was conducted to assess cultural appropriateness, use and

cer is a first of its kind, culturally-safe space for Aboriginal and Torres

early effectiveness of the resources.

Strait Islander people affected by cancer, community, and their health

Methods: A Program logic and ethically approved1 evaluation method-

professionals.

ology were developed and implemented with review, input, and advice
provided by the Aboriginal Program Development Committee (APDC)

1. Supply Nation. Available: https://supplynation.org.au/

at all stages.
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A mixed method approach, combining qualitative and quantitative

∙ Comprehensive stakeholder consultation, including public and tar-

data, was used. Four semi-structured interviews with targeted key

geted engagement with priority populations: Aboriginal and Torres

stakeholders and a review of project documentation and resource

Strait Islander people, people living in rural and remote areas; people

usage data were undertaken internally by the Aboriginal Project Offi-

from culturally diverse backgrounds.
∙ The analysis of 680 evidence statements extracted across ten

cer in conjunction with the Evaluation and Planning Team. Analysis of
interviews included a combination of narrative analysis and grounded
theory.
A self-assessment of adherence to general co-design principles was
undertaken using A Guide to Build Co-Design Capability2 as the guiding

evidence and consultation activities, to identify 73 priorities.
∙ A two-stage Delphi priority-setting process.
∙ A national stakeholder priority-setting workshop to reach consensus on priorities spanning the Optimal Care Pathway.

framework (the Framework).
Results: A key outcome for the project was the establishment of the

Results: The Roadmap identified 33 priorities for collective action.

APDC comprised of 13 trusted members from across NSW.

These priority areas cover prevention, early detection, diagnosis, treat-

The three resources developed were deemed culturally appropriate by

ment, supportive and palliative care, and pancreatic cancer research.

those interviewed and accepted for use by stakeholders.

Seven early implementation priorities are underway: Two relating to

Over 7100 resources were disseminated to over 70 organisa-

research (in partnership with MRFF) and five relating to (1) enhanced

tions. Early findings suggest they are being promoted, distributed and

awareness (2) surveillance, (3) early detection, (4) defined pathways

used by recipients across NSW.

for rapid access to pain management and palliative care, (5) culturally

Project activity aligned with each guiding principle within the Frame-

responsive models of care.

work, suggesting that elements of co-design had been applied.

Conclusion: Collaborative investment and implementation of the

Conclusions: The project led to establishment of an Aboriginal gov-

roadmap’s priorities provides opportunities for national transforma-

ernance committee for Cancer Institute projects which now supports

tional change. Designing implementation for priority populations with

our ongoing projects. The consultative approach produced a cultur-

a focus on equitable outcomes will enable improvements for all

ally appropriate resource that has acceptance from the Aboriginal

Australians affected by pancreatic cancer.

community in NSW.
262
1. Aboriginal Health and Medical Research Council (AH&MRC)

Telehealth maintains access to early phase clinical trials

during the Covid-19 pandemic

Human Research Ethics Committee Reference Number: 1479/18.
2. Agency for Clinical Innovation (2019), A Guide to Build Co-design
Capability, V1; 0289 [08/19].

Jyoti Parmar1 , Neha Aggarwal2 , Oksana Zdanska1 , Jacob Yousif1 ,
Joshua Hurwitz3,1 , Eleanor Handel1 , Anthony Rodrigues1 , Amy
Prawira4 , Anthony Joshua3,1 , Rasha Cosman3,1 , Jia Liu1,3,5
1 The

261

Guiding transformative change to address inequity across

the pancreatic cancer care continuum

Kinghorn Cancer Centre, St Vincents Hosptial, Sydney, Darlinghurst,

NSW, Australia
2 Medical Oncology, The Canberra Hospital, Canberra, ACT, Australia
3 St

Vincents Clinical School, The University of New South Wales, Dar-

Sarah McNeill1 , Susan Hanson1 , Caroline Nehill1 , Chris Baggoley2 ,

linghurst, NSW, Australia

Lorraine Chantrill3 , Dorothy Keefe1

4 Medical Oncology, Prince of Wales Hospital, Randwick, NSW, Australia

1 Cancer Australia, Strawberry Hills, NSW, Australia

5 The University of Sydney, Camperdown, NSW, Australia

2 PanKind, Manly, NSW, Australia
3 Department Medical Oncology, Illawarra Shoalhaven Local Health District,

Wollongong, NSW, Australia

Aims: The COVID-19 pandemic substantially disrupted healthcare
globally. Quarantine, travel restrictions, health worker furloughs and
institutional mandates to limit non-essential clinical activity signifi-

Aim: Pancreatic cancer is the third leading cause of cancer death in

cantly impacted upon trials recruitment abroad. The purpose of this

Australia and has a five-year survival rate of 11.5%. Significant clini-

review was to compare the demographics and enrolment for patients

cal, psychological, and social burdens contribute to the poor outcomes

referred to The Kinghorn Cancer Centre (TKCC) Phase 1 Unit between

experienced by Australians affected by pancreatic cancer. In March

January 2020 and March 2022, with historical data from the same

2020, Cancer Australia was invited to work with key stakeholders to

institution from the twelve months prior to determine the impact of

develop the National Pancreatic Cancer Roadmap. The aim was to iden-

COVID-19 on Phase 1 activity.

tify key priorities for collaborative action across the pancreatic cancer

Methods: A single institutional retrospective study was performed

care continuum to improve survival and outcomes for Australians

utilising a purpose-built Phase 1 database. Data extracted from elec-

affected by pancreatic cancer.

tronic medical records and trials electronic data capture software

Methods: The Roadmap was developed through an evidence-based,

included patient demographics, date and method of first review,

collaborative and consensus approach, this included:

consent date, screen-failure rate, date to enrolment, duration on
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trial and outcome post-trial. Analyses were performed in SPSS

impact of this model on their decision to participate or not. Not having

V26.0.

the principal investigator residing in their town was not considered a

Results: Four hundred and thirty-four patients were referred/seen in

safety concern by 94% of the participants. When asked if they would

the Phase 1 unit between January 2020 and March 2022 (16/month),

travel to a metropolitan centre for a placebo-controlled study, only

of which 341 (79%) were consented/screened onto a Phase 1 trial and

20% of patients indicated that they would definitely go, 40% indicated

157 (46%) proceeded to treatment. The proportion initial consulta-

that they definitely would not and 40% were uncertain.

tions using telehealth increased from 11.3% to 45.3% pre-post pan-

Conclusions: Rural cancer patients were overwhelmingly satisfied in

demic (P < 0.0001). However, the proportion of interstate referrals or

participating in a clinical trial locally through a regional cancer centre

regional/remote referrals did not change likely to widespread increase

or through the ATM. More research is needed into reducing barriers

in telehealth utilisation. Pandemic-induced lockdowns decreased abso-

for rural cancer patients to enrol onto clinical trials, including the role

lute numbers of Phase 1 referrals in the short term, however did not

of the teletrials.

influence enrolment or screen failure rates. Further mitigation strategies successfully employed at our Phase 1 unit included treatment-athome, teleconsenting, Phase 1 coordinators/investigators working in

264

split teams, and remote monitoring.

glioblastoma: A population-based study in Queensland

Patterns of treatment and outcomes for patients with

Conclusion: The COVID-19 pandemic did not impact upon the demographics of Phase 1 referrals to a major metropolitan hospital,

Suzi Poulgrain1 , Julie Moore2 , Phillippa Youl2 , Kimberley Budgen1 ,

however absolute numbers of referrals were influenced by lock-

Mark Pinkham1

downs/outbreaks. Telehealth was successful at maintaining access to

1 Cancer Services, Princess Alexandra Hospital, Brisbane, QLD, Australia

trials for patients in need and should be continued to allow equity of

2 Queensland

access to Phase 1 trials.

tralia

Cancer Control Analysis Team, Woolloongabba, QLD, Aus-

Aim: To assess for variations in patterns of care in first line treatment
263

Patient satisfaction with new models of clinical trial

participation: a cross-sectional study at a rural cancer centre

and survival for patients with glioblastoma (GBM) in Queensland.
Methods: This retrospective population-based study used data from
the Queensland Oncology Repository, a comprehensive repository

Andrew O. Parsonson1,2 , Rob Zielinski3,4

which contains demographic, diagnosis, and treatment data on

1 Department

Queenslanders diagnosed with cancer. The study population included

of Medical Oncology, Macarthur Cancer Therapy Centre,

Campbelltown, NSW, Australia

patients aged 18+ years diagnosed with glioblastoma (GBM) from

2 Clinical

2009 to 2019. We examined patterns of treatment according to age

Trials Unit, Macquarie University Hospital, Macquarie University,

NSW, Australia

group and location. Cox Proportional Hazards model was used to

3 Department

examine the risk of death.

of Medical Oncology, Orange Health Service, Orange, NSW,

Australia

Results: Of 2334 patients diagnosed with glioblastoma, 60.4% were

4 Western Sydney University, Campbelltown, NSW, Australia

male, 1.2% were First Nations peoples and median age at diagnosis
was 64 years (range 18–85). These patients were treated across 58

Aim: To determine rural cancer patient attitudes toward clinical trials,

public and private centres with approximately 70% receiving their pri-

including the Australian Teletrial Model (ATM).

mary treatment in five of these centres. Frontal and temporal lesions

Methods: Patients being recruited onto a clinical trial in Western NSW

were the most common (31.0% and 26.4%, respectively). The most

Local Health District were approached to participate in a 23-item

common treatment approaches were combination surgery, radiation

questionnaire, regarding different aspects of participation in clinical

therapy (RT) and chemotherapy (CT) (39.4%), surgery and RT (20.1%)

trials. Patients were also invited to provide suggestions for improve-

and surgery only (18.1%) of which more than half were a biopsy alone.

ment.

One in ten patients had no treatment with this being more common in

Results: Surveys were given out to consecutive patients enrolled into

those aged 70+ years (p < 0.001). Median GBM-specific survival for

a clinical trial in the Western NSW Local Health District over a period

patients who received treatment was 10.1 months and 2.1 months for

of 9 months. 37 valid questionnaires were returned. Median age was

those who did not receive treatment (p < 0.001). Risk of GBM-specific

66 (range: 33–84). Just under one half of patients took greater than

death occurring before 10.1 months was associated with increasing age

one hour to travel to the trials centre, with 10% needing to travel for

(p < 0.001), higher comorbidity burden (p < 0.001) and not receiving

longer than three hours. The majority of patients (87%) had not pre-

RT or CT (p < 0.001 and p < 0.001, respectively). There was no signif-

viously participated in a clinical trial but all patients were happy to be

icant correlation between death from GBM and socioeconomic status,

approached about enrolling onto a clinical trial. Of patients who par-

location nor being of First Nations origin.

ticipated in the ATM, 22% patients stated that being offered a teletrial

Conclusion: While survival following a diagnosis of GBM remains

would be make them more likely to participate, 33% said it would make

poor, multimodality treatment confers a significant survival advantage.

no difference with their decision to enrol and 44% uncertain of the
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Treatment outcomes did not differ significantly across metropolitan

Conclusion: We cannot elucidate if HRQOL in RCS is better or worse

and regional areas.

than in UCS. Results were heterogenous in global and subscale scores.
Further research requires standardised HRQOL instruments suited to
the survivorship phase, greater involvement of people with different

265

Is health-related quality of life in rural cancer survivors

cancer types and diversity in geographical locations.

better or worse than in urban survivors? A systematic review
Eli Ristevski1 , Sarah Latham2 , Victoria White3 , Kate Webber4,5 , Colin

266

Wood6 , Karolina Lisy6,7,8 , Nikki Davis9 , Colin O’Brien9 , Michael

within Cancer Council SA’s 13 11 20 service

Recognising gender identity: Promoting inclusive practice

Jefford6,7,8
1 Monash University, Monash Rural Health, Warragul, Victoria, Australia

Amanda Robertson1 , Karen Hall1 , Julia Morris1

2 Medical Oncology, Alfred Health, Melbourne, Victoria, Australia

1 Cancer Council SA, Eastwood, SA, Australia

3 Deakin

University, School of Psychology, Melbourne, Burwood, Victoria,

Australia

Aim: LGBTQIA+ people face disproportionate cancer-related health

4 Medical Oncology, Monash Health, Melbourne, Victoria, Australia

disparities. Creating an inclusive environment for LGBTQIA+ peo-

5 School

ple can foster a relationship with healthcare providers and improve

of Clinical Sciences, Monash University, Melbourne, Victoria, Aus-

tralia

communication about client needs. In response, Cancer Council SA

6 Department of Health Services Research, Peter MacCallum Cancer Centre,

implemented an inclusive and accepting model of care into its 13 11

Melbourne, Victoria, Australia

20 Information and Support service for people impacted by cancer.

7 Australian

The model included asking a caller’s gender identity and where appro-

Cancer Survivorship Centre, Peter MacCallum Cancer Centre,

Melbourne, Victoria, Australia

priate, facilitating conversations around gender and sexuality, and

8 Sir

cancer.

Peter MacCallum Department of Oncology, University of Melbourne,

Melbourne, Victoria, Australia

Methods: A half-day training was developed in consultation with

9 Cancer Advocate, Melbourne, Victoria, Australia

LGBTQIA+ community stakeholders and delivered to Cancer Council
SA 13 11 20 nurses. A self-report survey evaluated how the train-

Background: While there is evidence of inferior cancer survival out-

ing influenced nurses’ knowledge and understanding of cancer among

comes for people in rural areas, there is no systematic evidence

the LGBTQIA+ community, and their experiences of asking a caller’s

whether health-related quality of life (HRQOL) is lower in rural can-

gender identity.

cer survivors (RCS) than urban cancer survivors (UCS). We conducted a

Results: Training was developed in collaboration with SAMESH, a

systematic review to describe HRQOL outcomes in RCS and compared

partnership between Shine SA and Thorne Harbour Health. Train-

outcomes with urban UCS.

ing was delivered by SAMESH and provided information regarding

Methods: We searched Medline, Embase, CINAHL and PsycINFO

gender- and sexual-diversity; health impacts of social stigma; anti-

(2000–2022) for studies with adults in rural/regional/remote areas

discrimination laws; and creating a safe and inclusive environment.

who had completed definitive primary cancer treatment and were no

Approaches to asking a caller’s gender and discussing gender-related

longer receiving anticancer therapy. Studies with and without an urban

sensitive information were informed by the training. These practices

comparator and using a validated HRQOL instrument were included. A

were refined in consultation with Shine SA nurses and LGBTQIA+

narrative synthesis of studies was conducted.

community members before being adopted into the 13 11 20 care

Results: Nineteen studies involving 6205 participants; 3780 (61%)

model.

were rural were included. Participants’ mean age was 60 years, pre-

Results of the survey will inform understanding of how practice is

dominately female (89%) and within 1–5 years post-diagnosis. Most

enhanced or challenged by acknowledging gender-identity, from the

studies were from the United States (n = 11) and included rural-only

perspective of Cancer Council SA 13 11 20 nurses.

(n = 12) and breast cancer-only (n = 12) participants. Thirteen different

Conclusions: Cancer Council SA recognises the need to provide ser-

HRQOL questionnaires were used, only two were survivorship spe-

vices and care to LGBTIQIA+ people that is inclusive and accepting.

cific. Of the seven studies with an urban comparator, seven different

By providing person centred care and sensitively identifying people of

HRQOL instruments were used and five focussed on breast cancer only

this community by asking their gender identity, the Cancer Council SA

populations. Of the four studies reporting global HRQOL, two showed

13 11 20 Information and Support service strives to minimise distress,

better scores in UCS, one in RCS and one found no difference. Within

reduce inequities and meet the information and support needs of this

HRQOL domains, RCS had better emotional/psychological/mental

diverse group.

(4/7 studies) and functional (2/3 studies) well-being. No differences
between cohorts were found in social wellbeing (0/4 studies). Better
physical well-being was found in 3/7 studies with RCS, 1/7 study with
UCS and 3/7 studies found no difference between cohorts.
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One participant’s narrative in a grounded theory study:

platform for our advocacy to improve optimal cancer care and cancer

Cancer treatment for muscle invasive bladder cancer,

outcomes for all Australians, affected by all cancers.

disadvantages experienced living in rural Australia

The cost of cancer is the first chapter of the NCCP under development
and was selected due to the increasing impacts of financial toxicity in

Carli Shaw1 , Adele Baldwin1 , Carina Anderson2

cancer. The financial toxicity definition and other development work

1 Central Queensland University, Rockhampton

from COSA’s Financial Toxicity Working Group is central to the policy

2 University of Southern Queensland, Ipswich

development.
Integral to the process of developing this chapter will be Issues Based

Aims: The aim of this study is to better understand the challenges expe-

Forums which will seek input from experts across Australia, includ-

rienced by patients with cancer related cognitive impairment following

ing COSA members. These will assist in defining the policy and seek

chemotherapy.

policy solutions to decrease the impact of direct and indirect costs

Method: This study adopted a constructivist grounded theory method-

of cancer and address the changing financial circumstances of people

ology. Theoretical sampling included partners and carers of patients

affected by cancer.

who had completed adjuvant or neoadjuvant chemotherapy for a solid

This presentation will share the learnings from the development of the

malignancy in Australia approximately six months prior to interview.

NCPP and discuss the Cost of Cancer chapter as the leading example.

Limited consent was utilised, with the purpose of the study disclosed
to identify quality of life concerns after cancer treatment. The purpose
DPYD Genotype-guided personalised fluoropyrimidine

of limited consent was to ensure that information shared during quali-

270

tative interviews was not limited to only data believed to be related to

dosing: Determining the barriers and enablers of implementation

cognitive impairment. Data were generated through semi-structured
interviews and analysed using constant comparison.

Cass White1 , Stephen Ackland1 , Rodney Scott1,2 , Christine Paul1

Results: The study is ongoing, with analysis continuing. The disadvan-

1 College

tages associated with receiving multimodal cancer treatment in a rural

Callaghan, NSW, Australia

setting experienced by one participant warrants dissemination. Thus,

2 Molcular Medicine, Pathology North, John Hunter Hospital, , New Lambton

the focus of this paper is a narrative that provides an insight into the

Heights, New South Wales, Australia

of Health, Medicine and Wellbeing, University of Newcastle,

carer burden and quality of life challenges experienced in the first ten
months from diagnosis of muscle invasive bladder cancer. This partic-

The application of implementation research theory can identify factors

ipant’s story is uniquely theirs, however the challenges faced share

that impact the successful implementation of new clinical interventions

similarities with collective stories.

and highlight areas for further enhancement to improve intervention

Conclusion: Models of care that incorporate rural healthcare in plan-

accessibility and sustainability.

ning phases of complex cancer treatment will support the holistic

Aim and method: We aim to understand the perceived barriers

healthcare needs of rural patients both during and after treatment.

and enablers identified by stakeholders toward the implementation
of an upfront screening service identifying patients with dihydropy-
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Establishing a National Cancer Care Policy – Cancer

Council

rimidine dehydrogenase (DPYD) gene variants as part of a feasibility
study. DPYD variants can predispose patients to increased toxicity
when exposed to fluoropyrimidine (FP) chemotherapies (capecitabine

Kate Whittaker1 , Raylene Cox1 , Drew Meehan1 , Tanya Buchanan1 ,

and 5-fluorouracil). Semi-quantitative questionnaires were circulated

Megan Varlow1

to stakeholders; medical oncologists, oncology trainees, pharmacists

1 Cancer Council Australia, Sydney, NSW, Australia

and nurses involved in the care of oncology patients in both inpatient and outpatient capacities. Data was collated and analysed by two

Cancer care policy is often developed in siloed tumour streams,

independent assessors, utilising the Theoretical Domains Framework

retrofitted in response to announcements from politicians and unsus-

identify common themes.

tainably funded, or established to address unmet needs across a short

Results: Thirty stakeholders participated across four sites within

time period. While this is not always the case, these factors make it

Hunter New England and Central Coast Local Health Districts. Data

challenging for policy makers to take a big picture view, resulting in

saturation was estimated at ∼60%. Domains include: Knowledge (Bar-

many people affected by cancer not being supported to receive optimal

riers: lack of awareness of recent data supporting use/ availability

cancer care.

of testing); Social and Professional Role (Enablers: interest in reducing

Time, perspective, and resources are not always adequately afforded

toxicities for patients); Belief about Consequences/ Capabilities (Barrier:

to cancer care policy. In response to this, Cancer Council has com-

questioning the effectiveness in reducing health utilisation while main-

menced development of a National Cancer Care Policy (NCCP). This

taining efficiency; Enablers: interest in trials, innovation and health

will become the companion to our National Cancer Prevention Policy,

service improvement, enthusiasm to be early adopters of new inter-

elevate cancer care policy, and provide an evidence-based public-facing

ventions); Environmental Context and Resources (Barriers: wait time for
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results, lack of infrastructure and accessibility of guidelines; Enablers:

ent between CALD and non-CALD population (42.8 vs 43.8 months,

availability of internationally recommended guidelines).

p = 0.76). No specific differences were highlighted when analysed by

Conclusion: Intuitively, some barriers and enablers typically showed an

tumour location or histology.

inverse relationship. Factors identified within this study are similar to

Conclusions: CALD patients were more likely to present with gas-

those identified in international studies focused toward DPYD geno-

tric cancers and receive perioperative chemotherapy than non-CALD

typing, although we acknowledge the limited data within this realm.

patients who had a predominance of oesophageal cancers and treat-

Themes identified will form the foundation for strategy devel-

ment with neoadjuvant chemo-radiation. This may reflect genetic and

opment to be implemented alongside a larger scale clinical trial

etiological difference in gastric and oesophageal cancers in CALD

prospectively evaluating DPYD genotype-guided FP-dosing and toxic-

patients. Despite this, survival of CALD and non-CALD populations was

ities and cost-effectiveness within the Australia health care system.

similar.
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Tumour characteristics and outcomes of gastric and

oesophageal cancer patients treated with curative intent in

272

culturally and linguistically diverse (CALD) patients in South

in Australia: A scoping review

Factors that influence cancer clinical trials participation

Western Sydney
Kyung Ha (Kathy) You1,2 , Zarnie Lwin1,2 , Elizabeth Ahern3,4 , David
Robert Yoon1,2,3 , Stephanie Lim2,3,4 , Ray Asghari5 , Annette Tognela2,4 ,

Wyld1,2 , Natasha Roberts1,2

Aflah Roohullah1,3,4 , Stephen Della-Fiorentina2,4 , Mark Lee1 , Tara L.

1 Cancer

Roberts2,6,3 , Wei Chua1,2,6,3 , Weng Ng1,2,3

Queensland, Australia

1 Medical Oncology, Liverpool Hospital, Sydney, NSW, Australia

2 Faculty

2 School of Medicine, Western Sydney University, Sydney, NSW, Australia

Australia

3 Ingham Institute of Applied Medical Research, Sydney, NSW, Australia

3 Department

4 Medical

Australia

Oncology, Macarthur Cancer Therapy Centre, Sydney, NSW,

Australia

Care Services, Royal Brisbane and Women’s Hospital, Herston,
of Medicine, University of Queensland, Brisbane, Queensland,
of Medical Oncology, Monash Health, Clayton, Victoria,

4 School of Clinical Sciences, Monash University, Clayton, Victoria, Australia

5 Medical Oncology, Bankstown-Lidcombe Hospital, Sydney, NSW, Australia
6 School of Medicine, University of NSW, Sydney, NSW, Australia

Introduction: Equity in oncology clinical trial participation has been
declared a priority. We have responded by assessing factors influencing

Background: Gastric and oesophageal cancers cause significant

oncology clinical trial participation in the Australian context.

cancer-related morbidity and mortality in Australia. Multimodality

Aims: This scoping review aimed to identify and map the current litera-

treatment remains the cornerstone for curative intent treatment for

ture describing factors that influence cancer clinical trial participation

locally advanced disease. Culturally and linguistically diverse (CALD)

in Australia.

populations affected by cancer often have poorer health outcomes

Methods: A scoping review was conducted based on Joanna Briggs

compared to non-CALD populations which may be due to poorer health

Institute methodology. On 20 June 2022, we searched the MEDLINE,

literacy and unequal access to healthcare, resources and support

CINAHL, Embase, SCOPUS databases and conducted a grey literature

networks.

search in Google Scholar, Grey Literature Report and Web of Sci-

Aim: We compared the differences in tumour characteristics and out-

ence Conference Proceedings. Two independent reviewers performed

comes in patients treated with curative intent multimodality therapy

screening for title and abstract followed by full text using predefined

for gastric and oesophageal cancers across different cultural back-

inclusion criteria. Data was then extracted using a customized extrac-

grounds in South Western Sydney Local Health District (SWSLHD).

tion tool. At each step, a pilot of 10% studies was conducted to assess

Methods: All patients treated with chemotherapy between 2010 and

inter-rater reliability. We collated and reported results following the

2020 for non-metastatic gastric and oesophageal cancer across four

Preferred Reporting items for Systematic Reviews and Meta-Analyses

institutions in SWSLHD were identified from an electronic database.

(PRISMA) extension for scoping review. Qualitative data underwent

CALD patients were defined as those born in a predominantly

thematic analyses. Quantitative data was analysed descriptively.

non-English speaking country or whose preferred language was not

Results: Six hundred and forty-nine studies were identified once dupli-

English. SPSS was used to perform the statistical analyses.

cates were removed. Forty-four studies proceeded to full text review

Results: Two hundred and twelve patients (94 CALD and 118 non-

with 34 studies being included in the final analysis. Studies included

CALD respectively) were identified. A greater proportion (28.7% vs

surveys (n = 16), expert commentary (n = 5), randomized control

14.4%, p = 0.01) of CALD patients were female. CALD patients had

trial (n = 5) and mixed methods studies (n = 4). Key qualitative

a predominance of gastric cancers (70.2% vs 21.1%, p < 0.001).

themes identifying factors included ‘patient knowledge about clini-

Only 7% of all CALD patients had oesophageal cancer vs 45% of

cal trials’, ‘sociodemographics’, ‘resources supporting clinical trials’ and

non-CALD patients (p < 0.001). CALD patients also presented with

‘accessibility of clinical trials’.

earlier stage disease when compared to non-CALD patients (41.9 vs

Conclusion: This scoping review provides new insights into the fac-

57.4%, p = 0.01). Median overall survival was not statistically differ-

tors that can influence equitable cancer clinical trial participation in
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Australia. The current fragmented state of the literature presents an

2 School

opportunity to build new knowledge which may better inform health

Australia

policy, improve future clinical trial design, and deliver equitable cancer

3 Department

care for all.

Brisbane, Queensland, Australia
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Queensland, Australia

of Medicine, The University of Queensland, Brisbane, Queensland,
of Medical Oncology, Royal Brisbane and Women’s Hospital,

4 Department of Medical Oncology, The Prince Charles Hospital, Chermside,

Evaluating automated data extraction for lung cancer

pathology reports in NSW Cancer Registry

5 School of Medicine and Dentistry, Griffith University, Gold Coast, Queens-

land, Australia
Hanyu Chen1 , Sheena Lawrance1 , Claire Cooke-Yarborough1
1 Cancer Institute NSW, Sydney, NSW, Australia

Aim: To evaluate the real-world treatment patterns and outcomes for
patients with pleural mesothelioma (PM), particularly in the era of

Aims: The New South Wales Cancer Registry (NSWCR) continues

immunotherapy.

to evaluate artificial intelligence (AI) software, which uses Natural

Methods: This retrospective audit included patients with PM diag-

Language Processing and complex algorithms to extract data from

nosed within the Sunshine Coast and Metro North Health Ser-

electronic pathology reports. This project aimed to evaluate its abil-

vices (Queensland) from January 2017 to August 2022.

ity to extract selected lung cancer data variables, and to develop a

and treatment characteristics and outcomes were recorded. Data

semi-automatic data extraction approach for lung cancer reports.

was analysed using descriptive statistics and Kaplan Meier survival

Methods: Twenty-two standard data items in Structured Reporting

method.

Protocol for Lung Cancer 2nd edition were mapped to data items in

Results: Of 102 patients, 82% were male with a median age of 73

the software. Those evaluated include macroscopic features (e.g. later-

years (range 48–91) and 86% had baseline ECOG of 0–1. Subtypes

ality), microscopic features (e.g. grade), ancillary markers (e.g. immuno-

included: epithelioid (61%), biphasic (14%), sarcomatoid (12%), or

histochemistry and biomarkers) and TNM stage. Automatic and manual

unspecified/unknown (14%). Surgical interventions included: pleurec-

extractions (gold standard) were compared, and discrepancies were

tomy/decortication (2%) and VATS pleurodesis (35%). First-line sys-

evaluated.

temic treatment included: platinum/pemetrexed (39%), ipilimumab and

Results: Agreement scores were high when the data domain was

nivolumab (17%), durvalumab and chemotherapy on trial (13%), pem-

straightforward, for example, an 89% agreement for a ‘positive’/ ‘neg-

brolizumab (1%), clinical trial (2%), and 28% had best supportive care

ative’ result for Napsin A staining. Data items with specific titles such

(BSC). 12-month overall survival (OS) and progression-free survival

as T stage and TTF-1 also had higher agreement scores (88% and

rates were 58% (95% CI: 49–69) and 30% (95% CI 20–44) respectively.

87% respectively). Where there were discrepancies or multiple values

By subtype, 12-month OS rates were 67% (95% CI: 55–80) for epithe-

extracted, a null value resulted. AI software could not recognise some

lioid, 62% (95% CI: 41–95) for biphasic and 37% (95% CI: 17–80) for

texts and symbols such as ‘washing’/’brushing’ as procedure and ‘+’/‘−‘

sarcomatoid PM. There was a trend toward improved OS with first-line

in results of ancillary markers. In contrast to earlier evaluations (breast,

immunotherapy (doublet or with chemotherapy) over chemother-

colorectal and prostate), N stage only had an agreement score of 38%,

apy alone (HR 0.54, 95% CI: 0.27–1.08, p = 0.068). 12-month OS

as lymph nodes denoted as ‘N1’ or ‘N2’ were mistakenly extracted as N

rates were 84% (95% CI: 66–100) for ipilimumab and nivolumab,

stage values.

83% (95% CI: 64–100) for durvalumab and chemotherapy, 65% (95%

Conclusions: The results revealed the impact of the variability in report

CI: 51–81) for chemotherapy alone, and 26% (95% CI: 14–49) for

structure and descriptive phraseology complicated by the co-existence

BSC.

of several diagnosis and test results. Based on the results, the AI engine

Conclusion: In our unselected real-world population, a significant pro-

is being further improved. Where data items can be reliably extracted

portion of patients with PM did not receive active therapy and whilst

to pre-populate data fields, especially those of specific interest such

immunotherapy has broadened treatment options (PBS July 2021),

as staging and biomarker status, there will be an added advantage for

here it did not significantly improve OS compared to chemotherapy.

reporting at a population level.

Optimising suitability for therapy and trials is critical to meaningfully

Patient

improve real-world survival for PM.
275

Real-world outcomes for patients with pleural

mesothelioma: A multisite retrospective cohort study
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Exploring lung cancer patient awareness, attitudes and

practices of food-drug interactions with their targeted oral
anticancer medications

Kar Ven Cavan KVCC Chow1,2 , Cassie C.T. Turner1,2,3 , Brett B.H.
Hughes2,3,4 , Kathleen K.H. Houston1,5 , Zarnie Z.L. Lwin2,3,4 , Bryan B.C.

Sonia Cuan1 , Deirdre D’Souza1 , Joo Hee Hwang1 , Sheenal Prasad1 ,

Chan1,2,5

Melanie Rabbets2 , Helen Parker3 , Bernadette Nicholl4 , Lisa Pont5

1 The Adem Crosby Centre, Medical Oncology, Sunshine Coast Hospital and

1 Westmead

Health Service, Birtinya, Queensland, Australia

Australia

Cancer Care Pharmacy, Westmead Hospital, Westmead, NSW,

2 Crown Princess Mary Cancer Centre, Westmead, NSW, Australia
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3 School of Health Sciences, Faculty of Medicine & Health, The University of

3 La Trobe University, Wodonga, VIC, Australia

Sydney, Sydney, NSW, Australia

4 UNSW

4 Library, Westmead Hospital, Westmead, NSW, Australia

Australia

5 Discipline

5 Border Medical Oncology Research Unit, Albury Wodonga Regional Cancer

of Pharmacy, Graduate School of Health, University of Technol-

School of Clinical Medicine, Rural Clinical Campus, Albury, NSW,

ogy, Sydney, NSW, Australia

Centre, Albury, NSW, Australia

Background: Targeted oral anticancer medications (T-OAMs) have

Aims: To explore real-world outcomes in a regional setting, assessing

improved outcomes in molecular sub-types of lung cancer, offer-

1, 2 and 5-year lung cancer overall survival. Uptake of clinical trials,

ing dosing convenience and better tolerability than intravenous

immunotherapy and targeted therapies were also analysed.

chemotherapy. T-OAM bioavailability is altered through interaction

Methods: Border Medical Oncology and Haematology maintains a real

with bio-active foods such as grapefruit or dose-timing relative to

time ICD10 code-based registry of all patients, linked to DOB, diagno-

meals, risking over or under-dosing with higher toxicity or reduced

sis date and DOD. From this, a retrospective analysis was performed

effectiveness.

in June 2022, of patients with lung cancer who were diagnosed and

Aim: To investigate knowledge, awareness and avoidance of food-drug

managed from January 2015 to June 2021.

interactions (FDIs) in lung cancer patients on T-OAMs.

Results: 674 patients were included.

Methods: Single centre, non-randomised, multidisciplinary, qualitative

metastatic disease at diagnosis. The 1, 2 and 5-year survival and

study. Advanced lung cancer patients attending Westmead Hospi-

the percentage uptake for immunotherapy for all subtypes and

tal outpatient clinics prescribed T-OAMs for at least three months

stages is shown in Table 1. Corresponding data for patients with

were invited to participate in a 30-min semi-structured interview.

metastatic NSCLC is shown in Table 2. Uptake of targeted therapies and

Recruitment continued until data saturation. Interviews were tran-

clinical trials each year was less than 10%.

362 (53.7%) patients had

scribed verbatim and thematically analysed using NVivo® . Westmead
Human research ethics committee approval was obtained (2019/
ETH11743).

Conclusions: Immunotherapy is being used by clinicians in a regional

Results: Data saturation was reached after 11 interviews. Most partici-

setting for lung cancer treatment, and its uptake has paralleled some

pants were female (82%), age range was 45–90 years and T-OAM treat-

improvement in 1 and 2-year survival compared to our historical

ment duration range was 4–90 months. Three key themes emerged:

practice data.

knowledge of FDIs, awareness of different information sources and
preferences for information provision. In general, most participants
Tepotinib in patients with MET exon 14 (METex14)

were unaware of the interaction between T-OAMs and bioactive foods.

279

Those aware of the FDI reported avoidance of relevant foods however,

skipping NSCLC: Analysis of all patients from VISION Cohorts A

there was confusion regarding what foods were implicated. All par-

and C

ticipants recalled receiving written information on commencement of
their T-OAM but none were aware of specific cautionary information

Malinda Itchins1 , Michael Thomas2 , Marina Garassino3 , Enriqueta

such as ancillary labels on medication boxes. Participants highlighted

Felip4 , Hiroshi Sakai5 , Xiuning Le6 , Remi Veillon7 , Egbert Smit8 , Julien

the need for ongoing additional information and there was a strong

Mazieres9 , Alexis Cortot10 , Jo Raskin11 , Santiago Viteri12 , James

preference for one-to-one education regarding their T-OAM early in

Yang13 , Myung-Ju Ahn14 , Yi-Long Wu15 , Rui Ma16 , Jun Zhao17 , Aurora

their treatment.

O’Brate18 , Karin Berghoff19 , Rolf Bruns20 , Gordon Otto21 , Paul Paik22

Discussion: A strong need for ongoing patient education around

1 North Shore Private Hospital, St Leonards, NSW, Australia

T-OAMs and potential FDIs was found. Participants expressed a

2 Thoraxklinik,

clear preference to receive written information resources, explained

ter Heidelberg (TLRC-H), The German Center for Lung Research (DZL),

in detail by a health professional during face-to-face consulta-

Heidelberg, Germany

tion and for ongoing educational support throughout their cancer

3 Department

treatment.

dei Tumouri, Milan, Italy, Department of Medicine, Section of Hematol-

University Heidelberg and Translational Lung Research Cen-

of Medical Oncology, Fondazione IRCCS Istituto Nazionale

ogy/Oncology, Knapp Center for Biomedical Discovery, The University of
Chicago, IL, USA
277

Changing landscape of lung cancer survival in a regional

Australian centre

4 Department

of Oncology, Vall d’Hebron Institute of Oncology (VHIO),

Barcelona, Spain
5 Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan

Ortis Estacio1,2 , Natalie Chilko1,2 , Christopher Steer1,3,4 , Craig

6 Department of Thoracic Head and Neck Medical Oncology, The University

Underhill1,2,3,4 , Kerrie Clarke1 , Jacqueline McBurnie5 , Richard Eek1

of Texas MD Anderson Cancer Center, Houston, TX, USA

1 Border

7 CHU Bordeaux, service des maladies respiratoires, Bordeaux, France

Medical Oncology and Haematology, Albury Wodonga Regional

Cancer Centre, Albury, NSW, Australia

8 Department

2 Albury Wodonga Health, Albury, NSW, Australia

dam, The Netherlands

of Thoracic Oncology, Netherlands Cancer Institute, Amster-
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Table 1.
N

Year
2015

80

1-year survival (%)

2-year survival (%)

5-year survival (%)

53.8

38.8

25

1 L immunotherapy (%)
7.5

≥2 L immunotherapy (%)
11.3

2016

90

55.6

36.7

18.9

15.6

14.4

2017

127

55.9

40.2

23.6

14.2

15.0

2018

106

56.6

38.7

34.0

11.3

2019

118

61.9

49.2

38.1

5.1

2020

104

55.8

44.2

0

2021*

49

61.2

46.9

0

* 6 months data

Table 2.
Year

N

1-year survival (%)

2-year survival (%)

2015

26

30.8

19.2

7.7

3.8

15.4

2016

35

34.3

17.1

11.4

5.7

20.0

2017

51

35.3

23.5

11.8

11.8

31.4

5-year survival (%)

1 L immunotherapy (%)

≥2 L immunotherapy (%)

2018

59

39.0

18.6

27.1

20.3

2019

48

58.3

43.8

52.1

10.4

2020

44

38.6

56.8

0

2021*

19

52.6

73.7

0

9 CHU de Toulouse, Institut Universitaire du Cancer, Toulouse, France

22 Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New

10 Univ. Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020 –

York, NY, USA, Weill Cornell Medical College, New York, NY, USA

UMR-S 1277 – Canther, F-59000, Lille, France
11 Department

of Pulmonology and Thoracic Oncology, Antwerp University

Hospital (UZA), Edegem, Belgium
12 Dr

Rosell Oncology Institute, Dexeus University Hospital, QuironSalud

Aim: Tepotinib, a MET TKI, is approved for the treatment of METex14
skipping NSCLC. Here we report analysis of all patients with METex14
skipping in the Phase II VISION study (Cohort A: >2-years’ follow-up;

Group, Barcelona, Spain

confirmatory Cohort C: >9-months’ follow-up); data cut-off February

13 Department

20, 2022.

of Medical Oncology, National Taiwan University Cancer

Center, Taipei, Taiwan

Methods: Patients with advanced METex14 skipping NSCLC, received

14 Section

of Hematology-Oncology, Department of Medicine, Samsung

tepotinib 500 mg (450 mg active moiety) once daily. Primary end-

Medical Center Sungkyunkwan University School of Medicine, Seoul, South

point was objective response by IRC using RECIST v1.1. Pre-planned

Korea

exploratory analysis of brain lesions was conducted by IRC using

15 Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospi-

RANO-BM criteria.

tal & Guangdong Academy of Medical Sciences, Guangzhou, China

Results: Patients in Cohorts A+C (N = 313) had a median age of 72.0

16 Medical

years (range 41–94), 49.2% were male, 47.6% had smoking history,

Oncology, Department of Thoracic Cancer, Cancer Hospital of

China Medical University, Liaoning Cancer Hospital & Institute, Shenyang,

80.5% had adenocarcinoma histology and 73.8% had ECOG PS 1.

Liaoning, China

Treatment-naïve patients (1 L; overall, n = 164) had an ORR of

17 Key

Laboratory of Carcinogenesis and Translational Research (Ministry

56.1%; median duration of response (mDOR), progression-free survival

of Education/Beijing), Department of Thoracic Oncology, Peking University

(mPFS), and overall survival (mOS) were 46.8, 12.6 and 19.1 months,

Cancer Hospital and Institute, Beijing, China

respectively. Among 111 1 L patients enrolled via tissue biopsy (T+),

18 Global Medical Affairs, Merck Healthcare KGaA, Darmstadt, Germany

ORR was 56.8% with mDOR, mPFS, and mOS of 46.8, 16.3 and 25.9

19 Global Patient Safety, Merck Healthcare KGaA, Darmstadt, Germany

months, respectively.

20 Department

of Biostatistics, Merck Healthcare KGaA, Darmstadt, Ger-

21 Global

many

Previously treated patients (overall [n = 149] and T+ [n = 97]) had an
objective response rate (ORR) of 45.0% and 49.5%, with mDOR of 12.4

many
Clinical Development, Merck Healthcare KGaA, Darmstadt, Ger-

and 10.2 months, mPFS of 13.7 and 11.5 months, and mOS of 20.9 and
20.4 months.
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Intracranial (i) disease control rate in patients evaluable by RANO-BM
(n = 43) was 88.4% with iPFS of 20.9 months.
Treatment-related adverse events (TRAEs) occurred in 91.7% of
patients (Grade ≥3 34.2%); including (≥15%) peripheral oedema (any

∙ Initial imaging to
∙ ○Biopsy: 22 days (range 0–202)
∙ ○Treatment: 48 days (range 0–462)
∙ Diagnostic biopsy to treatment 21 days (range 0–433)

grade/Grade ≥3: 66.5/10.9%), nausea (23.3/0.6%), hypoalbuminemia
(23.0/3.2%), diarrhoea (22.4/0.3%), and increased blood creatinine

Conclusion: A large data base of lung cancer diagnosis and manage-

(21.7/0.6%). Permanent discontinuation due to TRAEs occurred in

ment in a regional centre provides a unique opportunity to explore

14.7% of patients.

potential modifiable contributors to improve poor outcomes in this

Conclusion: In VISION, the largest clinical trial of a MET inhibitor

high-risk patient group through survival and regression analysis.

in METex14 skipping NSCLC, tepotinib showed robust and durable efficacy, particularly in 1L patients, and promising intracranial activity was
observed.

1. Victorian Cancer Registry. Cancer in Victoria: Statistics & Trends
2019. Cancer Council Victoria, Melbourne, Victoria 2020. Available
from: https://www.cancervic.org.au/downloads/cec/cancer-in-vic/
Cancer-in-Victoria-2019.pdf

280

Understanding the drivers for poor outcomes in lung

cancer patients in a Victorian Regional Centre

2. Cancer Council Victoria and Department of Health Victoria 2021,
Optimal care pathway for people with lung cancer, 2nd edn, Cancer
Council Victoria, Melbourne. Available from: https://www.cancer.

Bridget Josephs1 , Cassandra Moore1 , Hieu Chau1 , Tricia Wright1

org.au/assets/pdf/lung-cancer-optimal-cancer-care-pathway

1 Latrobe Regional Hospital, Traralgon, VIC, Australia

Introduction: Regional Victoria has poorer outcomes for lung cancer
than metropolitan Melbourne 1.
Detailed information regarding the diagnosis of lung cancer is critical
to understand this problem.
Aim: To understand drivers of poor outcomes in regional centres and
identify potential modifiable variables through:
∙ A comprehensive retrospective audit of lung cancer diagnosis.
∙ Assessing timelines and their influencers against the Lung Cancer
Optimal Care Pathway (OCP)2.

281

Examining the unmet needs of older patients with lung

cancer patients: A systematic review
Nicole Knox1 , Louise Hickman2 , Shalini Vinod3 , Meera Agar3,4
1 University of Wollongong, Wollongong
2 University of Wollongong, Wollongong
3 SWSLHD, Liverpool Hospital
4 University of Technology Sydney, Ultimo

Aims: This systematic review of literature aims to analyse the (1)
amount and (2) type of unmet needs of older lung cancer patients.

Method: Data from a retrospective cohort of all patients with a diagnosis of lung cancer presented to the Gippsland Lung cancer MDM
between 1/1/2020 and 31/12/2021 was analysed.
Results: During the study period, 274 patients were diagnosed with
lung cancer.
Males (56.2%) and females (43.8%) were diagnosed at similar ages 71
(range 38–90) years and 70 (range 42–89) years respectively. More
than 95% had a smoking history.
Metropolitan referrals occurred in 36% of cases. Only 17% of regional
referrals were received from Primary Care.
More than 30% of cases required access to metropolitan services
including endobronchial ultrasound (EBUS) and complex cardiothoracic or neurosurgery.
Sixty (60) percent were diagnosed with stage IV disease. Adenocarcinoma (45%) was the most common histology followed by squamous cell
carcinoma (20%) and small cell (15%).
Treatment decision for 72% were palliative intent and 75% of patients
had died at the time of analysis.
OCP timing measured by the median number of days were met however the large range shows delays to treatment for individuals, for
example:

Methods: A systematic review of the published literature on unmet
needs of older lung cancer patients, (2002 and April 2022) was
conducted using CINAHL, MEDLINE, Embase and Scopus electronic
databases. Eligibility criteria for the selected studies included all types
of quantitative and qualitative studies assessing the unmet needs
of older (≥65 years) lung cancer patients. Studies were included if
data specific to lung cancer patients ≥65 years could be extracted.
Two researchers independently screened titles/abstracts and full text
articles.
Results: A total of 1175 articles were screened resulting in 34 articles
that meet the inclusion criteria. A narrative synthesis was chosen due
to the heterogeneity of the results of multiple different study designs.
Over three quarters (85%, 29/34) of studies included unmet needs
in lung cancer populations above 18 years, therefore data on the age
group ≥65 years was sparse and had to be extracted for this review. Of
these extracted results, older age was often associated with a reduction in unmet needs when compared to younger age groups lung cancer
populations. Although the results demonstrate that older lung cancer
patients experienced greater unmet needs and poorer quality of life
when studied in comparison with other types of cancer patients as a
cohort.
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Conclusion: Unmet needs in lung cancer patients are significant, how-

Conclusion: We have presented some real word data from the past

ever older patients are often excluded from studies due to poor

decade around the treatment patterns and long-term outcomes in

performance scores and cognitive decline. Older patients included in

stage III NSCLC patients. Equally, more robust, prospective studies

lung cancer unmet need studies are enrolled in trials that do not specify

would help delineate the optimal treatment modality in these patients

the older age group as their population. Given the high burden of lung

who still face a dismal prognosis.

cancer, further research is needed to better understand unmet needs
of the older patient with lung cancer.
283
282

Treatment patterns and long-term survival outcomes for

patients with stage III non-small cell lung cancer – A

Real-world comparative data on addition of Atezolizumab

to platinum-doublet chemotherapy in extensive stage small cell
lung cancer – A single South Australian institution experience

retrospective study
Yao J. Ly1,2 , Christopher Hocking1,2 , Rohit Joshi1,2 , Dainik Patel1,2 ,
Seema Dr Kumari1 , Deme Dr Karikios2,1 , Roland Dr

Hooi Hong1,2 , Mark McGregor1,2 , Annabel Smith1,2 , Vineet Kwatra1,2

Yeghiaian-Alvandi3 , Peter Dr Flynn4 , Lucy Prof Morgan5,1 , Lisa Kay6 ,

1 Medical

Pei Dr Ding2,1

tralia

1 Sydney

2 University of Adelaide, Adelaide, SA, Australia

Medical School, University of Sydney, Camperdown, New South

Oncology Unit, Lyell McEwin Hospital, Elizabeth Vale, SA, Aus-

Wales, Australia
2 Medical Oncology, Nepean Hospital Cancer Care Centre, Kingswood, New

Aims: Atezolizumab was listed on the pharmaceutical benefits scheme

South Wales, Australia

in March 2020 for use in combination with carboplatin and etopo-

3 Radiation

side for first line treatment of extensive stage small cell lung cancer

Oncology, Nepean Hospital Cancer Care Centre, Kingswood,

New South Wales, Australia

(ES-SCLC) based on the IMpower133 study. We aimed to investigate

4 Surgical

the survival benefits of additional Atezolizumab to platinum doublet

Department, Nepean Hospital, Kingswood, New South Wales,

chemotherapy for ES-SCLC in the real-world setting.

Australia
5 Respiratory

and Sleep Medicine, Nepean Hospital, Kingswood, New South

Wales, Australia
6 Nepean

Cancer Research Biobank, Nepean Hospital, Kingswood, New

South Wales, Australia

Methods: Retrospective single centre study. Patients were identified
from hospital databases. Group A commenced chemotherapy alone
from September 2018 to March 2020 while Group B commenced treatment with chemotherapy plus Atezolizumab between March 2020 and
June 2021. Data collection variables included patient demographics,

Aim: Lung cancer is the leading cause of cancer-related deaths in Aus-

date of diagnosis, number of cycles received, reason for stopping treat-

tralia with poor long-term survival outcomes. Stage III NSCLC is a

ment and date of death. All patients were followed for 15 months.

highly heterogenous group with diverse tumour characteristics and

Results were analysed through a Kaplan-Meier method.

multiple, possible treatment options. We present retrospective data

Results: Thirty-one patients were included in the study, fifteen in group

on patient characteristics, treatment patterns and long-term outcomes

A (chemotherapy) and sixteen in group B (Atezolizumab). Patients in

in stage III NSCLC patients treated at a single cancer centre in NSW,

both groups received carboplatin and etoposide. The median age at

Australia.

diagnosis was 69.5 years, similar for both groups. The median overall

Methods: Stage III NSCLC patients were identified from the ‘Nepean

survival was 6 months for group A compared to 8.1 months for group B.

Cancer Research Biobank’. Patient demographics, cancer-related

Overall survival rate at 15 months was 13.3% in group A compared to

information and long-term follow-up data were collected and

25% in group B. In the IMpower133 study, the overall survival outcome

analysed.

was 10.3 months in platinum-doublet chemotherapy and 12.3 months

Results: 88 patients were eligible for the study having their diagnosis

in Atezolizumab combination with chemotherapy. Three patients were

established between March 2012 and April 2020, with 61% of them

continuing maintenance Atezolizumab at the end of the study period.

diagnosed as stage IIIA, 35% IIIB and 4% IIIC. Induction chemotherapy

Ten patients stopped Atezolizumab due to disease progression and

was administered in 20% of the patients. 48% of the study population

three patients due to toxicity.

underwent surgery and 38% underwent CCRT. Both median PFS and

Conclusion: The addition of Atezolizumab to platinum-doublet

OS were superior in stage IIIA patients in comparison to stage IIIB (and

chemotherapy for treatment of ES-SCLC at our institute resulted in

IIIC) patients (22 versus 11 months, p = 0.018 and 58 vs 19 months,

increased median overall survival. Although the survival times are

p = 0.048, respectively). Patients who were younger (<65 years old),

shorter in both groups compared to IMpower133, we demonstrate

good ECOG performance status (ECOG PS <2) and females had better

a comparative benefit of adding Atezolizumab in the real-world

prognosis on univariate analysis. There was a non-statistically signif-

setting.

icant trend towards better median OS with CCRT in comparison to
surgery (58 vs 37 months, p = 0.87).

1. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair
MJ, et al. First-line atezolizumab plus chemotherapy in extensive-
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284

Investigating symptoms of lung cancer: A guide for all

health professionals
Tamsin Farrugia1 , Vivienne Milch1,2 , Anna Boltong1,3 , Dorothy Keefe1
1 Cancer Australia, Strawberry Hills, NSW, Australia
2 The University of Notre Dame Australia, Sydney, NSW, Australia
3 Kirby

Institute, UNSW Medicine, The University of New South Wales,

Sydney, NSW, Australia
Aims: Lung cancer is the fifth most commonly diagnosed cancer
and the leading cause of cancer death in Australia.1 Early diagnosis
improves survival,2 however, non-specific symptoms and smokingrelated stigma can cause delays in diagnosis.3,4,5 Increasing awareness
about appropriate investigation and referral of people with suspected
lung cancer is critical to improving outcomes. Cancer Australia’s clinical resource, investigating symptoms of lung cancer: a guide for all health
professionals (the Guide) was released in 2020 to increase awareness
amongst health professionals of recommendations for investigating
symptomatic people with suspected lung cancer, and support early and
rapid referral into the multidisciplinary diagnostic pathway.
Methods: In 2021, Cancer Australia undertook an innovative multifaceted digital implementation strategy to maximise the reach and
uptake of the Guide by health professionals and implement into
primary care.
Results: To increase the reach and uptake of the Guide, Cancer
Australia released:
∙ Clinical learning e-modules (titled ‘A systematic approach to investigating symptoms of lung cancer’) based on the Guide, developed in
partnership with Lung Foundation Australia, which provide casebased learning with a consumer story as the focus, and recommendations from the Guide presented throughout, and
∙ An interactive, mobile-optimised digital diagnostic tool to be used at
the point of care, and for educational purposes.
Since release, the digital tool has been viewed over 16,000 times. The
online clinical learning modules have seen 321 enrolments, with 96%
of completing health professionals rating their learning outcomes were
entirely met.
Conclusion: The freely accessible online clinical learning modules and
the digital diagnostic tool provide health professionals with interactive, easily accessible, digital resources to enhance education of the key
recommendations in the Guide. They encourage health professional
awareness about lung cancer risk factors, symptoms and signs that
may be due to lung cancer, optimal timeframes for investigation and
referral, and the importance of multidisciplinary care.
1. Australian Institute of Health and Welfare (AIHW) 2022. Cancer
data in Australia. Cat. no. CAN 122. Canberra: AIHW

survival-rate/relative-survival-stage-diagnosis-lung-cancer
3. Weller DP, Peake MD, Field JK. Presentation of lung cancer in primary care. NPJ primary care respiratory medicine. 2019;29(1):21
4. Bradley SH, Kennedy MPT, Neal RD. Recognising Lung Cancer in
Primary Care. Advances in therapy. 2019;36(1):19–30
5. Chambers SK, Dunn J, Occhipinti S, et al. A systematic review of
the impact of stigma and nihilism on lung cancer outcomes. BMC
Cancer. 2012; 12 (1): 184
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Impact of age on adverse event outcomes in advanced

NSCLC treated with first-line anti-PD-(L)1 ± chemotherapy
Alice Morris1 , Rebecca Tay1 , Allison Black1 , Louise Nott1 , Renae
Grundy1 , Karen Wills2 , Jessica Roydhouse2
1 Royal Hobart Hospital, Hobart, Tasmania, Australia
2 Menzies

Institute of Medical Research, University of Tasmania, Hobart,

Tasmania, Australia
Background: Persons ≥65 years represent two-thirds of advanced
non-driver mutated NSCLC whereby anti-PD-(L)1 ± chemotherapy
is standard first-line treatment. We evaluate the impact of age on
treatment outcomes including immune related adverse events (irAEs)
incidence and admission rates at one Australian tertiary centre.
Methods: Advanced NSCLC patients treated with first-line anti-PD(L)1 ± chemotherapy were identified retrospectively via multidisciplinary meeting referral and cross-referenced with electronic medical
records. Demographic, treatment outcome and adverse event data
was analysed using R-Studio for descriptive statistics and log-binomial
models.
Results: Between Oct 2019 and Feb 2022, 278 patients with newly
diagnosed NSCLC were identified; n = 130 presenting with advanced
disease. Of this cohort, n = 77 received first-line anti-PD-(L)1 ±
chemotherapy (chemoIO n = 63, 82%, IO alone n = 14, 18%). Median
age was 64 yrs (range 36–84) with a higher proportion of older (≥65
years n = 48, 62%), non-squamous (n = 57, 74%) and ECOG-1 (n = 61,
79%) patients. PD-L1 expression was 0% (n = 24, 31%), 1–49% (n = 28,
36%) and ≥50% (n = 24, 31%). Older age was associated with higher
rates of hospitalisation for any cause (<65 years 60% vs ≥65 years
76%; RR 1.27, 95% CI 0.89–1.82) secondary to admission for febrile
neutropenia (n = 6 vs n = 0), infection (n = 9 vs n = 5) and irAEs
(n = 16 vs n = 3). Admissions attributed to disease-related symptoms were equal in older vs younger patients (n = 9 vs n = 9). Older
age was associated with higher incidence of any (<65 years 26% vs
≥65 years 54%; RR 2.10, 95% CI 1.05–4.18) and grade 3+ (<65 years
29% vs ≥65 years 52%, RR 1.82, 95% CI 0.53–6.23) irAEs. The impact
of GCSF utilisation, treatment regimen and survival analysis will be
presented.
Conclusion: Patients ≥65 years with advanced NSCLC treated with
first-line anti-PD(L)1 ± chemotherapy are at higher risk of treatment

17437563, 2022, S3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/ajco.13869 by Henry Ford Health System, Wiley Online Library on [22/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

164

related AEs including hospitalisation for neutropenia, infection and

1 Department

severe irAEs compared to younger patients.

ACT, Australia

of Medical Oncology, Canberra Health Services, Canberra,

2 Australian National University Medical School, Canberra, ACT, Australia
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Clinicians’ perspectives on lung cancer referral pathway

in a regional health service

Intracranial metastases occur in 30%–50% of patients with non-small
cell lung cancer (NSCLC) and have a poor prognosis despite current
therapies utilising systemic chemotherapy, neurosurgery and radio-

Zulfiquer Otty1,2 , Amy Brown1,2 , Gail Kingston1 , Rebecca Evans2 ,

therapy. In contrast to the robust evidence for using immunotherapy

Sarah Larkins2 , sabe Sabesan1,2

to treat intracranial metastases in melanoma,1-4 evidence for intracra-

1 Townsville University Hospital, Townsville, QLD, Australia

nial responses in NSCLC are limited to retrospective studies and case

2 College of Medicine and Dentistry, James Cook University, Townsville, QLD,

reports describing third-line immunotherapy treatment.5-10

Australia

This case series describes durable, complete, cerebral and leptomeningeal responses to first-line pembrolizumab in a highly-

Aims: Efficient and streamlined referral of patients with suspected

selected group of three treatment-naive, ALK/EGFR-negative NSCLC

lung cancer is essential in providing equitable cancer care. As part

patients with low-volume intracranial metastases and very high PD-

of evaluating the Townsville Lung Cancer Referral Pathway (TLCRP)

L1-expression (80–100% Tumour Proportion Score). Overall survival

implementation, we explored clinicians’ experiences and perspectives

ranged from 13 to 54 months and ongoing. Progression-free survival

about the pathway.

ranged from 10 to 49 months and ongoing- while maintaining East-

Methods: This is a descriptive qualitative study nested within a broader

ern Cooperative Oncology Group (ECOG) performance status of 0–1.

implementation science framework. Semi-structured interviews with

All three patients experienced moderate to severe immune-related

General Practitioners (GPs) and lung cancer specialists in Townsville

adverse effects (IRAE).

Hospital and Health Service (THHS) were conducted. Recruitment

This case series highlights evolving hypotheses that first-line pem-

continued until data saturation. The interviews were audio-recorded,

brolizumab treatment in NSCLC may result in durable complete

transcribed and analysed qualitatively using an iterative thematic

intracranial response- even with leptomeningeal disease- and can be

technique by two researchers.

used as an adjunctive treatment with other neurosurgical and radio-

Results: Twenty interviews were conducted, 14 with GPs and six with

therapy modalities. Severe IRAE may also be a predictive marker for

specialists, including respiratory physicians and oncologists.

treatment response. Future clinical trials can specifically investigate

Most GPs use the TLCRP as they found it useful to manage a person

first-line immunotherapy in NSCLC and the correlation between very

suspected with lung cancer and was easily accessible via the relevant

high PD-L1 expression, IRAE severity and intracranial response rates.

website. Fewer GP referrals were rejected if they used the TLCRP. The
specialists felt that TLCRP streamlined the lung cancer referral process
and encouraged appropriate use of resources. Junior GPs appeared
more likely to use the TLCRP compared to senior colleagues. Oncologists reported seeing fewer undiagnosed lung cancer patients after
TLCRP implementation.
The common barriers to use of TLCRP were lack of awareness of
TLCRP, lack of time to use it and problems encountered with the electronic referral platform. In addition, unwillingness on the part of some
GPs to change their referral habit was a barrier to adoption of TLCRP.
Many clinicians felt that there should be better integration of GP and
specialist care.
Conclusions: We found most clinicians were satisfied with the web portal and content of the TLCRP and found it useful in the referral process
of people with suspected lung cancer. Further measures may have to be
taken to reduce barriers in implementing the TLCRP.

1. Kluger HM, Chiang V, Mahajan A, et al. Long-Term Survival
of Patients with Melanoma With Active Brain Metastases
Treated With Pembrolizumab on a Phase II Trial. J Clin Oncol.
2019;37(1):52–60.
2. Long GV, Atkinson V, Lo S, et al. Combination nivolumab
and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol.
2018;19(5):672–681.
3. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients
with melanoma and brain metastases: an open-label, phase 2 trial.
Lancet Oncol. 2012;13(5):459–465.
4. Tawbi HA, Forsyth PA, Algazi A, et al. Combined Nivolumab and
Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med.
2018;379(8):722–730.
5. Arias Ron D, Labandeira CM, Areses Manrique MC, et al. Dramatic
Response of Leptomeningeal Carcinomatosis to Nivolumab in PDL1 Highly Expressive Non-small Cell Lung Cancer: A Case Report.
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Durable complete leptomeningeal and intracerebral

responses to first-line Pembrolizumab in highly-selected
non-small cell lung cancer patients: A case series
Yi Tong Vincent Aw1,2 , Geoffrey Peters1,2

Front Oncol. 2019;9:819.
6. Crino L, Bronte G, Bidoli P, et al. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung
cancer. Lung Cancer. 2019;129:35–40.
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7. Di M, Zhang L. Pembrolizumab for non-small cell lung cancer with

Conclusions: Our data adds to the growing evidence that suggests that

central nervous system metastases: A two-case report. Thorac

combination nutritional – haematological surrogates are predictive in

Cancer. 2019;10(2):381–385.

survival outcomes for patients with NSCLC. This is the first Australian

8. Dudnik E, Yust-Katz S, Nechushtan H, et al. Intracranial response

data to report the possibility of PNI as a surrogate marker for PFS in the

to nivolumab in NSCLC patients with untreated or progressing

stage III NSCLC setting. Further research regarding its predictive utility

CNS metastases. Lung Cancer. 2016;98:114–117.

in larger cohorts is required for incorporation into predictive survival

9. Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab

models.

for management of patients with NSCLC and brain metastases:
long-term results and biomarker analysis from a non-randomised,
open-label, phase 2 trial. Lancet Oncol. 2020;21(5):655–663.
10. Goldman JW, Crino L, Vokes EE, et al. Nivolumab (nivo) in patients
(pts) with advanced (adv) NSCLC and central nervous system
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Role of hybrid FDG PET/contrast CT parameters at early

restaging for subsequent response to immunotherapy in
advanced NSCLC

(CNS) metastases (mets). J Clin Oncol. 2016;34(15 suppl):9038.
Dalveer Singh1
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Prognostic Nutritional Index (PNI) predicts progression

free survival in patients with unresectable stage III non-small cell
lung cancer treated with consolidation durvalumab
Udit Nindra2,1 , Adel Shahnam3 , Samuel X Stevens4 , Abhijit Pal2 , Po
Yee Yip1 , Tamiem Adam5 , Jenny Lee4 , Michael Boyer4 , Steven Kao4 ,
Adnan Nagrial3 , Victoria J. Bray2
1 Medical Oncology, Campbelltown Hospital, Campbelltown, Australia
2 Liverpool Hospital, Liverpool, NSW, Australia
3 Medical Oncology, Westmead Hospital, Sydney, Australia
4 Medical Oncology, Chris O’Brien Lifehouse, Sydney, Australia
5 Medical Oncology, Bankstown-Lidcombe Hospital, Bankstown, Australia

Background: The prognostic nutritional index is a surrogate marker
combining baseline albumin and neutrophil count and has been predictive of both progression free survival (PFS) and overall survival in
metastatic non-small cell lung cancer (NSCLC). This study investigates
the role of PNI as a surrogate for the survival outcomes for patients
with unresectable stage III NSCLC treated with chemoradiation followed by durvalumab.
Methods: This retrospective observational study was conducted
across six sites in Sydney, Australia. It included all patients diagnosed
with unresectable stage III NSCLC treated with chemoradiation and
who received at least one cycle of durvalumab between January 2018
and September 2021. The PNI was calculated as 10 × serum albumin
value (g/dL) + 0.005 × total lymphocyte count (per mm3) in peripheral
blood.
Results: One hundred and forty-four patients were included in the
analysis. The mean age was 66 years. The median PNI was 13.6 in the
total cohort. Patients were stratified into either PNI < 13.5 (PNI-Low)
or PNI > = 13.5 (PNI-High). At a median follow-up of 21.8 months
from durvalumab initiation, median progression free survival (PFS) in
PNI-High group was not reached versus 19.9 months in the PNI-Low
group (HR 0.58, 95% CI 0.34–0.99, p = 0.049). There was no statistically significant difference in overall survival between the two groups.
Multivariate analysis demonstrated that PNI remained independently
prognostic for PFS when stratified with age or presence of significant
cardiac or respiratory comorbidities (p = 0.048).

1 Qscan Radiology Clinics, Annerley, QLD, Australia

Aims: We investigate whether clinically applicable semi-quantitative
parameters derived from hybrid FDG PET diagnostic contrast
enhanced CT (FDG PET/CECT) can predict immunotherapy treatment
response in non-small cell lung cancer (NSCLC) patients. The secondary aim was to assess the relationship of immune-related adverse
events (irAEs) and metabolic activation of lymphoid cell-rich organs
activation to response in patients continuing on immunotherapy.
Methods: Thirty-two patients who underwent hybrid FDG PET/CECT
before and at first restaging after starting immunotherapy and with
minimum 12 month 3 monthly FDG PET/CECT, were retrospectively analysed. Imaging semi-quantitative parameters extracted were:
SUVmax target lesion target lesion necrosis, SUVmax of dominant
node and subsequently ΔSUVmaxTL ΔSUVmaxnode. These PETderived parameters were correlated to responding or stable disease as
assessed by both RECIST 1.1 and iRECIST 1.1. IrAEs, if present, were
also described and correlated with clinical benefit as determined by
continuation of therapy by the oncologist. SUVmax of the spleen and
bone marrow (as indicators of activation of lymphoid cell-rich organs)
at restaging scans were also correlated to clinical benefit.
Results: Of 32 eligible patients, 10 (31%) experienced iCPD,
8 (25%) showed iSD, 9 (28%) had iPR and 5 (16%) had iCR.
ΔSUVmaxTL (p = 0.008) and ΔSUVmaxnode (p < 0.001) were significantly associated with iPD vs. non-iPD. The presence of irAEs or
spleen/marrow activation were not correlated to response rates.
Conclusion: We describe semi-quantitative parameters on FDG
PET/CECT by using the early interval metabolic delta and baseline
necrosis as potential clinically useful and practical tools for iimmunotherapy treatment response evaluation in NSCLC. Metabolic activation of spleen/marrow from immunotherapy and irAEs in patients
deriving continued clinical benefit were not significant factors influencing response.
1. Ferrari C, Santo G, Merenda N, Branca A, Mammucci P, Pizzutilo P, Gadaleta CD, Rubini G. Immune Checkpoint Inhibitors
in Advanced NSCLC: [18F]FDG PET/CT as a Troubleshooter in
Treatment Response. Diagnostics (Basel). 2021 Sep 15;11(9):1681.
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chemoimmunotherapy for extensive stage small cell lung cancer

The role of thoracic radiotherapy (TRT) in the era of

(ES-SCLC)
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COVID-19 impacts on lung cancer diagnosis, management

Cassie L. Turner2,3,1 , Tito E. Prasetio2,4 , Shannon O’Berine4 , Georgina

and timeliness in Victoria, Australia

Anderson2,5 , Brett G.M. Hughes3,4,1 , Dinesh Vignarajah2,5 , Joanne

Luc te Marvelde1,2 , Margaret Brand3 , Shantelle Smith3 , Sue N

1 Department

Evans1,3 , John R Zalcberg3 , Rob G Stirling4

Herston, QLD, Australia

1 Victorian

2 The

Castelli2,3 , Zarnie Lwin3,4,1 , Kathleen Houston2 , Bryan A. Chan2,5

Cancer Registry, Cancer Council Victoria, Melbourne, VIC, Aus-

tralia
2 School

of Medical Oncology, Royal Brisbane and Women’s Hospital,

Adem Crosby Cancer Centre, Sunshine Coast University Hospital and

Health Service, Birtinya, QLD, Australia
of Public Health and Preventive Medicine, Faculty of Medicine

3 School

of Medicine, The University of Queensland, Brisbane, QLD, Aus-

Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia

tralia

3 Cancer

4 Department of Medical Oncology, The Prince Charles Hospital, Chermside,

Research Program, School of Public Health and Preventive

Medicine, Monash University, Melbourne, VIC, Australia

QLD, Australia

4 Allergy

5 School of Medicine, Griffith University, Gold Coast, QLD, Australia

Immunology and Respiratory Medicine, Alfred Health, Monash

University, Melbourne, VIC, Australia
Background: Recent trials have demonstrated improved overall surObjectives: To describe impact of COVID-19 on lung cancer inci-

vival (OS) with the addition of immunotherapy to platinum/etoposide

dence, stage at diagnosis, treatment utilisation and timeliness of care

chemotherapy in ES-SCLC. However, in these studies thoracic radio-

in Victoria, Australia.

therapy (TRT) was excluded, and its role in the current treatment

Design: Retrospective study using population wide Victorian Cancer

paradigm is unclear.

Registry data and clinical data from the Victorian Lung Cancer Registry,

Aim: To examine treatment patterns and outcomes for ES-SCLC

comparing data pre-COVID (2019 and Q1 of 2020) with the COVID era

treated with chemoimmunotherapy, with a focus on TRT utilisation.

(April 2020 onwards).

Methods: A retrospective audit of patients with ES-SCLC diagnosed

Setting: Population wide data on lung cancer diagnoses diagnosed in

within Sunshine Coast and Metro North Hospital and Health Services

2019 and 2020 in Victoria, and 4,485 cases with additional clinical data.

from March 2020 to March 2022 was undertaken.

Preliminary results: In the COVID-era, 177 fewer males (−12%) and

ics, systemic therapy, radiation data, toxicity and outcomes were

four fewer females (−0.3%) were diagnosed with lung cancer. Clinical

recorded. Descriptive statistics and Kaplan Meier survival analysis

stage at diagnoses for NSCLC was higher on average in Q2 2020 and

were utilised.

was similar to the pre-COVID distribution in Q2 and Q4. No changes

Results: A total of 50 patients treated with chemo-immunotherapy

were detected in the stage distribution for SCLC. The proportion of

were identified across three sites (median age 63 years; 56% female).

patients whose time from referral to diagnosis was ≤28d decreased

Seven patients (14%) received TRT with doses ranging from 30 to

with increasing with volume of referrals but was higher in the COVID

50 Gy. The majority had stage IIIC (n = 2) or IVA (n = 2) disease

era (74.6%) compared with the pre-COVID era (67.5%), not caused by

at baseline, and only three had extra-thoracic metastases. Indica-

a decrease in volume. The proportion of patients receiving any anti-

tions for TRT included: persistent bulky thoracic disease following

cancer treatment reduced slightly from 84% in the pre-COVID era

chemo-immunotherapy (n = 3); responding thoracic disease without

to 81% in the COVID era (p = 0.022). Time from diagnosis to treat-

extra-thoracic metastases (n = 2); concurrent TRT due to symp-

ment (≤14d; 37.3% of patients on average) was not associated with

tomatic thoracic disease (n = 1) and persistent low volume thoracic

Demograph-

volume of new diagnoses, nor did change in the COVID-era (p = 0.13).

disease with low volume extra-thoracic burden (n = 1). In the over-

The proportion of NSCLC patients who received guideline concordance

all population, progression-free survival at 6-months was 42% (95%

treatment did not differ between pre-COVID (83.1%) and the COVID

CI:30%–58%). Median OS was 9.24 months, and six and 12-month OS

era (81.7%; p = 0.31).

were 78% and 36% (95% CI: 25%–53%) respectively. Median OS in

Conclusion: Less males were diagnosed with lung cancer in the COVID-

those receiving TRT was 15.3 months. TRT was generally well tolerated

era. Although the health care system in Victoria had many disruptions

with only one patient experiencing grade ≥3 toxicity (pneumonitis).

following COVID restrictions, no negative impact on treatment utili-

Conclusions: TRT utilisation occurred in a minority of patients under-

sation nor timeliness was observed. In fact, timeliness from referral to

going chemo-immunotherapy in ES-SCLC. As expected, TRT when

diagnoses improved in the COVID era.

utilised, was in those with minimal or no extra-thoracic disease and/or
bulky residual thoracic disease following chemotherapy. TRT appeared
to be well tolerated in these select patients. The role of TRT has yet to
be determined in ES-SCLC treated with chemo-immunotherapy.
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Investigating the incidence febrile neutropenia in small

cell lung cancer (SCLC): Does adding ‘G’ make it ‘all G’?

The toxicity profile is well defined with pyrexia being a commonly
observed side effect. The underlying aetiology is unclear; elevated levels of proinflammatory cytokines in the serum of treated patients,

Michael Whordley1 , Marissa Ryan1 , Nicholas See1 , Courtney Hill2

however, suggest activation of the monocyte/ macrophage system.

1 Pharmacy

Hemophagocytic lymphohistiocytosis (HLH) is an acute and rapidly

Department, Cancer Services, Princess Alexandra Hospital,

Brisbane, QLD, Australia

progressive systemic inflammatory disorder that is mediated by aber-

2 Pharmacy

rantly activated macrophages and characterized by cytopenia and

Department, Princess Alexandra Hospital, Brisbane, QLD, Aus-

excessive cytokine production. Next to a primary genetic form, HLH

tralia

can by triggered by various causes, including infections, cancer, and
Aim: To investigate the incidence of Febrile Neutropenia (FN) in

drugs.

patients receiving chemotherapy (±) atezolizumab for the treatment of

We report on a 42-year-old patient with resected stage IIID BRAF

Small-Cell Lung Cancer (SCLC), either limited stage (LS-SCLC) or exten-

V600E-mutant melanoma who developed HLH shortly after commenc-

sive stage (ES-SCLC), ± granulocyte-colony stimulating factor (G-CSF)

ing adjuvant treatment with Dabrafenib and Trametinib.

support.

The patient presented to our emergency department with fever,

Method: A retrospective audit was conducted at a metropolitan

headache and skin rash; Dabrafenib and Trametinib were ceased on

hospital between 01/01/2019 and 31/05/2022 on patients receiv-

arrival and laboratory tests demonstrated thrombocytopenia and lym-

ing standard of care (SOC) treatment who were diagnosed with

phopenia. Septic workup and imaging were uninformative. Shortly

SCLC. Collection parameters included patient demographics, disease

after admission, the patient’s condition deteriorated rapidly with the

stage, treatment administered, and if G-CSF was administered at each

patient developing multiorgan failure requiring inotropic support and

cycle. FN incidence was compared between those patients who did and

intubation in the intensive care.

did not receive G-CSF.

A diagnosis of HLH was made based on fever > 38.5oC, bicytope-

Results: The majority of the 137 patients completed four cycles of

nias, splenomegaly, markedly elevated ferritin levels >100,000 ng/ml

platinum-etoposide based therapy (± atezolizumab) with 46 patients

and hypofibrinogenemia. A bone marrow aspirate demonstrated an

re-challenging after the four initial cycles (counted as cycle one again).

increased number of histocytes. Other acquired causes of HLH as viral

Out of all of the cycle one treatments (n = 163), 20 patients (12%) expe-

infections and autoimmune disorders were excluded, and treatment

rienced FN and were admitted to hospital. 13/20 (65%) patients with

with methylprednisolone and tocilizumab was initiated, leading to a

FN were not prescribed G-CSF, while 7/20 (35%) patients received G-

rapid clinical response.

CSF (p = 0.06). For the LS-SCLC group, the use of G-CSF resulted in

This case is the third reported patient developing HLH under

a statistically significant decrease in FN incidence with 1/38 patients

BRAF/MEK inhibitor therapy. HLH should be recognised as a rare side

in the-G-CSF group compared to 6/38 patients in the non-GCSF group

effect of this treatment modality and may represent an extreme mani-

(p = 0.05). While for the ES-SCLC group, there were 6/125 and 7/125 in

festation of commonly recognized pyrexia with these agents. Ongoing

the G-CSF and non-G-CSF groups, respectively (p = 0.78). All patients

translational research aims to further elicit the mechanisms of pyrexia

with FN following cycle 1, had G-CSF added ± a treatment dose reduc-

and HLH associated with BRAF/MEK inhibitor therapy.

tion for subsequent cycles. FN incidence dropped to 2% on cycle two
and remained low thereafter. There was one known fatality (limited
stage SCLC) due to severe neutropenic sepsis.

295

Conclusion: The addition of G-CSF to cycle 1 lowered FN incidence

What does that look like?

Equitable cancer care for women with ovarian cancer –

in patients with SCLC and was statistically significant for the LS-SCLC
group. A larger study is warranted to investigate upfront G-CSF with

Helen Gooden1 , Elsa Larsen1 , Bree Stevens1 , Clare Scott2

SOC treatment is required, or at least considered for specific patient

1 Australia

cohorts.

NSW, Australia
2 Walter

293

Hemophagocytic lymphohistiocytosis associated with

New Zealand Gynaecological Oncology Group, Camperdown,

and Eliza Hall Institute of Medical Research, University of Mel-

bourne, Parkville, VIC, Australia

targeted therapy using Dabrafenib and Trametinib
Introduction: Ovarian cancer has the poorest survival rate of all gynaeTaha Dr Al-Mufti1 , Oliver Dr Klein1 , Zee Wan Dr Wong1 , Nicole Dr

cological cancers at 48%. It is the sixth most common cause of cancer

Potasz1

death for women in Australia.1

1 The Department of Medicine – Oncology unit, Peninsula Health, Frankston,

The National Framework for Gynaecological Cancer Control (2016)2 iden-

VIC, Australia

tified priorities for equitable cancer care as: “greater awareness of
symptoms of gynaecological cancer, timely investigation and referral of a

Targeted therapy using BRAF/MEK inhibitor therapy is a mainstay of

woman who may have symptoms. . . improve earlier detection, enabling

melanoma management in patients with early and late-stage disease.

more timely treatment and improving the chances of long-term survival.”
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McRae, R. (2016)3 found despite its prevalence, cancer forms a minute

Objective: This project aims to survey patients undergoing chemother-

component of medical student assessment highlighting both clinical

apy to determine their satisfaction with the medication profile and to

and assessment gaps in cancer education. Starmer et al. (2020)4 noted

better understand what information patients deem important, along

it is ‘disturbing that some medical graduates feel their medical school

with how often medicine profiles should be provided to patients during

has underprepared them for [these] interactions.’

their appointments.

Aim: Survivors share their lived experience with future diagnosticians

Method: Participants were interviewed whilst receiving their cycle two

to raise awareness of ovarian cancer to promote timely diagnosis.

or cycle six chemotherapy treatments. Participants were asked a mix-

Survivors advocate for equitable cancer care for all women; person-

ture of quantitative and qualitative questions about their experience

centred cancer care and good health communication.

using the medicine list and invited to give feedback.

Method: Survivors Teaching Students® is an experiential learning pro-

Results: 94% of participants found the medicine profile at least a

gram for medical/ nursing students, targeting identified priority areas:

little bit useful in the management of their cancer supportive med-

raise awareness of signs and symptoms of ovarian cancer; enhance medical

ications, with 77% of patients referring to the profile at least twice

curricula learning opportunities. This consumer led international pro-

at home. Cycle two and six participants responded similarly to the

gram provides a unique student experience through engaging them

amount and type of information they would like to receive, along with

with ‘real-life experience’.

how often they would like to receive the medicine profile. Participants

Conclusion: Students evaluation (n = 6000) demonstrate effectiveness

were appreciative to have written information about their medicines,

of this learning – ‘The poor prognosis, little awareness and support avail-

expressing that it’s easy to forget all the information they are being

able compared to other more common types of cancers make it an incredibly

given.

difficult experience’ and survivors (n = 110) who report significant bene-

Discussion: This survey supports the continued utilisation of medicine

fits for them as: feelings of hope and healing, sense of purpose and regaining

profiles as part of the pharmacist education service and how patients

control of one’s life.

find this valuable. Participants described ways they think the medicine
profile can be improved such as hiding non dosing time slots and the

1. https://www.canceraustralia.gov.au/cancer-types/ovariancancer/statistics.

use of italics. These suggestions among others will be reviewed for
implementation into the service.

2. Cancer Australia, 2016. National Framework for Gynaecological
Cancer Control, Cancer Australia, NSW.
3. McRae, R. (2016) How best to teach and learn about cancer in
medical schools: moving towards a patient-centred approach that
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Circadian rhythm disrupting behaviours and cancer

outcomes in breast cancer survivors: A systematic review

reflects the needs of Australia. Cancer Forum. Vol 40, Issue 3.
4. Starmer, D.L. et al. (2020) Student Exposure to Cancer Patients:

Kelly D’cunha1 , Yikyung Park2 , Melinda M. Protani1 , Marina M.

an Analysis of Clinical Logbooks and Focus Groups in Clinical Year

Reeves1

Medical Students. Journal of Cancer Education. 35:760–765

1 Faculty of Medicine, School of Public Health, The University of Queensland,

Brisbane, QLD, Australia
2 Division
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A survey of patient satisfaction with pharmacist

of Public Health Sciences, Department of Surgery, Washington

University School of Medicine, St Louis, MO, USA

education with medication profiles for cancer supportive
medications

Background: Circadian rhythm disruptors (e.g., night shift work, light
at night) have emerged as risk factors for breast cancer, however evi-

Scott S.B. Bates1 , Kimberly-Ann KK Kerr1,2 , Kirsty K.T. Tait3,4 ,

dence on their influence on prognosis is limited. A small but growing

Chen-Yao C.H. Hung1

body of literature suggests mechanistic behaviours underpinning cir-

1 SA Pharmacy, Adelaide, SA, Australia

cadian rhythm disruption (i.e., sleep patterns and eating behaviours)

2 Digital Heallth SA, Digital Health SA, Adelaide, SA, Australia

may influence breast cancer outcomes, though this evidence is yet to

3 SA Pharmacy, Adelaide, SA, Australia

be summarised. Given that breast cancer survivors experience altered

4 UniSA, Adelaide, SA, Australia

eating and sleeping patterns following a cancer diagnosis, understanding the association between post-diagnosis behaviours and outcomes

Background: The provision of medicine information to patients is a

is important to inform interventions targeting these behaviours. There-

critical role of the pharmacist. To help support education, patients are

fore, we systematically summarised literature examining the influence

given a personalized list containing all their cancer supportive medi-

of post-diagnosis circadian rhythm disrupting behaviours on cancer

cations, detailing how to take the medicine(s) at home along with key

outcomes in women with breast cancer.

information. This is the first study to our knowledge to investigate con-

Methods: A systematic search of five databases from inception to

sumer satisfaction with medicine lists delivered by pharmacists in the

January 2021 was conducted. Original research published in English,

cancer setting.

assessing the relationship between post-diagnosis sleeping patterns
and eating behaviours, and breast cancer outcomes were considered.
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Risk of bias was assessed using the Newcastle-Ottawa Assessment

also utilised. Severe toxicity (grade 3–5) requiring hospital admission

Scale for Cohort Studies.

occurred in 40/373 (11%). Four treatment-related deaths occurred.

Results: Eight studies published original evidence addressing sleep

Treatment breaks followed all severe irAE. Nearly 50% were re-

duration and/or quality (k[number of studies] = 7) and, eating time

challenged. Rash (7%), colitis (6%), pneumonitis (3%), hepatitis (3%)

and frequency (k = 1). Longer sleep duration (>9 h versus [referent

most common. 32/373 (9%) required IV methylprednisolone and inflix-

range] 6–8 h) was consistently associated with increased risk of all out-

imab in three. Tertiary centre transfer for irAE management occurred

comes of interest (HR range: 1.37–2.33). There was limited evidence

in 9%. There was no difference in overall survival between severe irAE

to suggest that higher sleep quality is associated with lower risk of

and the total cohort (21.73 vs 22.9 months, p = 0.2).

all-cause mortality. Shorter nightly fasting duration (<13 h versus ≥13

Conclusions: Optimal management of ICI related severe irAE in a

h) was associated with higher risk of breast cancer outcomes (HR

regional setting is achievable with contemporary protocols and respon-

range: 1.21–1.36).

sive metropolitan support.

Conclusion: Our review suggests that circadian rhythm disrupting
behaviours influence cancer outcomes in women with breast cancer. While causality remains unclear, to further understand these

301

associations future research directions have been identified. Addi-

Cancer patients diagnosed (2013–15)

Cardiovascular hospitalisations in Queensland Lung

tional well-designed studies, examining other exposures (e.g., light
exposure, temporal eating patterns), biomarkers, and patient-reported

Abbey Diaz1 , Daniel Lindsay1,2 , Shafkat Jahan1 , Gail Garvey1

outcomes, in diverse populations (e.g., breast cancer subtype-specific,

1 University of Queensland, Herston, QUEENSLAND, Australia

socio-demographic diversity) are warranted.

2 QIMR

Berghofer Medical Research Institute, Herston, Queensland, Aus-

tralia
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Incidence and management of severe immune-related

adverse events in a regional Australian setting

Cancer patients are at higher risk of developing and dying from cardiovascular disease than the general population, largely due to exposure
to cardiotoxic cancer treatments and higher prevalence of risk factors

Amy Davies2,1 , Danielle Roscoe3 , Tricia Wright3 , Mahesh Iddawela2,3

common to both cancer and cardiovascular disease. There is limited

1 Latrobe Regional Hospital, Traralgon

Australian data on the incidence of cardiovascular disease after can-

2 Department

cer. Internationally, most studies on cardiotoxicity have focused on

of Medicine, School of Clinical Sciences, Monash University,

Melbourne, VIC, Australia

breast cancer. As lung cancer survival rates improve, there is need to

3 Latrobe Regional Hosptial, Traralgon

understand the issues facing this population.
For this analysis we analysed a subset of the CancerCostMod dataset,

Background: Immune checkpoint inhibitors (ICIs) are now standard-

including all Queensland adults diagnosed with lung cancer during

of-care across several tumour types and in various disease settings.

2013–15. Everyone had 2 years of hospital admission data prior to can-

ICIs act by enhancing an immune response and thus associated with

cer diagnosis to measure cardiovascular disease history (CV history)

toxicity which mirrors autoimmunity yet possess a different natural

and three and half years follow-up data to measure new cardiovascular

history. Management of severe immune-related adverse events (irAE)

hospitalisation after cancer. The proportion of the cohort hospitalised

is resource intensive, usually requiring additional specialty input – both

during the follow-up period was calculated, and the excess risk of

limited in a regional setting.

cardiovascular hospitalisation between groups was investigated by

Aim: To describe presentation and management of severe irAEs within

modelling time from cancer diagnosis to first cardiovascular hospital-

regional setting.

isation, censoring for death and end of study, using Cox proportional

Methods: A retrospective cohort of regional Victorian patients

hazard regressions.

(Latrobe Regional Hospital, Bairnsdale Regional Health Service, Cen-

Four thousand three hundred and sixty-nine Queenslanders diagnosed

tral Gippsland Health) receiving at least one dose of ICI (pem-

with lung cancer are included in this analysis. 12.4% had a history of

brolizumab, nivolumab, ipilimumab, atezolizumab, cemiplimab, durval-

cardiovascular hospitalisation, which was associated with older age

umab, avelumab) between 1 July 2018 and 30 June 2021. Clinicopath-

and being male. 17.4% of the cohort had a hospitalisation for car-

logical, cancer treatment, toxicity (as per CTCAE v5) and survival data

diovascular disease during follow-up. The proportion hospitalised for

was obtained. Statistical analysis performed using excel and R.

cardiovascular disease during follow-up increased with increasing age

Results: Total of 373 patients, with 232 (62%) male. Median age

and decreasing residential remoteness and was higher in those with

69 years (IQR 63–75). Over 80% (313/373) were ECOG 0-1 and

CV history than without (28.0% vs. 15.9%, p < 0.01). Lung cancer

mean Charlson score 8.7. Eighty percent (302) had metastatic disease.

patients with a CV history had a 2.4 times increased risk of being hos-

208/373 (55%) had lung cancer, followed by melanoma (25%), others

pitalisations for cardiovascular disease during follow-up, and this did

<10%. Nivolumab was the most common ICI (65%), used in combi-

not reduce when adjusting for age, sex, Indigenous status, residential

nation with ipilimumab in 2%. Pembrolizumab (32%), Atezolizumab

remoteness and residential socioeconomic advantage.

(9%), Durvalumab (5%), Avelumab (<1%) and Cemiplimab (<1%) were
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Recent hospitalisation for cardiovascular disease is a strong predictor

Ivanova K., Evans S., Rome R., Pilgrim C., Zalcberg J., Cossio D.

of cardiovascular hospitalisation after lung cancer diagnosis.

Background: In 2021, VCR led a study to assess the feasibility of collecting registry derived stage (RD-stage) for pancreatic, liver, stomach,
endometrial and ovarian cancers.

302

Variations in ethno-linguistic disparities as risk factor for

prostate cancer and its aggressiveness in South Africa

Methodology: Business rules for deriving RD-stage were developed
by VCR using AJCC Cancer Staging Manual 8th edition and endorsed
by tumour-specific Expert Working groups comprising cancer special-

Kazzem Gheybi1 , Vanessa Hayes1,2 , Eboneé Butler3 , Riana Bornman2

ists responsible for delivering cancer care. The developed business

1 University of Sydney, Camperdown, NSW, Australia

rules for pancreatic and endometrial were assessed for feasibility of

2 School

collection by population-based cancer registries (PBCRs). In Victoria,

of Health Systems and Public Health, University of Pretoria,

Pretoria, South Africa

RD-Stage was calculated by medical coders in the VCR on diag-

3 Division

noses between 2018–20 and validated against stage data collected

of Cancer Prevention, National Cancer Institute, National Insti-

tutes of Health, Rockville, Maryland, USA

from medical records by the Upper Gastrointestinal Clinical Registry
(UGICR) and the National Gynae Oncology Registry (NGOR).

Introduction: Having an African ancestry is a well-established risk

Results: Level of completeness of stage data able to be reported by

factor for advanced prostate cancer (PCa) and southern Africa has

PBCRs at baseline ranged from 0% to 75% for pancreatic cancer and

one of the highest mortality rates for PCa in the world. Meanwhile,

from 0% to 98% for endometrial carcinoma.

southern Africa has the highest genetic diversity globally, and many

For pancreatic cancer, RD-Stage could not be derived for 165/457

ethno-linguistic groups reside in the region. However, no studies have

(36%) cases and was not captured for 189/457 (41%) cases in

investigated the significance of this diverse ethnical disparities with

UGICR. There was concordance at stage level (I–IV) for 218/229

other epidemiological variables in risk of prostate cancer and its

(95.8%, Kendall’s coefficient of concordance = 0.92) cases.

aggressiveness.

For endometrial cancer, RD-Stage could not be derived for 64/457

Methods: This population-based study was performed as a part of the

(14%) cases and was not captured for 44/441 (10%) cases in

ongoing South African Prostate Cancer Study (SAPCS). We investi-

NGOR. There was concordance at stage level (I-IV) for 393/410

gated a series of epidemiological risk factors including demographic

(95.8%, Kendall’s coefficient = 0.95) cases.

and lifestyle factors in the participants (741 diagnosed PCa cases and

Discussion and Conclusion: A barrier to routine capture of RD-Stage

505 controls). Statistical methods were used to find the association of

data by PBCRs is lack of access to administrative data reporting

different variables with risk of PCa and the advanced disease.

metastatic disease at diagnosis. RD-Stage performs well against stage

Results: Our findings suggest that the Nguni ethnicity is more likely

collected by clinical quality registries, where it is available in both. A

than other ethnicities to be diagnosed with PCa (OR = 1.63, 95%

recommendation to Cancer Australia is that stage at diagnosis to be

CI = 1.02–2.63). Erectile dysfunction, gynecomastia and vertex/ com-

collected and reported in a standard format at a national level by

plete baldness patterns were other risk factors associated with PCa.

PBCRs.

Subsequently, we have assessed factors associated with advanced PCa
(ISUP = 4/5), and showed that men of Tsonga ethnicity are significantly more likely to present with advanced diseases (OR = 3.43 95%

304

CI = 1.62–7.27), even after adjustment for all covariates. Living in areas

anticancer medicines approved by the US food and drug

with higher poverty index was also associated with advanced PCa.

administration

Audit of data sharing by pharmaceutical companies for

Discussion: Studies to investigate the reason for the high prevalence of advanced PCa among men of African ancestry are lacking.

Natansh D. Modi1 , Ashley M. Hopkins1 , Michael J. Sorich1

This research revealed that African ethnicities are associated with

1 College

advanced stage disease regardless of the epidemiological risk factors.

SA, Australia

of Medicine and Public Health, Flinders University, Bedford Park,

Economic status showed to have a significant association not only for
PCa, but also for disease aggression. These results can be improved by

Background: Individual participant data (IPD) sharing enriches the

studies from other regions of sub-Saharan Africa with broad coverage

post-approval evidence-base, informs future study designs, and facil-

of the population and alignment with genetic risk factors.

itates novel secondary analyses. Since 2014, the pharmaceutical
industry has acknowledged the importance of IPD sharing via endorsing their commitments to transparent IPD sharing with qualified

303

RD-stage at diagnosis for pancreatic and endometrial

cancer: Validation process of the developed business rules

researchers (i.e., >95% of big-pharma companies have an IPD sharing
policy). This study examined whether the IPD for key oncology trials
supporting the registration of anticancer medicines approved within

Kris Ivanova1 , Sue Evans1

the past decade were eligible for sharing.

1 VCR, Melbourne, VIC, Australia

Methods: Pivotal trial results supporting FDA-approved anti-cancer
medicines within the past decade were identified from product labels.
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The main outcome was frequency of IPD sharing eligibility. IPD sharing

status (aOR2.79, 95%CI = 2.27–3.43) and mental distress (aOR9.01,

eligibility was confirmed by identification of a public listing of the trial

95%CI = 7.25–11.20) the most. Comorbid blood conditions increased

as eligible for sharing or a positive response to a standardised enquiry

the odds of poor health (aOR2.93, 95%CI = 1.62–5.29) but not distress

to the sponsor.

(aOR1.27, 95%CI = 0.68–2.35) alone.

Results: From 2011 to 2021, 115 industry-sponsored anticancer

Conclusions: Comorbidities in people with cancer were more common

medicines were approved by the FDA, based on the evidence of 304

and were generally associated with inferior health status when com-

industry-sponsored trials. Of the 304 trials, 136 (45%) were eligible for

pared to people without cancer, although the magnitude of the effect

IPD sharing. Data sharing rates differed substantially between industry

varied by comorbidity type. A comorbid mental illness was associated

sponsors. The most common reason (89 of 168 trials) a trial would not

with the worst health outcomes for cancer survivors. Further research

be shared was that the collection of long-term follow-up data was con-

into identifying individuals at the highest risk of a poor health outcome

tinuing. Of the top 10 anticancer medicines by global sales, nivolumab,

is required for targeting interventions.

pembrolizumab, and pomalidomide had the lowest eligibility rates for
data sharing (<10% of trials).
Conclusion: There has been a significant increase in IPD sharing for
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industry-sponsored oncology trials over the past 5 years. However, it

the Barwon Southwest region of Victoria

Impact of COVID-19 on cancer diagnosis notifications in

was found that >50% of queried trials for FDA-approved anticancer
medicines were ineligible for IPD sharing. Data accessibility would

Graham Pitson1 , Leigh Matheson1 , Alison Patrick1 , Margaret Rogers1

be substantially improved if, upon registration of a medicine, all data

1 Barwon

supporting the registration was made available.

tralia

South Western Region Integrated Cancer Services, Geelong, Aus-

Aims: COVID-19 has had much publicised impacts on cancer diagnosis
305

The health outcomes in people with cancer and

comorbidities: The Australian National Health Survey analysis

within Victoria. Statewide there are thought to be over 2000 undiagnosed malignancies since the start of the pandemic, particularly in men
and within melanoma, prostate cancer and head and neck malignancies.

Huah Shin Ng1 , Richard Woodman1 , Bogda Koczwara1

Regional and local patterns of presentation may differ from statewide

1 College

data and local data suggesting under diagnosis may assist in regional

of Medicine and Public Health, Flinders University, Bedford Park,

SA, Australia

service planning.
Methods: Prior statistical analysis using Victorian Cancer Registry

Aims: Comorbidities are associated with inferior health outcomes but

(VCR) data has been used to identify a shortfall in cancer diagnoses.

data on the influence of specific comorbidities is limited. We compared

VCR notifications for 2019–2021 inclusive for the Barwon southwest

health outcomes between persons with and without cancer accord-

region were utilised for this review. Notifications for the five most

ing to their index comorbidity using data from the Australian National

common cancers were assessed for major variations in notifications,

Health Survey 2017–18.

taking a pragmatic approach to classify a major variation where noti-

Methods: A cross-sectional comparison of adults aged ≥25 years was

fications changed by more than 10% from 2019 levels in either or both

performed comparing self-assessed health status (measure of per-

of 2020/2021.

ception of health, categorised as poor or good health) and mental

Results: Total notifications did not change significantly from 2019–

distress (measure of negative emotional states, categorised as high-

21 (3676, 3777, 3731, respectively). Likewise, there were no obvious

very high or low-moderate distress) between persons with and without

reductions in notification by sex or in older patients. While breast can-

cancer by 12 different comorbidities. Data were analysed using logis-

cer notifications dropped in 2021 but rebounded in 2022 (424, 348,

tic regression with adjustment for sociodemographic and lifestyle

453), diagnoses of DCIS increased each year (36, 55, 68). Lung cancer

factors.

notifications dropped in 2021–22 (336, 249, 269) as did notifications

Results: There were 1982 persons (52% female) with and 12,635

of colorectal cancer (452, 418, 361), while prostate cancer notifications

persons (51% female) without cancer. Cancer patients were older

rose (531, 662, 654) and melanoma notifications were fairly consistent

(53% vs. 18% aged ≥65 years), more often born in Australia (80%

(145, 158, 141).

vs. 67%) and have a comorbidity (91% vs. 75%) compared with those

Conclusions: Using a pragmatic approach to identifying major varia-

without cancer. Persons with cancer were more likely to report a

tions in cancer notifications during the COVID-19 pandemic, regional

poor health status than those without cancer for each comorbid-

data suggests a reduction in lung cancer and colorectal cancer diag-

ity except for skin and infectious diseases; the adjusted odds ratio

noses in our region. Unlike reported statewide data, there was not

(aOR) ranged from 1.34 (95%CI = 1.01–1.79) for digestive disorders

an obvious drop in notifications of prostate cancer or melanoma. Fur-

to 2.11 (95%CI = 1.78–2.52) for musculoskeletal diseases. A comor-

ther analysis of this data may help better identify cohorts with under

bid mental illness increased the odds of reporting both poor health

diagnosis in our region.
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Oncology social determinants of health

tains Local Health District (NBMLHD) is responsible for providing
health care to ∼350,000 residents, including Indigenous, culturally

Linh Van1 , Mark A. Boyd1,2 , Kate E. Neadley2 , Christopher Hocking1

and linguistically diverse and socioeconomically disadvantaged com-

1 Lyell McEwin Hospital, Northern Adelaide Local Health Network, Adelaide,

munities. NBMLHD requires an evidence-based bereavement model of

SA, Australia

care that identifies all aspects of bereavement processes and incorpo-

2 Faculty

rates recommendations for their diverse communities. The aim of this

of Health and Medical Sciences, The University of Adelaide,

Adelaide, SA, Australia

research is to develop a bereavement clinical pathway that identifies
all aspects of bereavement processes: screening, education, training,

Aims: Adverse social determinants of health (SDoH) lead to health

follow-up and care provision.

outcome disparities including in people living with cancer. Little is

Methods: This systematic approach to the development of the

known about the prevalence of social factors affecting people with can-

bereavement clinical pathway will involve:

cer. This study describes the unmet social needs of people living in a
disadvantaged area of Australia receiving treatment for cancer.
Methods: We recruited 141 people ≥18 years old with any cancer
diagnosis receiving treatment at the Northern Adelaide Cancer Cen-

1. Systematic review of the literature to identify international frameworks and implementation factors of relevance to the Australian
context; and

tre. Participants completed a locally developed Social Health Screening

2. Qualitative interviews with key stakeholders who provide bereave-

Tool, which included 10 questions across 7 social determinant domains.

ment support to explore current routine practice, gaps in services

We collected age, country of birth, education level and Healthcare Card

and resources, and identify barriers and facilitators to implement-

access. Descriptive analyses summarised the data and the prevalence

ing a bereavement clinical pathway.

of unmet social needs.
Results: Mean (SD) age of participants was 60 yo. The youngest and

Results: We will present the findings of the systematic review and

oldest participants were 18 and 88yo respectively. Seventy percent

qualitative analysis, as well as describe the proposed NBMLHD

were Australian born; 18% UK born. Over 75% had completed at

bereavement clinical pathway.

least Year 10 education. The number of unmet needs reported per

Conclusions: The bereavement clinical pathway developed from this

individual varied, with 72% of participants reporting at least one unmet

research will be implemented into practice within NBMLHD and future

social need. Twenty-three people (16%) reported ≥3 unmet social

research will involve an evaluation of the model to determine key

needs. One individual reported 8 unmet needs. The most prevalent

implementation outcomes for feasibility, acceptability, and adherence.

adverse SDoH was unemployment (53%), followed by rental or mort-

Further, the results of this research will inform the development of a

gage stress (21%), feeling unsupported by family and community (17%),

brief education resource to build capacity for health professionals and

household bills (13%) and food insecurity (12%). The majority felt safe

volunteers that covers identified knowledge gaps.

in their home and neighbourhood.
Conclusions: This study highlights the challenges of unmet social
needs in unwell people living with disadvantage and the importance
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of systematic screening to facilitate detection. The SDoH screening

information and support services (CISS) create social value for

tool is being used in a follow-up clinical trial using a Health Navi-

Australian society

Stakeholders’ perspectives on how telephone cancer

gator to assist people living with cancer address unmet needs. Integrating SDoH screening into practice may augment patient-centred

Jessica Bucholc1,2 , Claire Hutchinson3 , Danielle Spence2 , Nikki

healthcare, improve quality of life and reduce emergency department

McCaffrey1,2

presentations and admissions.

1 Deakin

Health Economics, Institute for Health Transformation, Deakin

University, Geelong, VIC, Australia
2 Cancer Council Victoria, Melbourne, VIC, Australia
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Developing a person-centred bereavement care service

3 Caring

Futures Institute, College of Nursing and Health Sciences, Flinders

for health professionals working with diverse communities

University, Adelaide, South Australia, Australia

Nicci Bartley1 , Laura Kirsten2 , Cindy Wilson2 , Betsy Sajish2 , Claire

Aims: There is currently no evidence on the social return on invest-

Cooper1 , Joanne Shaw1

ment (SROI) to inform the future funding and direction of telephone

1 Psycho-Oncology

CISS. Developing a Theory of Change (TOC) is the first, critical step

Cooperative Group, University of Sydney, Sydney, NSW,

in SROI and clarifies assumptions, describing how telephone CISS cre-

Australia
2 Nepean

Cancer and Wellness Centre, Nepean Hospital, Kingswood, NSW,

Australia

ates social value for the wider community. The aim of this study was
to develop a TOC from stakeholders’ experiences and perspectives to
underpin the SROI analysis of Cancer Council Victoria’s telephone CISS

Aims: Evidence-based bereavement care is not routinely provided or
delivered by trained staff in Australian hospitals. Nepean Blue Moun-

(131120).
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Methods: Sixteen convenience sampled key stakeholders (some iden-

Background: CAR-T therapy is a novel treatment for haematological

tified as multiple stakeholder types: five patients/survivors, two

malignancies. Eligibility criteria in Australia are patients with multiply

carers, four service providers, three healthcare professionals, five

relapsed or refractory diffuse large b-cell lymphomas who have had

researchers) participated in three facilitated, online focus groups and

two or more lines of systemic treatment (e.g. chemotherapy, stem cell

two interviews to identify the resources (inputs) into 131,120, activ-

transplant), all which are well documented to increase risk of malnutri-

ities (outputs) and outcomes, and describe how the service brings

tion. There is limited information on the nutritional status of patients

about change. The discussions were recorded, transcribed, coded the-

prior to, and following, CAR-T therapy.

matically and formulated as a logic model (TOC). The TOC was then

Aims: To assess the nutritional status of patients before CAR-T therapy

circulated to participants for checking to enhance trustworthiness.

and observe post-treatment nutritional status, symptoms and dietetic

Results: Key resources identified included staffing, information and

interventions.

communication technology (ICT), training and organisation overheads.

Methods: Eligible participants received proactive nutrition assessment

Activities included information provision, supportive and therapeutic

and consultation prior to CAR-T therapy as part of a wider study

communications and referrals to other services. Participants hypothe-

evaluating the feasibility of multimodal prehabilitation (Nov 2020–

sized that contacting 131,120 enhances callers’ knowledge on prevent-

Dec 2021). Pre-treatment, nutritional status and sarcopenia were

ing, detecting, diagnosing, treating, surviving and living with cancer

assessed using patient-generated subjective global assessment (PG-

and provides support on how best to do this. Increased knowledge,

SGA), hand grip strength (HGS) and appendicular lean mass (ALM) via

greater empowerment, and reduced unmet needs promotes healthy

bioimpedance spectroscopy. Usual care was followed post-treatment.

behaviours and leads to improved health, wellbeing and more targeted

The need for dietetic intervention and frequency of nutrition-related

and appropriate use of healthcare services.

symptoms post CAR-T therapy were recorded.

Conclusion: Based on stakeholders’ views, data on personnel, infras-

Results: Fifteen participants (54% female, mean age 61 years (45–

tructure, ICT and training costs, knowledge and empowerment levels,

71) and body mass index 24.7 kg (19.4–33.9 kg/m2 ) were included.

unmet needs, wellbeing and healthcare use are needed to inform a rig-

All participants were well-nourished at baseline with one deemed sar-

orous SROI of 131,120. This is the first stage in a multi-study program

copenic (using cut-offs for HGS and ALM). Post CAR-T therapy, 33%

of research defining the economic and social return on investment of

(n = 5) required dietetic intervention including oral nutrition support.

Victoria’s 131,120 service.

Of these, common nutrition-related symptoms were nausea (n = 3/5,
60%), vomiting, diarrhoea and dysgeusia (each n = 2/5; 40%). At time of
dietetic intervention, 80% (n = 4/5) were malnourished (PG-SGA B/C).
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Nutritional status of patients undergoing Chimeric

Antigen Receptor T-Cell (CAR-T) therapy; a feasibility study

Conclusions: In one-third of participants CAR-T therapy was associated with nutrition-related symptoms that required dietetic intervention, and 80% of participants receiving dietitian contact were

Danika Carty1 , Hilmy Ismail2,3 , Emily Traer2,3 , Bernhard Riedel2,3,4 ,

malnourished, indicating risk of nutritional status decline post CAR-T.

Nicole O’Leary5 , Simon Harrison5 , Jessica Crowe6 , Erika Kotowicz6 ,

Further research is needed to investigate the nutritional implications

Lara Edbrooke7,8 , Maria Ftanou9 , Erin Laing1 , Jenelle Loeliger1

of CAR-T therapy in a larger sample and to test the effectiveness of
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post-treatment nutrition interventions on nutritional outcomes in a
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of Haematology and Flow Cytometry, Laverty Pathology,
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7 Department of Reproductive Medicine, Royal Hospital for Women, Sydney,

of Medicine, University of Notre Dame, Daringhurst, NSW, Aus-

tralia

NSW, Australia
8 School of Women’s and Children’s Health, University of New South Wales,

Introduction: Chemotherapy predisposes women to abnormal uterine

Randwick, NSW, Australia

bleeding, such as potentially life-threatening menorrhagia and irreg-

9 Department

ular menses, which may be associated with premature ovarian failure

Australia

and infertility.

10 School

Aims: The purpose of this study was to explore the incidence of men-

tralia

of Haematology, St Vincent’s Hospital, Darlinghurst, NSW,

of Medicine, University of Notre Dame, Daringhurst, NSW, Aus-

strual history documentation and counselling before, during and after
cancer treatment.

Introduction: Cancer treatment can significantly reduce reproduc-

Methods: Retrospective chart review of 143 consecutive women aged

tive potential in female patients. Despite best-practice recommen-

18–49 receiving anticancer treatment at a major tertiary hospital

dations, women are not commonly offered fertility preservation

between 2017 and 2020. Data collected included primary diagnosis,

referrals.

stage of cancer, treatment(s) received, rates of remission or progres-

Aim: To examine the incidence of fertility counselling in women of

sion, prior reproductive history, contraceptive use, thromboembolic

childbearing age receiving anticancer therapies.

complications, involvement of a specialist gynaecologist, menstruation

Methods: Our group conducted a retrospective chart review at a

advice received, and signs or diagnosis of premature ovarian failure.

major Australian cancer centre of premenopausal females aged 18–49

Results: Only 15.4% had their menstrual history taken at the ini-

years diagnosed with cancer between 2017 and 2020. Data collected

tial consult, and 47.0% at a subsequent consult with their treating

included demographics, cancer diagnosis, treatment(s) received, fertil-

oncologist or haematologist. Only one patient had menstrual distur-

ity history, timing and documentation of fertility discussions, referrals

bance documented by a gynaecologist. The majority (82.5%) of patients

to specialist gynaecologists, and fertility outcomes.

with a menstrual history documented experienced menstrual distur-

Results: A total of 143 patients met inclusion criteria. Only 12.6%

bance post-treatment, most commonly amenorrhoea (48.5%), irregular

had a reproductive health history documented at the first consult,

menses (22.3%), menorrhagia (12.6%), menopause (10.7%), dysmen-

and just over half (58%) had a fertility preservation discussion at

orrhoea (4.9%) and iron deficiency secondary to bleeding (1.9%).

some point with their primary haematologist or oncologist. A quarter

Dysmenorrhoea and iron deficiency were more likely to be treated

(25.9%) saw a specialist gynaecologist to discuss fertility preservation

than other disturbances.

options, and 11.2% were offered a referral but declined. Of those with

Conclusion: Menstruation disturbance is common in women receiv-

fertility-related outcomes documented, 21.0% had return of menses,

ing anticancer treatment. Menstrual care should be integral to can-

15.4% had >1 oocyte cryopreserved, 9.1% had already completed

cer care for women, and higher engagement could be achieved

their families, 9.1% did not want children, 7.7% experienced premature

through the education of medical staff and allied health professionals,

menopause, 2.1% managed a successful pregnancy and birth, 1.4% had

information technology systems automating prompts and gynaecol-

embryos cryopreserved, and 1.4% unsuccessfully attempted in vitro

ogist referral pathways, regular audits to ensure compliance, better

fertilisation.

alliances between cancer and fertility specialists, and the creation of

Conclusion: In an Australian major cancer centre only a quarter of

accessible patient information to promote awareness and facilitate

women of reproductive age with cancer saw a fertility preservation

discussion.

specialist. Promoting and facilitating reproductive counselling needs
to be addressed by better relationships between fertility gynaecologists and oncologists/haematologists, implementation of technology
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Rates of fertility discussions and counselling before,

during and after anticancer treatments: Women deserve gender

systems ensuring fertility preservation discussions, and improved staff
education.
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surveillance cancer patients

Establishing a shared care service (GPCanShare) for
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of Haematology and Flow Cytometry, Laverty Pathology,

Background: After completion of cancer-related treatments, patients

Australia
4 Department

Macquarie Park, NSW, Australia

in remission enter surveillance monitoring. Traditionally, patients are

5 Kids Cancer Centre, Sydney Children’s Hospital, Sydney, NSW, Australia

followed up by their medical specialist throughout the whole surveil-

6 Nelune Cancer Centre, Prince of Wales Hospital, Randwick, NSW, Australia

lance period. With an estimated 151 000 people diagnosed with cancer

7 Department of Oncology, St Vincent’s Hospital, Sydney, NSW, Australia

each year; this model of care may not be feasible.

8 Department of Reproductive Medicine, Royal Hospital for Women, Sydney,

A strategy implemented by Sydney Eastern Sydney Local Health Dis-

NSW, Australia

trict (SESLHD) is to incorporate shared care (GPCanShare) between

9 St

the patient’s general practitioner (GP) and also their medical spe-

Vincent’s Clinical School, University of New South Wales, Randwick,

NSW, Australia

cialist. GPCanShare involves alternating visits between their local

10 School

GP and medical specialist to ensure patients are followed up as per

of Medicine, University of Notre Dame, Daringhurst, NSW, Aus-

tralia

survivorship clinical guidelines.
Aim: The establishment of GPCanShare aims to optimize care for

Introduction: Cancer treatment can significantly affect patient

cancer patients. This includes the ability to improve communication

sexual function, through physical alterations and psychosocial

between the GPs and medical specialists, provide clinical and edu-

impacts.

cational support to GPs and streamline urgent referrals back to the

Aim: To investigate the incidence of sexual history documentation and

medical specialist if required.

counselling before, during and after cancer treatment.

Methods: Patients suitable for the shared care follow-up are flagged by

Methods: Our group conducted a retrospective chart review at a

the care coordinators or medical specialists. Verbal Consent is gained

major Australian cancer centre of premenopausal females aged 18–49

between the patient and their local GP. Care plans with scheduled

years diagnosed with cancer between 2017 and 2020. Data collected

follow-up dates and times are distributed to the patient and their local

included primary diagnosis, stage of cancer, treatment(s) received,

GP. Cancer diagnoses that have limited evidence-based surveillance

rates of remission or progression, involvement of a specialist gynaecol-

guidelines are adapted to take into account the patient’s medical his-

ogist, details of any sexual function/dysfunction discussions, and what

tory, tumour grading, ECOG status, goals of care and any limitations

treatment was offered.

with seeing GPs.

Results: A total of 143 patients met inclusion criteria. Only 9.8% had

Results: Since the commencement of this service, we have recruited

their sexual history taken by their haematologist or oncologist, and

150 patients into GPCanShare. Overall, we have projected to save a

4.2% had their sexual histories documented by a gynaecologist. Forty

total of 45 clinic hours at the cancer centre. Fact sheets have been

patients had documented sexual dysfunction, most commonly vagi-

developed for GPs to identify “red flag” symptoms that require urgent

nal dryness (55%), dyspareunia (28%), body image concerns (28%),

specialist assessment.

bacterial vaginosis (20%), decreased libido (18%), vaginal GVHD (3%),

Conclusion: GPCanShare has allowed an alternative sustainable

and muscle spasms affecting coitus (3%). When these issues were dis-

method for the follow up of cancer surveillance patients. An area of fur-

cussed, they were often addressed by requesting gynaecologist, sexual

ther focus may involve streamlining patient care between the different

health specialist and/or psychologist reviews, or by prescribing oint-

medical specialities like Radiation Oncologists, Medical Oncologist and

ments, antifungals, antidepressants, lubricants, laser treatments, inser-

Surgeons.

tion of an intrauterine device, dilators, vaginal moisturisers, topical
oestradiol or inserts.
Discussion: This rate of sexual function history taking is exception-

1. Cancer in Australia 2021; Australian Institute of Health and Welfare (AIWH).

ally low. Women’s sexual function concerns are rarely raised by
physicians or volunteered by patients. To overcome existing barriers,
there needs to be improved education of physicians on sexual dysfunc-
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tion, implementation of systems to facilitate sexual history taking, and

multidisciplinary prehabilitation in the Autologous Stem Cell

the provision of patient information sheets to facilitate knowledge and

Transplant population: A theory-based interview study

Enablers and barriers to referral and delivery of

discussion.
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Health service nutrition practices and associations with
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clinical outcomes in patients undergoing resection for upper
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Aims: Health care professionals (HCPs) play a vital role in the effectiveness of a prehabilitation program, but information is limited about what

Background: Perioperative nutrition support is strongly recommended

assists HCP deliver an effective service. This study evaluated allied

for patients with upper gastrointestinal (UGI) cancer to optimise

health clinicians’, nurses’ and haematologists’ perceptions of enablers

outcomes. This study aimed to investigate health service nutrition

and barriers to two behaviours: referral for, and delivery of, multidisci-

practices of sites providing care to patients undergoing surgery for UGI

plinary prehabilitation prior to autologous stem cell transplant.

cancer within Australia, and associations with patient outcomes.

Methods: Based on the Theoretical Domains Framework (TDF) of

Methods: The 27 tertiary sites participating in the NOURISH point

behaviour change, we conducted semi-structured interviews, purpo-

prevalence study completed a purpose-built site-specific survey

sively sampling 14 participants at a tertiary cancer centre. Discipline-

regarding the provision of perioperative nutrition support services and

specific topic guides were designed based on the TDF and the

outpatient clinics, and the use of evidence-based nutrition care path-

behaviours appropriate to each discipline. Interviews were audio-

ways/protocols. Data from the 200 patients undergoing gastrectomy,

recorded, transcribed verbatim, anonymised, analysed by content

pancreatectomy or oesophagectomy who participated in the preva-

analysis (grouping, then labelling, thematically similar responses) and

lence study was investigated using multivariate analysis to determine

classified into theoretical domains. Structured rules were used to

associations with the sites’ use of a nutrition care pathway/protocol.

classify themes as high, medium or low priority.

Outcomes included malnutrition prevalence, preoperative weight loss

Results: Fifty enablers and 31 barriers were identified; with 26 and

and receipt of dietetics intervention, intraoperative feeding tube inser-

16 classified as high priority, respectively. Four domains had the most

tions, provision of nutrition support day one post-surgery, length of

frequent high-priority enablers: Social professional role and identity

stay and complications.

(e.g., multidisciplinary teamwork); Beliefs about consequences (e.g.,

Results: Eighty-five percent of sites reported having some form of

patients will benefit from prehabilitation); Memory, attention and deci-

outpatient clinic service; however, a routine service was only avail-

sion processes (e.g., refer as early as possible); and Environmental

able at 26% of sites preoperatively and 37% postoperatively. The

context and resources (e.g., electronic medical records are benefi-

majority of sites (>92%) reported having dietetics services available in

cial). High-priority barriers were most prevalent in four domains:

chemotherapy/radiotherapy. Most preoperative services were embed-

Memory, attention and decision processes (e.g., conflicting views about

ded into multidisciplinary surgical/oncology clinics (70%); however, this

who should be referred); Environmental context and resources (e.g.,

was reported for only 44% of postoperative clinics. Only 44% utilised

lack of time); Social influences (e.g., families); and Emotions (e.g.,

a nutrition care pathway/protocol. The use of a nutrition care path-

patients’ emotions).

way/protocol was associated with lower rates of malnutrition (OR (95%

Conclusion: Participants reported more enablers to prehabilitation

Confidence Interval (CI)) 0.5 (0.3, 0.9), p = 0.048), higher rates of pre-

referral and delivery than barriers. These findings can support delivery

operative dietetics intervention (OR (95% CI) 2.2 (1.1, 4.5), p = 0.036),

of prehabilitation programs in hospital settings where uptake remains

intraoperative feeding tube insertions (OR (95% CI) 2.9 (1.2, 6.9),

low. Future prehabilitation services should include interventions tar-

p = 0.018) and evidence based guideline compliant care day one post

geted at high-priority enabler domains: Social professional role and

surgery (OR (95% CI) 3.5 (1.6, 7.9), p = 0.002).

identity; Beliefs about consequences; Memory, attention and decision

Conclusions: This study demonstrated varied perioperative nutri-

processes; and Environmental context and resources.

tion services in UGI cancer. The use of nutrition care pathways and
protocols was associated with improved clinical outcomes.
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Hanging connections in cancer survivorship care delivered

via telehealth: Reflections from the Sydney Cancer Survivorship

330

A qualitative study of factors influencing Advanced Care

Planning in oncology

Centre multi-disciplinary team
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Introduction: The Sydney Cancer Survivorship Centre (SCSC) runs a

6 Faculty

face-to-face multi-disciplinary team (MDT) visit for each new patient.

Australia

This enables patients to be assessed by each member of the MDT. In

7 Westmead Hospital, Western Sydney Local Health District, NSW, Australia

of Science, Medicine and Health, University of Wollongong, NSW,

March 2020 the clinic rapidly transitioned to telehealth delivery in
response to the COVID-19 pandemic.

Background: Advance Care Planning (ACP) is a patient-centred pro-

Aim: To explore the experiences of delivering survivorship care via

cess that enables individuals to consider their goals and priorities, and

telehealth.

make plans with their healthcare team for future care needs. Oncology

Methods: Using an interpretive descriptive qualitative methodology,

clinicians care for a significant number of critically ill patients and are

we conducted focus groups (FG) and individual interviews with MDT

central to facilitating and documenting ACP conversations. The bene-

members from SCSC. One FG was conducted in person, all others via

fits of ACP in oncology are widely supported by Australian and interna-

the zoom platform. Discussions were audio-recorded and transcribed

tional guidelines. However, reported rates of clinician involvement in

for analysis.

ACP are low and documentation of ACPs remain suboptimal.

Results: Thirteen people participated in three FG or two individual

Aims: The aim of the study is to (1) explore oncology clinicians’ ACP

interviews. Four key themes were identified: What is lost; Relation-

knowledge, decision making and routine practice, and factors that

ships; Logistical issues; and, Telehealth skills.

influence the ACP process (2) enhance understanding of the supports

Within ‘Relationships’ there were impacts on team relationships

needed for oncology clinicians to increase ACP completion.

which became more fragmented without in person contact. With

Methods: Participants were purposefully sampled for participation in

patients, telehealth was easier where relationships had already been

semi-structured interviews conducted between November 2021 and

established. Establishing rapport with new patients was more dif-

March 2022. Interviews were recorded and transcribed, and data was

ficult. ‘What is lost’ identified the limited ability to garner visual

analysed by coding transcripts to the Theoretical Domains Framework

cues, vital signs, and conduct physical examinations. While patient

(TDF) in a deductive thematic analysis. The data was then analysed

reported outcome measures assisted in overcoming some issues, with-

utilising an inductive approach to thematically generate explanatory

out visual cues, assessment was more challenging. ‘Logistical issues’

sub-themes within identified domains.

were both positive and negative, with positive outcomes for patients:

Results: Participants (n = 11) included medical/radiation oncology con-

reduced travel time, time off work, parking, and costs. Whereas,

sultants (54.5%) and oncology advance trainees (45.5%). Interview

time required to prepare patients for the clinic was greater, engaging

length ranged from 17.5 to 35.5 min. Codes were mapped to all 14

with interpreters challenging, and technical issues commonly com-

TDF domains. Delivery of ACP was linked to knowledge, confidence,

promised interactions. Participants noted telehealth requires specific

attitudes and experience, as well as factors related to environmental

skills from both staff and patients. Determining patients able to man-

context and resources. All participants associated ACP with best-

age telehealth was challenging. Staff noted developing skills in tele-

practice but noted barriers to delivery include; limited legal literacy,

health, particularly how to detect more subtle cues or communicate

a lack of formal training, inter-disciplinary communication, workload,

effectively.

professional experience and confidence, EMR usability, and patient

Conclusions: The SCSC clinic transitioned successfully to telehealth.

characteristics (i.e. psychological state, health literacy).

However, there is a need to improve telehealth platforms, skills of staff

Conclusion: The socio-cultural environment surrounding ACP is

to communicate and assess patients, and management of patient flow

extremely complex, and associated with multiple co-dependent fac-

through the clinic.

tors. Future quality improvement programs should be designed
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accordingly to ensure ACP interventions are appropriately targeted to

pants represented all MDT disciplines, predominantly surgery (32%),

the implementation context.

radiation (23%) and medical (20%) oncology, and nursing (18%),
across six Australian states, with an even spread of experience
level.
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Conclusions: This study identified an Australian set of evidence-based

Measurement that matters: an Australian set of

multidisciplinary colorectal cancer quality indicators

CRC QIs prioritised by clinical importance. This set is unique in representation of all domains of care and disciplines involved in the patient
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linked databases and local datasets of routinely collected electronic
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medical record data.

1 Faculty of Medicine and Health, University of Sydney, Camperdown, NSW,

Australia
2 Radiation

Oncology Network, Western Sydney Local Health District,

332

Genetic testing in prostate cancer: a scoping literature

review

Westmead, NSW, Australia
3 Department of Surgery, Westmead Hospital, Westmead, NSW, Australia
4 Westmead Clinical School, University of Sydney, Sydney, NSW, Australia

Kim Edmunds1 , Shiksha Arora1 , Matthew Roberts2 , David Fairbairn3 ,

5 Crown Princess Mary Cancer Centre, Western Sydney Local Health District,

Paul Scuffham4 , David Smith5 , Suzanne Chambers6 , Lisa Horvath7 ,

Westmead

Haitham Tuffaha1

6 Sydney West Cancer Network, Western Sydney & Nepean Blue Mountains

1 Centre

Local Health Districts, NSW, Australia

Queensland, Brisbane, QLD, Australia

7 Cancer Therapy Centre, Liverpool Hospital, Liverpool, NSW, Australia

2 The University of Queensland, Brisbane, QLD, Australia

8 South

3 Molecular

Western Clinical School, University of New South Wales, Randwick,
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Australia
Background: Colorectal cancer (CRC) care is complex and should

7 Chris O’Brien Lifehouse, Sydney, NSW, Australia

be delivered by multi-disciplinary teams (MDTs). To ensure consistent high quality care, measurement to identify and rectify

Aims: To identify and synthesise existing guideline recommendations

variations in care is essential. This requires the identifica-

for genetic testing of prostate cancer (PCa) to develop a comprehen-

tion of clinically relevant, evidence-based quality indicators

sive list of possible strategies (i.e., who should be tested and how) for

(QIs).

consideration by a multidisciplinary Delphi panel. This is part of a larger

Aims:
ity

To

identify

indicators

for

a

priority
measuring

set

of

evidence-based

colorectal

cancer

qual-

care

in

program of work to determine the value of genetic testing for PCa in
Australia.

Australia.

Methods: Consistent with the PRISMA-ScR Statement, we con-

Methods: This study utilised a 2-step Delphi technique to pri-

ducted a scoping review of guidelines for genetic testing of PCa.

oritise a set of 93 evidence-based CRC QIs identified by the

A comprehensive search strategy was developed. We searched

research team in a systematic review. Round 1 was conducted

four electronic databases (PubMed, Embase, CINAHL, PsycInfo)

by expert workshop to ‘include/exclude’ QIs based on relevance

and the grey literature, including websites of key organisations

to Australian MDTs. Round 2 was conducted by online survey to

(e.g., NCCN, Philadelphia Consensus, EAU, AUA, ESMO, eviQ).

rate QIs for clinical importance against a 4-point Likert scale and

Guidelines published in English over the past 15 years were

provide comments. An inferential analysis was conducted to mea-

included.

sure survey results for concordance and a thematic analysis of

Results: The search generated 658 citations and after removal of

comments.

duplicates and title and abstract screening, 24 guidelines remained.

Results: In Round 1, workshop participants (n = 12) assessed 93

After full text review, 21 guidelines were synthesized for inclu-

QIs and produced consensus on retaining 49 QIs. In Round 2, sur-

sion in the scoping review. These represented seven official clin-

vey participants (n = 44) rated QIs and a final 25 QIs across all

ical organisations, were based on a clearly defined process with

domains of care and disciplines were prioritised with a concor-

research evidence to support recommendations and consensus from

dance level >80%. Approximately one third of prioritised QIs are

a panel of experts. Nine reviews of existing guidelines were also

related to surgical treatment (35%), whilst other QI domains include;

included, involving a rigorous methodology and consensus from a panel

diagnostic work up, neo-adjuvant and adjuvant therapy, follow-up

of experts, modified due to country-specific and/or implementation

and supportive care, and management of metastatic disease. Partici-

considerations.
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Conclusion: This review of guidelines showed that genetic testing

334

for PCa is generally supported and recommendations are similar

prophylaxis

Prescribing rates of pneumocystis jirovecii pneumonia

across organisations. This is particularly true for men with early
onset disease, family history of high-risk disease and metastatic

Yun Megan Foo1 , Tamara Lennon1 , Melvin Chin1

disease. However, recommendations are often based on lower-

1 Prince of Wales Hospital, Randwick, NSW, Australia

level evidence or expert opinion and concerns were raised in
the literature regarding implementation and a lack of available

Background: Pneumocystis jirovecii pneumonia (PJP) is a poten-

services, equity of access, psychosocial issues and the need for

tially severe illness affecting oncology patients on long-term high-

more research to strengthen the clinical and economic evidence

dose steroid therapy as part of treatment regimens or symptom

base.

management.
Method: A retrospective audit was conducted of all medical oncology
inpatients within three months at a major tertiary hospital in Sydney,

333

Safety and feasibility of six months of high intensity

Australia. In response to the results, a survey was conducted of pre-

interval training in breast, prostate and colorectal cancer

scribers in medical oncology and palliative care to clarify the clinical

survivors

reasoning for omission and find effective interventions to improve PJP
prophylaxis prescribing rates. Prescribers were asked to rank from

Morgan J. Farley1

least helpful to most helpful, interventions to improve PJP prophylaxis

1 School of Human Movement and Nutrition Sciences, University of Queens-

prescribing rates.

land , Brisbane, QLD, Australia

Results: One hundred and eighty-three inpatients were eligible. Thirtythree were identified as high-risk patients based on steroid dose and

Introduction: Exercise reduces the risk of cancer recurrence and

duration as per the EviQ guidelines. Three patients were on appropri-

improves the health and quality of life of people with breast, prostate,

ate prophylaxis, one was being treated for PJP, and a further 29 were

and colorectal cancer. However, the safety of exercise, and the opti-

not on any prophylaxis. Within that group, seven patients were on end-

mum and minimum doses of exercise required to elicit these health

of-life care and did not require PJP prophylaxis as part of medication

benefits remain unknown. This is due, at least in part, to poor assess-

rationalisation. There was no documented reason for the absence of

ment and reporting of whether the prescribed exercise doses are

PJP prophylaxis in the remaining high-risk 22 patients.

actually completed by the participants. This study aims to evaluate

Twenty-three prescribing clinicians were surveyed with 11 responses.

the safety (i.e., adverse and serious adverse events) and feasibility

The main reason identified for the low PJP prophylaxis rate was

(i.e., attendance and withdrawal) of six months of high intensity inter-

lack of clarity regarding the steroid plan at commencement. This

val training (HIIT) in supervised and unsupervised settings in breast,

was attributed to multiple prescribers across the inpatient and out-

prostate, and colorectal cancer survivors.

patient settings and poor documentation. There was also individual

Methods: A total of 164 breast, prostate, and colorectal cancer sur-

prescribers’ lack of certainty regarding intended dose and duration

vivors completed one month of HIIT sessions on an exercise bike

of the steroids. Of interventions to improve PJP prophylaxis, Phar-

supervised by Accredited Exercise Physiologists. Participants were

macist Reviews (25.0%) was ranked most helpful, then Technological

then provided a gym membership to continue these sessions unsu-

Help (21.8%), Inclusion in Ward Meeting discussions (20.2%), Inclu-

pervised for the next 6 months. All adverse events, serious adverse

sion as a Clinical Quality Indicator (16.5%) and Education Sessions

events and withdrawals were recorded by study Accredited Exercise

(16.5%). A repeat audit will be conducted after intervention implemen-

Physiologists and participants.

tation, to assess effectiveness and hopefully improve PJP prophylaxis

Results: There were no serious adverse events. Ten exercise-related

prescribing rates.

grade 1 adverse events occurred, of which were due to exacerbation
of pre-existing conditions (i.e., knee/back pain, low blood pressure,

1. Prophylaxis – Pneumocystis jirovecii (carinii) pneumonia in cancer

epilepsy, and arthritis). The remaining two adverse events were due to

patients v.6, eviQ Cancer Treatments Online, Cancer Institute

hypertension and syncope. All adverse events affected a single exer-

NSW, viewed 12th August 2022, https://www.eviq.org.au/clinical-

cise session only. There was a 16% withdrawal rate, of which 25% were

resources/side-effect-and-toxicity-management/prophylaxis-

medically-related. Attendance and intensity adherence was high dur-

and-treatment/220-pneumocystis-jirovecii-pneumonia-pjp-

ing the supervised phase (99%), but was lower during the unsupervised

prophyl

phase (i.e. 70%).
Conclusions: Supervised HIIT is safe and feasible in people living
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beyond breast, prostate, and colorectal cancer. Unsupervised HIIT is

utilisation, costs, and outcomes in Victoria for patients with

safe and achievable however, strategies to improve attendance are

cancer

The PRIMCAT cohort study: Analysis of treatment

required.
Fanny Franchini1,2 , Karen Trapani1 , Piers Gillett1 , Koen Degeling1 ,
Benjamin Daniels3 , Sallie Pearson3 , Ou Yang1 , Yuting Zhang1 , Peter
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Gibbs4 , Ben Solomon2 , Grant McArthur2 , Jayesh Desai2 , Stephen

2 Menzies Centre for Health Policy and Economics, The University of Sydney,

Fox2 , Maarten IJzerman1,2

Sydney, NSW, Australia

1 University of Melbourne, Melbourne, VIC, Australia

3 University of Sydney, Sydney, NSW, Australia

2 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

4 NSW Health, Mid North Coast Local Health District, NSW, Australia

3 University of New South Wales, Sydney, NSW, Australia

5 NSW Health, Western NSW Local Health District, NSW, Australia

4 Walter and Eliza Hall Research Institute, Melbourne, VIC, Australia

6 NSW Health, South Western Sydney Local Health District, NSW, Australia
7 NSW Health, Southern NSW Local Health District, NSW, Australia

Aims: The PRedicting the population health economic IMpact of new

8 University of South Australia, Adelaide, SA, Australia

and current CAncer Treatments (PRIMCAT) is a MRFF-funded program

9 University of Wollongong, Wollongong, NSW, Australia

that aims to estimate population health economic impact of new cancer

10 Cancer Institute NSW, NSW Health, St Leonards, NSW, Australia

treatments ahead of market approval. To achieve this, we first need to
understand what the current landscape is. We established a Victorian-

Background: Health services have an imperative to routinely collect

wide retrospective cohort study which will generate contemporary and

Patient Reported Measures (PRMs) to inform patient and clinical deci-

timely evidence around the real-world utilisation, costs, and outcomes

sion making, service delivery, and improve patient outcomes. Existing

of cancer treatments for several cancers: melanoma, lung, colorectal,

PRMs do not capture the parts of life that are valued by First Nations

prostate, and breast.

peoples that contribute to their wellbeing (e.g. culture, community

Methods: The PRIMCAT cohort study comprises all adults aged 18

and family). The WM2Adults (WM2A) is a new holistic wellbeing mea-

years and over who had a confirmed cancer diagnosis in Victoria

sure underpinned by Indigenist research methodologies that privileges

between 2010 and 2019 (updated annually). These adults were iden-

the voices of over 2345 First Nations adults nationwide. WM2A is

tified from the Victorian Cancer Registry and data was linked to

a strengths-based measure that includes 32 items, grounded in the

several datasets within the Centre for Victorian Data Linkage (Vic-

interconnection of family, community and culture.

torian Admitted Episodes Dataset, Victorian Emergency Minimum

Method: In partnership with the Cancer Institute NSW, the Directors

Dataset, Victorian Death Index, Elective Surgery Information System,

of Aboriginal Health and Cancer Services across four Local Health Dis-

Victorian Radiotherapy Minimum Dataset, Victorian Integrated Non-

tricts in NSW, the WM2A measure will be implemented to measure and

Admitted Health, Victorian Cost Data Collection). Once the cohort was

respond to the wellbeing of First Nations adult cancer patients. The

established, the AIHW Data Linkage Unit further linked the records

project is a 3-phase implementation-evaluation, mixed methods design,

to Medicare Benefits Scheme, Pharmaceutical Benefits Scheme, and

prioritising Indigenist methodologies and informed by the i-PARIHS

National Death Index.

framework.

Results: The cohort totals 180,721 adults across included cancer

Early-findings: It is feasible to incorporate the WM2A measure into the

types, with breast and prostate cancers representing the majority

CINSW electronic PRMs system which is currently in use across NSW

(24% and 25.8%). We take a data-driven approach to analyse patients’

cancer centres. Eight cancer service sites across four Local Health Dis-

characteristics as well as diagnostics and treatment rates of the Vic-

tricts are included in our study. Phase 1 includes Yarning workshops

torian population by year/rurality. Treatment pathways are mapped

with staff, and individual Yarns with patients and community mem-

by combining PBS and the Victorian-state datasets. Cost modelling is

bers, to identify the barriers and enablers to implementing the WM2A

underway.

measure at the local level. We will report the results of these Yarns.

Conclusions: To date, the PRIMCAT cohort study represents the

Implications: Our study will transform how cancer services measure

largest cancer-focused linked dataset of its kind in Australia and spans

and respond to the wellbeing needs of First Nations adult cancer

the entire continuum of care, enabling its in-depth analysis. This ret-

patients, by establishing a feasible, evidence-based approach for broad

rospective cohort study will provide evidence-based data to inform

scale implementation of PRMs into cancer services usual practice.

Health Technology Assessment (HTA) in Australia.
337

Delivering supervised group exercise to patients with

cancer via telehealth: An implementation study using the RE-AIM
336

Implementation of the What Matters 2Adults (WM2A)

wellbeing measure into cancer services in New South Wales
Alana Gall1 , Kirsten Howard2 , Kate Anderson1 , Michelle Dickson3 ,
Robyn Martin4 , Lisa Fletcher4 , Brendon Cutmore5 , Ruth Jones5 ,
Nathan Jones6 , Sandra Avery6 , Jackie Jackson7 , Melissa Mudie7 ,
David Roder8 , David Currow9 , Kimberley Williamson10 , Karina
McCarthy10 , Cynthia Lean10 , Shelley Rushton10 , Gail Garvey1
1 First

Nations Cancer & Wellbeing Research Team, The University of

Queensland, Herston, QLD, Australia

framework
Elise M. Gane1,2,3 , Jennifer Tan2 , Elizabeth C. Ward1,3 , Raymond J.
Chan4,5 , Mark B. Pinkham6 , Nicolas H. Hart4,5 , Jocelyn Williames2 ,
Elizabeth Pinkham2
1 School

of Health and Rehabilitation Sciences, The University of Queens-

land, Brisbane, QLD, Australia
2 Physiotherapy

Department, Princess Alexandra Hospital, Brisbane, QLD,

Australia
3 Centre for Functioning and Health Research, Metro South Health, Brisbane,

QLD, Australia
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Futures Institute, College of Nursing and Health Science, Flinders

University, Adelaide, SA, Australia
5 Cancer

Palliative Care Outcomes Centre, Queensland University of Tech-

nology, Brisbane, QLD, Australia
6 Radiation Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia

Background: A multifaceted approach is needed to overcome the
geographic disparity in trials opportunity in non-metropolitan Australia. The Victorian TrialHub program aims to improve regional patient
access to trials, partly through regional trials workforce development.
Methods: TrialHub is funded by the Australian Government Depart-

Aims: Assess the implementation of a telehealth supervised group
exercise (tele-exercise) program for patients with cancer, using the
RE-AIM framework (Reach, Effectiveness, Adoption, Implementation,
Maintenance).
Methods: Cancer patients with medical clearance and access to home
internet participated in a physiotherapy-led tele-exercise program,
comprising twice-weekly sessions for 12 weeks and featuring aerobic, resistance and balance exercises. A Garmin activity tracker was
worn during sessions. Subjective (fatigue, quality of life) and objective
(muscle strength, cardiorespiratory fitness, balance) measures were
taken pre and post-program. Qualitative interviews (analysed using
thematic and content analyses) and an online survey were completed
post-program.
Results: Reach: Twenty-six eligible participants consented and were
enrolled. Twenty-four commenced the program, most of whom were
female (92%), diagnosed with breast cancer (75%), treated with
surgery (96%), chemotherapy (88%) or radiation therapy (54%). Effectiveness: FACIT-F scores indicated reduced fatigue (mean difference
5.8 [95% CI 1.9–9.8], p < 0.01). Improvements were seen across several strength, fitness and balance outcomes (e.g. upper body strength
+5.6 [2.6–8.6] kg, p < 0.01). There were no changes to quality of life
(FACT-G).
Adoption: Participants found classes easy to integrate into daily routines and felt it helped avoid negative aspects of in-person exercise (e.g.
COVID-19 exposure, parking). Recruitment improved after introducing a 6:30 am class. Most (78%) participants felt very confident using
the technology. Viewing heart rate via the Garmin device contributed
to feeling safe whilst exercising. Implementation: 21 of 24 participants

ment of Health through the Community Health and Hospitals Program. Implementing a fellowship program has involved collaboration
between central hub (Alfred Health (AH)) and regional sites. At
Bendigo Health (BH) where an established Cancer Trials program
existed, the TrialHub program provided 0.5 EFT staffing for a dedicated
doctor in clinical trials. Since January 2021 this fellow has worked
on-site regionally, with virtual metropolitan mentorship provided. At
Latrobe Regional Hospital (LRH), AH haematology fellows rotating
weekly to LRH commenced in May 2022. This has provided workforce
for a dedicated haematology clinical trial clinic as well as establishing a
research bone marrow pathology service.
Results: At BH the mentored trials fellow is an associate investigator on 13 open to recruitment studies, and principal investigator on a
registry. Regular virtual attendance in metropolitan early-phase feasibility meetings is complementing local supervision and learning. The
process of participant identification, consent, eligibility determination
and review has been streamlined with dedicated trials staffing. Regular
screening activities ensure reliable participant capture across multiple tumour streams. At LRH over 3 months 18 patients across the
breadth of haematologic malignancies were screened resulting in clinical trial enrolment at local and metropolitan sites. Travel remains a
reason for individuals declining access to clinical trials in this early
sample.
Conclusions: Establishment of a clinical trials fellowship program
within the TrialHub program has enabled regional sites to develop
clinical trials capabilities appropriate to respective stage of development, with infrastructure, support and mentorship provided by an
established metropolitan unit.

completed the program. Mean number of sessions attended was 22.
Maintenance: Participants suggested feasible improvements to program orientation, discharge, and the exercise classes. All felt comfortable using the internet for tele-exercise. The majority considered a
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Patient vignettes reflecting the impact of The Australian

Rare Cancer Portal on patients with Rare Cancer

telehealth class as equal to an in-person class (15 of 18, 83%).
Conclusions: A telehealth group exercise program for people with

Lia A. Papadopoulos2,1 , Chloe L. Georgiou1,3 , Damien Kee2,1,4,5 ,

cancer was successfully implemented. Further information is needed

Caldwell Reece1 , Ke Helen1 , Bourne Allison1 , Haurat Javier1 ,

regarding non-breast cancer patients and non-tertiary hospital
settings.

Maureen Turner1 , David Goldstein1,6,7 , Clare Scott2,1,5,8
1 Australian Rare Cancer Portal, Melbourne, VIC, Australia
2 WEHI, Fairfield, VIC, Australia
3 Bendigo Health, Bendigo, VIC, Australia
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Innovation in regional cancer trials workforce

development: The TrialHub Fellowship Program
Chloe L. Georgiou1 , Tricia Wright2 , Narelle McPhee1 , Andrew
Spencer3 , Rob Blum1 , Mark Voskoboynik3 , Anne Woollett3
1 Bendigo Health, Bendigo, VIC, Australia
2 Latrobe Regional Hospital, Traralgon, VIC, Australia
3 Alfred Health, Melbourne, VIC, Australia

4 Medical Oncology, Olivia Newton John Cancer and Wellness Centre, Austin

Health, Heidelberg, VIC, Australia
5 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
6 Nelune Center Centre, Prince of Wales Hospital, Randwick, NSW, Australia
7 Prince of Wales Clinical School, UNSW, NSW, Australia
8 Royal Melbourne Hospital, Parkville, VIC, Australia
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Background: Patients with a rare cancer (RC) diagnosis face unique

and their carers value receiving copies of these letters and if they

challenges. Vast geographical distances in the Australian setting fur-

experienced improved understanding of their condition/treatment

ther compound challenges in accessing RC sub-specialist expertise,

and doctor/patient communication. Secondary aims were to ensure

clinical trials, research options and non-reimbursed therapies.

providing copies was sustainable.

Methods: The ARCP is a national free online referral platform funded

Methods: Using Plan-Do-Study Act (PDSA) cycles with consumer advo-

by Omico, with support from BioGrid Australia, Rare Cancers Australia

cate participation in the project, increasing numbers of patients were

(RCA), and The WEHI Stafford Fox Rare Cancer Program (SFRCP).

consented to receive copies of letters. Patient/carer experience was

Nine hundred and twenty-four referrals RC in early (30%) and late

captured via an anonymous 8 question online survey and a series of

stages (70%) derive from 62 referring clinicians from every Aus-

process measures were used to assess sustainability during each cycle.

tralian state and from both regional and metropolitan centres. Over 50

Results: Between February and July 2022, >200 patients/carers

experts from Australia and internationally have provided case advice.

at Bendigo Health consented to receive copies of their oncologist

Referring clinical impact surveys and case reports were analysed to

letter. 48 surveys were returned and multiple other patients pro-

identify impacts of the ARCP.

vided informal feedback. Survey responses were strongly positive,

Results: Five patient case vignettes are exemplars: 47F EGFR-

>90% patients/carers reported the letters: improved understanding

G719mut malignant phyllodes accessed Afatinib via CAS; 30F fibro-

of their condition and treatment plan; made them feel more included

lamellar cancer sequenced on resection, treated on Phase 1 trial, then

in their care; wanted to keep receiving the letters; and found the

self-funded Lenvatinib; 39M with NUT midline carcinoma accessed

letters useful as a record. Multiple other positive outcomes were

BETi; 71F BRAFV600E LGSOC from regional centre enrolled on

reported and the process was proven sustainable. 86% of patients did

therapeutic trial. These demonstrate ARC Portal patient impacts of:

not find the letters confronting or upsetting. The majority of infor-

Overcome financial barriers to genomic sequencing; Coordination with

mal feedback was positive, and only three patients provided negative

industry; Anticipatory advice for early disease; Linking with charity

feedback.

fundraising; Overcoming geographical barriers; Links with clinical trial

Conclusions: Providing patients with copies of their oncologist

networks; Identifying molecularly guided therapy.

GP letters can lead to improved communication with patients

Our reports provide expertise drawing from, on average, two to

and is generally perceived as positive outcome by oncology

five experts and directly altered the treatment delivered to patients

patients.

in 20/48 of surveyed referrer respondents. We identify access to
investigator-driven research efforts to overcome financial barriers to
genomic sequencing via the MoST Program funded by OMICO and
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the WEHI-SFRCP. The ARC Portal expands patients’ treatment options

health interventions in older patients with cancer: A systematic

via coordination with clinical trial networks, industry, and RCA for

review

Barriers and enablers of uptake and adherence to digital

fundraising assistance. The majority of patients (82.5%) have provided
consent to access biomarker and tumour specimens.

Syarafina S. H. Hasnan1 , Bogda B.K. Koczwara2 , Samuel S.A.

Conclusion: The ARC Portal offers patients access to excellent rare

Aggarwal1 , Leila L.M. Mohammadi1

cancer care. Formal assessment of relevant endpoints is underway.

1 Flinders University, Bedford Park, SA, Australia
2 Medical Oncology, Flinders Medical Centre, Bedford Park, SA, Australia

340

Providing patients with copies of oncology letters

Aims: Digital health interventions (DHIs) allow patients prompt and
remote access to health information and services. Since 2005, the

Samuel Harris1 , Shona Critch2 , Julie Symons3 , Michelle Hird1 , Robert

World Health Assembly has been advocating for the development of

Campbell1

an infrastructure to ensure equitable access to DHIs. To enable this, a

1 Bendigo Cancer Centre, Bendigo Health, Bendigo, VIC, Australia

comprehensive understanding of the patterns of use of DHIs amongst

2 Bendigo Health, Bendigo, VIC, Australia

different patient populations is required. As little is known about the

3 Loddon Mallee Integrated Cancer Serivce, Bendigo, VIC, Australia

pattern of use of DHIs among older patients (≥65 years old) with cancer, our study aimed to assess barriers and enablers of uptake and

Background: Oncologist letters to General Practitioners provide an

adherence to DHIs among this patient population.

important record of oncology consultations. In Australia it is not com-

Methods: A systematic search was done on CINAHL, Cochrane,

mon for patients to be routinely provided copies of oncologist letters

Emcare, JBI, MEDLINE, Proquest, and SCOPUS for English-language

to GPs. There is evidence to suggest that copying correspondence to

primary qualitative and mixed methods studies since inception until

patients increases patient’s involvement in and understanding of their

September 2021. Data was appraised using the Mixed Methods

care and that patients generally report high rates of satisfaction when

Appraisal Tool and thematic synthesis was done.

receiving copies of correspondence.

Results: Five studies comprising of 61 patients and 23 caregivers met

Aim: We undertook a healthcare improvement project to copy patients

the eligibility criteria. All studies examined barriers and enablers to

into their oncologist GP letters. Our aim was to determine if patients

uptake of DHIs but only two studies examined barriers and enablers to
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adherence. Two themes – usability and perceived usefulness – emerged

mortality, peri-operative complications. Treatment-related outcomes

from all analyses. High usability to uptake was facilitated by minimalist

included modification to treatment plans, generally to a less inten-

and age-appropriate design. High usability to adherence was facili-

sive treatment and treatment completion. Service-related outcomes

tated by customisability of DHIs and availability to provide feedback

such as health care utilisation and length of stay were not commonly

on DHI design. High perceived usefulness to uptake was facilitated by

reported in reviews. Finally, few reviews reported use of frameworks

DHIs’ ability to provide health information and to connect the patient

to guide GA implementation.

to their healthcare team. High perceived usefulness to adherence

Conclusion: Implementation of GA as part of standard care in Aus-

was facilitated by DHIs ability to provide reminders and contingency

tralian cancer services requires clearly defined outcomes and care

plans, reinforce long-term treatment plans, and keep healthcare teams

pathways.

updated on patients’ progress.
Conclusions: The limited amount of data and similarities of the themes
(usability and perceived usefulness) to other patient populations ren-

343

der the need for more studies to further elucidate barriers and

treatment for gynaecological cancer: A conversation analytic

enablers of uptake and adherence to DHIs among older patients with

study of outpatient consultations

Discussing diet, nutrition, and body weight after

cancer.
Lizzy Johnston1,2,3 , Stuart Ekberg4 , Bronwyn Jennings5 , Nisha
Jagasia5 , Jolieke van der Pols2
342

Implementation of geriatric assessments in cancer care:

An umbrella review

1 Viertel

Cancer Research Centre, Cancer Council Queensland, Fortitude

Valley, QLD, Australia
2 School

of Exercise and Nutrition Sciences, Queensland University of

Sharon He1 , Heather Shepherd2 , Meera Agar3 , Joanne Shaw1

Technology, Kelvin Grove, QLD, Australia

1 School of Psychology, Faculty of Science, The University of Sydney, Camper-

3 Population

down, NSW, Australia

Herston, QLD, Australia

2 Susan

4 School

Wakil School of Nursing and Midwifery, Faculty of Medicine and

Health, The University of Sydney, Camperdown, NSW, Australia

Health Program, QIMR Berghofer Medical Research Institute,

of Psychology and Counselling, Queensland University of Technol-

ogy, Kelvin Grove, QLD, Australia

3 Improving Palliative, Aged and Chronic Care through Clinical Research and

5 Department

Translation (IMPACCT), Faculty of Health, University of Technology Sydney,

Brisbane, QLD, Australia

of Gynaecological Oncology, Mater Hospital Brisbane, South

Ultimo, NSW, Australia
Aims: To generate direct observational evidence for understanding
Aims: Geriatric assessments (GA) can assist with identifying older can-

how diet, nutrition, and weight-related topics are discussed during

cer patients at risk of treatment complications and guide treatment

follow-up after treatment for gynaecological cancer, as recommended

decision-making. However, there is uncertainty about what defines a

by survivorship care guidelines.

GA in cancer care and the factors that impact on GA implementation

Methods: Women who had completed treatment for endometrial

in oncology settings. The aim of this umbrella review was to summarise

or ovarian cancer within the previous 12 months and were attend-

and synthesise the evidence for (i) what constitutes a GA in cancer care,

ing outpatient follow-up at the participating institution during the

(ii) how a GA is conducted, (iii) which outcomes are used to assess the

data collection period were invited to participate. Of 46 women

efficacy of GA and (iv) how implementation of GA in oncology settings

who attended, 34 (74%) consented to participate. Of these partic-

is reported.

ipants, 30 consultations were able to be audio-recorded, creating

Methods: We searched six electronic databases: PsycINFO, MEDLINE,

a data corpus involving four gynae-oncologists, 30 outpatients (19

Embase, CINAHL, The Cochrane Library and Web of Science using key-

endometrial and 11 ovarian cancer survivors), and 11 family mem-

words and MeSH terms. Eligible reviews included systematic reviews

bers/friends. Audio-recorded consultations were transcribed and anal-

with or without meta-analyses that (i) described the use or value of GA

ysed using conversation analysis, a qualitative methodology that uses

in cancer settings or (ii) information related to implementation of GA

direct observation rather than self-report methods to understand how

in cancer settings. Two reviewers reviewed articles for eligibility; data

people perform social actions, such as the delivery and receipt of

was extracted, and quality appraisal was conducted. The review was

healthcare, through their talk in conversation. Participants were not

registered with PROSPERO:CRD42022338842.

aware of the specific analytic focus until data collection had been

Results: Of the 3494 titles and abstracts screened, 128 full-text articles

completed.

were reviewed and 35 reviews were selected for the umbrella review.

Results: From 21 instances in 18 consultations, diet, nutrition, or

A GA varied from interviews, self-administered assessments, medical

weight-related talk continued beyond initiation if the issue raised by

assessments to chart reviews. Most systematic reviews reported that

the patient (either as a stand-alone topic or in response to a clinician

GA were performed prior to treatment by a range of health profes-

query) was ostensibly relevant to the clinical activity being undertaken

sionals (oncologists, cancer nurses and geriatricians) or patient self-

at the time. These instances led to care-related outcomes (i.e., gen-

report. Common patient-related outcomes included treatment toxicity,

eral dietary recommendations, referral to support, behaviour change
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counselling) only when the patient identified needing further sup-

information with other health professionals it did not appear to be

port. Diet, nutrition, or weight-related talk was not continued by the

utilized effectively in patient management. Patterns and reasons for

clinician if it was not immediately relevant to the current clinical

patients’ CAM use should be explored prospectively to establish clear

activity.

roles of health professionals in managing patients’ CAM use during

Conclusions: The contingent nature of these discussions means

treatment.

there can be missed opportunities for the provision of dietary
information and support post-treatment. Additional avenues for
dietary needs assessment and referral should be considered to
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optimize the consistent delivery of diet, nutrition, and weight-related

complementary and alternative medicine (CAM) use during

information and support post-treatment for gynaecological cancer.

anti-cancer treatment?

What factors can influence cancer patients’

Ellen Jones1 , Lisa Nissen2 , Carol Windsor3 , Kathryn Steadman4 ,
344

Exploring clinical documentation and management of

Alexandra McCarthy5

cancer patients’ complementary and alternative medicine (CAM)

1 Redcliffe Hospital, Redcliffe, QLD, Australia

– What are we missing?

2 Faculty

of Health, School of Clinical Sciences, Queensland University of

Technology, Brisbane, QLD, Australia
Ellen Jones1 , Lisa Nissen2 , Carol Windsor3 , Kathryn Steadman4 ,

3 Faculty of Health, School of Nursing, Queensland University of Technology,

Alexandra McCarthy5

Brisbane, QLD, Australia

1 Redcliffe Hospital, Redcliffe, QLD, Australia

4 School of Pharmacy, University of Queensland, Brisbane, QLD, Australia

2 Faculty

5 School

of Health, School of Clinical Sciences, Queensland University of

Technology, Brisbane, QLD, Australia

of Nursing, Midwifery and Social Work, University of Queensland,

Brisbane, QLD, Australia

3 Faculty of Health, School of Nursing, Queensland University of Technology,

Brisbane, QLD, Australia

Aims: To explore which factors, including age, gender, and treatment

4 School of Pharmacy, University of Queensland, Brisbane, QLD, Australia

intent, may influence cancer patients’ CAM use during anti-cancer

5 School

treatment.

of Nursing, Midwifery and Social Work, University of Queensland,

Brisbane, QLD, Australia

Methods: A retrospective study was undertaken from 1st January to
31st January 2017, comparing patients’ CAM use documented in med-

Aims: To understand the clinical documentation and management of

ication charts by doctors with the medication lists as recorded by the

patients’ use of CAM during anti-cancer treatment and the potential

pharmacists. The review time period ensured the group represented

gaps.

typical patients irrespective of the treatment intent (curative or pal-

Methods: A retrospective study was undertaken from 1st January

liative) or type of cancer treatment involved (intravenous, oral, or a

to 31st January 2017, comparing patient CAM use documented in

combination of all). Descriptive statistics were used to analyse the

their medication chart by doctors with the comprehensive medica-

data. The normality of the data and the comparisons between different

tion lists documented by the pharmacists in the patient electronic

variables were performed using Statistical Package for Social Sciences

record. Inconsistencies in the documentation between doctors and

(SPSS version 23).

pharmacists were noted. The review time period ensured the group

Results: One hundred and seventy-one patients were reviewed with

represented typical patients irrespective of the treatment intent (cura-

86 patients identified with CAM use. The mean age was 67.3 years

tive or palliative) or type of cancer treatment involved (e.g. intravenous,

(SD = 12.2), 65.1% (56/86) were female, 29% (25/86) and 71%

oral).

(61/86) received curative and palliative treatment respectively. Vita-

Results: One hundred and seventy-one patients were reviewed with

mins/minerals were the most used CAM. There was a weak correlation

86 patients identified during the review to be using CAM. The mean

between the number of CAM treatments used and age group, gender

age was 67.3 years (SD = 12.2), 65.1% (56/86) were female, 29%

and treatment intent (rs = 0.106 vs. rs = −0.140 vs. rs = 0.099, respec-

(25/86) and 71% (61/86) received curative and palliative treatment

tively). However, no statistically significant associations between the

respectively. Only five patients had their CAM use documented by the

number of CAM used and age group, gender and treatment intent (age

doctor in their medication chart, whereas the pharmacists’ lists showed

group ×2(16) = 12.843, p = 0.684; gender ×2(8) = 11.254, p = 0.188;

50.3% (86/171) of the patients used CAM during treatment. There was

or treatment intent ×2(8) = 8.604, p = 0.377) was found.

no robust evidence to support the use or indication for 25% (11/44)

Conclusions: Cancer patients may be on multiple medications for their

of CAM agents listed on the medication lists (e.g. red clover, shark

anti-cancer treatment. The potential interactions with CAM medi-

cartilage for prostate cancer).

cations can be challenging to predict and prioritize. While no clear

Conclusions: The results of this study highlighted a large discrepancy in

association with age, gender, or treatment intent was observed within

CAM documentation and a lack of clear management plan for patients

this review, there should be further investigation of patients’ prefer-

and health professionals. While the pharmacists’ medication list aims

ences and reasons for choosing CAM to help guide treatment planning

to assist with medication management and serve as a tool to exchange

and education.
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Exploring pattern of complementary and alternative

medicine (CAM) use over cancer patients’ course of treatment

Background: Oncology pharmacy services aim to provide patients
with the best possible care and access to appropriate and readily
available treatments. Without local cytotoxic compounding facilities, a

Ellen Jones1 , Lisa Nissen2 , Carol Windsor3 , Kathryn Steadman4 ,

remote oncology pharmacy service presents a unique set of challenges

Alexandra McCarthy5

including time and temperature sensitive treatment logistics.

1 Redcliffe Hospital, Redcliffe, QLD, Australia

Objective(s): To describe an Oncology Pharmacist’s important roles

2 Faculty

and responsibilities within a remote hospital setting.

of Health, School of Clinical Sciences, Queensland University of

Technology, Brisbane, QLD, Australia

Action (Method): As the sole oncology pharmacist in a remote setting,

3 Faculty of Health, School of Nursing, Queensland University of Technology,

it is important the pharmacist is involved in every step of the patient

Brisbane, QLD, Australia

journey; from pre-treatment assessment through to education, devel-

4 School of Pharmacy, University of Queensland, Brisbane, QLD, Australia

opment and maintenance of chemotherapy care plans and succinctly

5 School

ordering and checking the chemotherapy itself.

of Nursing, Midwifery and Social Work, University of Queensland,

Brisbane, QLD, Australia

Evaluation: Consistent and thorough involvement and well-defined
roles and responsibilities of the oncology pharmacist in a remote

Aim: Exploring the pattern of cancer patients’ CAM use over their

setting can result in accurate, consistent and organised medication pre-

course of anti-cancer treatment.

scribing, ordering, administration and documentation. This provides a

Method: A prospective mixed-methods study was conducted from

remote oncology pharmacy service with a solid foundation in providing

1st January 2018 to 31st December 2019, capturing patients’ medica-

optimal patient care presently and into the future.

tion use (conventional and CAM) over the course of their anti-cancer

Discussion: Infrastructure in remote settings to compound cytotoxic

treatment irrespective of CAM preferences and treatment intents

medicines is limited. The cancer journey is naturally subject to change

(curative or palliative). Patients’ intention to use CAM was collected

with dose reductions and changes in therapy as well as urgent refer-

through a structured questionnaire and semi-structured interviews

rals to start treatment. Well organised and planned delivery times of

encompassing factors that may influence CAM use (e.g. demographics,

medicines to a remote setting is integral. Treatments that are time

attitudes/beliefs about CAM, self-perceived QOL/health status, and

sensitive and only allow a short window from manufacture to admin-

patient preferences about CAM). Patient interviews were repeated

istration before expiry present a challenge in providing the best care.

every three-months where applicable over the patients’ respective

The pharmacist is a key source of information and advice for the team

treatment courses. Descriptive statistics were used to analyse the

and patients, ensuring patients are provided the best care in a stream-

quantitative data collected. Data collected from patient interviews

line fashion. A pharmacist in a remote setting is essential to provide

were transcribed and analysed via thematic analysis.

knowledge and problem solving skills to ensure patients with cancer

Results: Initially, 122 patients were recruited with the number reduc-

continually have proper access to highly specialised medicines and

ing over consecutive surveys (1–4), due to treatment completion or

receive the best possible care.

interruptions (e.g. radiation/surgery). Although CAM use was unpredictable, it was found that CAM behaviours between the curative and
palliative cohorts were comparable and consistent, either as users or

347

non-users, with the intentions for use being for health optimization.

personalised nutrition and physical activity for management of

Some decisions related to CAM use were made through collaborations

cancer-related malnutrition and muscle loss

e-ENHANCE: Co-design of an e-platform to enhance

with doctors and pharmacists according to clinical needs and appropriateness. Additionally, patients identified as CAM users displayed a

Nicole Kiss1 , Emily McNeil1 , Eric O2 , Brenton Baguley1 , Robin M.

commitment to integrating CAM with treatment where possible. Yet,

Daly1 , Linda Denehy3 , Lara Edbrooke3 , Abbas Khosravi4 , Patricia M.

non-CAM users could also share similarities with the users.

Livingston5 , Jenelle Loeliger6 , Natalie Maxwell Davic7 , Nicki Colls7 ,

Conclusion: CAM use or non-use is clearly an individual decision. How-

Victoria White8 , Anna Ugalde9

ever, regular medication reviews during treatment and building rapport

1 Institute

with patients are key to establishing trust, which also facilitates effec-

Victoria, Australia

tive communication and better patient care where integration of CAM

2 Digital Engagement, Deakin University, Burwood, Victoria, Australia

with anti-cancer treatment is necessary.

3 Physiotherapy Department, University of Melbourne, Melbourne, Victoria,

for Physical Activity and Nutrition, Deakin University, Burwood,

Australia
4 Institute
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for Intelligent Systems Research adn Innovation, Deakin Univer-

sity, Geelong, Victoria, Australia
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1 Department
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tralia

of Pharmacy, Alice Springs Hospital, Alice Springs, NT, Aus-

and Speech Pathology Department, Peter MacCallum Cancer
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8 School of Psychology, Deakin University, Burwood, Victoria, Australia

5 Flinders University, Adelaide, South Australia, Australia

9 Institute for Health Transformation, Deakin University, Burwood, Victoria,

6 Department of General Practice, Monash University, Melbourne, Australia

Australia
Background: AYA with cancer commonly experience sexuality conBackground: Access to nutrition and exercise services for people with

cerns during and post treatment. Evaluation and management of these

cancer-related malnutrition varies widely across health services. This

critical aspects are often neglected by health professionals due to fac-

study aimed to develop a web-based platform, co-designed with health

tors such as poor knowledge, confidence and communication, lack of

professionals and consumers, to enhance current clinical care and

comfort, time and prioritisation of sexuality concerns. It is not known

improve access to evidence-based nutrition and exercise programs for

what policy and practice tools are available to bridge this evidence gap.

people with cancer-related malnutrition.

Aims: To scope, analyse and map the literature on policy and practice

Methods: Oncology health professionals and people with a lived expe-

tools, specific to AYA oncosexology education and training programs,

rience of cancer-related malnutrition were invited to participate in

for health professionals.

co-design interviews to understand perceptions of the critical com-

Methods: A scoping review was conducted using the Joanna Briggs

ponents of a web-based platform to deliver evidence-based nutrition

Institute methodology. A search strategy was developed using key

and physical activity advice. Health professionals were also asked to

words initially tested in OVID MEDLINE. The formal search was con-

consider how the platform could be implemented into practice. Inter-

ducted in July 2022 in Medline, EMCARE, EMBASE and PsychINFO

views were transcribed and thematic analysis completed to determine

(all on OVID platform) for articles: published after 2012; in English;

common needs and concepts. Feedback from the co-design interviews

qualitative, quantitative, mixed method studies, case studies, review

informed the creation of the e-ENHANCE web-platform.

articles or grey literature; in patients aged 15–39 years. Articles were

Results: Interviews based on co-design methods were completed with

excluded if they did not meet these criteria, only examined potential

14 health professionals (100% female, mean (range) age 59.5 (25–

education/training programs or health professionals’ knowledge, atti-

57) years) and five people with cancer (100% female, mean (range)

tudes or practices, or only focused on patients’ perspectives. Retrieved

age 53.5 (57–62) years). Health professionals noted the need to con-

articles were extracted into Covidence and two screening rounds were

sider patient characteristics with regard to accessing the platform,

independently performed by two authors each for the final analysis and

particularly variations in health and technology literacy, motivation

evidence synthesis.

and current health status. Features deemed important by health pro-

Results: After removing 1140 duplicate records, 1825 records were

fessionals and people with cancer included simple messages, incorpo-

screened of which 1523 were excluded and 302 full texts assessed

rating user-friendly images and video, reminders and rewards, engag-

for eligibility. The final number of studies included along with other

ing (interactive) content, comprehensive and credible information,

quantitative findings will be reported against the PRISMA-ScR report-

personalised content and easy navigation. Clinician awareness and

ing checklist. Results from the basic content analysis to organise

endorsement, sustainability, flexibility and variations in service provi-

qualitative findings into higher level categories will also be presented.

sion within health services were identified as important considerations

Conclusions: Evidence gaps, limitations and implications for research

for implementation into practice.

will be discussed. We will seek stakeholders’ views on whether our

Conclusions: People with cancer and health professionals informed the

findings are locally relevant and how they can inform improvements in

development of the e-ENHANCE platform which features evidence-

health professional oncosexology policy and practice tools.

based content designed for varying degrees of health literacy with the
ability to tailor content to individual needs. Future work will involve

349

user acceptance testing, refining the platform with consumers and a

optimal radiotherapy utilisation rate for older adults with lung

pilot trial of e-ENHANCE within health services.

cancer

Development of an age- and comorbidity-adjusted
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Introduction: Optimal radiotherapy utilisation (RTU) modelling esti-

a robust tissue transport protocol to ensure optimal tissue viability

mates the proportion of people with cancer who would benefit from

prior to cryopreservation. This protocol involves engaging reliable

radiotherapy. Older adults with cancer may have comorbidities which

specialist logistics, with transportation in specially conditioned Credo

impact on physiological reserve and affect radiotherapy recommenda-

Cubes for optimal quality control. The tissue is transferred in either

tions. Assessment of medical comorbidities is an important component

locally sourced IVF media, or a tissue transport solution. Tissue cry-

for the assessment of treatment suitability. These have not been

opreservation is performed published international guidelines1 . The

considered in previous RTU models.

service operates with a centralised dedicated nurse coordinator and

Aim: We aimed to develop an age- and comorbidity-adjusted optimal

laboratory staff, providing 24 h support to rural oncology centres.

RTU model for patients with non-small cell lung cancer (NSCLC) and

Follow up is provided to the referring centres and the patients.

small-cell lung cancer (SCLC).

Results: NOTTCS has successfully provided this service for 56 young

Methods: New South Wales Cancer Registry data (2010–2014) for

patients (50 females, six males), of which 15 were younger than 13

patients diagnosed with NSCLC and SCLC was linked to radiotherapy

years. All tissue samples were received within 24 h from retrieval sites

data (2010–2015) and hospitalisation data (2008–2015). The Can-

in all states and territories of Australia. All patients had potentially

cer Specific ‘C3 all sites’ comorbidity index was derived from hospital

viable tissue cryopreserved.

records for each patient. The index cut-off for treatment eligibility was

Conclusions: NOTTCS has been successfully established, addressing

≥3. This data was then incorporated into an established lung can-

a previously unmet need for access to contemporary fertility preser-

cer decision tree model to calculate the optimal age and comorbidity

vation for young cancer patients outside tertiary centres. The service

RTU. The actual RTU was calculated using the linked datasets. Four

provides high level coordination, specialised laboratory conditions for

age groups were examined: <60, 60–69, 70–79 and 80+ years, with

tissue cryopreservation quality control and proven logistical capabil-

particular focus on patients aged 80+ years.

ities. We can now provide access to gonadal tissue fertility preser-

Results: Fourteen thousand six hundred and ninty-six patients were

vation to all Australians, consistent with current cancer treatment

diagnosed with NSCLC and 1839 patients were diagnosed with SCLC.

guidelines2 .

The age- and comorbidity-adjusted optimal RTU decreased with
increasing age for both patient groups.

352

For patients with NSCLC, the optimal comorbidity adjusted- RTU for

implementation of a model of allied health survivorship cancer

patients aged 80+ was 49%. The actual RTU for patients aged 80+

care within a community health setting

The ‘Good Life – Cancer Survivorship’ program –

years was 25%.
For patients with SCLC, the optimal comorbidity adjusted- RTU for

Rebecca McIntosh1 , Carina Martin1 , Lahiru Russell2,3 , Anna Ugalde4

patients aged 80+ was 49%. The actual RTU for patients aged 80+

1 healthAbility, Box Hill, VIC, Australia

years was 32%.

2 Centre

Conclusions: For patients with NSCLC and SCLC, the actual RTU was

Transformation, Deakin University, Geelong, VIC, Australia

less than the optimal RTU. This gap requires further research.

3 Centre

for Quality and Patient Safety Research in the Institute for Health
for Quality and Patient Safety Research, Eastern Health Partner-

ship, Box Hill, VIC, Australia
4 Institute

350

A FERTILE FUTURE for CANCER patients: and update on

for Health Transformation, Deakin University, Burwood, VIC,

Australia

improvements on options in Australia
Aims: Cancer survival is improving rapidly due to advances in treatAndrea Martin1 , Debra Gook1,2 , Genia Rozen1,2 , Fatima Figueiredo1 ,

ment and earlier detection. Effective care coordination between oncol-

Nicole Merry1 , Kate Stern1,2

ogy settings and community health could support survivors transition

1 The Womens – Parkville, Parkville, VIC, Australia

to allied health services and empower them to self-manage their health

2 Melbourne IVF, East Melbourne, VIC, Australia

and wellbeing. This study aimed to implement and evaluate a referral
pathway to a community-based model of survivorship care, the Good

Aim: To provide equitable access to ovarian and testicular cryopreser-

Life Cancer Survivorship program.

vation, which requires specialised laboratory techniques, for young

Methods: Survivors referred to the program were undergoing or had

patients at risk of infertility because of their cancer diagnosis and

completed cancer treatment, and unable to participate in intensive

treatment, regardless of their geography, gender, and age in Australia.

ambulatory oncology rehabilitation. The acceptability, adoption, feasi-

Method: The National Ovarian and Testicular Tissue Transport and

bility and fidelity of the program were evaluated, with data collected

Cryopreservation Service (NOTTCS) was established at RWH in late

on; health service utilisation across four community health services

2019. This program established a rapid-response process involving liai-

delivering the program, perspectives of consumers and health profes-

son with rural and remote centres to provide the opportunity for young

sionals with interviews and a focus group and a consumer survey. The

cancer patients to have their gonadal tissue retrieved and transported

focus group and interviews were recorded, transcribed and themati-

to a centralised fertility preservation centre for processing and stor-

cally analysed; descriptive statistics were used for the health service

age. The service provides education, consultation, logistic support, and

utilisation and consumer survey.
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Results: Thirty-nine referrals were made by the oncology service

354

to the community survivorship program.

metropolitan and rural trial sites in Victoria, Australia

A total of 162 allied

Differences in cancer clinical trial characteristics between

health appointments were scheduled with a median of four appointments per cancer survivor and high attendance rates (89%). The

Narelle McPhee1 , Michael Leach1 , Claire Nightingale2 , Samuel

most accessed services were integrated care coordination (48%) fol-

Harris3 , Eva Segelov4,5 , Eli Ristevski6

lowed by physiotherapy (19%) and dietetics (11%). The majority of

1 School of Rural Health, Monash University, Bendigo, Victoria, Australia

cancer survivors had the need for two or more allied health refer-

2 Melbourne

rals.

Melbourne, Melbourne, Victoria, Australia

The key themes that emerged from the focus group and

School of Population and Global Health, The University of

interviews included the impact of the referral pathway, continuation

3 Department

of survivorship care within community health and opportunities for

Australia

sustainability.

4 Department of Oncology, Monash University, Clayton, Victoria, Australia

Conclusions: A community-based allied health program was adopted,

5 Department

feasible and acceptable to support cancer survivors in managing their

Monash University, Clayton, Victoria, Australia

health. Community-based models of survivorship care have the poten-

6 Monash University, Monash Rural Health, Warragul, Victoria, Australia

of Medical Oncology, Bendigo Health, Bendigo, Victoria,

of Medicine, School of Clinical Sciences, Faculty of Medicine,

tial to support people with cancer and reduce the burden on oncology
health services.

Aim: To examine whether characteristics of rural Victorian cancer

Acknowledgements: This project was supported by the Victorian

clinical trials (CCTs) differ from those of metropolitan Victorian CCTs.

Government.

Methods: Using Clinical Trials Management Scheme data sourced
from Cancer Council Victoria, we produced cross-tabulations of
CCT location (metropolitan/rural) by six trial characteristics: trial
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Tackling cancer-related financial toxicity to improve

health services and equity

phase, tumour stream, intervention, sponsorship type, and numbers of new and follow-up participants per trial (participants/trial).
The metropolitan-to-rural ratio was calculated for each characteris-

Jordana McLoone2,1 , Raymond Chan3 , Megan Varlow4 , Kate

tic category. Mean/average (standard deviation [SD]; range) numbers

Whittaker4 , Daniel Lindsay5 , Carla Thamm6 , Lillian Leigh7 , Laura

of participants/trial were also calculated by location. Pearson’s chi-

Muir8 , Gillian Mackay9 , Deme J. Karikios10,11 , Lee Hunt12 , Kim

squared tests were performed to check for differences in character-

Hobbs13 , David Goldsbury14 , Doreen Nabukalu15 , Louisa G.

istics between metropolitan and rural sites (p-value <0.05). Trial site

Gordon5,6,15

locations were categorised using the Modified Monash (MM) Model.

1 Kids Cancer Centre, Sydney Children’s Hospital, Sydney, NSW, Australia

Results: Data were obtained from 43 trial units. Seven were rurally

2 UNSW, Kensington, NSW, Australia

located (MM2-7). Overall, 1501 CCTs (90%) were conducted at

3 Caring

metropolitan sites and 168 (10%) at rural sites. For every nine trials

Futures Institute, College of Nursing and Health Sciences, Flinders

University, Bedford Park, South Australia, Australia

available at a metropolitan site, one was available at a rural site. On

4 Cancer council, Sydney, New South Wales, Australia

average, metropolitan sites had 1.2 (SD = 2.8; range = 0–42) new

5 Faculty

and 2.5 (SD = 7.3; range = 0–189) follow-up participants/trial while

of Medicine, University of Queensland, Brisbane, Queensland,

Australia

rural sites had 0.8 (SD = 1.8; range = 0–10) new and 1.13 (SD = 2.3;

6 School

range = 0–12) follow-up participants/trial. Statistically significant dif-

of Nursing and Cancer and Palliative Care Outcomes Centre,

Queensland University of Technology, Brisbane, Queensland, Australia

ferences between metropolitan and rural sites were observed for all

7 Rare Cancers Australia, Bowral, New South Wales, Australia

trial characteristics except for trial intervention and the number of

8 Cancer Council NSW, Sydney, New South Wales, Australia

new participants/trials. For each characteristic, the largest differences

9 Clinical Oncology Society of Australia, Sydney, New South Wales, Australia

in CCT availability between metropolitan and rural sites were: other

10 Medical

oncology, Nepean Hospital, Kingswood, New South Wales, Aus-

11 Nepean

haematological trials (37:1), phase I trials (24:1), >6 participants/trial
(new: 19:1; follow-up: 16:1), commercially sponsored trials (11:1), and

tralia
Clinical School, University of Sydney, Sydney, New South Wales,

non-drug intervention trials (10:1). Rural sites had no trials available
for head and neck cancer, sarcoma and cancers of the central nervous

Australia
12 Cancer Voices NSW, Sydney, NSW, Australia

system.

13 Oncology

Conclusion: Outside metropolitan Victoria, there is reduced availabil-

Social Work Australia & New Zealand, Westmead Hospital,

Westmead, NSW, Australia

ity and mix of CCTs. Rural cancer patients who wish to participate in

14 The Daffodil Centre, University of Sydney, Sydney, NSW, Australia

CCTs need to travel to metropolitan trial sites where a larger number

15 Population Health

and variety of CCTs are available.

Department, QIMR Berghofer Medical Research Insti-

tute, Brisbane, QLD, Australia
Publish consent withheld

17437563, 2022, S3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/ajco.13869 by Henry Ford Health System, Wiley Online Library on [22/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

189

POSTER ABSTRACTS

POSTER ABSTRACTS

355

Views and experiences of cancer clinical trial participants

at a regional cancer centre: A qualitative study

3 Department

of Medical Oncology, Prince of Wales Hospital, Sydney, NSW,

Australia
4 Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia

Narelle McPhee1 , Diane L. Hughes1 , Eli Ristevski2

5 Department

1 Bendigo Cancer Centre, Bendigo Health, Bendigo, VIC, Australia

Australia

2 Monash University, Monash Rural Health, Warragul, VIC, Australia

6 Translational Cancer Research Network Consumer Advisory Panel, Sydney,

of Neurology, Royal Prince Alfred Hospital, Sydney, NSW,

NSW, Australia
Aim: To examine rural and regional cancer patients’ views and expe-

7 Chris O’Brien Lifehouse, Sydney, NSW, Australia

riences of being in a cancer clinical trial (CCT) with a focus on how

8 Sydney Medical School, The University of Sydney, Sydney, NSW, Australia

patients decide to join a trial and their views on trial processes and data

9 Patricia

management.

Sydney, NSW, Australia

Ritchie Centre for Cancer Care and Research, Mater Hospital,

Methods: A qualitative descriptive design was used (HREC approval
LNR/21/BH/77595). Purposive sampling was employed to recruit

Aims: Patients with cancer treated with neurotoxic chemotherapy are

patients currently on a CCT to participate in a semi-structured inter-

at-risk of developing neurological symptoms that can impact their

view at a regional cancer centre. Questions were developed with input

functional capacity and quality of life (QoL). However, there are no

from the local cancer consumer advisory group. In-person or Zoom

standardised clinical pathways to assess and manage chemotherapy-

interviews were conducted, audio-recorded and transcribed verba-

induced peripheral neurotoxicity (CIPN). This study aimed to deter-

tim. Data were analysed using Braun and Clarke’s thematic analysis

mine consensus on statements regarding a CIPN assessment and

methodology.

management clinical pathway.

Results: Thirteen interviews have been conducted with seven females

Methods: A CIPN clinical pathway (CIPN-Path) was developed based

and six males. Participant mean age was 65.4 (±7.9 years) and treat-

on current evidence and reviewed by a 10-member expert multi-

ment was for breast, colorectal, lung or skin cancer. Treatment was

disciplinary and consumer panel. The CIPN-Path is a health service

provided with curative or non-curative intent, in the metastatic and

delivery pathway for CIPN assessment, management and decision-

non-metastatic setting. Analysis of the data generated the follow-

making. Agreement with 18 statements regarding four content themes

ing four preliminary themes. Health professional-related; deep trust

(‘pre-treatment review’, ‘screening and assessment’, ‘management and

in their medical oncologist who discussed the CCT and who cared for

referral’, ‘CIPN-Path feasibility’) were assessed using a 2-stage Del-

them during the trial and the need for follow-up with their treating

phi survey process to reach consensus. Respondents rated statements

oncologist to address questions such as wanting to learn more about

using a 5-point Likert scale to determine level of agreement, with

trial progress. Humanistic-related; consideration of others, willingness

consensus defined as ≥80% of respondent agreement with each

to share personal data to enable doctors to learn, and improve future

statement.

cancer treatment and altruism to help other cancer patients. Travel-

Results: Seventy Australian respondents participated (medical oncol-

related; willingness to travel and attend trial appointments. Personal

ogists/haematologists (31%), nurses (24%), neurologists (16%), allied

gain; satisfaction with care, gratitude for the opportunity to participate

health (11%)). Consensus was reached for 14 of 18 items after stage

and strong satisfaction with trial processes.

1, and all items after stage 2. Feedback was obtained for all items

Conclusion: Understanding the experience of participants in CCTs pro-

to refine the CIPN-Path. There was agreement for important charac-

vides valuable knowledge about why patients consent and how they

teristics of the CIPN-Path including pre-treatment screening, regular

view the whole CCT process. This provides the foundation to inform

patient-reported assessment, and a stepped-care approach to investi-

future strategies to aid in the retention and recruitment of rural and

gating and managing symptom burden. There was a lack of agreement

regional cancer patients in CCT.

in who should oversee CIPN assessment. Open-text responses highlighted timely access to specialised services (e.g. neurology or allied

313

Development and consensus of ‘CIPN-path’: A clinical

pathway for the assessment and management of
chemotherapy-induced peripheral neuropathy
David Mizrahi2,1 , David Goldstein2,3 , Matthew C Kiernan4,5 , Louisa
Robinson3 , Omali Pitiyarachchi3 , Susan McCullough6 , Phil
Mendoza-Jones6 , Peter Grimison7,8 , Frances Boyle8,9 , Susanna B

health) may not be practical for all, as access to care will differ by
site-based resources.
Conclusions: There was overall agreement regarding the CIPN-Path
to assess and manage CIPN, which can be adapted accordingly to the
resources of each site. The CIPN-Path may assist teams across different health services to identify CIPN symptoms, aid decision-making,
reduce morbidity and improve QoL of patients with CIPN.

Park4
1 The

Daffodil Centre, a joint venture with Cancer Council NSW, The
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Assisted dying the perspective from health services staff

University of Sydney, Sydney, NSW, Australia
2 Prince

of Wales Clinical School, University of New South Wales, Sydney,

NSW, Australia

Tenille Moselen1 , Amelia Hyatt 1 , Geraldine McDonald1
1 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

17437563, 2022, S3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/ajco.13869 by Henry Ford Health System, Wiley Online Library on [22/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

190

Background: The VAD act commenced in Victoria Australia on 19 June
2019. The legislation underpinning this act is complex and unique,
and ensuring staff are well-supported in their implementation of VAD
in practice is important. This study therefore aimed to understand
the experiences and perspectives of staff involved with the operation
and implementation of the VAD clinical intervention at a specialist
oncology tertiary health service in Melbourne Australia.
Methods: In February 2021, an exploratory study was employed,
comprising of a cross-sectional survey to investigate the experiences

The results identified four consumer priority areas:
1. Information and communication – Improved access to medical
information and greater staff sensitivity.
2. Navigation – Improved access to supports and peer navigation.
3. Building capacity –Partner in patients care to better advocate for
themselves.
4. Support Networks – Peer support expanded, support for carers and
families.

of health services staff with VAD, specifically: processes and proce-

An evaluation of the event found 92% of consumers agreed the Patient

dures, emotions and values, interactions with colleagues, supporting

Parliament was worthwhile, 95% were satisfied with opportunities to

patients and families, and support and training needs. Quantitative

contribute, 92% felt they could share their thoughts on improvements

data were analysed descriptively; qualitative open-text responses

and 92% felt they could share perspectives on what’s important to

were analysed thematically.

them.

Findings: Eighty-nine health services staff completed surveys. Overall,

Conclusion: The Patient Parliament proved to be an effective strategy

staff described the complexity of navigating VAD in practice, describ-

to engage consumers to collect valuable feedback and guide strategy

ing the uniqueness of each experience. Key areas of support for health

development for a tertiary health service. The methodology is useful.

services staff comprised of ongoing training and education, developing
staff communication skills, assistance with workload management, and

358

improved debriefing and peer support. In terms of values, participants

dehydrogenase genotyping to individualise fluoropyrimidine-based

discussed employing iterative consideration throughout the implemen-

chemotherapy in a contemporary Australian setting

Cost-benefit of pre-treatment dihydropyrimidine

tation of VAD to reaffirm their moral decisions related to VAD.
Conclusion: Assessment of staff perspectives regarding the implemen-

Hansoo Kim1 , Tivya Kulasegaran2 , Melissa Eastgate2,3 , David Wyld2 ,

tation and clinical practice of VAD identified a range of multifaceted

Matthew Burge2 , Mark Nalder2,4

experiences, processes, and support and education needs. Understand-

1 Griffith University, Nathan, QLD, Australia

ing and addressing the key issues identified will be important for the

2 Cancer

long-term sustainability of VAD, to support staff working in a setting

QLD, Australia

that offers assisted dying, and to provide guidance and support for

3 School of Medicine, University of Queensland, Brisbane, QLD, Australia

future implementation in other jurisdictions and countries.

4 Centre

Care Services, Royal Brisbane and Women’s Hospital, Brisbane,

for Health Services Research, University of Queensland, Brisbane,

QLD, Australia
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Consumer engagement through a patient parliament
Background: Adverse events (AEs) due to fluoropyrimidine-based anti-

Fiona Mouritz1 , Tenille Moselen1 , Geri McDonald1 , Anna Jones 1 ,

cancer treatment are strongly influenced by interindividual variability

Allison Odgen1

in the enzyme dihydropyrimidine dehydrogenase (DPD). A major cause

1 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

of DPD deficiency is the presence of certain variants of the encoding gene DPYD. International studies have found that pre-treatment

Background: Effective consumer engagement is essential to provid-

DPYD genotype guided dose reductions is cost-effective in reducing

ing relevant and appropriate health care. A tertiary oncology health

severe AEs, however data in the Australian setting is limited.

service in metropolitan Melbourne took an innovative approach to con-

The objective of this study is to assess the cost-benefit of pre-

sumer engagement by hosting a Patient Parliament. The aim of the

treatment DPYD genotyping for patients receiving fluoropyrimidines

Patient Parliament was to engage meaningfully with all consumers and

in an Australian clinical setting.

hear their ideas on how we can improve our future service delivery.

Methods: A cost-benefit model was developed to compare costs and

Method: From November 2021 to February 2022 consumers were

number of grade 3–4 AEs for patients tested for the DPYD geno-

engaged in the online Patient Parliament consultation process to col-

type versus a historical cohort. The proportion of patients with grade

lect mixed-methods data. The model used a co-design approach guided

3–4 AEs was informed by a DPYD trial conducted in Queensland. Costs

by a consumer panel to develop the event agenda and questions.

of AEs were estimated using Australian Refined Diagnosis-Related

After the Patient Parliament event smaller workshops were conducted

Groups (AR-DRG) data. A cohort of 1000 patients was simulated.

online with consumers to explore the key priority areas in depth.

One-way sensitivity analyses were performed.

Results: Overall, 77 consumers attended the Patient Parliament, and

Results: The model estimated that there would be an additional 80

45 attended the smaller workshops. Consumers were from all 13

grade 3–4 AEs in the historical cohort compared to the DPYD cohort.

tumour streams, with the majority from Haematology (22%) and

This came at a cost of $85,294 equal to $1075 paid per AE avoided.

Breast (22%). The consumers were patients (87%), carers (7%), family

The breakeven cost for the test is estimated to be $175/patient and

members (3%) and volunteers (3%).

there would be a cost saving of $85/patient if the cost of the test was
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$90. The sensitivity analyses showed that costs of gastrointestinal AEs

1 Peter MacCallum Cancer Centre, Parkville, VIC, Australia

were the main driver of the cost-benefit analysis with a break-even
price of between $111 and $238. All the sensitivity analyses resulted

Aims: To present the impact of COVID-19 on inpatient cancer care

in cost-savings if the cost of the test was $90.

across Victorian health services by comparing the changes in patient

Conclusion: DPYD testing is projected to help avoid 80 grade 3–4

and admission numbers for the years 2019–2021.

AEs per 1000 patients treated with fluoropyrimidine-based anticancer

Background: The COVID-19 pandemic disrupted cancer care, includ-

therapy. DPYD genotyping is likely to result in costs saving if the cost of

ing delaying diagnoses and treatment, and halting clinical trials. Despite

testing is less than $175 per patient.

cancer-related services remaining available, utilisation dropped in
2020 due to a range of factors.
In 2020, the Victorian Cancer Registry (VCR) recorded 2420 fewer
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Victorian integrated cancer services: Advance care

planning practices in Victorian cancer services

individual diagnoses, a decline of 7%, likely due to COVID-19.1 VCR
modelling data shows that the decline in cancer incidence reported in
2020 continued into 2021.2

Linda Nolte1 , Cate O’Kane2 , Alison Patrick2

Methods: Analysis of cancer activity to understand the change in activ-

1 NEMICS, Austin Health, Heidelberg, VIC, Australia

ity between 2019 (pre-COVID-19) and 2020 and 2021 using a subset

2 BSWRICS, Barwon Health, Geelong, VIC, Australia

of cancer-specific patient data from the Victorian Admitted Episode
Dataset (VAED).

Introduction: Advance care planning (ACP) conversations may result

Results: Analysis of VAED data shows despite 28290 fewer admissions

in preferences for future medical decisions being documented in an

(−6%) and 16,782 fewer patients (−10%) for patients with both malig-

advance care directive (ACD), the identification of the person’s medi-

nant and non-malignant neoplasms in Victoria from 2019 to 2020. The

cal treatment decision maker (MTDM), and storage of this information

most significant decline in admissions were in May (−23%) and August

in the health record, for when a person can no longer make their own

(−18%) which coincided with COVID lockdowns 1 and 2.

decisions. The goal of ACP is that people receive preference aligned

In 2021, this trend reversed and admission and patient numbers

care.

increased by 8% and 10% respectively when comparing to 2020, but

Aim: To understand current practices relating to ACP and the preva-

had barely increased when compared to 2019, with lung cancer new

lence of ACD documents in the health records in Victorian cancer

admissions down 2.6%. There was growth in admissions mid-year with

services.

August having a 29% increase compared to the previous year. Octo-

Method: The study involved a mixed methods design. The study exam-

ber had a slight decrease in admissions (−0.6%) compared to 2020

ined a statewide, retrospective, cohort of Victorians who died from

following 113 days of rolling lockdowns (lockdowns 3–6).

cancer between 1 July 2018 and 30 June 2019, for patterns of end-

Conclusions: Previous trends have shown ∼4% annual increase in

of-life care. Data sources included the Victorian Cancer Registry, the

activity however between 2019 and 2021 there was only 2% increase.

Victorian Death Index, Victorian Admitted Episode Dataset, the Vic-

Our analysis mirrors evidence that COVID-19 has negatively impacted

torian Emergency Minimum Dataset, and the Victorian Integrated

cancer care which would suggest a surge in activity and late stage

Non-Admitted Health dataset. The study also examined ACP systems,

cancer diagnoses in 2022.

policy, and resources across 73 Victorian health services via survey.
Results: Of the 10,145 people who died from cancer, 55% were male,
39% lived outside a metropolitan area. 67% of patients died in an acute
or palliative care bed in a hospital. Only 12% had documented evidence
of an ACD and 10% evidence of their MTDM. Of the 73 health services,
38% had a dedicated ACP workforce. 27% (n = 20) of ACP policies did

1. https://www.cancervic.org.au/about/media-releases/2022-mediareleases/june/more-men-than-women-in-victoria-are-livingwith-undetected-cancer.html
2. https://www.abc.net.au/news/2021-10-03/melbourne-longestlockdown/100510710

not include health professional obligations and 34% (n = 25) did not
include guidance on enactment of preferences.
Conclusion: This study identified variation in ACP practice from opti-

361

mal care. There is a lack of planning for future medical treatment

psychosexual intervention for couples post-allogeneic

decisions and a low prevalence of ACDs in the health records of peo-

haematopoietic stem cell transplantation

Evaluating the feasibility and acceptability of a

ple facing end-of-life care for cancer. The Victorian Integrated Cancer
Services have been tasked to implement recommendations and action

Brindha Pillay1 , Yvonne Panek-Hudson2 , Teresa Garcia2 , David

service improvement activities.

Ritchie2 , Michael Jefford3,4 , Cassandra Shields5,6 , Jo Gniel7 , Jo
Phipps-Nelson8,4 , Allison Drosdowsky8 , Sarah Blaschke8 , Steve Ellen1 ,
Maria Ftanou1
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The impact of COVID-19 on cancer diagnoses in Victoria

1 Psychosocial

Oncology Program, Peter MacCallum Cancer Centre, Mel-

bourne, Australia
Sandra Picken1 , Abi McBride1
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2 Clinical

Haematology, Peter MacCallum Cancer Centre and Royal Mel-

bourne Hospital, Melbourne, Victoria, Australia
3 Australian

314

Advance care planning in cancer services: The evidence,

national collaboration and sustainable resource development

Cancer Survivorship Centre, Peter MacCallum Cancer Centre,

Melbourne, Victoria, Australia

Helena Rodi1 , Linda Nolte1

4 Sir

1 Advance

Peter MacCallum Department of Oncology, University of Melbourne,

Melbourne, Victoria, Australia

Care Planning Australia, Austin Health, Melbourne, Victoria,

Australia

5 Australian Centre for Emotionally Focused Therapy, Brisbane, Australia
6 School

of Psychology, University of Queensland, Brisbane, Queensland,

Aim: To improve advance care planning (ACP) evidence-based

Australia

resources for people with cancer, support people, and oncology health

7 Landscape of Life, Melbourne, Australia

professionals across Australia.

8 Cancer

Methods: Rapid literature review was conducted in January 2020 to

Experiences Research, Peter MacCallum Cancer Centre, Mel-

bourne, Australia

determine the barriers and facilitators of ACP in cancer services. In
addition, two national, online cross-sectional surveys were conducted:

Purpose: Allogeneic haematopoietic stem cell transplantation

(1) of adults with cancer and support people; (2) of oncology health

(HSCT) can have a long-term impact on survivors’ sexual func-

professionals. Survey responses were collected, and descriptive anal-

tioning and consequently, their relationship satisfaction. This

yses completed. National ACP and cancer networks were established

study aimed to examine the feasibility and acceptability of a five-

including representation from oncology peak-bodies and organisa-

session psychosexual intervention for HSCT survivors and their

tions. Evidence-based ACP content, resources, and education were

partners.

developed and disseminated nationally.

Methods: Participants were recruited from Peter MacCallum Cancer

Results: Literature review and survey results highlighted the benefits

Centre and Royal Melbourne Hospital Allogeneic Transplantation Ser-

of ACP for people with cancer, their families and oncology services.

vice. To be eligible survivors were required to be more than 3 months

However, very few people with cancer had documented their val-

post-allogeneic HSCT. The intervention comprised two components: 1.

ues and preferences for medical treatment. The national survey of

A psychosexual education session exploring medical/behavioural treat-

consumers and support people highlighted that people with cancer

ment options for sexual dysfunction, delivered by a specialist nurse 2.

were more likely to discuss their preferences with family or friends

A four-session Emotionally-Focused Therapy-based relationship edu-

than doctors. The national survey of health professionals found simi-

cation programme for couples delivered by a clinical psychologist.

lar low understanding and uptake of ACP. Survey results demonstrated

Measures assessing relationship quality, sexual functioning, anxiety,

important gaps in education and information provision for people with

and depression were administered pre- and post-intervention. Fea-

cancer, support people, and oncology health professionals.

sibility was measured via participation rate, adherence to the inter-

Over 27,000 resources aimed at consumers were printed or viewed

vention and compliance with completing main measures. Acceptability

online and over 16,000 health professionals were supported through

of the intervention was assessed via patient and partner satisfaction

receiving relevant ACP information or education across the one-year

surveys.

period. ACPA’s National ACP Week Campaign was delivered and

Results: Eight of 85 (9.4%) eligible survivors and their partners partici-

reached 3.25 million Australian’s nation-wide, improving awareness of

pated in the study. Reasons for declining participation included: feeling

ACP in the community.

uncomfortable due to sensitive nature of intervention; no relation-

Conclusion: Despite increasing awareness of ACP, understanding

ship/sexual function issues; and experiencing ongoing medical issues

amongst people with cancer, support people and oncology health pro-

that required attention. Six of eight couples (75%) attended at least

fessionals remains low. This may affect people with cancer receiving

four intervention sessions and five of eight (62.5%) completed the main

preference aligned treatment and end-of-life care. More focus on

study measures post-intervention. Five of eight couples completed

collaboration and disseminating ACP content, resources, and educa-

questions regarding perception of change in sexual and relationship

tion through existing networks and channels is required to increase

satisfaction: four reported that sexual satisfaction and relationship

understanding and implementation in Australian oncology services.

satisfaction was somewhat or much better post-intervention; one
reported no change. All five couples agreed or strongly agreed the
intervention helped them understand relationship issues that influ-

362

enced sexual wellbeing.

survivorship: Understanding age differences in the role of

Conclusion: The intervention was deemed acceptable. However, fea-

telehealth

Meeting the needs of rural/regional cancer patients in

sibility criteria were not met, with low enrolment rate. Couples who
participated adhered to the intervention and considered it benefi-

Karina Dr Rune2,1 , Tamara Dr3 , Hattie Dr Wright4 , Cindy Professor

cial. Other strategies to identify and manage sexual concerns are

Davis4

required.

1 School of Health and Behavioural Sciences, The University of the sunshine

Coast, Sippy Downs, Queensland, Australia
2 Psychologist and lecturer, Sippy Downs, QLD, Australia
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3 School

of Social Policy & Practice, University of Pennsylvania, Pennsylva-

outcome and measured this to be $40,333 for 5-year LC benefit and

nia, USA

$72,600 for 5-year OS benefit for lung cancer.2 The aim of this study

4 The University of the sunshine Coast, Sippy Downs, QLD, Australia

was to estimate the cost of first RT course for lung cancer and calculate
the costs for LC and OS benefit by stage at diagnosis.

Background and Aims: Access to health services and quality of life are

Methods: All RT activities for lung cancer with curative and palliative

important factors for long-term cancer survivorship. The COVID-19

intents were extracted from Liverpool Hospital RT information system

pandemic has significantly impacted cancer care globally. In response

(MOSAIQ; Elekta, Stockholm, Sweden) from July 2017 to June 2020.

to the pandemic, reconfiguration of services and adoption of telehealth

RT activities and associated costs were consolidated. RT activity costs

have been essential for continuation of services, while also offering an

were based on the previous study.2 Average cost of treatment course

alternative approach to cancer care and support. This study explores

was calculated (average cost of activities per fraction X no. of fractions).

the role of telehealth in providing health and supportive services to

Cost per outcome ratio was estimated from cost of total fractions per

Australian rural/regional cancer patients during COVID-19 and their

5-year LC and OS gain.

attitudes on the quality of these services to inform future practice.

Results: Four hundred and fifty-six lung cancer patients received

Methods: Rural/regional cancer patients and survivors (n = 66) com-

30,535 radiotherapy activities. Average cost of activities per fraction

pleted an online survey regarding the transition and delivery of

was $327 for all stages, and $392, $295, $348 for stage I–II, III and

health and support services via telehealth during COVID-19. Data

IV, respectively. The average cost of treatment courses for 5-year LC

was collected as part of a bi-annual survey on client satisfaction at a

and OS gain were $49,590 and $87,737 for all stages. For stages I–

rural/regional community cancer wellness centre in Australia.

II and III, the average costs were $42,032 and $39,801 for 5-year LC

Results: Participants included 71% females with 48% younger (under

and $73,556 and $70,126 for 5-year OS benefit. For 1-year benefit,

64 years), and 52% older cancer patients and survivors (65 years and

the costs were $8,406 & $7,960 for LC and $14,711 & $14,025 for OS,

over), with a mix of cancer presentations. Younger participants were

respectively.

significantly (p < 0.05) more likely to use allied health services via

Conclusions: Monetary value estimates of the cost of RT fractiona-

video/telehealth during COVID-19 compared to their older counter-

tion schemes over LC and OS benefits were comparable to previous

parts. The preferred format for nursing health services in the future

estimates.2 RT is an inexpensive treatment option in the management

was face-to-face (59% for younger and 42% for older participants) tele-

of lung cancer.

health (10% for both groups), and mixed (31% for younger and 48% for
older participants). Although not statistically significant (p>.05), it is

1. Hanna T, Shafiq J, Delaney G, Vinod S, Thompson S, Barton

interesting that the older cohort had a greater preference for a mixed

M. The population benefit of evidence-based radiotherapy: 5-

modality of face-to-face and telehealth in meeting their future health

Year local control and overall survival benefits. Radiother Oncol

service needs.

2017;126:191–197.

Conclusions: Telehealth has benefits for the delivery of health and sup-

2. Batumalai V, Wong K, Shafiq J, Hanna TP, Gabriel G, Heberle J,

portive services to rural/regional cancer patients. Nurses can play a key

Koprivic I, Kaadan N, King O, Tran T, Cassapi L, Forstner D, Delaney

role in assessing the support needs of cancer survivors and facilitate

GP, Barton M. Estimating the cost of radiotherapy for 5-year local

strategies to ensure that survivors have the skills necessary to access

control and overall survival benefit. Radiother Oncol. 2019 Apr

telehealth support.

20;136:154–160.
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Cost estimation of radiotherapy for local control and

Digitally-delivered models of exercise support for

Haematological cancer survivors: A cross-sectional survey study

overall survival benefit of lung cancer

exploring factors associated with likelihood of uptake

Jesmin Shafiq2,1,3 , Vikneswary Batumalai3,4 , Karen Wong2,1,3 ,

Camille E. Short1,2 , Lara Edbrooke3,4 , Shaza Abo3,4 , Tamara Jones1 ,

Nasreen Kaadan1,3 , Alexandra Powell1 , Geoff Delaney2,1,3 , Shalini

Catherine Granger3,5 , Linda Denehy3,4

Vinod2,1,3

1 Melbourne

1 SWSLHD Cancer Services, Liverpool Hospital, Liverpool, NSW, Australia

Behaviour Change, Parkville, VIC, Australia

2 Collaboration

2 Melbourne

for Cancer Outcomes Research and Evaluation (CCORE),

School of Psychological Sciences, Melbourne Centre for
School of Health Sciences, University of Melbourne, Parkville,

Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia

VIC, Australia

3 South

3 Department

Western Sydney Clinical School, University of New South Wales,

of Physiotherapy, Melbourne School of Health Sciences,

Sydney, NSW, Australia

University of Melbourne, Parkville, VIC, Australia

4 GenesisCare, Sydney, NSW, Australia

4 Department

of Health Services Research, The Peter MacCallum Cancer

Centre, Melbourne, VIC, Australia
Background: Optimal use of radiotherapy (RT) in lung cancer results in

5 Department

12% 5-year local control (LC) and 6% 5-year overall survival (OS) ben-

VIC, Australia

efit at the population level.1 Our previous study assessed RT costs per

of Physiotherapy, The Royal Melbourne Hospital, Melbourne,
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Aim: To explore factors associated with uptake of digitally-delivered

people with cancer) and health-related quality of life (HRQL) can be

exercise models to support treatment readiness and recovery among

positively impacted by physical activity, GHS adapted questions from

Haematological cancer survivors.

existing patient-reported outcome (PRO) measures to assess these

Methods: A survey study via Qualtrics was conducted (August 2021)

constructs and evaluate the GHS module. We aimed to pre-test the

among adults self-reporting a diagnosis of Haematological cancer

six adapted PRO items assessing fatigue and HRQL for acceptability,

within the last five years. Three models of digitally-delivered exercise

comprehensibility, and face validity.

support (video teleconferencing, live coaching with remote monitoring,

Methods: Pre-testing was done in two phases: (i) expert review; and,

self-guided web-based program with minimal contact) were described.

(ii) cognitive debriefing interviews. In Phase 1, the research team

Participants were asked to report the likelihood of uptake for each

reviewed six items for clarity, face validity, and relevance. In Phase

model on a 5-point Likert scale (not at all likely to extremely likely).

2, semi-structured cognitive interviews were conducted with adults

Response reasons were collected via an open-ended question. Demo-

(≥18 years of age, of any gender, diagnosed with any cancer) enrolled

graphic, health and exercise behaviours were also recorded. Ordinal

in GHS coaching program. Interviews were done via phone and audio

regression was used to explore participant characteristics associated

recorded. Dominant trends across interviews were considered.

with likelihood of uptake of each model on a complete case basis.

Results: Feedback from phase 1 suggested simplifying items and reduc-

Open-ended responses were analysed thematically.

ing recall period from two to one week. In Phase 2, eight people

Results: Participants (N = 70) were generally representative of the

participated in cognitive interviews, reporting the items were easy

target population. Though those meeting physical activity guidelines

to understand, clear, not intrusive, and easy to answer via phone.

(67%) and those diagnosed with myeloma (63%) were overrepre-

Problems were identified with item content (unclear words/phrases),

sented. Average time since diagnosis was 2.2 years (SD 1.7). Self-

number of items, response options and recall period. Suggestions made

reported likelihood of uptake was highest for the remote monitoring

included: simplifying items, revise items from six to five to reduce cog-

model, followed by the web-based minimal contact model (65% ver-

nitive load, change the phrase ‘your cancer’ to ‘your physical condition’,

sus 60% rating ‘extremely’ or ‘quite a bit’). Video-teleconferencing was

and to modify recall period based on feedback from Phase 1 and 2.

the lowest rated model (54%). Living outside of a major city and hav-

Conclusions: This study demonstrated broad acceptability and com-

ing a university degree were associated with higher likelihood ratings.

prehensibility of the items assessing fatigue and HRQL with some sug-

English as a second language was associated with a lower likelihood rat-

gestions for improvements. Evaluation of the measurement properties

ing for the minimal contact model. Participant open-ended responses

of these items in a larger study is needed.

highlighted both facilitators (e.g., flexibility) and barriers (e.g., lack of
social connection, ill-health) for implementing the models.
Conclusions: This study provides important insights into which
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patients may be less interested or able to participate in digitally-

patient-reported measure – The Radiation therapy-related

delivered models of exercise support, and subsequently for whom such

Inconvenience Questionnaire (RIQ)

Development and implementation barriers of a new

programs may be most suitable and what barriers and facilitators
should be considered.

Chindhu Shunmugasundaram1,2 , Puma Sundaresan3,4 , Kate White5 ,
Madeleine King2 , Chris Milross3,6 , Matthew Fuller7 , Lucinda Rodd7 ,
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Get healthy service cancer module – Content validation

of fatigue and quality of life questions
Chindhu Shunmugasundaram1 , Rachel Campbell2,1 , Jasmine Yee1 ,
Sandra Davidson3 , Haryana Dhillon1
1 Centre for Medical Psychology & Evidence-based Decision-making, School

of Psychology, Faculty of Science, The University of Sydney, Sydney, NSW,
Australia
2 Psycho-Oncology Cooperative Research Group, University of Sydney, NSW,

Australia
3 Centre

for Population Health, Ministry of Health, St Leonards, NSW,

Australia
Aims: The Get Healthy Service (GHS), launched in 2009, is a free
government-funded telephone-delivered coaching service aimed at
encouraging healthy lifestyle behaviours. The GHS recently added
a module specifically designed to support people with cancer to be
physically active. Since fatigue (most common symptom reported by

Claudia Rutherford5,2
1 Centre

for Medical Psychology and Evidence-based Decision-making,

School of Psychology, The University of Sydney, Sydney, NSW, Australia
2 Quality

of Life Office, School of Psychology, The University of Sydney,

Sydney, NSW, Australia
3 Sydney Medical School, The University of Sydney, Sydney, NSW, Australia
4 Radiation

Oncology Network, Western Sydney Local Health District,

Sydney, NSW, Australia
5 Susan

Wakil School of Nursing and Midwifery, Cancer Nursing Research

Unit, The University of Sydney, Sydney, NSW, Australia
6 Radiation Oncology and Medical Services, Chris O’Brien Lifehouse, Sydney,

NSW, Australia
7 Radiation Oncology, Central West Cancer Centre, Orange, NSW, Australia

Aims: Radiation therapy (RT) is an essential and cost-effective treatment modality for cancer and can benefit approximately 50% of cancer
patients and contribute to 40% of all cancer cures. Yet, its utilisation in cancer is low globally. Several factors contribute to this
including perceived inconvenience related to accessing and utilising
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RT. To quantitatively assess the latter, a new tool – the Radiation

qualitative literature on patient and healthcare provider experiences

therapy Inconvenience Questionnaire (RIQ) – was developed. Post-

of using PREMs in clinical practice.

development, RIQ was adapted to two versions – clinical-use and

Methods: Medline, Embase and PsycInfo were systematically

research-use. This study aimed to (i) pre-test both versions of RIQ and

searched from inception to May 2021. Additional searching of

(ii) explore barriers and facilitators to implementing them in routine

reference lists for all included articles and relevant review articles

clinical practice and clinical trials.

were performed. Retrieved articles were screened for eligibility

Methods: Semi-structured cognitive interviews were conducted with

by one reviewer and 25% cross-checked by a second reviewer

patients undertaking RT, recruited via three hospitals, to examine

across all stages of the review. Full texts meeting eligibility cri-

content validity, acceptability, and comprehensibility of both versions

teria were appraised against the COREQ checklist for quality

of RIQ. Interviews identified inconsistencies, relevance, and clarity

assessment. Thematic analysis was used to analyse textual data

of items. Semi-structured interviews with healthcare professionals

extracted.

involved in the delivery of care to individuals undertaking RT, explored

Results: Electronic searches identified 2683 records, of which 20 stud-

barriers and facilitators to routine usage. Thematic analysis was used

ies met eligibility criteria. Healthcare providers’ attitudes towards

to identify themes.

PREMs were mixed; extracted data were synthesized into six themes:

Results: Patients (N = 15) identified problems in content, instructions,

facilitators to PREM implementation; barriers to PREM implementa-

layout, length, and response options; consequently, 25 items were

tion; healthcare providers’ attitudes towards using PREMs; patients’

revised and eight removed, resulting in a final 29-item Clinical-RIQ.

attitudes towards using PREMs; advantages of using PREMs in clinical

33 items were revised, and three removed for redundancy, resulting

practice; limitations and practical considerations to reduce resis-

in a final 36-item Research-RIQ. Clinicians (N = 16) identified staff-

tance of PREM usage. The primary factors facilitating and impeding

and patient-specific barriers to implementing RIQ in clinical practice.

the use of PREMs include organizational-, staff- and patient-related

Perceived facilitators included: (a) workplace facilitators, (b) mode of

factors.

administration, and (c) imparting knowledge.

Conclusion: Results can be used to guide the usage and implementa-

Conclusions: This study demonstrated acceptability and comprehensi-

tion of PREMs in clinical settings by addressing the identified barriers

bility of the 29-item RIQ-Clinical and 36-item RIQ-Research amongst

and building on the perceived benefits to encourage adoption of

cancer patients undertaking RT and treating clinicians. The next phase

PREMs. Results around facilitators to PREM implementation and prac-

will evaluate the RIQ’s measurement properties in a larger clinical

tical considerations could also promote appropriate use of PREMs by

study. The barriers and facilitators identified can guide future imple-

healthcare providers, helping to improve practice and the quality of

mentation of RIQ-Clinical and Research in clinical practice and clinical

care based on patient feedback.

trials respectively.
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Patient and healthcare provider perceptions on using

patient-reported experience measures (PREMs) in routine clinical

Review of utilisation of Oral Chemotherapy Clinic (OCC)

to improve quality of care for metastatic breast cancer patients
receiving oral anti-cancer agents

care: A systematic review of qualitative studies
Priyadarshini Sinha1 , Caitlin Murphy1
Chindhu Shunmugasundaram1,2 , Rachel Campbell1,2 , Angela Ju2 ,

1 Oncology, Western Health, Melbourne, Victoria, Australia

Madeleine King2 , Claudia Rutherford3,2,4
1 Centre

for Medical Psychology and Evidence-based Decision-making,

Background: The symptom urgent review clinic (SURC) was estab-

School of Psychology, The University of Sydney, Sydney, NSW, Australia

lished at Western Health in 2013 to assess chemotherapy patients

2 Quality

presenting with new symptoms or treatment complications. Based on

of Life Office, School of Psychology, The University of Sydney,

Sydney, NSW, Australia

this model, the oral chemotherapy clinic (OCC) was established in 2015

3 Susan

to educate patients and provide timely reviews for those on oral cancer

Wakil School of Nursing and Midwifery, Cancer Nursing Research

Unit, The University of Sydney, Sydney, NSW, Australia

therapies.

4 Daffodil Centre, The University of Sydney, Sydney, NSW, Australia

Aims:

Aims: Patient-reported experience measures (PREMs) measure

1. Assess the utilisation of the OCC by metastatic breast can-

a patient’s perception of quality-of-care. With increasing quality

cer (MBC) patients prescribed non-hormonal oral treatments

improvement studies in clinical practice, use of PREMs has surged.

(Capecitabine, Cyclophosphamide, Palbociclib, Ribociclib, Abemaci-

PREMs can be used to enhance quality, experience & outcomes of

clib).

healthcare and facilitate patient engagement. As a result, knowledge

2. Investigate the number of unplanned episodes of care provided

about stakeholder experiences of using PREMs to assess quality-

by OCC which would otherwise have occurred in Emergency,

of-care across diverse clinical settings is needed to inform PREM

outpatient departments or general practitioners.

implementation efforts. Hence, this study systematically reviewed the
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Methods: Between April 2015 and May 2022, episodes of care for

assessed pre-service (before their first PSW session) and post-service

MBC patients receiving oral agents were extracted from the SURC

(3 months after pre-service survey) (N = 36). Satisfaction with the PSW

databases. Data were reviewed for presenting complaint and episode

service was explored with this sample, a separate sample of 43 service

outcomes; all data was de-identified. Data were missing May 2017–

users, and via semi-structured interviews: the latter also exploring the

January 2018 during database redesign.

impact of the service.

Results: Ninety-one patients were identified with total of 171

Results: Significant decreases were found in levels of psychological

unplanned SURC encounters. Of these, 19 (11%) encounters were

distress (Mean T0 = 22.7, T1 = 19.4, p = 0.001), stress associated

escalated for either review by SURC registrar or admission. During Apr

with parents’ concerns (Mean T0 = 5.6, T1 = 3.9; p = 0.005), and

2015–Apr 2017, in nine of 21 (43%) toxicity reviews, phone advice

the severity of parenting-related concerns during cancer (PCQ; Mean

was sufficient to address concerns. From 2018–2022, 133 of 151

T0 = 2.9, T1 = 2.3; p = 0.001). Parental confidence in their ability to

(88%) encounters were successfully managed with phone advice alone.

help their child with cancer-related concerns significantly increased at

Only nine (6%) encounters were advised to present to their general

post-service (Mean T0 = 46.7, T1 = 62.8, p = 0.001). Satisfaction with

practitioner/Emergency with fever and respiratory distress the most

the PSW service was very high. Key themes from the interviews were:

common complaints requiring escalation of care.

Cancer Affects the Whole Family, Positive Impact of the Service on

Conclusion: This review demonstrates utility of the OCC in diverting

Families, Improved Parenting and Communication Issues, and Need for

patients to the oncology department and facilitating admission where

PSWs to Follow-Up with Parents.

appropriate. By proactively managing symptoms and toxicities from

Conclusions: Along with high levels of parent-reported satisfaction,

oral agents it is likely the OCC, similar to SURC, reduces presentations

the PSW service was found to be effective in improving parents’ psy-

to Emergency and general practitioners. This data suggests increasing

chosocial and parenting outcomes. These findings provide evidence for

clinician referrals and uptake of the OCC would benefit patients by cen-

the clinical utility and need for integrated, cross-sector care to support

tralising their management in the oncology department where they are

families impacted by cancer.

well known.
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Effectiveness of a novel cross-sector in-hospital service

Primary prevention of skin cancer in primary care

settings – A scoping review

for parents who are cancer patients and their adolescent and
young adult children

Amelia K. Smit3,2,1 , Kate Dunlop1 , Nehal Singh4 , Nikki Woolley5 ,

Xiomara Skrabal Ross1 , Fiona E.J. McDonald1,2 , Stephanie Konings3 ,

1 Daffodil

Elena Schiena4 , Jo Phipps-Nelson5 , Fran Hodgson6 , Pandora

Council NSW, The University of Sydney, NSW, Australia

Patterson1,2

2 Melanoma

1 Canteen Australia, Newtown, NSW, Australia

Australia

2 Faculty of Medicine & Health, The University of Sydney, Sydney, New South

3 The University of Sydney, Faculty of Medicine and Health, Sydney School of

Wales, Australia

Public Health, Sydney, NSW, Australia

3 Psycho-Oncology Department, Clinique Saint-Jean, Brussels, Belgium

4 Australian

4 Department of Allied Health, Peter MacCallum Cancer Centre, Melbourne,

NSW, Australia

Australia

5 Cancer Institute NSW, Sydney, NSW, Australia

5 Office

6 Royal Prince Alfred Hospital, Sydney, NSW, Australia

Diona L Damien2,6,7 , Kylie Vuong8 , Anne E Cust3,2,1

of Cancer Research, Peter MacCallum Cancer Centre, Melbourne,

Centre, The University of Sydney, a joint venture with Cancer
Institute Australia, The University of Sydney, Sydney, NSW,

Institute of Health Innovation, Macquarie University, Sydney,

Victoria, Australia

7 The University of Sydney, Sydney, NSW, Australia

6 Social Work, John Hunter Hospital, Newcastle, New South Wales, Australia

8 School

of Medicine and Dentistry, Griffith University, Brisbane, QLD,

Australia
Aims: Parental cancer poses psychosocial challenges for parents
and their adolescent and young adult (AYA) children, with common

Background: Skin cancer is highly preventable through primary pre-

concerns including confidence in parenting ability and communica-

vention activities such as avoiding UV exposure during peak times and

tion about cancer with their AYA children. To address this, a novel

regular use of sun protection. General practitioners (GPs) and primary

cross-sector service (Parent Support Worker; PSW) supporting parent-

care nurses are often the first point of call for skin cancer concerns and

patients, their partners, and AYA children was implemented and eval-

are well placed to promote sustained primary prevention behaviours.

uated in three Australian hospitals. This presentation focuses on the

Aim: To review the evidence on skin cancer primary prevention activ-

effectiveness of the PSW service, parent satisfaction, and the impact

ities in primary care settings, including the associated barriers and

of the service on families.

enablers to delivering skin cancer prevention.

Methods: In this mixed-methods study, parents’ psychological distress

Methods: We conducted a comprehensive search using a strategy

(K10), parenting concerns (PV9 and PCQ), and parents’ cancer self-

aligned with the SPIDER tool for Qualitative and Mixed-Methods Evi-

efficacy in helping their children (CASE Help Child sub-scale) were

dence Synthesis in Embase, Medline, PsychInfo, Scopus, Cochrane
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Central and CINAHL, and relevant grey literature sources such as can-

were mapped against Proctor’s implementation framework.2 Factors

cer and skin cancer peak bodies and primary care organisations. The

impacting on implementation success (e.g. adoption, uptake) were

literature was limited to publications from 2014 that included skin

identified through mapping to the Consolidated Framework for Imple-

cancer primary prevention activities within primary care settings, for

mentation Research.3

example involving GPs and primary care nurses, for studies or pro-

Results: One thousand six hundred and ninety publications were iden-

grams conducted in Australia and countries with comparable health

tified. Twenty-two studies were eligible for inclusion (10 RCTs, six eval-

systems. This work was funded by the Cancer Institute NSW.

uations, five observational/exploratory studies, one case study). Most

Results: A total of 25 peer-reviewed journal articles and 28 grey liter-

studies reported on cancer-specific support groups (breast, n = 16,

ature resources were included in the review. We identified four key

73%; ovarian n = 1, 5%; prostate, n = 1; 5%; brain, n = 1; 5%) rather than

types of primary prevention activities: behavioural counselling; risk

mixed cancer groups (n = 3; 14%). Majority (n = 20; 91%) were patient

assessment and delivering risk-tailored information; new technologies

only; one (5%) was for family members and one (5%) for caregivers and

for early detection with linked primary prevention information; and

family members. Most were delivered face-to-face (n = 19; 86%); one

education and training programs for the primary care workforce. Sev-

(5%) was online; and one (5%) had a hybrid format (simultaneous face-

eral key enablers and barriers were identified; examples of enablers

to-face/teleconference). Most (n = 18; 82%) were weekly. Most were

include pairing with early detection activities, easy-to-understand

informed by a psycho-theoretical framework, typically supportive-

patient information, fitting with existing workflows and systems; exam-

expressive group therapy. Key outcomes included: psychosocial or

ples of barriers include unclear requirements, lack of confidence in

affective mood (e.g. mood disturbance, traumatic stress) (n = 6; 27%);

prevention counselling, competing demands, low priority, lack of time,

quality-of-life (n = 2; 9%); pain symptoms (n = 2; 9%); and survival

and limited availability of GP services especially in regional and remote

(n = 6; 27%). Initial reports of survival benefit were not replicated.

areas.

Several studies demonstrated short- and medium-term psychosocial

Conclusions: These findings highlight potential opportunities for

benefits. Further benefits included connection, knowledge sharing,

enhancing skin cancer prevention activities in primary care.

normalisation of death/dying, acceptance and meaning-making. Frequently reported implementation outcomes included: acceptability,
feasibility and fidelity; few reported sustainability. Key determinants of
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Professionally-led support groups for people living with

successful implementation included facilitators’ skills/experience, hav-

advanced cancer: A systematic scoping review of effectiveness

ing more than one facilitator, mode of operation (i.e. face-to-face or

and factors critical to implementation success within real-world

teleconference) and resourcing.

healthcare settings

Conclusion: Professionally-run support groups for people with
advanced cancer improve psychosocial outcomes and quality-of-life.

Zhicheng Li1 , Kitty-Jean Laginha1 , Frances Boyle2 , Michele Daly3 ,

Participants and facilitators reported high levels of acceptability.

Fiona Dinner4 , Pia Hirsch5 , Kim Hobbs6 , Laura Kirsten7 , Sophie
Lewis2 , Carolyn Mazariego1 , Roslyn McAuley8 , Mary O’Brien5 ,
Amanda O’Rielly9 , Natalie Taylor10 , Lisa Tobin11 , Andrea L. Smith1
1 The Daffodil Centre, University of Sydney, Sydney, NSW, Australia

1. Arksey, H. & O’Malley, L. Scoping studies: towards a methodological
framework. Int J Soc Res Method 8, 19–32 (2005).
2. Proctor, E. et al. Outcomes for Implementation Research: Concep-

2 University of Sydney, Sydney, NSW, Australia

tual Distinctions, Measurement Challenges, and Research Agenda.

3 Consumer representative, Sydney, NSW, Australia

Administration and Policy in Mental Health and Mental Health

4 Consumer representative, Melbourne, VIC, Australia
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Services Research 38, 65–76 (2011).
3. Damschroder, L. J. et al. Fostering implementation of health ser-

6 Westmead Centre for Gynaecological Cancers, Sydney, NSW, Australia

vices research findings into practice: a consolidated framework for

7 Nepean Cancer Care Centre, Sydney, NSW, Australia

advancing implementation science. Implementation Science 4, 50

8 Think Pink, Melbourne, VIC, Australia

(2009).

9 Support group facilitator, Sydney, NSW, Australia
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Cancer malnutrition and sarcopenia: How risky is it?

Aim: To examine effectiveness of professionally-led support groups for

Belinda Steer1,2 , Kate Graham1 , Nicole Kiss2 , Jenelle Loeliger1,2

people with advanced cancer and identify factors critical to implemen-

1 Nutrition

tation success within real-world healthcare settings.

bourne, Victoria, Australia

Method: Databases (MEDLINE; PsychINFO; CINAHL) and the grey

2 Institute

literature were searched for empirical publications and evaluations.

Australia

and Speech Pathology, Peter MacCallum Cancer Centre, Mel-

for Physical Activity and Nutrition, Deakin University, Geelong,

Articles were double-screened for eligibility and data systematically extracted, charted and summarised using a modified Arksey
and O’Malley scoping review

methodology.1

Implementation factors

Aims: Cancer-related malnutrition prevalence has been reported in
Victoria four times since 2012. Less is known about the prevalence
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(and risk) of cancer-related sarcopenia within the Australian context.

surgery, letter correspondence with surgeon, general practitioner, clin-

Malnutrition and sarcopenia are both independently associated with

ical notes written by SCSC team and biochemistry results (if available)

adverse outcomes in people with cancer, and early identification is

during the first 12-months after initial SCSC visit were audited.

essential. The aim of this study was to determine the prevalence of

Results: Median age 63 years (range 43–88); 67% male; 58% gastric

malnutrition and sarcopenia risk within the Victorian adult cancer

cancer. Median time from diagnosis to initial SCSC consult was 10-

population.

months. At initial survivorship appointment, 23/48 (48%) survivors

Methods: A multi-site point prevalence study was conducted across

were taking at least one vitamin or mineral supplement; most com-

Victorian acute health services in July 2022. Adults with cancer receiv-

monly vitamin D. In longitudinal follow-up the SCSC team made at

ing ambulatory radiotherapy and/or chemotherapy, and multi-day stay

least one dietary supplement recommendation to 22/28 (79%) sur-

inpatients were included. Malnutrition risk was assessed using the Mal-

vivors, surgeons to six (21%), GPs to three (11%) and endocrinologists

nutrition Screening Tool and sarcopenia risk was assessed using the

to two (7%) survivors. Other clinicians each made at least one rec-

SARC-F.

ommendation to one (4%) survivor. Overall, 87% (42/48) of survivors

Results: A total of 21 health services (26 sites) recruited 1663 adult

were documented to be taking supplements at some stage during their

oncology patients into the study (n = 264 inpatients, 16%). Thirty-

SCSC visits. In total, 38 survivors had at least one blood test to deter-

six percent of all patients were at risk of malnutrition with preva-

mine vitamin/mineral status: the SCSC team ordered tests for 27/38

lence highest in inpatients (64%) compared to chemotherapy (33%)

(71%) survivors, GPs 18 (47%), and surgeons 15 (39%). Other clinicians

and radiotherapy (27%) ambulatory patients. Nineteen percent of all

(endocrinologists, gastroenterologists) each ordered tests for 3 (8%) or

patients were at risk of sarcopenia with prevalence highest in inpa-

fewer survivors.

tients (40%) compared to chemotherapy (15%) and radiotherapy (15%)

Conclusions: Not all UGI survivors were taking supplements. Clinical

ambulatory patients. Ten percent of all patients were at risk of both

practice regarding vitamin/mineral surveillance and supplementation

malnutrition and sarcopenia, and of those not at risk of malnutrition,

for UGI cancer survivors after surgery is inconsistent. Further research

144 patients (14%) were at risk of sarcopenia.

should focus on developing evidence-based clinical pathways to ensure

Conclusions: Malnutrition and sarcopenia risk are highly prevalent in

best standard practice.

adult oncology patients, especially in multi-day stay inpatients. This
study demonstrates the importance of a clinical model that includes
An evaluation on the pharmacy and nursing impact of

a systematised malnutrition and sarcopenia risk screening program to

315

facilitate appropriate nutrition (and other multi-modal) assessments

switching doxorubicin syringes to infusion bags in an Australian

and interventions.

metropolitan cancer specialty hospital

373

Cecilia Ngo1 , Whiter Tang1

Audit of clinical practice on monitoring micronutrient

status of UGI cancer survivors attending Sydney Cancer

1 Pharmacy,

Survivorship Clinic (SCSC)

Australia

Sim Yee (Cindy) Tan1,2,3 , Man Wah Cheung4 , Sheena Singh2 , Kim

Aim: To evaluate the impact of switching doxorubicin syringes to infu-

Kerin-Ayres 1,5 , Carolyn Wildbore1,5 , Ashanya Malalasekera1 , Janette

sion bags on pharmacy compounding and nursing administration in the

Vardy1,3

day therapy unit.

Chris O’Brien Lifehouse, Camperdown, New South Wales,

1 Concord Cancer Centre, Concord Hospital, Concord, NSW, Australia

Method: The cost of consumables used, amount of doxorubicin recy-

2 Nutrition

cled and discarded as wastage was compared between the year before

and Dietetics Department, Concord Hospital, Concord, NSW,

Australia

the switch in February 2021 and the year after. A survey was dis-

3 Sydney Medical School, University of Sydney, Concord, NSW, Australia

tributed to all nursing staff in the day therapy unit on their perspectives

4 The University of Sydney, Sydney, NSW

on the impact of the switch.

5 Nursing Services, Concord Hospital, Concord, NSW, Australia

Results: There was a cost saving of $4542.57 in consumables comparing the year before and the year after switch, as well as a total of 679mg

Background: Patients with upper gastrointestinal (UGI) cancer after

more doxorubicin being recycled and 3095mg less doxorubicin being

surgery with curative intent could be at nutritional risk, especially

discarded as wastage. This compares 2607 syringes being made (1186

for micronutrient deficiencies. There are no recommendations for

doses) in the year before, to 1228 bags (and doses) in the year after.

UGI survivors for vitamin/mineral supplementation or surveillance of

Anecdotally, the infusion bags are easier and quicker to make and has

micronutrient status. This study aimed to explore practice of clinicians

a perceived lower risk of spills. Twenty-three nurses responded to the

monitoring micronutrient status and investigate prevalence of UGI

survey and most agreed that IV bag was easier to administer compared

survivors taking supplements.

to syringe (65% strongly agree, 22% agree). A majority thought IV bag

Methods: Fifty-three UGI survivors attended the SCSC from July 2015

causes less repetitive strain injury (52% strongly agree, 22% agree) and

to April 2022; 48 survivors consented to be included in the data

most thought IV bag gives nurses less cytotoxic exposure (57% strongly

analysis, 28 had longitudinal data. Survivors’ discharge summary after

agree, 26% agree). Just over half of respondents neither agreed nor
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disagreed that IV bag causes less extravasation (52%) and that patient

375

would prefer IV bag over syringe (55%).

resistant prostate cancer

Genetic counselling and testing – Metastatic castrate

Conclusion: There is significant cost savings to pharmacy by switching
from doxorubicin syringe to infusion bag and nurses found administer-

Jan Wakeling1 , Andrew Hill1 , Krystle Giuffrida1

ing infusion bags easier and safer. Further studies should be conducted

1 Tasman Health Care, Southport, QLD, Australia

to evaluate the impact on patients.
Background: In April 2022, Medicare introduced new item numbers
for genetic testing in men with metastatic castrate resistant prostate
374

A qualitative study on the experiences of physical activity

among women diagnosed with ovarian cancer

cancer (mCRPC) to determine eligibility for olaparib under the PBS.
This change resulted in increasing numbers of men being referred
for genetic testing. There are unique social and ethical issues that

Kellie Toohey1,2 , Catherine Paterson1,2,3,4 , Celeste E. Coltman1,5

need to be considered in these men, who, until recently have been

1 University of Canberra, Bruce, ACT, Australia

underrepresented in genetics clinics.

2 University

Aim: This study aimed to determine the genetic counselling issues

of Canberra, Prehabilitation, Activity, Cancer, Exercise and

Survivorship (PACES) Research Group, Bruce, ACT, Australia

encountered by medical oncologists, when considering somatic and/or

3 ACT

germline testing for this group of patients, and what support genetic

Health Services, Palliative Care, Canberra Hospital, ACT Health

Services, Canberra, ACT, Australia

counsellors could provide.

4 Robert Gordon University, Aberdeen, AB10 7QB, Scotland

Methods: This pilot study, was conducted during July 2022. Clinicians

5 Research Institute for Sport and Exercise, Bruce, ACT, Australia

were interviewed by a genetic counsellor and asked to identify the
issues they encountered when arranging genetic testing for mCRPC.

Aims: Ovarian cancer is the leading cause of death among gynae-

The doctors also reported on the level of disease education and

cological cancers, with low survival rates and high disease burden.

resources they provided to these patients.

Most women experience reduced physical activity following diagno-

Results: The issues reported included: access to suitable tumour tis-

sis, despite its known benefits. Little is known about the barriers and

sue for testing; deciding if a new biopsy if needed; the limitations of

enablers to physical activity among women affected by ovarian cancer.

germline testing for making treatment decisions; the cost of additional

The primary aim of this study was to explore the barriers and enablers

genomic testing; limited time for genetics education; and identifying

to participation in physical activity in women diagnosed with ovarian

appropriate resources to provide to patients.

cancer.

Conclusion: Genetic counsellors can play an important role in provid-

Methods: A qualitative descriptive study design was conducted and

ing support to medical oncologists and in counselling men with mCRPC

semi-structured interviews were completed with nine women diag-

who are undergoing mainstream genomic testing. This study confirms

nosed with ovarian cancer (stage I–IV; 40–77 years). The interviews

the results of other studies that show the importance of providing

took place at the participant’s home via telephone or online video

education to oncologists and patients regarding multigene next gener-

conferencing software Coviu© . An inductive thematic approach, as

ation sequencing in tumour samples plus/minus subsequent germline

described by Braun and Clarke, 2006 was used. The organisation and

genetic testing (Shirdarreh et al., 2021).

coding of data were completed by hand using NVivo computer software (Version 12.6.0, QSR International Pty Ltd.). Weekly discussions
occurred among the research team to ensure that themes accurately

316

represented participant views. The consolidated criteria for reporting

Implementation recommendations from early adopters in

qualitative studies (COREQ) 32-item checklist was followed.

Australia

Informed financial consent processes in cancer services:

Results: Thematic analysis of the findings revealed that the main
barriers to physical activity were: (1) the lack of referral to an exer-

Carolyn Mazariego1 , Raylene Cox2 , Kate Whittaker2 , Elizabeth

cise professional within the multidisciplinary cancer team, (2) fear of

Kennedy1 , Megan Varlow2

injury after surgery and during treatment, and (3) treatment-related

1 The

side-effects inhibiting participation. However, participants also per-

University of Sydney, Sydney, NSW, Australia

ceived benefits of physical activity which included: physical and

2 Cancer Council Australia, Sydney, NSW, Australia

Daffodil Centre, a joint venture with Cancer Council NSW, The

psychological health benefits, improving cancer outcomes, and social
motivations as key enablers of physical activity.

Despite the known negative psychological and physical impacts finan-

Conclusions: Physical activity interventions for women with ovarian

cial toxicity has on people affected by cancer, a gap remains in the

cancer should address the unique barriers reported by this cohort. Fur-

establishment of standard processes to ensure that informed financial

ther research and service development are needed to design robust

consent (IFC) is obtained within cancer care settings. Through imple-

and flexible referral pathways across both private and public cancer

mentation process mapping, this study aimed to understand existing

services to ensure timely referrals to qualified exercise professionals

pathways of establishing IFC to develop recommendations as to how

following a diagnosis of ovarian cancer.

IFC can be implemented in various cancer clinical care settings.
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Australian medical professionals were invited to participate in semi-

Results: Seventeen HCPs (0.5–31 y prostate cancer experience) par-

structured interviews. Participants were approached if they had pre-

ticipated. We identified five themes related to exercise: (1) HCP rela-

viously demonstrated or discussed having some level of IFC process

tionship with exercise; (2) perceptions and experiences with prostate

already in place, labelling them ‘early adopters.’ We drafted a generic

cancer and treatments; (3) current practice; (4) barriers to promo-

process map to guide interviews and used The Consolidated Frame-

tion; and (5) facilitators to promotion. Subthemes related to current

work for Implementation Research to inform the development of the

practice were identified: (1) exercise discussions – variability between

interview questions.

HCP groups, with radiation oncologists and nurses discussing with

Ten participants agreed to be interviewed. IFC processes varied across

most men, but radiation therapists rarely; and (2) referral pathways

professional speciality (i.e., general practice, surgery, radiation oncol-

– many aware of programs but low rates of referral. Prostate nurses

ogy and medical oncology) and healthcare settings (i.e., public and

were perceived to be primarily responsible for coordinating access to

private). Individualised process maps were established and confirmed

exercise.

by the different participants. Key components of IFC processes were

Conclusions: Conversations about exercise and referral to programs

characterised and led to the development of an aggregated process

by radiation oncology HCPs are inconsistent and differ by role.

map which provides recommendations on essential practices to ensure

While radiation therapists valued exercise as beneficial for men,

the Standard for IFC is met. Barriers and enablers to the delivery of IFC

they perceived exercise discussions to be beyond their role and

were identified and the study produced examples of practical actions

lacked specific knowledge. Education for HCPs may increase exercise

and recommendations for healthcare professionals and services to

knowledge and confidence in leading discussion, increasing the like-

consider when adopting IFC processes.

lihood of exercise promotion and referral as part of routine clinical
practice.
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Experiences of healthcare professionals promoting

exercise for men with prostate cancer: A qualitative exploration

377

Jasmine Yee1,2 , Ishan Narendran 1 , Renée Bultijnck1,3 , Julia Hunter4 ,

Yvonne Zissiadis1 , Christobel Saunders2,3 , Sarah Wise4 , Julia M. R.

George Hruby4 , Thomas Eade4 , Andrew Kneebone4 , Haryana

Schulz2 , Angela Ives5

Dhillon1,5
1 CeMPED,

Breast cancer bundle of care: A pilot study

1 Radiation Oncology, GenesisCare, Perth, WA, Australia

School of Psychology, The University of Sydney, Campderdown,

2 GenesisCare, Alexandria, NSW, Australia

NSW, Australia

3 James

2 Sydney School of Health Sciences, The University of Sydney, Camperdown,

Victoria, Australia

NSW, Australia

4 Centre

3 Department of Human Structure and Repair, Ghent University, Ghent, East

nology Sydney, Sydney, New South Wales, Australia

Flanders, Belgium

5 Cancer

4 Department

Western Australia Medical School, Perth, Western Australia, Australia

of Radiation Oncology, Northern Sydney Cancer Centre, St

Stuart Chair of Surgery, University of Melbourne, Melbourne,
of Health Economics Research and Evaluaton, University of Techand Palliative Care Research and Evaluation Unit, University of

Leonards, NSW, Australia
5 Psycho-Oncology Cooperative Research Group (PoCoG), School of Psychol-

GenesisCare has partnered with University of WA and St John of God

ogy, The University of Sydney, Campderdown, NSW, Australia

Hospital – Subiaco to pilot a new program for early-stage breast cancer patients aimed at improving patient experience and outcomes while

Aims: Exercise is effective for ameliorating treatment side effects and

confirming the feasibility of bundling within the Australian system. The

enhancing quality of life for men with prostate cancer receiving andro-

Bundle offers all the services that an early-stage breast cancer patient

gen deprivation therapy. Despite the benefits, few men engage in

would typically utilise during the first year of treatment for a known,

sufficient levels of activity. Healthcare professionals (HCPs) are ide-

capped cost the patient of $2500 (HBF members) or $2800 (Med-

ally placed to promote exercise during interactions with men. The aim

ibank members). Services include surgery, medical oncology, radiation

of this qualitative study was to explore radiation oncology HCPs per-

oncology, radiology, pathology, physiotherapy, dietetics and clinical

ceptions and experiences of exercise promotion for men with prostate

psychology as well as a patient navigation service. By providing a Bun-

cancer.

dle with a known, capped out of pocket as well as a patient navigator

Methods: HCPs involved in the care of men with prostate cancer at

and visibility of services, we aim to reduce stress and improve the

the Radiation Oncology Clinic at the Northern Sydney Cancer Centre

outcomes and experiences of patients.

(radiation oncologists/registrars (n = 7), nurses (n = 2), and radiation

UTS’s Centre for Health Economics Research and Evaluation is inde-

therapists (n = 8)) were enrolled. HCPs participated in semi-structured

pendently evaluating the Pilot. The evaluation will collect clinical,

interviews (n = 12) or a single focus group (n = 5), exploring topics

service use, and financial data, ICHOM PROMs, EQ-5D, All. Can

such as perceptions of exercise for men receiving ADT and experi-

PREMS as well as interviews with patients and providers. It will com-

ences discussing exercise. Interviews were transcribed and analysed

pare the outcomes and experience of Bundle patients with those whose

thematically.

care is organised and paid for in within the current system mechanisms
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and assess the financial sustainability and broader applicability of the

379

payment model. As this is the first time a Bundle to this scope has been

cancer survivorship

Shared care using a web-based care plan tool in breast

delivered in cancer care in Australia, the evaluation findings will be
disseminated broadly.

Y ianna C riticos1 , Jeremy Chow1 , Carole Harris1 , Heidi Alfred1

The development of the Bundle and the Evaluation has required broad

1 Cancer Care Services, St George Hospital, Sydney, NSW, Australia

collaboration with key stakeholders including clinicians, payors, policy
and system advisors, and leaders in value-based health care to design

Background: A study on shared care in breast cancer survivorship

the Bundle and overcome barriers to establishment. We aim to focus

has been commenced where individualised care plans are conveniently

on the approach, barriers and lessons learned to date in the Bundle

created using a web-based tool.

Pilot oral/ poster presentation and contribute to sharing of learnings

Both acute services and general practitioners (GP) have a significant

in value-based health care.

role in surveillance care. Surveillance monitors the risks associated
with cancer recurrence, enables patients and all health providers’
expectations to be managed accordingly, promotes early identifica-

378

Occupational therapy and physiotherapy in a new

cancer-specific palliative unit: A retrospective audit

tion and intervention of post cancer psychosocial issues and treatment
related side effects, and empowers patients to independently seek
healthcare.

Grace Butson1 , Anthea Udovicich1 , Lara Edbrooke1,2 , Lucy Bucci1 ,

Aim: The aim of the study is to promote shared care in breast cancer

Celia Marston1,3

surveillance, facilitate effective communication between all involved,

1 Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

define responsibilities among healthcare providers and promote the

2 University of Melbourne, Melbourne, Victoria, Australia

enhancement of healthy lifestyle interventions.

3 The Royal Melbourne Hospital, Melbourne, Victoria, Australia

Method: The shared care model is introduced to breast cancer surveillance patients by the oncologist and clinical nurse consultant (CNC).

Background: Occupational therapy (OT) and physiotherapy (PT) are

After gaining consent, CNC’s use a web-based tool where patient infor-

critical to optimising the functional performance of people with

mation is entered into a secure online database and individualised

advanced cancer and facilitating discharge home for end-of-life care.

care plans are generated. Care plans include diagnosis information,

A new palliative care unit opened in September 2020 in a spe-

treatment summaries, follow-up plan, contact details of healthcare

cialist cancer hospital in Australia with dedicated OT and PT ser-

providers and request for GP’s to be involved in the promotion of

vices. The nature of OT and PT interventions delivered in cancer-

healthy lifestyle interventions.

specific palliative care units are under-reported and warranted

Results: Shared care using the web-based tool was found to be a

evaluation.

safe and preferred model of care among patients. There have been

Aims: To describe (1) the frequency and duration of OT and PT

no discrepancies in survival outcomes or delays in cancer recurrence

interventions; and (2) the functional characteristics and discharge

identification. Effectively, a reduction in 11.75 clinic hours has assisted

destination of participants who received these interventions.

the triage of urgent referrals. Requests for GP intervention regarding

Method: A retrospective audit of all patients admitted to the palliative

healthy lifestyle promotion has led to over 60% of patients accessing

care unit (PCU) and referred to OT and/or PT from January 1st to June

allied health services under the Chronic Disease Management plan.

30th 2021.

Conclusions: Shared care in breast cancer surveillance can be consid-

Results: Seventy percent of patients (n = 130) admitted to the PCU

ered as an acceptable model of care. To improve care coordination,

received OT and/or PT interventions. The median (IQR) number of con-

future focus should be directed at restructuring long term follow up

tacts each participant received was 3.00 (1.00, 8.00) for OT and 2.50

between oncology subspecialties like radiation and medical oncologist,

(1.00, 5.00) for PT. The median (IQR) duration (min) of each contact was

and surgeons.

110.00 (30.00, 256.00) for OT and 69.00 (33.75, 140.00) for PT. Participants typically had high care needs with a median (IQR) AKPS of 50
(40, 60) and a median (IQR) RUG-ADL of eight (4, 12.50) on admission

380

to the palliative care unit. Seventy-six percent of participants seen by

located patients with neuroendocrine cancer

A model of care for the shared management of regionally

OT and PT died in the palliative care unit, while 21% were discharged
home.

Chloe McAinch2,1 , Michael Michael3 , Sachin Joshi4,1 , Grace Kong3 ,

Conclusion: The majority of participants received OT and PT as part of

Simone Leyden5 , Leah Neeson3 , Megan Rogers3 , Kate Wakelin3 ,

their admission to the PCU. This included participants who remained

Stewart Harper1 , Dilu Rupassara6

in the unit for end-of-life care as well as participants who discharged

1 Gippsland Regional Integrated Cancer Service, Traralgon, VIC, Australia

home. This highlights that OT and PT have a role that extends across

2 Monash Health, Melbourne, Australia

assessment and discharge planning. Future research is needed to

3 Peter MacCallum Cancer Centre, Melbourne, Australia

unpack the types of interventions provided and the impact on patient,

4 Latrobe Regional Hospital, Traralgon, Australia

carer and service outcomes.

5 Neuroendocrine Cancer Australia, Melbourne, Australia
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6 Western

Central Melbourne Integrated Cancer Service, Melbourne, Aus-

was colitis accounting for 35% (n = 8) of admissions, followed by pneumonitis and hepatitis accounting for 22% (n = 5) of admissions each.

tralia

The mean length of stay was 8.83 days for patients with colitis (Range:
The aim of the project was to facilitate equitable care through co-

6–19; Median 6.5); 13 days for pneumonitis (Range: 3–14; Median

delivery using a ‘provider alliance model’ between Gippsland and the

7.5) and 6.8 days for hepatitis (Range 3–12, Median 5). Other IRAEs

Peter MacCallum Cancer Centre (PMCC). The identified objectives of

including arthritis and myositis (13%, n = 3), neurological IRAEs of

this project were: improving care coordination and communications;

meningitis and cerebellitis (9%, n = 2) and dermatitis with concurrent

upskilling and improving the capacity of Gippsland-based clinicians to

uveitis accounted for 4% (n = 1). Seventy-four percent of the admis-

provide neuroendocrine cancer care; and developing a model of care

sions were secondary to grade three severity. Approximately 63% of

to deliver world-leading care closer to home.

those patients received intravenous corticosteroids, 37% received oral

Methods: A multidisciplinary team came together over a period of 12

steroids. Upon discharge, 83% (n = 19) of patients’ IRAEs were down-

months to develop a model of care. The initiative was project managed

graded by at least 1 grade. Grade 3 Hepatitis and Grade 2 pneumonitis

and funded by the Gippsland Regional Integrated Cancer Service, with

were equally responsible for the 17% (n = 4) that did not downgrade

representatives from Latrobe Regional Hospital, PMCC, Neuroen-

in severity prior to discharge. Immunotherapy was ceased in 87% of

docrine Cancer Australia and Western Central Melbourne Integrated

the patients (n = 20). No patients died from IRAEs during their admis-

Cancer Service contributing. Six meetings were held virtually during

sions. Four patients (17%) had complications: two had steroid induced

the project period. The group reviewed the typical patient journey, the

hyperglycaemia, one patient had delirium and one had iatrogenic fluid

flow of information and referrals between the health services, as well

overload.

as available international literature. Gippsland-based clinicians were

Conclusion: Our audit showed patients required a significant number

sponsored to attend a whole-day workshop at PMCC. A free hybrid

of days in hospital. A majority of patients responded to steroids but had

specialist education session was organised in Gippsland for all cancer

persistent symptoms at discharge.

care professionals.
Results: A model of care was produced by group consensus over the
To improve outcomes of patients >65 years attending the

course of the project. The model focuses on using existing health ser-

382

vice resources, communication between clinicians and teams, optimal

Onco-Geriatric service at St Vincent’s Hospital Melbourne

referral to and use of multidisciplinary team meetings, and consensus-

(SVHM) by providing comprehensive, holistic and integrated

based timeframes for high quality care delivery. Three clinicians from

geriatric care

Gippsland attended the PMCC workshop. Eighteen clinicians attended
the specialist education session.

Dilu Ms Rupassara1 , Sandra Picken1 , Lesa Ms Stewart2 , Anne Ms

Conclusions: Partnerships between regional health services and

Savage2 , Victoria Ms Burton2 , James Dr Mahon2 , Sue-Anne Prof

metropolitan centres of excellence are necessary to ensure equitable

McLachlan1 , Richard Dr Kane2

access to care for all Australians with neuroendocrine cancer. Shared-

1 Western

care initiatives with a focus on access to multidisciplinary care will

bourne, VIC, Australia

ensure the complex and varied needs of this patient group are met.

2 Geriatric

and Central Melbourne Integrated Cancer Services, East MelMedicine and Cancer Services, St Vincent’s Hospital Melbourne,

Melbourne, Victoria, Australia
381

Retrospective audit of oncology patients admitted with

immunotherapy related adverse events and subsequent outcomes

Aim: To improve outcomes of patients >65 years attending the OncoGeriatric service at St Vincent’s Hospital Melbourne (SVHM) by
providing comprehensive, holistic and integrated geriatric care.

Arshya Pankaj1 , Wei-Sen Lam1

Background: Most new diagnoses of cancer are in older adults. In

1 Fiona Stanley Hospital, Perth, WA, Australia

SVHM, 57% of people with cancer are aged over 65 years. The complex health conditions of older adults with cancer may impede timely

Aim: To understand the impact of inpatient care of complications of

diagnosis, appropriate referrals, and maintaining independence, and

immunotherapy

wellbeing. Their complex healthcare needs means they require extra

Methods: Patient admissions under medical oncology at Fiona Stanley

support to get equitable and timely access to optimal care close to their

Hospital (FSH) secondary to immunotherapy related adverse events

home.

(IRAEs) were audited for patient characteristics, treatment, length of

Method: In August 2021, the Geriatric Medicine and Cancer Services

stay and outcomes from January to April in 2022.

at SVHM, in partnership with Oncology at Goulburn Valley Health

Results: Between January and April in 2022, 348 patients were dis-

implemented the Onco-Geriatric Clinic to provide comprehensive geri-

charged from medical oncology at FSH. Sixteen percent (n = 62) of

atric assessments (CGA) and management plans for older patients with

these patients were being treated with immunotherapy at time of

cancer.

admission and 37% of these patients (n = 23) were admitted secondary

The Western and Central Melbourne Integrated Cancer Service

to presumed IRAEs and included in the audit. The most common IRAE

(WCMICS) and Hume Integrated Cancer Service (HRICS) assisted in

17437563, 2022, S3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/ajco.13869 by Henry Ford Health System, Wiley Online Library on [22/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

203

POSTER ABSTRACTS

POSTER ABSTRACTS

re-designing the clinic. Implementation activities consisted in stream-

Methods: CVDL developed the Victorian data Access Linkage Trust

lining referral process to increase access to the service, developing

(VALT) for the release and analysis of linked data. Data is accessed

promotional resources, interdisciplinary case discussion for every

within the secure cloud environment of the VALT with analysis under-

patient attending the clinic, and tailored management plans based on

taken via Virtual Machines (VMs). Each VICS have their own VM in the

the CGA assessment.

VALT.

Results: Since inception, over 70 older Victorians have attended

Results: Data access through the VALT allows high compliance with

the clinic. Of the 30 SVHM patients who attended, 17 opted

privacy legislation and information management standards than has

for telehealth indicating the success of the model in empow-

previously been possible, as well as reduction of the security, pri-

ering patients to choose how and where they receive their

vacy, and storage burden. It allows approved access to further health

care.

administrative datasets, and centralising tools and processes to reduce

All attended were enabled in making decisions around their choice for

duplication of effort, enhancing collaboration between the VICS.

treatments, had assessments of their gait, mobility, cognition, conti-

The transition into the VALT involved the development of business

nence, nutrition, and discussion around advance care planning. Person-

requirements, technical specifications, and a service protocol to ensure

alised plans were developed for each patient, based on individualised

roles and responsibilities for the VICS and CVDL are specified.

interdisciplinary case discussions.

A new, centralised database schema and data transformation process

Conclusion: The clinic, one of the first of its kind in Victoria provides

for the VICS, and associated training materials to support the move

integrated care beyond the hospital walls for older Victorians with

were developed.

cancer by sustainable provision of CGA in a timely, person-centred

Conclusions: The transition into the VALT has proven to be a signifi-

fashion.

cant technical and change management process. However ultimately
the benefits of improved data governance, security and consistency

1. Berger NA, Savvides P, Koroukian SM, Kahana EF, Deimling GT,

across the VICS will be a significant success.

Rose JH, Bowman KF, Miller RH. Cancer in the elderly. Trans Am
Clin Climatol Assoc. 2006;117:147–55; discussion 155–6. PMID:
18528470; PMCID: PMC1500929.
2. Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM,
Burhenn PS, Canin B, Cohen HJ, Holmes HM, Hopkins JO, Janelsins
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A single centre retrospective study of medically futile

treatment and time-appropriate acute resuscitation plan
documentation

MC, Khorana AA, Klepin HD, Lichtman SM, Mustian KM, Tew WP,
Hurria A. Practical Assessment and Management of Vulnerabili-

Prasanth Sekar1 , Nikita Allan2,3 , Hari Babu1 , Robert Mason1 , Jasotha

ties in Older Patients Receiving Chemotherapy: ASCO Guideline

Sanmugarajah1,4

for Geriatric Oncology. J Clin Oncol. 2018 Aug 1;36(22):2326–

1 Gold Coast University Hospital, Southport, QLD, Australia

2347. doi: 10.1200/JCO.2018.78.8687. Epub 2018 May 21. PMID:

2 Royal Brisbane and Women’s Hospital, Herston, QLD, Australia

29782209; PMCID: PMC6063790.

3 University of Queensland, Brisbane, QLD, Australia

3. Magnuson, A., Dale, W., & Mohile, S. (2014). Models of Care in Geriatric Oncology. Current geriatrics reports, 3(3), 182–189. https://

4 School

of Medicine and Dentistry, Griffith University, Southport, QLD,

Australia

doi.org/10.1007/s13670-014-0095-4
Aims: This study aimed to identify the application of futile anti-cancer
therapy at a single institution through analysis of patients receiving
383

Victorian integrated cancer services (VICS) transition to

the victorian data access linkage trust (VALT)

anti-cancer therapies within the last four weeks of life and the setting and timing of Acute Resuscitation Plan (ARP) discussions at this
institution.

Sandra Picken1 , David Moloney1

Methods: Oncology patients at the Gold Coast University Hospital who

1 Peter MacCallum Cancer Centre, Parkville, VIC, Australia

died after receiving cytotoxic chemotherapy and/or immunotherapy
between January 2018 and December 2019 were analysed for timing

Aims: To describe the process of the VICS transitioning to a secure,

of treatment to death and ARP completion including setting (inpatient

cloud-based environment for accessing administrative cancer data via

vs outpatient vs emergency department (ED)) and time-to-death.

virtual machines (VMs).

Results: Five hundred and twenty-six patients died after any treatment

Background: The Centre for Victorian Data Linkage (CVDL) require

in the period analysed; 44.7% (235) were patients aged <65-years-old.

improved and simplified access to, improved accuracy of, and bet-

16.9% (89) died within 4 weeks of receiving treatment; 60% (53) were

ter secured sensitive patient administrative health data for the VICS.

<65-years-old. 83.0% (437) patients received treatment >4 weeks

The VICS are Victoria’s only dedicated cancer improvement network.

before death; 23% (102) were <65-years-old. 90.0% (473) had docu-

Previously this data was available via a protected CSV file which

mented ARPs, 44.3% of whom were <65. The majority (85.8%) were

was downloaded by each VICS for local data storage and analysis to

completed as in-patients, 4% in the ED and 10.1% as outpatients. Perti-

facilitate cancer services improvement.

nently, 48.0% (227) of patients had ARPs completed within 4 weeks of
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death, and 52.0% (246) >4 weeks from death. In the outpatient setting,

around domains such as intimacy, sexual desire, and sexual functioning

62.9% (35) had their ARPs completed >4 weeks from dying, compared

being less important during treatment.

to 37.1% (13) <4 weeks of death. In those patients where an ARP dis-

Conclusion: While interest in sex was not found to be an important

cussion took place more than four weeks from death, 9.8% (24/246)

domain for a majority of participants regardless of treatment period,

received treatment within 4 weeks.

the perceived importance of sexual activity was. Perceived importance

Conclusion: At our institution, a greater percentage of younger

increased with time since treatment, demonstrating the long-term

patients receive anti-cancer therapy versus older patients at end-of-

importance participants place on being sexually active. This could

life. Most patients had ARP discussions as in-patients; approximately

assist in the provision of interventions and information relevant to the

half of all patients with ARPs died within 4 weeks of completed docu-

long-term sexual health of women with OTP cancer.

mentation; this appeared less likely when discussions were initiated in
outpatients. Earlier advanced care planning may be a useful tool to initiate discussion regarding treatment goals, prevent futile treatments
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and are an on-going area for quality improvement.

preferred name data collection at Peter MacCallum Cancer

Implementation of sexual orientation, gender identity and

Centre
385

Importance and interest in sexual activity following

Antonela Vogranic1 , Steph Chau1 , Laura Pumo2 , Helen Benny1 , Kirsty

ovarian, tubal and peritoneal cancer treatment: A mixed-methods

Rogash2 , Tanya McKenzie1 , Sarah Boltuck3

study

1 Peter MacCallum Cancer Centre, Parkville, VIC, Australia
2 Parkville EMR Team, Melbourne, Australia

Alice Sporik1 , Sharnel Perera1 , Paul Cohen2 , Simon Hyde3 , Sue

3 Epic Systems Corporation, Verona, USA

Hegarty4 , Natalie Heriot5 , Hayley Russell4 , Penelope Schofield6 , John
Zalcberg1

Approximately 9% of Australian adults identify as lesbian, gay, bisexual,

1 Monash University, Melbourne, VIC, Australia

trans, queer, pansexual, intersex, asexual, or ‘other’ (LGBTQIA+). Mem-

2 King Edward Memorial Hospital, Subiaco, WA, Australia

bers of the LGBTQIA+ community are known to be at increased risk

3 University of Melbourne, Melbourne, VIC, Australia

for certain cancers, late diagnosis of cancer, and lower quality of care

4 Ovarian Cancer Australia, Melbourne, VIC, Australia

due to stigma, cultural insensitivity, and lack of health care provider

5 Ambulance Victoria, Melbourne, VIC, Australia

awareness to LGBTQIA+ healthcare needs.

6 Swinburne

Sexual orientation, gender identity and preferred name (SGN) infor-

University of Technology, Monash University, Melbourne, VIC,

Australia

mation is important to provide inclusive, safe and patient- and familycentred cancer care. Staff at the Peter MacCallum Cancer Centre

Aim: This study investigates the relationship between time since OTP

(Peter Mac) will be able to document gender identity, sexual orienta-

cancer treatment and interest in sexual activity.

tion, pronouns, and preferred name in the Parkville electronic medical

Method: Women with OTP cancer took part in a focus group and/or

record (EMR), a system shared with The Royal Children’s Hospital, The

online survey assessing the importance and relevance of items in

Royal Melbourne Hospital and The Royal Women’s Hospital, enabling

the EORTC QLQ C30/OV28 (mean age = 59.11 years). Impor-

quality and seamless healthcare for LGBTQIA+ patients across the

tance of sexual activity and interest was analysed against time

Parkville precinct in Melbourne, Victoria. Administrative and clinical

since treatment (during treatment, <6 months after treatment and

staff will have access to view and edit patients’ SGN information in

>6 months after treatment). One hundred and forty-eight women

the EMR, and patients can also update some SGN demographic fields

completed the survey, of which 24 attended one of four virtual

through the patient portal.

focus groups. Quantitative analysis was completed using a Pear-

In addition to EMR functionality training, staff will undertake a tai-

son chi-square test. Focus group data were analysed using thematic

lored education program called Safe to Speak, Safe to Ask, focussing

analysis.

on LGBTQIA+ cultural competence and sensitivity skills to encourage

Results: When completing the survey, 40.5% of participants had not

safe discussions for SGN information.

finished treatment, 29.7% had their last treatment <6 months ago and

Culturally competent SGN data collection for patients will improve the

29.7% had treatment >6 months ago. Overall, 31.7%, 40.9%, and 45.5%

quality of care for LGBTQIA+ patients at Peter Mac.

of women indicated the importance placed on sexual interest at timepoints for ‘currently in treatment’, ‘<6 months since treatment’, and
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‘>6 months since treatment’, respectively. However, this variance was

cancer nurses

Men’s health in oncology: a survey of (Australian) senior

not significant (p .169). In contrast, 50% of women whose treatment
was >6 months ago perceived engagement in sexual activity as impor-

Michael Whitehead1 , Mary Hayes1 , Christina Whitehead2

tant, compared to those who completed treatment <6 months ago

1 Cancer Services, St. Vincent’s Hospital Sydney, Sydney, NSW, Australia

(38.6%) and those currently in treatment (30%); p .009. These findings

2 Research Operations, Nepean Hospital, Sydney, NSW, Australia

were supported by focus group discussions where there was consensus
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Aims: Australian men are more likely than women to be diagnosed with

tocol. Desensitisation was well tolerated with no further reaction

cancer, and die from preventable cancers. Gendered health promotion

during subsequent infusions. On cycles 2–4 of desensitisation, the

has been shown to improve men’s engagement with health services,

two bag protocol was continued and the initial rate was progressively

with nurses playing a central role in information delivery and health-

increased. Patient 2 is due for cycle five at the time of writing. Patient

care design. The primary aim of this research was to survey senior

1 completed cycle 5–6 desensitisation, with pre-medication and a oane

clinical and executive nurses on their understanding and perception of

bag infusion. Cycle 7 was given as a straight 60 min infusion without

men’s health.

hypersensitivity, and she completed a further five cycles at normal rate

Methods: Cross-sectional quantitative online survey was attended by

without complication.

senior nurses within a single hospital setting in metropolitan Sydney,

Conclusion: For patients who experience hypersensitivity reactions to

NSW June 2022 and July 2022. Sampling selection was conducted of

pertuzumab, a desensitisation protocol should be considered to enable

nurses who currently hold senior clinical or management roles within

the safe and continued use of optimal agents. If initial desensitisation

the health district, with descriptive analysis applied to interpret the

is well tolerated, graduated step down to normal infusion rates can be

data sets.

considered.

Results: A total of 83 responses were received, representing a 32.8%
survey participation rate. 22.8% of respondents identified as senior

1. King J, Halabi A, Hughes T, Martin H, Koczwara B, Smith A. Per-

cancer nurses (n = 19). A key finding was that 52.6% of cancer nurses

tuzumab Anaphylaxis and Desensitisation. Poster presentation at:

believed gender to be a determinant of health, versus 61% of total

26th ASCIA Annual Conference; 2015 September 9–12; Adelaide.

respondents. Over 80% of cancer nurses believe that traditional masculine traits such as stoicism and machoism affect health-seeking
behaviour among men. Despite this, only 36.8% have discussed men’s
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specific agencies with their patients or clients.

cancer carers

Who is caring for the carer? Supporting the wellbeing of

Conclusions: The results of this single-site online survey of senior cancer nurses illustrate that while foundational understandings of gender

Peta Wright1 , Cassandra Haynes1 , Tenille Moselen1 , Geraldine

were divided, there remained strong endorsement for targeted men’s

McDonald1

health promotion to patients and the development of men’s health edu-

1 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

cational programs to support cancer nurses in providing holistic care
for their male patients.

Background: Often carers supportive care needs are overlooked. The
un-met needs of carers at a tertiary oncology health service identified
the need for improved information, communication, system naviga-

388

Pertuzumab desensitisation; Case reports

tion, and the capacity for consumers to partner in their healthcare and
support networks. To address this, a Carer Liaison Service model was

Kate Wright1 , Peter Fox1 , Bronwyn Andrew1

implemented in December 2021.

1 Orange Health Service, Orange, NSW, Australia

Method: The Carer Liaison Service model: includes a Carer Liaison
Officer (CLO) who provides tailored and ongoing support to carers,

Aim: Pertuzumab is a humanised monoclonal antibody preventing

assists in navigating the health system, coordinating a wellbeing plan

the dimerisation of HER2. Its addition to trastuzumab and taxane

and connecting with support services. A Carers Circle Peer Support

has demonstrated improved outcomes in patients with metastatic

group compliments the CLO, providing a safe space for carers to con-

HER2 positive breast cancer. Hypersensitivity reactions to per-

nect. Mixed-methods data were collected via a survey when carers first

tuzumab have been documented in case reports with successful

engage with or are referred to the CLO, to understand who is using the

desensitisation.1

service, how they are using it and their key needs.

These desensitisation protocols are time and labour

intensive, perpetual and can negatively impact on quality of life. We

Results: In the first 6 months the CLO supported 40 diverse car-

describe case reports of two patients treated using the King protocol

ers with their individual needs. Majority of the carers are who have

followed by a graduated return to normal dosing over six cycles.

accessed the service are female (76.5%), aged between 30–39 (23.5%)

Methods: Two female patients, aged 60 and 70-years-old presented

and 50–59 (23.5%), resided in metropolitan Melbourne (59%) and are

with HER2 amplified de novo metastatic breast cancer. Both were com-

the spouse/partner of the patient (52.9%). Carers accessed a range of

menced on paclitaxel, pertuzumab and trastuzumab and treated as per

supports including emotional, practical, navigation and peer support,

protocol. During cycle 4, 18 min and 10 min into pertuzumab infusion

information on internal wellbeing programs, referrals to internal ser-

respectively, both patients experienced facial flushing, dyspnoea, rigors

vices (social work, occupational therapy and spiritual care) and support

and hypotension. Given the clinical benefit of continuing pertuzumab,

in accessing external supports such as ‘Carers Gateway’. In this oncol-

following literature search, the decision was made to re-challenge both

ogy health service, supporting carers and their wider family to navigate

patients using desensitisation.

and understand palliative care has emerged as a key objective of the

Results: Both patients were pre-medicated with corticosteroids and

carers service, particularly providing emotional support and referrals.

antihistamines and initiated on the published desensitisation pro-
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Conclusion: The Carer Liaison Service model integrates the CLO into

3 Centre

the multidisciplinary team and connects carers with the system. The

Transformation, Deakin University, Geelong, VIC, Australia

for Quality and Patient Safety Research in the Institute for Health

implementation of this model can be useful for other health and
community services to better support their carers.

Background: Androgen deprivation therapy (ADT) in prostate cancer
predisposes men to weight gain, co-existing with lean muscle mass
loss, and multiple co-morbidities that negatively impact quality of

390

Incidence of side effects caused by treatment of patients

with prostate cancer-experience in a rural cancer centre

life. Dietary interventions are effective strategies to mitigating multiple ADT side effects, however whether men are referred, access and
partake in nutrition services is relatively unknown.

Mihitha Ariyapperuma1 , Kerin Young 1 , Rosemary David2

Methods: A qualitative study using semi-structured, audio recorded

1 Department of Heath, WA Country Health Service, Albany, WA, Australia

interviews were conducted in men with prostate cancer treated with

2 Medical Oncology, Royal Perth Hospital, Perth, WA, Australia

ADT for >3 months. Interviews explored (i) experiences of ADT, (ii)
accessibility, barriers, facilitators and/or use of nutrition services, and

Prostate cancer is the most common cancer diagnosis in the Great

(iii) the preferences for nutrition service delivery. Data were coded

Southern Region. In 2017 this represented 33.5% (n = 85) of all

using interpretative descriptive techniques of textual interview data,

male cancer diagnoses in the region, higher than the state-wide

and systematically summarised to generate thematical patterns, using

incidence of 28.4%. (WA Cancer Registry 2020). Side effects associ-

NVivo software.

ated with prostate cancer treatment seems to be under reported by

Results: Interviews were completed with 20 men with prostate cancer

patients.

(mean ± SD, 68.8 ± 5.7 years) treated with ADT (20.1 ± 6.2 months).

Thirty patients have completed the 18 point questionnaire with the

Thematic analysis revealed four overarching themes: (1) ADT and the

study continuing. Age of the patients ranged from 65 to 89. Majority of

new me: men revealed that weight gain, loss of muscle and strength,

patients had received previous treatments of either chemotherapy or

and fatigue from ADT were daily struggles that negatively impact self-

radiotherapy (n = 23) however only a minority of patients self-reported

perception; (2) time to take control: men reported making successful

having had surgical management for prostate cancer (n = 9).

changes in exercise to combat the physical changes from ADT, however

Urinary incontinence was identified as a moderate or significant

dietary changes were restrictive, non-evidence based and produced a

problem by 55% of patients and urinary control was identified as a sig-

yo-yo dieting effect; (3) knowledge is power: demand for nutrition ser-

nificant problem by 25%. 18% of patients identified urinary leakage

vices that specialise in prostate cancer with knowledge in addressing

as an issue. 32% of patients had to use at least one pad due to uri-

side effects from ADT; (4) diverse patients need diverse nutrition sup-

nary incontinence with two patients needing three or more pads daily.

port: that is individualised or group-based, commenced at the start or

Urinary frequency was identified by 42% of patients as a moderate to

partway through treatment, including peer or partner support, and

major problem with the same proportion of patients identifying weak

information-rich through multiple platforms.

urine stream and incomplete emptying as an issue.

Conclusion: Evidence-based nutrition services are an unmet need for

All the patients self-reported inability to attain an erection however

men treated with ADT. Future work is required to develop services

only 50% of those patients identified it as a problem. 44% of patients

that can be readily available and accessible to improve prostate cancer

identified hot flushes and breast enlargement as a significant issue.

survivorship care.

Importantly 40% of men in our population reported at least a small
problem with depression, two patients reporting this as a big problem. A lack of energy was frequently experienced by patients with 50%
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reporting this as a moderate or big problem.

interventions on body weight, lean and fat mass in adults

This study gives an idea about extent of treatment complications.

diagnosed with cancer: A systematic review and meta-analysis

The effectiveness of combined nutrition and exercise

Improving physician awareness and establishing dedicated services
can help in addressing these complications.

Brenton Baguley1 , Jack Dalla Via2 , Steve Fraser1 , Robin Daly1 , Nicole
Kiss1
1 Institute
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The perception of and access to nutrition services for

for Physical Activity and Nutrition, Deakin University, Geelong,

VIC, Australia

men with prostate cancer treated with androgen deprivation

2 Nutrition

therapy

sity, Perth, WA, Australia

Brenton Baguley1,2 , Caity Smith1 , Anna Ugalde3 , Nicole Kiss1,2

Background: Changes in body weight and composition (fat and lean

1 School

mass) are prominent side effects from cancer treatment. Nutrition and

of Exercise and Nutrition Sciences, Deakin University, Melbourne,

and Health Innovation Research Institute, Edith Cowan Univer-

VIC, Australia

exercise interventions are both key strategies to protect against these

2 Institute

adverse effects, however their impact when combined have not been

for Physical Activity and Nutrition, Deakin University, Geelong,

Victoria, Australia

comprehensively reviewed in adults with cancer.
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Objective: This systematic review and meta-analysis aims to assess

required increased visibility from the CNCCC. In order to meet the

the effects of combined nutrition and exercise interventions on body

requirements of this CNCCC role and the needs of patients across

weight and composition in adults with cancer.

Victoria, allied health staffing, supportive care and discharge plan-

Data Sources: Four databases were searched until January 2021. Eligi-

ning were identified as areas to focus on as a way of developing new

ble studies included combined nutrition and exercise randomised con-

guidelines.

trolled trials (RCTs), detailing the nutrition and exercise prescription,

As this new statewide service continues to expand, this CNCCC role

and reporting body weight and composition outcomes.

has driven the need for improved patient workflows, new patient

Data Extraction: Risk of bias was assessed through the Cochrane Col-

resources and improved discharge planning in order to provide com-

laboration tool. The number of participants, mean values and standard

prehensive care for patients across Victoria. In order to further develop

deviations of the outcome variables were extracted. Mean differ-

the role of the CNCCC in this statewide service, it will require ongoing

ences (MD) were pooled using random-effects models. Predetermined

review of guidelines and processes in collaboration with the entire MR

sub-group analyses included cancer type, intervention intent, exercise

Linac team on a regular basis.

modality, and use of behaviour change theory.
Results: Twenty-three RCTs were included in this review. Nutrition
plus exercise interventions significantly reduced body weight (MD
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−2.13 kg, 95% confidence interval [CI] −3.07, −1.19) and fat mass

adults with haematological malignancies

Exploring attitudes towards COVID-19 vaccination in

(MD –2.06 kg, 95%CI −3.02, −1.09), and lean mass (MD −0.42,
95%CI −0.82, −0.04). Subgroup analyses in women with breast cancer

Richard Blennerhassett1,2 , Nada Hamad3,4,5 , Lisa Grech6 , Cecily

showed that weight loss interventions, and interventions incorpo-

Forsyth1 , Jacqueline Jagger1 , Stephen Opat6,7 , Samuel Harris8 , Bryan

rating behaviour change theory, significantly reduced body weight

Chan9,10 , Alastair Kwok6,11 , Mike Nguyen6,11 , Nathan Bain11 , Daphne

and fat mass, but also reduced lean mass. Interventions aiming

Day6,11 , Eva Segelov6,11

to maintain body weight showed no changes in body weight as

1 Central Coast Haematology, North Gosford, NSW, Australia

intended.

2 School of Medicine and Public Health, University of Newcastle, Newcastle,

Conclusion: Combined nutrition and exercise interventions success-

NSW, Australia

fully reduce body weight and fat mass in adults with cancer but also

3 Department

reduced lean mass. In contrast, weight loss focused interventions were

NSW, Australia

associated with reduced lean mass.

4 School of Clinical Medicine, Medicine and Health, University of New South

of Haematology, St Vincent’s Hospital Sydney, Darlinghurst,

Wales, Kensington, NSW, Australia
5 School
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Challenges of a clinical nurse consultant-care coordinator

(CNCCC) in a new statewide service

of Medicine, University of Notre Dame Australia, Chippendale,

NSW, Australia
6 Department

of Medicine, School of Clinical Sciences, Monash University,

Clayton, VIC, Australia
Monique Blanchard1

7 Department

1 Radiation Oncology, Austin Health, Heidelberg, VIC, Australia

tralia

of Clinical Haematology, Monash Health, Clayton, VIC, Aus-

8 Department of Medical Oncology, Bendigo Health, Bendigo, VIC, Australia

In 2021 Austin Health established Victoria’s first statewide mag-

9 Department

netic resonance linear accelerator (MR Linac) radiotherapy service

Birtinya, QLD, Australia

through funding from the Victorian state government. This special-

10 School

ized oncology service was established to provide equitable access for

Australia

all Victorians to the latest state of the art radiation therapy treatment.

11 Department of Oncology, Monash Health, Clayton, VIC, Australia

of Oncology, Sunshine Coast Hospital and Health Service,

of Medicine and Dentistry, Griffith University, Birtinya, QLD,

The establishment of a unique clinical nurse consultant-care coordinator (CNCCC) role was introduced in to the statewide MR Linac service

Aims: People with haematological malignancies (HM) are at increased

to ensure comprehensive care to all patients.

risk of severe COVID-19 infection and death due to underlying immune

The MR Linac multidisciplinary team includes radiation oncologists,

deficiency and impaired vaccine responses. From March 2021, COVID-

radiation therapists, medical physicists, MRI radiographers, adminis-

19 vaccination was offered to patients with HM, as part of the

tration staff, a range of allied health professionals and the role of a

Australian COVID-19 vaccination rollout program. This study sought

CNCCC. While establishing patient care pathways to encompass the

to ascertain whether vaccine hesitancy was a barrier to optimal vac-

wider Victorian community, challenges and gaps were identified which

cine uptake and explored the attitudes of people with HM towards

led to the creation of guidelines specific to the statewide service.

COVID-19 vaccination.

With little resources to compare to, these tools were developed from

Methods: Between June and October 2021, an online survey was dis-

working collaboratively with the multidisciplinary team.

tributed to adults with HM at nine Australian health services. The

The shortfall of existing departmental workflows to include the

survey collected sociodemographic and clinical characteristics, and

CNCCC role as a primary stakeholder proved challenging at times and

attitudes towards COVID-19 and COVID-19 vaccination using the
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Oxford COVID-19 Vaccine Hesitancy Scale, the Oxford COVID-19

dence suggests many women with cancer avoid contraception due to

Vaccine Confidence and Complacency Scale, and the Disease Influ-

fearing worsening prognosis.

enced Vaccine Acceptance Scale-Six (DIVAS-6).

Aim: To investigate the documented rates of contraception counselling

Results: Of the 869 survey participants (mean age 64.2 years, 43.6%

and uptake in women of childbearing age at a major Sydney tertiary

female), 741 (85.3%) reported receiving at least one COVID-19 vaccine

hospital.

dose. Unvaccinated status was significantly associated with younger

Methods: Our group conducted a retrospective chart review at a

age, English as a non-dominant language, and shorter duration since

major Australian cancer centre of premenopausal females aged 18–49

diagnosis. Participants who were female or spoke English as their non-

years diagnosed with cancer between 2017 and 2020. Data collected

dominant language reported more negative attitudes towards vaccine

included primary diagnosis, stage of cancer, treatment(s) received,

side-effects. Unvaccinated participants were more likely to report

complications, reproductive history, documentation of contraceptive

greater concerns about the vaccine impacting on their HM and treat-

use, and involvement of gynaecologists.

ment (DIVAS-6 Vaccine Vulnerability subscale score: B (SE) = 2.71

Results: A total of 143 patients met inclusion criteria. At the time of

(0.35), p < 0.001). They were also more likely to report greater vac-

diagnosis, 8.4% of patients were taking the combined oral contracep-

cine complacency (DIVAS-6 Disease Complacency subscale score: B

tive pill (COCP), 4.9% had an intrauterine device, 0.7% were taking

(SE) = 1.79 (0.28), p < 0.001).

the progesterone only pill, and 0.7% had a contraceptive implant. Of

Conclusions: People with HM reported high vaccine uptake, how-

those using an oral contraceptive agent, 15.4% had a thromboembolic

ever, participants who are recently diagnosed with malignancy, female,

complication post cancer diagnosis. Only 23.1% received advice on

younger age or for whom English is a non-dominant language may

contraception from a physician or a pharmacist, with advice including

benefit from targeted education strategies to address their vaccine

avoiding pregnancy during treatment (33.3%), use of barrier contra-

concerns. Clinicians are well-positioned to address their patients’

ception (24.2%), ceasing the COCP (15.2%), IUD removal (12.1%), and

specific vaccine concerns and support the decision-making process,

IUD insertion (3%).

particularly with the need for COVID-19 vaccine boosters.

Discussion: All women with a cancer diagnosis should be counselled on
contraception. Considerations should include tumour type, thrombotic
factors, patient immunosuppression, haematological disorders, bone

Rates of contraceptive uptake and documentation of

395

density, drug interactions, and metabolic or cardiovascular effects.

discussion with anticancer therapy: Women deserve gender

Abstinence should not be assumed or recommended. To better facili-

specific care

tate contraception discussions, cancer specialists should receive education sessions on contraception, have centre-facilitated gynaecology

Verity Chadwick1 , Michaela Kim2 , Georgia Mills3 , Catherine Tang4 ,

referrals, and provide patients written information.

Antoinette Anazodo2,5,6 , Rachel Dear2,7 , Rachael Rodgers8,9 , Orly
Lavee2,3 , Samuel Milliken2,3 , Georgia McCaughan3 , John Moore2,3 ,
Nada Hamad3,10,11 , Joshua Hurwitz1,2

396

1 Royal North Shore Hospital, St Leonards, NSW, Australia

tested for pregnancy before chemoimmunotherapy: An Australian

2 School of Medicine, University of New South Wales, Sydney, NSW, Australia

Cancer Centre Experience

3 Department

A minority of women of child bearing potential are

of Haematology, St Vincent’s Hospital, Darlinghurst, NSW,
Verity Chadwick1 , Michaela Kim2 , Georgia Mills3 , Catherine Tang4 ,

Australia
4 Department

of Haematology and Flow Cytometry, Laverty Pathology,

Macquarie Park, NSW, Australia

Antoinette Anazodo2,5,6 , Rachel Dear2,7 , Rachael Rodgers8,9 , Orly
Lavee2,3 , Samuel Milliken2,3 , Georgia McCaughan3 , John Moore2,3 ,

5 Kids Cancer Centre, Sydney Children’s Hospital, Sydney, NSW, Australia

Nada Hamad3,10,11 , Joshua Hurwitz1,2

6 Nelune Cancer Centre, Prince of Wales Hospital, Randwick, NSW, Australia

1 Royal North Shore Hospital, St Leonards, NSW, Australia

7 Department of Oncology, St Vincent’s Hospital, Sydney, NSW, Australia

2 School of Medicine, University of New South Wales, Sydney, NSW, Australia

8 Department of Reproductive Medicine, Royal Hospital for Women, Sydney,

3 Department

NSW, Australia

Australia

9 School of Women’s and Children’s Health, University of New South Wales,

4 Department

Randwick, NSW, Australia

Macquarie Park, NSW, Australia

10 St

5 Kids Cancer Centre, Sydney Children’s Hospital, Sydney, NSW, Australia

Vincent’s Clinical School, University of New South Wales, Randwick,

of Haematology, St Vincent’s Hospital, Darlinghurst, NSW,
of Haematology and Flow Cytometry, Laverty Pathology,

NSW, Australia

6 Nelune Cancer Centre, Prince of Wales Hospital, Randwick, NSW, Australia

11 School

7 Department of Oncology, St Vincent’s Hospital, Sydney, NSW, Australia

of Medicine, University of Notre Dame, Daringhurst, NSW, Aus-

tralia

8 Department of Reproductive Medicine, Royal Hospital for Women, Sydney,

NSW, Australia
Introduction: For women of reproductive age with cancer, unplanned

9 School of Women’s and Children’s Health, University of New South Wales,

pregnancies and the use of contraception are often unaddressed. Evi-

Randwick, NSW, Australia
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Vincent’s Clinical School, University of New South Wales, Randwick,

and related outcomes compared to any control condition. Data were

NSW, Australia

pooled with meta-analysis. Quality of evidence was appraised using the

11 School

Revised Cochrane Risk of Bias Tool for Randomised Trials (RoB2), with

of Medicine, University of Notre Dame, Daringhurst, NSW, Aus-

data synthesised narratively. Grading of Recommendations, Assess-

tralia

ment, Development and Evaluations (GRADE) was applied to assess
Background: Chemotherapy is potentially harmful to a developing foe-

the certainty of the evidence.

tus and there is limited data on the foetal impact of chemoimmunother-

Results: Thirteen studies were included, which had high (69%) or

apy. Therefore, determining pregnancy status prior to initiation of

unclear (31%) risk of bias. Greatest confidence was found for physi-

chemoimmunotherapy should be standard of care.

cal exercise decreasing CIPN severity (SMD: −0.89, 95% CI: −1.37 to

Method: We reviewed electronic records from a large metropolitan

−0.41; p = 0.0003; I2 = 0%; n = 2 studies, n = 76 participants; GRADE

cancer referral centre to evaluate the uptake of pregnancy screening

level: moderate) and increasing physical function (SMD: 0.51, 95% CI:

and contraception documentation prior to and during first-line CIT.

0.02–1.00; p = 0.04; I2 = 42%; n = 3 studies, n = 120; GRADE level:

We searched our electronic outpatient medical record database for

moderate). One study per intervention provided preliminary evidence

Women of Child Bearing Potential (WoCBP) who were diagnosed with

for the positive effects of glutamine supplementation, an Omega-3

a malignancy and received outpatient-based chemoimmunotherapy

PUFA-enriched drink, and education for symptom self-management

between May 1 2015 and June 12 2020.

via a mobile phone game on CIPN symptoms and related outcomes

Results: A total of 415 WoCBP with a median age of 41 years (range

(GRADE: very low). No serious adverse events were reported.

19–55) were included. Only 17.1% were screened for pregnancy within

Conclusions: Strongest evidence with the most certainty was found

90 days prior to chemoimmunotherapy. One patient with early breast

for physical exercise as a safe and viable adjuvant to chemotherapy

cancer had a spontaneous miscarriage estimated at 3–4 weeks gesta-

treatment for the prevention and management of CIPN and related

tion, and neither the patient nor the treating oncologist were aware

physical function in people with advanced cancer. However, the con-

of this event. This was also the only patient who had a pregnancy test

fidence in the evidence to inform conclusions was mostly very low to

beyond the first cycle of chemoimmunotherapy during the course of

moderate. Future well-powered and appropriately designed interven-

their treatment.

tions for clinical trials using validated outcome measures, and clearly

Conclusion: Our results highlight a concerningly low rate of preg-

defined populations and strategies are warranted.

nancy screening in WoCBP receiving CIT. The implication of missing
a positive pregnancy test in this group of women could result in
foetal complication, accidental miscarriage, potential bleeding risks
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and avoidable psychosocial stress. This highlights the urgent need
for guidelines to mandate pregnancy testing in WoCBP receiving
chemoimmunotherapy and evidence-based implementation tools.

Maiko Crispin1 , Lorraine Lewis1 , Lorraine Lewis11 , Claire King1 , John
Atyeo1
1 Northern Sydney Cancer Centre, Marsfield, NSW, Australia
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Non-pharmacological self-management strategies for

chemotherapy-induced peripheral neuropathy in people with

Aims: To determine whether a unique Patient Care Radiation Therapist

advanced cancer: A systematic review and meta-analysis

(PCRT) role can improve the patient care experience and unite other
health professionals in ensuring optimal patient care.

Megan Crichton1 , Patsy M. Yates1 , Oluwaseyifunmi Andi Agbejule2 ,

Methods: The PCRT role was implemented in September 2019 as a

Amy Spooner1 , Raymond J. Chan2 , Nicolas H. Hart2

new model of Radiation Therapy (RT) driven patient care. A PCRT is

1 Cancer and Palliative Care Outcomes Centre, Centre for Healthcare Trans-

assigned to each treatment and planning team, and fosters effective

formation, School of Nursing, Queensland University of Technology, Kelvin

communication across the wider multidisciplinary team. To determine

Grove, QLD, Australia

if the PCRT could streamline the patient care experience earlier, a

2 Caring

Futures Institute, College of Nursing and Health Science, Flinders

University, Adelaide, SA, Australia

research team was established and a project initiated. The project
consisted of a staff perception survey and an observational study to
identify current and future patient care pathways.

Aims: Non-pharmacological self-management interventions for

Results: The response rate to the survey was 55%, with representa-

chemotherapy-induced peripheral neuropathy (CIPN) are of clinical

tion from all craft groups. Eight themes emerged from the analysis of

interest; however, no systematic review has synthesised the evidence

qualitative data submitted in the staff survey, and included Effective

for their use in people with advanced cancer.

Communication, Patient Centered Care, Role Delineation, Collabora-

Methods: Five databases were searched from inception to Febru-

tion, Personalised Care, Role Expansion, Information Provision and

ary 2022 for randomised controlled trials assessing the effect of

Time Constraints.

non-pharmacological self-management interventions in people with

The observational study determined that patient care pathways would

advanced cancer on the incidence and severity of CIPN symptoms

benefit from PCRTs being involved in new patient clinics, multidisciplinary team meetings and clinical meetings.
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Conclusion: A patient’s cancer care journey can be complex and diffi-

the Acceptability of Intervention Measure (AIM). The rate of consent

cult to navigate, with the rapid advancement of treatment techniques

was lower than expected (31/54, 57%).

and processes being more onerous for patient compliance. By identify-

Conclusion: MELCARE was feasible and acceptable with high levels of

ing gaps in our current cancer services, we can identify how a PCRTs

utility. This is the first survivorship program designed for people with

unique technical knowledge and skills, combined with their patient

metastatic cancer. It provides a model for addressing unmet support-

care skills, can be utilised earlier in the RT care pathway to improve

ive care needs in this emerging survivor group. Future studies should

the patient care experience while working collaboratively with all craft

consider its optimal timing, resourcing and cost-effectiveness.

groups.
400
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Feasibility, acceptability and utility of a pilot nurse-led

Unmet supportive care needs of people affected by

cancer in New South Wales

survivorship program for people with metastatic melanoma
Monica Gendi1 , Annie Miller1 , Rhiannon Edge1 , Haryana M Dhillon2 ,

(MELCARE)

Carolyn Mazariego3 , Elijah Tyedmers1 , Pareoranga Luiten-Apirana1 ,
Julia Lai-Kwon1 , Brooke Kelly2 , Sarah Lane1 , Rebecca Biviano1 , Iris

Sean Stolp1

Bartula1 , Frank Brennan3 , Ingrid Kivikoski4 , Jake Thompson5 ,

1 Cancer Council NSW, Woolloomooloo, NSW, Australia

Haryana Dhillon7,6 , Alexander M. Menzies5,8,9,10 , Georgina V.

2 University of Sydney, Sydney, Australia

Long1,8,9,10

3 The Daffodil Centre, a joint venture between Cancer Council NSW and the

1 Melanoma Institute Australia, Wollstonecraft, NSW, Australia

University of Sydney, Sydney

2 Melanoma Patients Australia, Varsity Lakes, QLD, Australia
3 Consumer Representative, Sydney, NSW, Australia

Aims: The study aimed to identify the prevalence and strength

4 Consumer representative, Brisbane, QLD, Australia

of supportive care needs of NSW adults with a past or current

5 Melanoma Institute Australia, Wollstonecraft, NSW, Australia

cancer diagnosis and the extent to which these needs are being

6 Psycho-oncology

met.

Cooperative Group, School of Psychology, Faculty of

Science, University of Sydney, Sydney, NSW, Australia

Methods: Participants completed an online survey that included mod-

7 Centre

for Medical Psychology and Evidence-Based Decision Making,

ified versions of the Supportive Care Needs Survey Short Form (Boyes

School of Psychology, Faculty of Science, University of Sydney, Sydney, NSW,

et al., 2009) and its additional Access to Services module. For each item,

Australia

participants indicated the strength of their need over the past month

8 Faculty

of Medicine and Health, University of Sydney, Sydney, NSW,

(weak; medium; strong) and the extent to which their need was met

Australia

(not at all met; partly met; completely met). Participants also responded

9 Mater Hospital, North Sydney, NSW, Australia

to questions about their use of and experiences with supportive care

10 Royal North Shore Hospital, Sydney, NSW, Australia

services, among other measures. The planned sample size was n = 800
and the final sample was n = 447 (179 past diagnosis; 268 current

Purpose: Immune checkpoint inhibitors (ICI) and targeted therapy

diagnosis).

(TT) have improved the survival of people with metastatic melanoma

Results: Participants reported a mean of 18.17 unmet supportive care

(PwMM). MELCARE is a nurse-led survivorship program for PwMM

needs (95% CI [16.77, 19.57]). The most commonly reported needs

who are long-term responders to ICI/ TT involving two telehealth

were in the physical and psychological domains, including uncertainty

consultations three months apart, needs assessment using the NCCN

about the future (80% of participants) and tiredness (77%). Despite opti-

Distress Thermometer (DT) and Problem List, and creation of a sur-

mal care pathway referral recommendations, only 34% of participants

vivorship care plan. We assessed its feasibility, acceptability and

were referred to the relevant Guide to Best Cancer Care and only 30%

utility.

of participants were referred to Cancer Council support services by

Methods: PwMM >18-years, >6 months post initiation of ICI with

their healthcare providers at the time of diagnosis. Content analysis

a complete response (CR) on computed tomography (CT) or >1 year

of free-text fields also highlighted lack of awareness about supportive

post initiation of ICI with a complete metabolic response on positron

care services and resources.

emission technology scan and a CR/ partial response (PR) on CT or >2

Conclusions: Psychological and physical supportive care needs are

years post initiation of TT with a CR on CT, able to have a telehealth

highly prevalent and commonly unmet among people affected by can-

consultation and complete online surveys were recruited.

cer, despite the existence of services aiming to address these needs.

Results: 31/54 (57%) people consented. Participants were male (21,

Understanding and addressing barriers to service access, including bar-

68%), median age 67 (range: 46–82), 11 (35%) receiving/ had received

riers to healthcare professional referral, is essential to improve the

ipilimumab and nivolumab, 27 (87%) had ceased treatment. Feasibil-

quality of life of people affected by cancer.

ity was demonstrated with 97% completing MELCARE. Utility was
demonstrated on a customised survey and supported by a reduction in
the mean DT score. Acceptability was demonstrated on 3/4 items on
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Australian cancer survivors’ unmet supportive care needs:

A meta-review of what’s next?

Background: Clinical awareness of complementary and integrative
medicine (CIM) and prescription of cannabis among health care professionals (HCPs) is important for many reasons. HCPs interact with

Martha Gerges1 , Carolyn Mazariego2 , Joshua Meyers1 , Bradley

patients to communicate information and can be credible sources who

Gellert1 , Jessica Sheppard1

could provide accurate and trusted information regarding CIM for

1 Cancer Council NSW, Woolloomooloo, NSW, Australia

patients who expressed an interest in seeking information about CM.

2 The

However, recent research reveals that most healthcare professionals

Daffodil Centre, University of Sydney, a joint venture with Cancer

Council NSW, Sydney, NSW, Australia

in cancer care have insufficient knowledge about CIM but they were
interested to learn.1,2 With prescribed medicinal cannabis (MC) rel-

Purpose: An exponential number of Australians are diagnosed

atively new to oncology in Australia, identifying changing attitudes,

with and, subsequently, survive cancer. As more Australians live

interest and perceived benefit isles an important contribution to the

with/beyond cancer, the need for effective supportive care measures

field. Few studies have investigated the attitudes and knowledge of

throughout the cancer continuum is essential. While people can live

CIM and MC among HCPs in oncology.

well after cancer, many experience a broad range of issues that may

Method: This was a prospective cross-sectional survey of a con-

impact their quality of life. This meta-review aimed to examine the

venience sample of healthcare professionals working at a single

unmet supportive care needs of cancer survivors in Australia, how the

comprehensive cancer hospital in Sydney, Australia.

health system can address issues in line with optimal care pathways,

Results: There were 117 responses to the survey. The majority of

and what policy/implementation strategies can be applied.

respondents believed that complementary therapies could benefit

Methods: Following a Cochrane-published methodology for rapid-

patients with cancer (92%) and wanted to learn more about their use

structured reviews, searches were conducted on PubMed (including

in cancer (89%). Respondents wanted to understand the benefits and

MEDLINE) and EMBASE. The meta-review focused on papers avail-

contraindications of all therapies (70%), and some specifically of herbs

able in English, published within the last ten years, on adult populations

(48%) and mind-body therapies (40%). There was strong support for a

(≥18 years) within the Australian-based context. Only review papers

pharmacy service to evaluate potential herb/supplement interactions

were included that explored supportive care domains outlined by Can-

with cancer treatment (82%). Attitudes towards medicinal cannabis

cer Australia’s Principles of Cancer Survivorship, including physical,

use in cancer care was most strongly influenced by the experiences of

psychological, social, cultural, information and spiritual needs.

patients and the increase in medical literature.

Results: A total of 1047 titles were retrieved, with 10 texts included

Further details and subgroup analysis of the results will be provided in

in this review, of which the majority included data from mixed can-

the presentation.

cer types (8/10). Reviews identified unmet supportive care needs in
domains including psychological and social (n = 6, respectively), informational (n = 5), physical (n = 4), and cultural (n = 1). Most papers

403

discussed multiple domains, while no included review discussed the

Australian patients with breast cancer

COVID-19 vaccine uptake and hesitancy amongst

unmet spiritual needs.
Conclusion: Addressing supportive care needs requires careful plan-

Jo Hudson1 , Amelia McCartney2,1 , Alastair Kwok2,1 , Lisa Grech2 ,

ning and implementation through consultation and advocacy with

Annette Tognela3 , Louise Nott4 , Rossa King4 , Mike Nguyen2,1 , Nathan

patients, communities and the health system. The objectives of any

Bain1 , Bryan Chan5,6 , Samuel Harris7 , Hieu Chau8 , Nada Hamad9,10,11 ,

new policy should be straightforward and have a patient-centred

Craig Underhill12,13 , Janne Williams14 , Kate Webber2,1 , Daphne

approach that includes buy-in from many stakeholders in a landscape

Day2,1 , Eva Segelov2,1

that makes implementation feasible, equitable and evidence-based. A

1 Department of Oncology, Monash Health, Clayton, VIC, Australia

shared-care model enables holistic care that will increase survivors’

2 Department

access to supportive cancer care, directly impacting quality of life,

Clayton, VIC, Australia

patient satisfaction, and overall improved experience within the health

3 Macarthur

system.

town, NSW, Australia

of Medicine, School of Clinical Sciences, Monash University,

Cancer Therapy Centre, Campbelltown Hospital, Campbell-

4 Icon Cancer Centre Hobart, Hobart, TAS, Australia
5 Department

402

Knowledge and attitudes toward complementary

of Oncology, Sunshine Coast Hospital and Health Service,

Birtinya, QLD, Australia

medicine and cannabis: a survey of health professionals working

6 School

in a cancer hospital in Australia

Australia

of Medicine and Dentistry, Griffith University, Birtinya, QLD,

7 Department of Medical Oncology, Bendigo Health, Bendigo, VIC, Australia

Suzanne Grant1,2 , Judith Lacey2 , Sarah Soliman1 , Maria Gonzalez1,2

8 Department

1 Western Sydney University, Sydney, NSW, Australia

tralia

2 Chris O’Brien Lifehouse, Sydney, NSW, Australia

9 Department

of Oncology, Latrobe Regional Hospital, Traralgon, VIC, Ausof Haematology, St Vincent’s Hospital Sydney, Darlinghurst,

NSW, Australia
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10 School of Clinical Medicine, Medicine and Health, University of New South

3 Department of Health Services Research, Peter MacCallum Cancer Centre,

Wales, Kensington, NSW, Australia

Melbourne, VIC, Australia

11 School

4 Institute for Physical Activity and Nutrition, Deakin University, Melbourne,

of Medicine, University of Notre Dame Australia, Chippendale,

NSW, Australia

VIC, Australia

12 Border Medical Oncology, Albury, NSW, Australia

5 Menzies

13 Rural

Australia

Medical School, University of New South Wales, Albury, NSW,

Health Institute Queensland, Griffith University, Brisbane, QLD,

Australia
14 Southern

Melbourne Integrated Cancer Service, East Bentleigh, VIC,

Australia

Aims: Designing effective programs that support breast cancer survivors to adopt and maintain regular exercise requires an understanding of characteristics that influence exercise behaviour. Psychological

Aims: Vaccination uptake is the principal focus of the world-wide

factors in particular are considered manipulable through behaviour

response to the COVID-19 pandemic. Vaccine hesitancy remains a

change intervention. The purpose of this analysis was to inform future

critical issue. Our aim was to ascertain rates and reasons for vaccine

theory-based interventions by exploring associations between exer-

hesitancy in people with breast cancer (BC) in Australia.

cise behaviour and three behavioural constructs from distinct theories:

Methods: Between June and October 2021, an anonymous online sur-

self-efficacy, motivation, and habits.

vey was conducted among people with solid organ cancer treated

Methods: Breast cancer survivors (n = 204) completed an online

at nine Australian treatment centres. Data collected included demo-

cross-sectional survey that collected demographic and disease char-

graphics and clinical characteristics. Vaccine hesitancy and related

acteristics, exercise levels (Godin Leisure Time Exercise Questionnaire

beliefs were assessed using the Oxford COVID-19 Vaccine Hesitancy

[GLTEQ] and a purpose-built resistance training item), and self-

Scale, the Oxford COVID-19 Vaccine Confidence and Complacency

efficacy (Multidimensional Self-Efficacy for Exercise Scale), motivation

Scale (OCVCCS), and the Disease Influenced Vaccine Acceptance

(Behavioural Regulation in Exercise Questionnaire V2), and habit

Scale-Six. Descriptive statistics, chi-squared and linear regression were

scores (Self-Report Habit Index). Multivariate linear regression models

used. Results for the BC subgroup are reported.

were used to identify psychological correlates of Total Activity (QLTEQ

Results: The BC subgroup (N = 986, mean age 58.4 years, 99% female)

Score) and Resistance Training (sessions/week).

comprised 36.6% of the responses in the solid cancer population

Results: Participants had a mean age of 57(11) years and were within

(N = 2691). Most (76%) were treated at metropolitan centres and

5-years post-diagnosis (median, min–max = 2, 0–5). Most partici-

64% were receiving ongoing treatment. Early BC was more commonly

pants were diagnosed with early-stage disease (72%) and engaged

reported than metastatic BC (77% vs. 23%). Overall, 82% self-reported

in sufficient levels of exercise (GLTEQ Score ≥24; 94%), though only

at least one COVID-19 vaccine dose. Unvaccinated participants were

44% completed two or more resistance training sessions/week. Iden-

more likely to diagnosed with BC for a shorter time (<2 years (22.1%)

tified motivation (ß[95%CI] = 7.58[3.91–11.24]; p = <0.01) and habits

vs ≥2 years (14.5%), p = 0.003). Participants with metastatic BC were

(ß[95%CI] = 4.43[1.48–7.38]; p = <0.01) were found to be signifi-

more likely to be unvaccinated and report greater disease-related vac-

cant correlates of Total Activity (as were body mass index and stage

cine concerns and hesitancy, when compared with participants with

of disease), whilst identified motivation (ß[95%CI] = 0.62[0.32–0.91];

early BC (all p < 0.05). When compared with participants with all

p = <0.01) and coping self-efficacy (ß[95%CI] = 0.02[<0.01–0.03];

other solid cancers, participants with BC reported more negative atti-

p = <0.01) were significant correlates of Resistance Training, explain-

tudes towards COVID-19 vaccine side-effects (OCVCCS Side-Effects

ing up to 26% and 15% of variance in Total Activity and Resistance

subscale mean scores: 5.19 (SD 1.91) vs. 5.46 (SD 1.82), p < 0.001).

Training exercise behaviour, respectively.

Conclusions: Despite a relatively high rate of self-reported vaccination,

Conclusions: Although preliminary, these results may support the

people with BC reported lower vaccine confidence when compared

application of integrated theory-based interventions for improving

with all other solid cancers. A better understanding of these inequal-

exercise behaviour among breast cancer survivors and provide insight

ities, and strategies to address vaccine confidence in people with BC,

into how intervention techniques from distinct theories may be best

particularly those with metastatic BC, should be developed.

integrated. Future research should explore these findings longitudinally to examine correlates of exercise maintenance and in a less active
sample.

404

Self-efficacy, motivation, and habits: Psychological

correlates of exercise among women with breast cancer
405

Acupuncture for treating a symptom cluster (pain,

Tamara L. Jones1 , Lara Edbrooke2,3 , Jonathon Rawstorn4 , Sandi

fatigue, sleep, neuropathy) for women with breast cancer: A

Hayes5 , Ralph Maddison4 , Linda Denehy2,3 , Camille Short1,2

feasibility study

1 Melbourne Centre for Behaviour Change, Melbourne School of Psychologi-

cal Sciences, University of Melbourne, Melbourne, VIC, Australia

K. Kwon1 , Kim Kerin-Ayres2 , Judith J.L. Lacey2,1,3 , Suzanne Grant2,1

2 Department

1 National

Australia

of Physiotherapy, University of Melbourne, Melbourne, VIC,

Institute of Complementary Medicine, Western Sydney Univer-

sity, Westmead, NSW, Australia
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2 Supportive Care, Chris O’brien Lifehouse, Camperdown, NSW, Australia

the past 5 years. It is primarily prescribed for refractory cancer and

3 Medical School, University of Sydney, Sydney, NSW, Australia

cancer related symptoms in the form of an oil with varying cannabinoid profiles. As with all new medications and therapies evaluation of

Aims: Many women (88%) who have received breast cancer treatment

practice is essential to safe and effective development and reflection of

with curative intent continue to experience numerous cancer and can-

prescribing, prescribing patterns.

cer treatment-related symptoms in the first 5 years after their primary

Method: A retrospective evaluation of prescribing of one practitioner

cancer treatment (Cheng, Devi, Wong, & Koh, 2014). These symp-

was carried out to identify: products prescribed, demographic of

toms commonly coexist, referred to as symptom clusters. Acupuncture

patients prescribed MC and their care needs and concerns. This eval-

based on Traditional Chinese Medicine (TCM) provides an approach

uation was of all products prescribed to cancer patients in a single

to managing these symptoms independently and when coexisting. This

institution between 07/2017 and 09/2021.

study examines: (1) the feasibility of a future randomized control trial

Results: Between the period of 07/2017–09/2021, 412 applications

evaluating acupuncture for managing a symptom cluster (pain, fatigue,

were made for approval of MC via SAS category B. Patient age rang-

sleep, numbness/tinging) in a cancer hospital setting and, (2) the poten-

ing from 17 to 87. Average days required for approval improved over

tial relationships between TCM syndrome diagnosis and a symptom

time from 20 (07/2017) to 1 (09/2021). The majority, 228 (55%) were

cluster.

for cancer and cancer related symptoms (general category) with 62

Methods: Single-centre, single-arm feasibility study, conducted at the

(15%) for anorexia only, 33 (8%) for Chemotherapy-induced Nausea

Chris O’Brien Lifehouse. We will recruit 20 women with breast cancer

and vomiting (CINV). The most commonly prescribed products were

who meet the inclusion criteria. Women will receive an individualized,

THC 10mg/ml: CBD 10 mg/ml whole plant balanced oil products, fol-

patient-centred course of acupuncture (eight treatments, 6 weeks).

lowed by a 2:1 CBD dominant product and CBD dominant full spectrum

Primary outcomes are acceptability (Acceptability of Intervention

products with ≤1 mg/ml THC. Patients were primarily in the outpatient

Measure), appropriateness (Intervention Appropriateness Measure),

setting but also prescribed and administered in the inpatient setting.

and feasibility (Feasibility of Intervention Measure). Secondary out-

Patient satisfaction, perceived benefit, change in symptom scores over

comes will investigate potential relationships between TCM syndrome

time is currently in the process of evaluation.

diagnosis and the symptom cluster. Additional analysis will monitor

Conclusion: The safe prescribing of MC, as with all new drugs and ther-

symptom burden and quality of life. Statistical significance is set at

apies is essential to the integration of therapy into standard of care.

p < 0.05.

Embedding research, retrospective reviews and symptom scores whilst

Results: In nine weeks, 15 participants were enrolled from 35 expres-

working closely with pharmacy team enables the progression of the

sions of interest or referrals to the study. Of these 35 women, three

integration of medicinal cannabis into symptom management in cancer

declined participation (8.6%), 10 were not eligible (28.6%), six have

patients.

upcoming enrolment interviews (17.1%), and 16 were eligible (45.7%).
Of the women who were eligible, 1 (6.3%) declined participation, and
15 (93.7%) were enrolled. Study is ongoing and further results will be

407

presented at the time of the conference.

self-reported symptom burden and wellbeing for breast cancer

Conclusions: Preliminary analysis suggests the study is feasible, espe-

patients at Chris O’Brien Lifehouse

A retrospective evaluation of Oncology Massage on

cially with high transition from eligible participants to enrolment.
These findings also suggest that women with breast cancer are wel-

Lizzie Milligan1 , Judith Lacey1 , Ki Kwon1 , Gillian Heller2 , Amanda

coming of acupuncture as a management for their cancer-related

Brand1 , Suzanne Grant1,3

symptoms.

1 Chris O’Brien Lifehouse, Camperdown, NSW, Australia
2 NHMRC

1. Cheng, K. K., Devi, R. D., Wong, W., & Koh, C. (2014). Perceived

Clinical Trials Centre, University of Sydney, Sydney, NSW, Aus-

tralia

symptoms and the supportive care needs of breast cancer survivors

3 NICM Health Research Institute, Western Sydney University, Sydney, NSW,

six months to five years post-treatment period. 18(1), 3–9.

Australia
Introduction: Patients undergoing treatment for breast cancer are bur-

406

Safe prescribing of medicinal cannabis in a comprehensive

cancer hospital in NSW

dened by symptoms impacting their physical, emotional, psychological
and mental wellbeing. Common physical burdens include pain, CIPN,
limited ROM and psychological burdens of anxiety and depression.

Judith Lacey1 , Jeffery Li1

Patients are increasingly seeking integrative services to support them

1 Chris

through allopathic cancer treatment. This is a retrospective study

O’Brien Lifehouse Comprehensive Cancer Centre, Camperdown,

NSW, Australia

evaluating the perceived benefit of oncology massage in improving
treatment related symptoms for breast cancer patients.

Introduction: Medicinal cannabis (MC) has been prescribed using Spe-

Methods: This was a retrospective quantitative study of 228 women

cial Access Scheme (SAS) and Authorised Prescriber Scheme (APS) for

with breast cancer that received oncology massage therapy at Chris

17437563, 2022, S3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/ajco.13869 by Henry Ford Health System, Wiley Online Library on [22/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

214

O’Brien Lifehouse between June 2018 and December 2020. The

Results: Of 156 participants enrolled, 133 participants completed the

Edmonton Symptom Assessment Scale (ESAS) was collected before

12 week study. The most common cancer types were breast (26%),

treatment to assess the broad range of symptoms experienced. The

gastrointestinal (25%) and gynaecological (19%). Compliance for par-

Measure Your Concerns & Wellbeing (MYCaW) was completed pre and

ticipants who completed 12 weeks of reporting using ePRO tool was

post massage to determine any perceived effects.

81.6%. Respondents expressed positive attitudes towards ePRO usage

Results: The most common symptoms were sleep disturbance, fatigue,

stating they would like to continue using ePRO during treatment.

numbness/tingling, hot flushes and reduced wellbeing. MYCaW sub-

Validation of ePRO was evaluated through toxicity associations with

category with the highest prevalence were aches and pains, followed by

chemotherapy drug classes.

lymphoedema, swelling, stiffness, impaired range of movement, sleep

Conclusions: Findings from this study suggests it is feasible to imple-

disturbance. Benefit in post scores suggests improvement in most

ment ePRO tools for detecting toxicities during routine clinical care.

symptoms from oncology massage.

Overall, patients had a positive attitude towards implementation of

Conclusions: Results from this study support the ongoing integration

ePRO for collecting information which can be used to improve delivery

of oncology massage into standard supportive care for breast cancer

of patient-cantered care.

patients, and informs future research into long term potential benefit
of oncology massage throughout breast cancer treatment.
409

The unmet supportive care needs of people affected by

cancer during the COVID-19 pandemic: An integrative review
408

Implementation and evaluation of ePRO: Electronic

patient-reported outcomes for monitoring toxicities associated
with systemic chemotherapy in a mixed cancer patient cohort

Helen S. Legge1,2 , Kellie Toohey1,2 , Phil Kavanagh1,2,3 , Catherine
Paterson1,2,4
1 Faculty of Health, University of Canberra, Canberra, ACT, Australia

Tali Lang1 , Thi Bich Ngoc Hoang2 , Farah Mian3 , Josh Farrington4 , Sai

2 Prehabilitation,

Kiran Gudla4 , Hieu Nim5 , Kirsten Seletto6 , Richardson Gary1,7

Research Group, Canberra, ACT, Australia

1 Cabrini Research, Malvern, VIC, Australia

3 University of South Australia, Justice and Society, Adelaide, SA, Australia

2 Faculty

4 Robert Gordon University, Aberdeen, Scotland, UK

of Information Technology, Monash University, Clayton, Victoria,

Activity, Cancer, Exercise and Survivorship (PACES)

Australia
3 Pharmacy, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Aims: To critically synthesise evidence regarding the support-

4 Medicity, Mount Waverley, Victoria, Australia

ive care needs of those living with cancer during the COVID-19

5 Murdoch Children’s Research Institute, Parkville, Victoria, Australia

pandemic.

6 Cabrini Health, Malvern, Victoria, Australia

Methods: An integrative systematic review followed a pre-registered

7 Oncology Clinics Victoria, Brighton, Victoria, Australia

protocol, reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) Guidelines. We searched

Background: Chemotherapy-associated toxicities are not usually

three databases (CINAHL, MEDLINE, and APA PsycINFO) using key

reported by patients in real-time, but often after the fact. This may

words, included all qualitative, quantitative, and mixed methods stud-

result in delayed treatment of toxicities leading to poorer health out-

ies respective of research design published between December 2019

comes, both in morbidity and quality of life. Patient reported outcome

and February 2022. All articles were double screened according to

measures (PROMs) are standardized measures used to obtain the

a pre-determined eligibility criterion with reference lists of the final

patient’s perspective and are increasingly used in healthcare to assess

included studies checked for further studies. The review process was

health outcomes and improve patient-cantered care.

managed using Covidence systematic review software. Data from the

Aims: To develop, validate and evaluate feasibility of implementing an

studies were extracted, methodological quality appraisal conducted,

electronic PROMs (ePRO) tool for reporting toxicities experienced by

and a narrative synthesis conducted.

cancer patients receiving intravenous chemotherapy during routine

Results: Eighteen publications were included. The findings identified

clinical care.

that individuals affected by cancer reported a range of physical, psy-

Methods: A proprietary ePRO tool was adapted to incorporate a

chological, social and health system unmet needs during the global

questionnaire consisting of nine common toxicities associated with

pandemic. There was fear of the unknown of the longer-term impact

chemotherapy treatment. This was tested prospectively in a mixed

that the pandemic would have on treatment outcomes, cancer care

cohort of solid and haematological cancer patients undergoing intra-

follow-up and clinical service delays.

venous chemotherapy through 2 day chemotherapy units at Cabrini

Conclusion: Many individuals living with cancer experienced unmet

Health, Melbourne. Participants were prompted weekly to self-report

needs and distress throughout the different waves of the COVID-19

toxicities and the severity using the ePRO tool from commencement of

pandemic, irrespective of cancer type, stage, and demographic factors.

treatment. The type, severity, and grade of toxicities were categorised

We recommend clinicians use these findings to identify the individ-

and evaluated according to chemotherapy drug class. Associations

ual person-centred needs to optimise recovery as we transition to the

between chemotherapy drug classes and toxicities were analysed.

post-pandemic cancer care.
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Practical factors that influence physical activity in women

living with metastatic breast cancer: A qualitative interview
study

Rationale and aims: The beneficial role of physical activity for people living with cancer is well established. However, the importance of

Mark Liu1 , Jasmine Yee1 , Justin McNab1 , Jane Beith1,2 , Sharon
Kilbreath1
1 The University of Sydney, Epping, NSW, Australia
2 Medical Oncology, Chris O’Brien Lifehouse, Sydney, NSW, Australia

physical activity to women living with metastatic breast cancer is not
known. As perceptions and beliefs influence willingness to be active, a
qualitative study was undertaken to explore what are their perceptions
and beliefs towards physical activity.
Methods: Women with metastatic breast cancer were recruited
through a metropolitan cancer centre to participate in semi-structured

Rationale and aims: Women living with metastatic breast cancer
(MBC) can benefit from physical activity. To enable effective physical
activity advice and services, it is important to understand the practical factors that may facilitate or prevent engagement. We explored in
women living with MBC: (i) their current physical activity habits, (ii)
practical and behavioural factors that influenced physical activity, and
(iii) the role of healthcare services in influencing engagement in being
physically active.
Methods: Semi-structured interviews were conducted with women
living with MBC recruited from a metropolitan cancer centre. Interviews explored their physical activity habits, barriers, facilitators, and
interests, guided by the Transtheoretical Model of behaviour change.
Interviews were transcribed and thematically analysed.
Results: Twenty-three women participated; mean age was 61 years
(range = 34–84) and mean time since metastatic diagnosis was 3.5
years (range = 0.4–8.5). Physical activity levels ranged from regular
participation in structured exercise to simple incidental activity. Eight
themes organised into three categories were identified: (1) pragmatic
factors included MBC-specific and other non-MBC health-related factors, time, work, and family-related factors, physical activity history
and physical activity preferences; (2) strategies for being physically
active included having the capacity to overcome barriers, and the
importance of routine and incidental activity, and; (3) health and physical activity services included the importance of tailoring advice
or programs to each individual, and perceived gaps in MBC-specific
health considerations such as pain and bone health management when

interviews about their physical activity experiences, motivations, and
goals, guided by the Transtheoretical Model of behaviour change.
Interviews were transcribed and thematically analysed.
Results: Twenty-three women participated; mean age was 61 years
(range = 34–84) and mean time since metastatic diagnosis was 3.5
years (range = 0.4–8.5). Twelve women were engaged with physical activity, seven intended to be active but found it challenging, and
four reported nominal interest in physical activity. Nine themes were
identified, organised into four categories: (1) predispositions towards
physical activity, supported by themes around the importance of
enjoyment and energy for physical activity, and positivity and mental resilience as facilitators; (2) health-related reasons for physical
activity, with themes around motivation from the various physical and
mental health benefits; (3) social influences, supported by themes
around exercising with others, social support and role models, and
navigation of others’ disparate opinions on MBC; and (4) specific connections between physical activity and MBC, supported by themes
around the uncertainty of prognoses motivates current physical activity, and the impact of unhelpful generalised perceptions of limitations
from MBC.
Conclusions: Participants described a wide-ranging spectrum of experiences and perceptions toward physical activity. Whilst most women
perceived improved physical and mental well-being from being physically active, some women were not engaged in being physically active.
Implementation strategies that address both their beliefs and those
around them may address this gap.

prescribing exercise programs.
Conclusions: Participants expressed diverse experiences with physical activity, with common notions on how physical activity is beneficial

412

but difficult in which to adhere. Whilst some barriers to engagement in

acceptability, and participant experiences of a novel 16-week

physical activity were unique to having cancer, many were not specific

classical ballet intervention for breast cancer survivors

Ballet after breast cancer: Investigating the feasibility,

to MBC. A patient-centred approach linked to their readiness to exercise may be effective for women who are currently inactive to engage
in physical activity.

Eliza Macdonald1 , Briana Clifford1,2 , David Simar1 , Christina
Signorelli1 , Rachel Ward1
1 UNSW, Sydney, Randwick, NSW, Australia
2 The University of Queensland, Brisbane, NSW, Australia

411

Perceptions and beliefs around physical activity in

women living with metastatic breast cancer: A qualitative

Aim: The ‘Ballet after breast cancer’ study sought to investigate the

interview study

feasibility, acceptability, and participant experiences of a 16-week
classical ballet intervention for breast cancer survivors, delivered

Mark G. Liu1 , Jasmine Yee1 , Justin McNab1 , Jane Beith1,2 , Sharon

face-to-face and/or online.

Kilbreath1

Methods: Breast cancer survivors attended 2 × 1-h weekly ballet

1 The University of Sydney, Epping, NSW, Australia

classes for 16 weeks. Primary outcomes of feasibility and acceptabil-

2 Medical Oncology, Chris O’Brien Lifehouse, Sydney, NSW, Australia

ity were assessed according to rates of enrolment and attendance, and
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feedback questionnaire. Secondary outcomes included quality of life

evaluating the effect of UBM on QOL following primary breast cancer

(QOL), upper-body disability, shoulder range of motion (ROM), muscu-

treatment.

lar strength, aerobic capacity, and physical activity levels. Participants

Methods: The study was prospectively registered in PROS-

were invited to attend study focus groups. Semi-structured discussions

PERO (CRD42020203445). CINAHL, Embase, Emcare, PsycInfo,

regarding perceived changes following ballet participation, program

PubMed/Medline and SPORTDiscus databases were searched to

design and delivery, and recommendations for future implementation

identify studies reporting QOL in individuals with and without UBM

were subject to thematic analysis.

following primary breast cancer treatment, using a multidimensional

Results: Thirty-one participants (77.5% of target) enrolled in the

QOL questionnaire. The primary analysis determined the standardised

program. Classes commenced face-to-face and moved online due

mean difference (SMD) in physical, psychological, and social wellbeing

to COVID-19 restrictions. Twenty-nine commenced the intervention

scores between UBM+/UBM- groups. Secondary analyses identified

[Female, 53.3 ± 10.8 yrs (Mean ± SD)] attending 77.6% [67.6, 87.5]

differences in domain scores between groups, according to QOL

(Mean [95%CI]) of sessions. Seventeen participants (54.4 ± 11.9yrs;

questionnaire.

54.2 ± 43 mnths post-diagnosis [Mean ± SD]) attended focus groups.

Results: Fifty-four studies were included, of which 37 were con-

Based on rates of enrolment and attendance, and participant feedback,

ducive to meta-analysis. Types of UBM included pain, lymphedema,

the program was deemed feasible and acceptable. Significant improve-

restricted shoulder ROM, impaired upper-body function, and upper-

ments in shoulder ROM and reductions in sedentarity were achieved.

body symptoms. UBM+ groups reported poorer physical (SMD −1.01);

Participants reported improved physical capacity and psychological,

psychological (SMD = −0.43) and social wellbeing (SMD = −0.61)

social, and cognitive wellbeing. In discussing experiences, five themes

than UBM- groups. Secondary analyses showed individuals with UBM

emerged: Embracing normal; Connection to others; Acceptance with-

reported having QOL poorer, or at least equal to, those without UBM

out judgement; Engagement; Learning and progress. The characteris-

across all domains.

tics of the ballet instructor emerged as key determinants of program

Conclusions: The findings of this systematic review and meta-analysis

engagement/enjoyment. Recommendations to improve future pro-

demonstrate the significant and negative impact of treatment related

grams included a hybrid delivery model, facilitated socialisation, and

UBM on QOL, pervading physical, psychological, and social domains.

the provision of learning resources.

Efforts to assess and minimise the impact of UBM across multiple life

Conclusions: Classical ballet delivered face-to-face and/or online is a

domains are warranted to mitigate impairment to QOL after breast

feasible and acceptable activity after breast cancer, leading to per-

cancer.

ceived improvements in physical, psychological, social and cognitive
wellbeing. The study provided preliminary evidence showing ballet

1. Sung, H., et al., Global Cancer Statistics 2020: GLOBOCAN Esti-

can improve shoulder ROM and reduce sedentarity. Findings invite

mates of Incidence and Mortality Worldwide for 36 Cancers in

future research investigating the comparative effectiveness of ballet

185 Countries. CA: A Cancer Journal for Clinicians, 2021. 71(3): p.

and honing its implementation after breast cancer.

209–249 https://doi.org/10.3322/caac.21660
2. Hayes, S.C., et al., Upper-body morbidity after breast cancer: incidence and evidence for evaluation, prevention, and management

413

Evaluating the effect of upper-body morbidity on quality

of life after primary breast cancer treatment: A systematic

within a prospective surveillance model of care. Cancer, 2012.
118(8 Suppl): p. 2237–49 https://doi.org/10.1002/cncr.27467

review and meta-analysis
Eliza Macdonald1 , David Simar1 , Amanda Hagstrom1 , Nadia Amorim2 ,

414

Katarina Markovic1 , Rachel Ward1 , Briana Clifford1,3

interference (HNSI), health-related quality of life (HRQL) and

1 UNSW, Sydney, Randwick, NSW, Australia

emotional distress trajectories during and after

2 University of Technology Sydney, Sydney, NSW, Australia

chemoradiotherapy (CRT) for HPV-associated oropharyngeal

3 The University of Queensland, Brisbane, NSW, Australia

cancer (HPVOPC): a TROG 12.01 secondary analysis

Aim: Improvements in breast cancer management continue to increase

Lachlan McDowell1,2 , Mathias Bressel3 , Madeleine T. King4 , June

survival rates and life expectancy after

treatment.1

Yet the adverse

Head and neck symptom severity (HNSS) and symptom

Corry6,5 , Liz Kenny7,8 , Sandro Porceddu8,9 , Christopher Wratten10 ,

effects of treatment may persist long term, threatening physical,

Andrew Macann11 , James E. Jackson12 , Danny Rischin2,13

psychological, and social wellbeing, leading to impaired quality of

1 Department

life (QOL). Upper-body morbidity (UBM) such as pain, lymphedema,

Melbourne, Victoria, Australia

restricted shoulder range of motion (ROM), and impaired function are

2 Sir

widely reported after breast cancer

treatment,2

but evidence demon-

of Radiation Oncology, Peter MacCallum Cancer Centre,

Peter MacCallum Department of Oncology, The University of Mel-

bourne, Melbourne, Victoria, Australia

strating the impact of UBM on QOL is inconsistent. Therefore, the

3 Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre,

aim of the study was to conduct a systematic review and meta-analysis

Melbourne, Victoria, Australia
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4 School

of Psychology, University of Sydney, Sydney, New South Wales,

415

Body composition changes in patients with breast cancer

pre- to post-exercise program

Australia
5 Department

of Medicine, University of Melbourne, Melbourne, Victoria,

Australia

Leah McIntyre1

6 GenesisCare St Vincent’s Hospital, Melbourne, Victoria, Australia

1 Physiotherapy, Mater Health Services, Brisbane, QLD, Australia

7 Department of Radiation Oncology, Royal Brisbane and Women’s Hospital,

Brisbane, Queensland, Australia

Aim: Current literature recommends exercise to provide improve-

8 Faculty

ments in fatigue and wellbeing during and after cancer treatment.

of Medicine, University of Queensland, Brisbane, Queensland,

Australia

This study measures changes in body tissue composition and fatigue

9 Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane,

in patients with breast cancer following an 8-week supervised group

Queensland, Australia

exercise class.

10 Department

Design: Participants had their body tissue analysis measured on the

of Radiation Oncology, Calvary Mater Hospital and Univer-

sity of Newcastle, Newcastle, New South Wales, Australia

SOZO before and after the program. The SOZO device measures mus-

11 Department

cle mass, fat mass and fluid volumes to provide a lymphoedema index

of Radiation Oncology, Auckland City Hospital and Univer-

sity of Auckland, Auckland, New Zealand

(LDex), calculated through bioimpedance analysis.

12 Icon Cancer Centres, Gold Coast, Queensland, Australia

Method: Eleven participants were recruited across two programs by

13 Department

direct invitation or responding to an advertising flyer. They were either

of Medical Oncology, Peter MacCallum Cancer Centre,

currently having or recently completed treatment at Mater Hospital

Melbourne, Victoria, Australia

Brisbane. Fatigue and SOZO measurements were recorded pre-and
Aims: This secondary analysis of a multicentre HPVOPC study

post-program to measure changes. Results were pooled to determine

aimed to identify patient-reported trajectories during and following

changes in the mean.

CRT.

Results: Pre-post program mean fat mass reduced 2.01% of body mass;

Methods: All 182 TROG12.01 patients were included.

HNSS

mean muscle mass increased 0.9%; mean LDex decreased by 1.86;

and HNSI (MDASI-HN), HRQL (FACT-G) and emotional distress

mean BMI decreased by 0.15. All these outcome measures are statis-

(HADS) were assessed before, during and after CRT. Latent class

tically non-significant. The Facit Fatigue Questionnaire improved 7.28

growth mixture modelling (LCMM) was performed to identify

points from 30.29 to 37.57 (maximum 52).

trajectories.

Conclusion: This is a small sample size and although BMI remained sta-

Results: The HNSS model identified 4 trajectory classes (HNSS1-4)

ble, we see trends towards a positive change in body tissue composition

distinguished by differences at baseline, at the peak of treatment symp-

with reduced fat mass, increased muscle mass, a decrease in fatigue

toms and during early (to 9w post CRT) and intermediate recovery

levels and no increase of LDex.

(9w–12m post CRT). All trajectories were stable beyond 12m. The

Key Practice Points

reference trajectory (HNSS4, n = 74) score was 0.1 (CI 0.1–0.2) at
baseline, peaking at 4.6 (CI 4.2–5.0), with rapid early recovery (1.1,

∙ Although BMI may remain stable, reductions in fat mass and

CI 0.8–2.2) and improvement to 12m (0.6, CI 0.5–0.8). HNSS2 (‘high

increases in muscle mass can be evident.
∙ The exercise program did not increase the lymphoedema index
∙ Exercise improves fatigue levels.

baseline’, n = 30) reported higher baseline scores (1.4, CI 0.8–2.0) but
was otherwise similar, HNSS3 (‘low acute’, n = 53) reported reduced
acute symptoms (2.5, CI 2.2–2.9) with stable scores beyond 9w post
CRT (1.1, CI 0.9–1.4). HNSS1 (‘slow recovery’, n = 25) had slower
recovery from an acute peak of 4.9 (CI 4.3–5.6) to 0.9 (CI 0.6–1.3)

416

Regional and rural clinical trial ambassador program

at 12m. Compared to HNSS4, the high baseline group were younger
(mean 53.6 vs 57.4), with fewer ECOG0 (87 vs 99%) or with higher

Anne Wollett1 , Rebecca McLean1 , Anne Wollett1

degree (38 vs 69%), with higher baseline anxiety (HADS, mean 6.8 vs

1 Alfred Health, Melbourne, VIC, Australia

4.4). The low acute group were older (mean 60.1), had fewer ECOG0
patients (87%) and were more likely to have received cetuximab (68%

Aims: Awareness and understanding of clinical trials in regional and

vs 43%). The slow recovery group had fewer with a higher degree

remote communities is low. TrialHub, a federal-funded program work-

(52%).

ing with regional hospital clinical trial units, identified the need to

LCMM
iety

also
and

identified
four

four

depression

HNSI,

two

trajectories,

HRQL,
which

three
will

anx-

improve messages on the value of clinical trials in hard-to-reach

be

areas, beyond traditional methods, as regional clinical trial availability

presented.

increases.

Conclusion: LCMM identified four distinct HNSS trajectories which in

Method: TrialHub has developed a regional clinical trial ambassador

combination with variations in patient characteristics may be clinically

program. They act as a real-life testimonial, an advocate who rep-

useful in identifying patients requiring increased support during and

resents clinical trials across a wide range of mediums and infiltrates

after CRT.

hard-to-reach communities.
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They have been on a clinical trial/ or have been the carer of a

highlights the importance of establishing processes to improve screen-

clinical trial participant, they want to share their story and expe-

ing, assessment, treatment, and multidisciplinary management of these

rience with their community. They are separate to the consumer

conditions. Currently, there are no published reports on practice align-

advisor, but still work hand-in-hand, they are an external voice in the

ment with the recommendations, and understanding factors related

community.

to adherence is an important evidence gap. We aimed to determine

They are supported, and equipped, to share their story – the good

adherence to the COSA position statement on cancer-related malnu-

and bad – in the capacity they feel comfortable and in their own

trition and sarcopenia screening, assessment, and treatment to identify

words. They are a trusted and additional source of information for their

improvement opportunities in a regional Queensland oncology unit.

community.

A retrospective chart audit of 100 randomly selected adult patients

Clinical trial ambassadors are located in different geographical regions,

(53% male; mean (SD) age 61.8 (1.3) years; 23% lung cancer) who com-

have diverse demographics such as age, interests, race and sex and

menced treatment in 2021 was conducted at time of diagnosis, cycle

cancer type.

1 (C1) of chemotherapy and/or immunotherapy, and 3 months follow-

Results: Over 12-months, our ambassadors have provided consistent

ing C1 (3M). Charts were audited against a data collection tool mapped

awareness among the Gippsland region, across the State and now

to the COSA position statement recommendations. Gaps were high-

nationally. They have become well-known, they’ve had people reach

lighted at all steps of the malnutrition and sarcopenia management

out to them, and have been involved in the following;

pathway. There was no screening, assessment, or treatment of sarcopenia. Malnutrition screening with a validated tool was significantly

∙ Two media interviews per month
∙ Two community and corporate speaking engagements per month

higher at C1 (diagnosis 26%, C1 73%, 3M 47%; p < 0.001). Referral to a

∙ Peer-to-peer advice

diagnosis). Nutrition assessment using a validated tool increased over

∙ Local, State and Federal government speaking
∙ Input into promotional material such as brochures and website

time (diagnosis 40% vs 3M 71%). A multidisciplinary team was available

∙ Social media content creation and distribution
∙ Blogging

input apart from dietetics. This audit provides early data reporting

∙ Videos

trition and sarcopenia. It has identified evidence-practice gaps with

dietitian varied (C1 27% and 44% for those with a high nutritional risk

at all points however no malnourished patients received allied health
adherence to the COSA position statement on cancer-related malnuthe current management of these conditions, highlighted areas for

Conclusion: This unique program will be expanded to more regional

further action, and contributes to the development of data describ-

areas, ensuring more Australians are receiving information about clin-

ing malnutrition and sarcopenia management practices in regional

ical trials from an ambassador in their community and through a

facilities.

structured and measured approach.
418
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Slipping through the cracks: Identifying opportunities to

Effects of exercise on physical function in adults with

haematological cancer: A systematic review and meta-analysis

improve malnutrition and sarcopenia management at a regional
oncology unit

Melanie J. Moore1 , Joseph Northey1 , Philip Crispin2 , Stuart Semple1 ,
Kellie Toohey1

Louise Moodie1 , Hannah Graham1 , Matthew Hiskens2 , Merran

1 University of Canberra, BRUCE, ACT, Australia

Findlay3,4 , Judy Bauer5

2 Haematology, Canberra Hospital, CANBERRA, ACT, Australia

1 Nutrition & Dietetics, Mackay Hospital & Health Service, Mackay, Queens-

land, Australia

Background: Individuals diagnosed with haematological malignancy

2 Mackay

(HM) experience significant declines in physical function (PF) due to

Innovation & Research Institute, Mackay Hospital & Health

Service, Mackay, Queensland, Australia

the biological nature of the malignancy and chemotherapeutic agents.

3 Cancer Nutrition, Sydney Local Health District, Sydney, New South Wales,

With promising evidence supporting the efficacy of exercise performed

Australia

throughout the cancer treatment trajectory for solid tumours, the

4 Living

application for HM is not yet clear.

Better with and After Cancer, Mariduli Budyari Gumal (SPHERE),

University of New South Wales, Sydney, New South Wales, Australia

Objective: To evaluate the efficacy of exercise to improve PF in HM

5 Department of Nutrition, Dietetics & Food, Monash University, Melbourne,

adult patients throughout the treatment trajectory.

Queensland, Australia

Method: A systematic review with multilevel meta-analysis was conducted. Four electronic medical databases were searched; MEDLINE

Malnutrition and sarcopenia are prevalent amongst those undergoing

(EBSCOhost), CINAHL, Scopus and CENTRAL for randomised control

cancer treatment; however, both are under-recognised and under-

trials (RCTs)of exercise interventions implemented during, or post-

treated. The 2020 Clinical Oncology Society of Australia (COSA)

treatment for adults diagnosed with a HM subtype of leukaemia,

position statement on cancer-related malnutrition and sarcopenia

lymphoma or multiple myeloma with an outcome measure of PF.
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Results: Twelve studies with a total of 812 participants were included

This study demonstrated the use of supportive care tools to identify

in our systematic review. Analysis of 36 dependent effect sizes from

breast cancer patients who are vulnerable to increased psychologi-

nine studies revealed structured exercise interventions improved PF

cal distress during the COVID pandemic. It also highlights the need to

(SMD = 0.39; 95%CI 0.21–0.57) compared to usual care or an active

address the limited access to psychological support services for cancer

control. Exercise prescription that included a multimodal design con-

patients in Gippsland.

sisting of aerobic and resistance exercise had a significant effect
on PF (p < 0.001), while exercise intensity had a significant effect

1. Carreira, H., Williams, R., Müller, M., Harewood, R., Stanway, S., &

when prescribed at a moderate (p = 0.003) and vigorous (p < 0.001)

Bhaskaran, K. (2018). Associations Between Breast Cancer Sur-

intensity.

vivorship and Adverse Mental Health Outcomes: A Systematic

Conclusion: This meta-analysis provides initial evidence for clinicians

Review. Journal of the National Cancer Institute, 110(12), 1311–

to recommend supervised moderate-vigorous intensity exercise with a

1327. https://doi.org/10.1093/jnci/djy177

multimodal design to improve PF in adults with an HM. Future research

2. Joshy, G, Thandrayen, J, Koczwara, B. et al. Disability, psychologi-

should aim to identify optimal prescription guidelines throughout the

cal distress and quality of life in relation to cancer diagnosis and

treatment trajectory.

cancer type: population-based Australian study of 22,505 cancer
survivors and 244,000 people without cancer. BMC Med. 2018 18,
372. https://doi.org/10.1186/s12916-020-01830-4
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Impact of the COVID-19 pandemic on supportive care

outcomes of breast cancer survivorship patients in Gippsland,
Victoria

420

Measuring cognitive dysfunction in Glioblastoma (GBM) –

An audit of current clinical practice in the use of
Harriet O ’ Rourke1 , Leah Savage1 , Eli Ristevski2 , Bhavini Shah1 ,

formal cognitive assessments at Sir Charles Gairdner Hospital

Sachin Joshi1 , Mahesh Iddawela1
1 Medical Oncology, Latrobe Regional Hospital, Traralgon, VIC, Australia

Ek Leone Oh1 , Chia Len1 , Caroline Zabczyk1 , Anne Long1

2 Monash Rural Health, Monash University, Melbourne, VIC, Australia

1 Sir Charles Gairdner Hospital, Nedlands, WA, Australia

Background: The psychological impact of breast cancer diagnosis and

Background: Cognitive impairment among patients with Glioblastoma

management are well known, and the COVID-19 pandemic may have

Multiforme (GBM) is clinically recognised but limited data exists to

exacerbated this distressing experience for these patients.

define the scope of the problem.1 Cognitive dysfunction may be the

Objective: We aimed to assess the supportive care outcomes and

first manifestation of tumour recurrence with significant impact on

level of psychological distress experienced by breast cancer patients

patients’ quality-of-life.1-4 Recognising neurocognitive dysfunction is

in our regional survivorship clinic during the COVID pandemic, in

important in assessing decision-making capacity and cognitive rehabil-

comparison to a pre-pandemic population. We also sought to deter-

itation may be beneficial for GBM patients.5-7 Cognitive impairment

mine whether using telehealth during the pandemic was preferred by

is not routinely assessed with no standard to assess the degree of

oncology patients.

cognitive impairment amongst GBM patients.8

Methods: All 49 patients who attended the breast cancer survivorship

Objective: Assess the current levels of cognitive assessments that are

clinic in 2019, and 50 patients who attended in 2021, were included

occurring in clinical practice by reviewing the number and types of cog-

in this study. Deidentified data was collected from the end of treat-

nitive assessment performed in this patient group. Results may inform

ment care plan. We also collected self-reported scores on The National

future recommendations for cognitive assessment in patient care.

Comprehensive Cancer Network Distress Thermometer (DT). Patients

Methods: We undertook a retrospective study and identified patients

with a self-reported DT score >4 were asked to complete the Kessler

above the age of 18 with newly diagnosed GBM, who were reviewed

Psychological Distress Scale questionnaire as a secondary assessment

by the medical oncology team in Sir Charles Gairdner Hospital (SCGH)

of depression and anxiety.

from September 2016 to January 2018. Patients with established

Results: Breast cancer patients in the 2021 pandemic cohort recorded

impairment or unsuitable for further chemotherapy were excluded. We

higher levels of distress (4.2/10) on the Distress Thermometer com-

reviewed patients’ electronic and physical medical records to evaluate

pared to the 2019 pre-pandemic cohort (2.4/10) (p = 0.0007). In

if any cognitive assessment was performed over a 24-month period.

the pandemic cohort, 38% of breast cancer patients reported a K10

Results: Of the 51 patients identified, 36 patients were included in

score >16 indicating a moderate-to-high or threefold population risk

this audit based on the inclusion and exclusion criteria. Eight of the

of having a current anxiety or depressive disorder, compared with

36 patients had formal cognitive assessments completed within 24

12% of the patients in the pre-pandemic cohort. Patients in the pre-

months of diagnosis. The Mini-Mental State Examination was the most

pandemic group most commonly identified physical concerns including

used cognitive assessment tool. Of 11 patients noted to have cognitive

fatigue (61%), poor sleep (43%), pain (33%) and neuropathy (31%).

decline, only one patient underwent formal cognitive assessment.

The key concerns of patients in the 2021 group were fatigue, anxiety,

Conclusions: Our audit confirms that cognitive assessment is not rou-

depression and fear of recurrence.

tine in the assessment of patients with GBM with only a minority of
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patients undergoing any form of cognitive testing. This concerningly

Embase, CINAHL and Cochrane CENTRAL and clinicaltrials.gov) were

included patients who were documented to have demonstrated signs

searched using key search terms. Articles were assessed accord-

of cognitive decline.

ing to pre-specified eligibility criteria. Data extraction and quality
appraisal was conducted. The findings were integrated in a narrative

1. Bergo E, Lombardi G, Guglieri I, Capovilla E, Pambuku A, Zagone V,

synthesis.

et al. Neurocognitive functions and health related quality of life in

Results: Of the 5863 publications screened, 118 articles were assessed

glioblastoma patients: a concise review of the literature. European

in full-text and 17 studies met the pre-screening eligibility crite-

Journal of Cancer Care.

ria. There were a range of study designs which included: randomised

2. Armstrong C.L., Goldstein B., Shera D., Ledakis G.E. & Tallent

controlled clinical trials (n = 11), quasi experimental (n = 4), cohort

E.M. (2003) The predictive value of longitudinal neuropsychologic

(n = 1), and case series (n = 1), covering a total of 1739 participants. The

assessment in the early detection of brain tumour recurrence.

prehabilitation interventions included: physical activity, peer support,

Cancer 97, 649–656.

pelvic floor muscle training, diet, nurse-led prehabilitation, psycho-

3. Meyers C.A. & Hess K.R. (2003) Multifaceted end points in brain

logical, and prehabilitation administration of phosphodiesterase-5

tumour clinical trials: cognitive deterioration precedes MRI pro-

inhibitors.

gression. Neuro-Oncology 5, 89–95.

Conclusions: Significant heterogeneity existed in the prehabilitation

4. Li J., Bentzen S.M., Li J., et al: Relationship between neurocogni-

intervention programs for men affected by prostate cancer in terms of

tive function and quality of life after whole-brain radiotherapy in

the composition, duration, method of administration, and the outcomes

patients with brain metastasis. Int J Radiat Oncol Biol Phys 2008;

measured to quantify their impact.

71: pp. 64–70

Implications for Cancer Survivors: This systematic review has iden-

5. Locke D.E., Cerhan J.H., Wu W., et al: Cognitive rehabilitation and

tified that multimodal prehabilitation interventions are an emerging

problem-solving to improve quality of life of patients with primary

area for practice and research among men affected by prostate can-

brain tumours: a pilot study. J Support Oncol 2008; 6: pp. 383–391

cer. Importantly, there has been a lack of focus on the inclusion of

6. Maschio M., Dinapoli L., Fabi A., et al: Cognitive rehabilitation train-

partners as critical companions during this distressing phase of the

ing in patients with brain tumour-related epilepsy and cognitive

cancer care continuum. For the moment, all members of the multi-

deficits: a pilot study. J Neurooncol 2015; 125: pp. 419–426

disciplinary team caring for people affected by prostate cancer are

7. Hassler M.R., Elandt K., Preusser M., et al: Neurocognitive training
in patients with high-grade glioma: a pilot study. J Neurooncol 2010;

encouraged to use the findings in this review to inform holistic models
of care.

97: pp. 109–11
8. Flechl B, Sax C, Ackerl M, Crevenna R, Woehrer A, Hainfellner J,
et al. The course of quality of life and neurocognition in newly
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diagnosed patients with glioblastoma. Radiotherapy and oncology.

men diagnosed with prostate cancer: A qualitative systematic

The experiences of supportive care among partners of

review
421

What are the effects of multimodal prehabilitation

interventions in men affected by prostate cancer? A systematic

Cara Roberts1 , Kellie Toohey1 , Catherine Paterson1
1 University of Canberra, Canberra, ACT, Australia

review
Background: Partners of men diagnosed with prostate cancer face
Catherine Paterson1 , Cara Roberts1 , Maria Kozlovskaia1 , Irmina

their own emotional struggles, as they navigate additional caregiver

Nahon1 , Kath Schubach1 , Sally Sara2 , Richard De Abreu Lourenco3 ,

responsibilities, while concurrently adjusting to the diagnosis and

Murray Turner1 , Raymond J. Chan4 , Thomas Lam5 , Henry Woo6 , Kellie

coping with greater illness uncertainty for their loved one.

Toohey1

Objective: This qualitative systematic review examined the unmet

1 University of Canberra, Canberra, ACT, Australia

supportive care needs of partners affected by prostate cancer.

2 Prostate Cancer Foundation of Australia, Sydney, Australia

Interventions/Methods: A meta-aggregation was conducted. Four

3 UTS, Sydney, Australia

electronic databases were search using key words. The methodology

4 Finders University, Adalaide, Australia

followed the Joanna Brigg’s Institute (JBI) for qualitative evidence syn-

5 University of Aberdeen, Aberdeen, Australia

thesis. The review process followed a registered priori review protocol

6 ANU, Canberra, Australia

and was reported using the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) guidelines. Data extraction and

Purpose: To synthesise existing evidence on the effects of multimodal

quality assessment was conducted in parallel.

prehabilitation interventions in men affected by prostate cancer on

Results: Twenty-one publications were included. A total of 239 find-

physical, clinical and patient reported outcome measures.

ings and 32 categories were synthesised into seven domains of unmet

Methods: A systematic review was conducted according to the

needs as experienced by partners. The domains of needs expressed

PRISMA 2020 Statement Guidelines. Electronic databases (Medline,

by the participants included: interpersonal/intimacy, physical/daily
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living, health care service, family-related, psychological/emotional

424

needs, spiritual, and social needs.

patients receiving fluoropyrimidine-based treatment

Prevalence of fluoropyrimidine-induced toxicities in

Conclusions: There are gaps in clinical service support, despite routine clinical consultation with healthcare professionals. Partner may

Lyndsey L. Pell1 , Aneeta A. Varkey2 , Michael G. Powell1 , Michael G.

diminish their social networks to protect their husband at the cost to

Powell2 , Vijay V. Suppiah4,3

their own self-preservation and well-being.

1 Cancer and Production, Southport, QLD, Australia

Implications for practice: Cancer organisations, policy makers,

2 Griffith University, Gold Coast, QLD, Australia

healthcare care professionals and researchers are slowly making

3 Australian

progress to acknowledge the unique support needs of partner affected

Adelaide, SA, Australia

by cancer. Healthcare professionals should encourage partners to be

4 Clinical

included in models of prehabilitation access timely support to address

Australia

Centre for Precision Health, University of South Australia,

and Health Sciences, University of South Australia, Adelaide, SA,

informational, intimacy, spiritual and daily living needs support.
Aims: While fluoropyrimidine (FP) toxicities related to dihydropyrimidine dehydrogenase (DPD) deficiency are well documented globally,
423

What are the unmet supportive care needs of people

affected by cancer: An umbrella systematic review

the impact of these enzymatic aberrations have not been explored
extensively in the Australian hospital setting. In this preliminary investigation, we aimed to study the prevalence of FP toxicities in patients

Catherine Paterson1 , Kellie Toohey1 , Rachel Bacon1 , Phil Kavanagh1 ,

receiving FP-based treatment at a tertiary Australian hospital.

Cara Roberts1

Methods: We conducted a retrospective audit of all patients over

1 University of Canberra, Canberra, ACT, Australia

18 years of age who received their first dose of fluorouracil or
capecitabine at the Gold Coast University Hospital between 1st Jan-

Objective: The aim of this umbrella systematic review was to critically

uary and 31st December 2020. The electronic medical record of each

synthesise unmet supportive care needs of people affected by cancer.

patient was analysed for known FP toxicities and details of adverse

Data sources: The Joanna Briggs Institute (JBI) umbrella review

events (AEs) were recorded, including severity according to the Com-

method provided an overall examination of the body of evidence. All

mon Terminology Criteria for Adverse Events (CTCAE v5.0). Subse-

qualitative, quantitative, and mixed methods reviews were included

quent management including changes or delays to the chemotherapy

irrespective of review design. Electronic databases were searched

regimen were also investigated.

using a wide range of search terms. All records were managed using the

Results: A total of 215 patients were included in this study: 107

software package Endnote ×12 and uploaded to Covidence systematic

patients received fluorouracil and 108 patients received capecitabine.

review software. Duplication of records were removed. A pre-selection

A total of 1083 AEs were reported. The most frequently reported

eligibility criterion was applied to all records. Data extraction, method-

toxicities in order of decreasing prevalence were fatigue (233 AEs;

ological quality assessment was conducted independently by two

21.5%), diarrhoea (164 AEs; 15.1%) nausea (157 AEs; 14.5%), hand

reviewers and a meta-level narrative synthesis conducted.

and foot syndrome (89 AEs; 8.2%), mucositis (78 AEs; 7.2%) and neu-

Conclusion: A total of 449 publications were identified and 28 sys-

tropenia (44 AEs; 4%). The most severe toxicities (grades 3 or 4) were

tematic reviews (representing a total of 612 publications) globally.

neutropenia (34 AEs; 3.1%), diarrhoea (23 AEs; 2.1%), nausea (8 AEs;

Irrespective of the type of cancer there were many commonalities in

0.7%) and chest pain (3 AEs; 0.3%). Treatment delays occurred in 62

relation to the reported experiences of unmet supportive care needs

instances, dose reduction occurred in 47 instances and cessation of

which therefore enables the development of targeted future clinical

therapy occurred in 47 instances.

trials, clinical guidelines, and policy contribution. In descending order

Conclusion: In Australia, toxicities from FP are common and can be

of frequency, the highest unmet supportive care needs were related to

of extreme severity. Adverse events may result in treatment delays

psychological/emotional (28/28), health system/information (27/28),

and early cessation of therapy, potentially impacting clinical efficacy

interpersonal/intimacy (19/28), social (18/28), physical (17/28), fam-

and quality of life. Further research is planned to investigate the

ily (16/28), practical (14/28), daily living (9/28), spiritual needs (7/28),

relationship between DPD deficiencies and FP toxicities.

patient-clinician communication (7/28) and cognitive needs (4/28).
Implications for Nursing Practice: This umbrella review has under-

425

scores fundamental shortcomings in care delivery irrespective of the

QLQ-C30 and QLQ-OV28 for routine PROMs data collection in

patient population and the type of cancer. People with cancer are

the National Gynae-Oncology Registry (NGOR): A thematic

continually reporting that their needs are not being met across many

analysis of the perspectives and content needs of women with

supportive care domains. It is time for change within the health care

ovarian cancer

Patient-determined appropriateness of the EORTC

system and to full leverage multidisciplinary person-centred models of
care to optimise recovery and survivorship experiences. In the mean-

Sharnel Perera1 , Alice Sporik1 , Penelope Schofield2 , Paul Cohen3 ,

time, policy makers and cancer care clinicians are encouraged to reflect

Simon Hyde4 , Sue Hegarty5 , Hayley Russell5 , Natalie Heriot6 , John

on these findings to address individualised care needs.

Zalcberg1
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1 Cancer

Research Program, Monash University, Melbourne, Victoria, Aus-

tralia

Introduction: CarerHelp is an online resource (www.carerhelp.com.au)
that was funded by a National Palliative Care Project grant. It provides

2 Department

of Psychological Sciences, Swinburne University of Technol-

information and resources to support Australians who are caring for

ogy, Hawthorn, Victoria, Australia

someone at the end of life.

3 Obstetrics and Gynaecology, University of Western Australia, 6009, West-

Aims: The aim of this project was to increase the reach and accessibility

ern Australia, Australia

of CarerHelp by developing new resources that focus on the needs of

4 Gynaecological Oncology, Mercy Hospital for Women, Melbourne, Victoria,

specific populations of carers including:

Australia
5 Support

Programs, Ovarian Cancer Australia, Melbourne, Victoria, Aus-

tralia

∙ Culturally and Linguistically Diverse communities
∙ Aboriginal and Torres Strait Islander peoples
∙ LGBTIQ+ communities
∙ People who may rely on care from a support worker or paid carer

6 Ambulance Victoria, Melbourne, Victoria, Australia

Aim: To gather consumer-identified salient indictors of ovarian, fal-

including those with disabilities.

lopian tube and primary peritoneal (OTP) cancer experiences and
outcomes from the EORTC QLQ-C30/OV28. This data will aid in the

Methods: The approach included:

development of a bespoke PROMs tool for use in the National Gynaecological Oncology Registry (NGOR), as a measure of QoL and QoC for

1. A scoping study to appraise current resources for diverse carers
and identify gaps

women with OTP cancer.
Methods: Four focus groups were held with a total of 24 OTP cancer

2. Consultation with stakeholders who understand the needs of

patients (Mean age = 62.6 years, SD = 10.22). The items in the EORTC

diverse carers including health professionals, organisations and

QLQ-C30/OV28 were discussed regarding their importance and relevance for the purposes of PROMs data collection in the NGOR. Data

cultural consultants
3. Reviewing current CarerHelp resources to identify which resources
to modify and what new resources would be created

were analysed via thematic analysis.
Results: Participants were predominantly from metropolitan areas

4. Working with a translation service

(66.7%), currently in treatment (50%), with stage III disease (54.2%). All

5. Developing artwork and graphic design

items of the EORTC QLQ-C30/OV28 were considered important to

6. Case studies of diverse carers

include in routine PROMs data collection within the NGOR.

All

women spoke of the considerable impact to their physical wellbe-

Results: The scoping study identified many quality resources for

ing and QoL while undergoing treatment, where symptoms such as

diverse populations focusing on end of life care. However, there was

neuropathy, fatigue, sleep disturbance, gastro-intestinal and genitouri-

limited content available in other languages, and gaps in resources for

nary symptoms became especially burdensome. Desire to engage in

diverse populations of carers.

intimacy was also diminished during treatment, where body image

Community consultation revealed modifications were required to

and related emotional states impacted their sense of self. All par-

existing CarerHelp resources, such as changing terminology around

ticipants urged collection of PROMs at least every 6-months from

death and dying, and including specific cultural practices around end

diagnosis, preferably using an online format.

The preferred for-

of life care, burial and bereavement. Artwork and graphics were also

mat should also include links and resources for evidence-based and

important in ensuring acceptability for some diverse groups. New

appropriate interventions (e.g. physiotherapy) to aid in symptom

links to external websites for resources for diverse carers were also

management.

identified and included.

Conclusions: The EORTC QLQ-C30/OV28 provides a comprehensive

Conclusion: CarerHelp now includes a range of new and modified

list of cancer experiences and outcomes that can act as key indicators of

resources for diverse population groups, ensuring all Australians have

wellness and QoL for women with OTP cancer. Participants recognised

access to trustworthy information delivered in an accessible format

the value in routine PROMs data collection as a means of chronicling

preparing them for their caring role.

their own cancer journey, which could also prove useful in a clinical
context, as a catalyst for refining and tailoring patient-centred care for
women with OTP cancer.
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The feasibility of ‘Beyond Cancer’, a multimodal support

intervention for transitioning back to ‘good’ work following
429

CarerHelp diversity – Resource development for diverse

breast cancer

populations of end of life carers
Dianne M. Sheppard1 , Georgia Halkett2 , Moira O’Connor2 , Georgina
Di Saward1 , Kristina Thomas1 , Mark Boughey1 , Jennifer Tieman2

Lamb3 , Michael Jefford4

1 Centre for Palliative Care, St Vincent’s Hospital, Melbourne, Australia

1 Monash University, Clayton, VIC, Australia

2 CareSearch – Flinders University, Adelaide, South Australia, Australia

2 School of Nursing, Midwifery and Paramedicine, Faculty of Health Sciences,

Curtin University, Perth, WA, Australia
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3 IPAR Rehabilitation, MedHealth, Melbourne, VIC, Australia

Introduction: Multidimensional geriatric assessment (GA) of older

4 Australian

patients with cancer has been shown to improve communication about

Cancer Survivorship Centre, Peter MacCallum Cancer Centre,

Melbourne, VIC, Australia

age-related concerns including ‘What Matters Most’, reduce treatment
toxicity and enable GA-guided supportive care.

Background/Aims: There is a recognised gap in services to support

Aims: To explore feasibility of adding Photovoice (PV) analysis of

breast cancer (BrCa) survivors to return to sustainable work, as part

patient-derived photographs to an electronic GA to enhance support-

of returning to wellness.

ive care (ESC) of older adults at Albury Wodonga Regional Cancer

Method: Beyond Cancer, a tailored multimodal return to work (RTW)

Centre.

support intervention, was co-developed by a multidisciplinary team

Methods: Eligibility: Age >70yrs, assessed for treatment at AWRCC,

including industry representatives, clinicians, researchers, Cancer

G8 screening tool <14. Randomisation to GA using electronic rapid

Council and consumer representatives. It was delivered largely face-

fitness assessment (eRFA) (+TUG and miniCOG) or eRFA + four

to-face by trained occupational rehabilitation (OR) consultants within

patient-derived photographs and recorded interview using PhotoVoice

the life insurance sector; key components included individualised

SHOWeD questions (1).

health coaching, RTW planning and monitoring, and employer edu-

Patients asked to provide photographs using four themes: 1. Identity

cation & support. Surveys and interviews with participants, and a

2. Something important to patient 3. Home environment 4. Trans-

consultant focus group examined perceived effectiveness and accept-

port. Thematic analysis of PV interview enabled creation of a 2-page

ability. Eligible participants were being / had been treated for BrCa and

summary for discussion at ESC MDM.

were referred to the Beyond Cancer program through their life insurer

Results/Outcomes: Eighteen patients randomised – eRFA alone (n = 9),

as part of their rehabilitation claim.

eRFA+PV (n = 9). Median age = 78 yrs (range 72–90). Median G8

Results: Eighty-four females with BrCa working prior to diagnosis were

score = 11.5 (range 10–14).

referred to Beyond Cancer between Feb 2019 – Feb 2021. Fifty-

Treatment intent: adjuvant (44%), curative (28%), palliative (22%), no

five BrCa survivors continued beyond initial assessment; health- and

treatment (6%). All patients completed eRFA (8 needed assistance).

treatment-issues were key barriers to participation. Average program

All patients on the eRFA+PV arm provided at least 2 photographs with

duration was 33 weeks with 78% participating in at least 2 components

4 patients providing >4 photos.

of the program; however, employer education and support component

Thematic analysis of PV interview enabled production of ESC summary

was not often utilised / required by this cohort. Preliminary indica-

sheet (Domains: Individual, Interpersonal Relationships, Community

tions of effectiveness were 70.9% fully or partially RTW, and significant

and Society, Transport and Home environment and Implications for

improvement in a range of biopsychosocial factors at follow up, includ-

treatment). Summary enabled insight into patient’s lived experience

ing quality of life, beliefs, perceptions and expectations around health

and ‘What Matters Most’. eRFA + ESC sheet + photos enabled patient-

and work, fatigue and cognitive symptoms. Qualitative feedback from

centred discussion at MDM and guided supportive care interventions.

consultants and program participants indicated that participation was

Conclusion: Addition of patient-derived photographs and PV interview

beneficial, providing validation that their experience was a normal

to a GA was feasible in older adults at a regional cancer centre and can

response to their circumstances, and assisting with goal setting to

be used to guide patient-centred, enhanced supportive care. Thematic

move toward work readiness.

analysis of recorded PV interview is not practical given time constraints

Conclusions/Implications: Preliminary evidence has shown that

however useful information may be derived from photographs alone.

Beyond Cancer is effective in supporting women with BrCa to return
to wellness and work and is acceptable to consultants and survivors.

1. Wang CC, Yi WK, Tao ZW, Carovano K. Photovoice as a participatory health promotion strategy. Health promotion international.
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Geriatric assessment (GA) in the instagram era: Adding

1998 Jan 1;13(1):75–86.

photographs to electronic ga to enhance supportive care (ESC) of
older adults with cancer
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A systematic review of multi-modal prehabilitation in

breast cancer
Christopher B. Steer1,2,3,4 , Darren Jayasuriya2 , Nicole Webb3 , Tshepo
Rasekaba4 , Kim Young4 , Mira Kapur2 , Stacey Rich4 , Irene Blackberry4
1 Border

Medical Oncology, Albury Wodonga Regional Cancer Centre,
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2 UNSW

School of Clinical Medicine, Rural Clinical Campus, Albury, NSW,

Australia
3 Albury Wodonga Health, Albury Wodonga Regional Cancer Centre, Albury,

NSW, Australia
4 John

Richards Centre for Rural Ageing Research, La Trobe University,

Wodonga, VIC, Australia

Kellie Toohey1,2 , Maddison Hunter1,2 , Karen McKinnon3 , Tamara
Casey3 , Murray Turner1,2 , Suzanne Taylor3 , Catherine Paterson1,2,4
1 University of Canberra, Bruce, ACT, Australia
2 University

of Canberra, Prehabilitation, Activity, Cancer, Exercise and

Survivorship (PACES) Research Group, Bruce, ACT, Australia
3 Australian

Capital Territory Breast Care, Calvary Public Hospital, Bruce,

ACT, Australia
4 Robert Gordon University, Aberdeen, AB10 7QB, Scotland
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Aims: Breast cancer is the most prevalent malignancy in women. Pre-

6 Department

habilitation may offer improvements in physical and psychological

School of Medicine, The University of Tokyo, Bunkyou-ku, Japan

wellbeing among women prior to treatment. The aim of this system-

7 Division of Palliative Medicine, Saitama Medical University Hospital, Irima

of Stress Sciences and Psychosomatic Medicine, Graduate

atic review was to determine efficacy of prehabilitation in women
diagnosed with breast cancer.

Aim: The purpose of this study was to consider whether there was

Methods: A systematic review has been performed according to Pre-

a significant difference in improvement of agitation and communi-

ferred Reporting Items for Systematic Reviews and Meta-Analyses

cation between intravenous haloperidol and intravenous chlorpro-

(PRISMA) Guidelines. Studies exploring the impact of prehabilitation

mazine in cancer patients with agitated terminal delirium 72 h after

interventions in women with breast cancer were included. Studies

administration.

were assessed independently according to pre-eligibility criterion.

Method: All terminally ill delirium patients treated in 15 pallia-

Data extraction and methodological quality were assessed in parallel,

tive care wards or by nine consultation teams were enrolled via

and a narrative synthesis was conducted.

the web. Richmond Agitation Sedation Scale-Palliative version, Delir-

Results: 3184 records were identified according to search criteria,

ium Rating Scale-Revised 98 (DRD-R98), Nursing Delirium Screening

14 articles were included. The articles comprised of quantitative ran-

Scale items 2–4, Communication Capacity Scale item 4 and Agita-

domised controlled trials (n = 7), quantitative non-randomised studies

tion Distress Scale item 2 were evaluated at the start of treatment

(n = 5), a qualitative study (n = 1), and a mixed method study (n = 1).

(T0) and 72 hours later (T1). In addition, we investigated the type

The majority of selected studies completed exercise programs (n = 4)

and administration route of antipsychotics used in T0, the presence

or had a component of exercise (n = 2), with two of these focusing

or absence of changes in medication in T1, and the psychotropic

on upper limb exercise. An additional two articles reported smoking

drugs used concomitantly in T1. We investigated whether there is

cessation, with single studies reporting on multi-modal prehabilita-

an improvement in DRS-R98 agitation item scores and DRS-R98

tion, and complementary and alternative therapies (n = 5) such as

communication item scores at T1 in agitated cancer patients who

psychosocial, aromatherapy, traditional medicine, relaxation, and com-

received intravenous haloperidol and intravenous chlorpromazine at

prehensive nursing interventions. In most studies, the prehabilitation

T0 and whether there was a significant difference between two

intervention was successful in improving outcomes such as: physical

groups.

function, quality of life, and psychosocial variables (P < 0.05). The qual-

Result: Of 818 enrolled, 424 had agitation at T0. Of these, 183 were in

itative data identified a preference for multi-modal prehabilitation,

the haloperidol group and 68 were in the chlorpromazine group. The

compared to unimodal with interest in receiving support for longer.

benzodiazepine concomitant rate was 52% in the haloperidol group

Conclusions: Prehabilitation for patients with breast cancer is an

and 54% in the chlorpromazine group. In both groups, improvement in

emerging research area that appears to improve outcomes, however

DRS-R98 agitation item scores was observed at T1, but there was no

ensuring adequate intervention timeframes, follow-up, and population

significant difference in improvement between the two groups. Exac-

groups should be considered for future investigations. This review pro-

erbation in DRS-R98 communication item score in both group was

vides emerging evidence that will contribute toward future research to

observed at T1, but there was no significant difference in exacerbation

inform the redesign of clinical models of prehabilitation to address the

between the two groups.

supportive care needs of patients diagnosed with breast cancer.

Conclusion: Intravenous haloperidol and chlorpromazine were similarly effective for terminal agitation. The results of this study need to
be validated in clinical trials.
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Which is more effective, intravenous haloperidol or

chlorpromazine, to improve agitation and communication in
agitated terminal delirium?

435

The experiences of fear of cancer recurrence in ovarian

cancer caregivers: A qualitative study
Megumi Uchida1,2 , Tatsuya Morita3 , Tatsuo Akechi1,2 , Takuya
Kawahara4 , Asao Ogawa5 , Kazuhiro Yoshiuchi6 , Satoru Iwase7

Kyra Webb1 , Louise Sharpe1 , Hayley Russell2 , Joanne Shaw1,3
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of Palliative Care and Psycho-oncology, Nagoya City University

Hospital, Nagoya, Aichi, Japan

NSW, Australia

2 Department

2 Ovarian Cancer Australia, Melbourne, VIC, Australia

of Psychiatry and Cognitive-Behavioural Medicine, Nagoya

City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan

3 The

3 Department

Faculty of Science, The University of Sydney, Sydney, NSW, Australia

of Palliative and Supportive Care, Palliative Care Team, and

Psycho-oncology Co-operative Group (PoCoG), School of Psychology,

Seirei Hospice, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka,
Aims: 50% of people with ovarian cancer report fear of cancer recur-

Japan
4 Department

of Investigator-Initiated Clinical Trials Promotion, Clinical

rence or progression (FCR). Whilst there is growing research exploring

research Promotion Center, University of Tokyo Hospital, Tokyo, Japan

patient FCR, little is known about caregiver FCR. To date, caregiver

5 Department of Psycho-Oncology Service, National Cancer Center Hospital

FCR research has predominately been conducted through the lens

East, Kashiwa, Chiba, Japan

of patient conceptualisations, limiting the development of caregiver-
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specific models, measures, and interventions. The aim of this study was

participants completed an online survey gathering demographic infor-

to explore experiences of FCR among caregivers of people with ovarian

mation including HRQOL exercise frequency, malnutrition and frailty

cancer.

risk using validated tools. A semi-structured telephone interview

Methods: Semi-structured telephone interviews were conducted with

explored perceptions and factors affecting diet and exercise behaviour.

caregivers of people with ovarian cancer. Participants, recruited

Data was analysed using thematic analysis.

through Ovarian Cancer Australia, also completed a short online sur-

Results: Nine participants (67 ± 2 yrs., six men) completed all mea-

vey collecting participant and patient demographic characteristics,

surements. Time since diagnosis was 12 (10.5;20) months, all were on

information about the patient’s disease and caregiver levels of FCR

antineoplastic treatment, four were sufficiently active, three at risk

using the Fear of Cancer Recurrence Inventory (Caregiver) (FCRI-c).

of malnutrition, and five were identified at risk of frailty. Three main

Qualitative interviews explored caregiver fears, how the fears and con-

themes emerged, (1) belief in the importance of diet and exercise for

cerns were experienced and the frequency and timing of FCR. Thematic

physical and mental wellbeing, (2) the ability to overcome barriers to

analysis was used to analyse the results.

diet and exercise guidelines, and (3) diet and exercise empowers and

Results: Twenty-four caregivers (54% male) participated in an inter-

gives hope. Identified enablers included knowledge, existing habits,

view. Most caregivers were providing care for their partner (n = 14).

problem solving skills, social support, self-belief, and instruction.

Thematic analysis revealed four inter-related themes and additional

Conclusions: Health promotion education and appropriate behaviour

sub-themes: (1) Fear and worry; (2) Liminality; (3) Hopelessness and

change support may enhance adherence to diet and exercise guidelines

(4) Caregiver’s role as protector. Underpinning the identified themes

in this group of older HCS.

was an overarching fear of one’s family member dying. Dual in nature,
the protector role functioned to protect both the patient and caregiver,
explaining various behaviours.
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Conclusions: Aspects of FCR unique to the caregiver were identified.

Findings from a telehealth ovarian cancer support program

Identifying symptom burden and unmet needs of women:

Caregivers play a crucial role in supporting people with ovarian cancer
and are also impacted by worries and concerns of cancer recurrence

Patsy Yates1 , Wei-Hong Liu1 , Vanissa Ong1 , Cyril Dixon2 , Rosetta

or progression. In the context of ovarian cancer, caregiver FCR is con-

Hart2 , Sue Hegarty2

ceptually different to patient experiences. Further research is critical

1 Cancer and Palliative Care Outcomes Centre, Centre for Healthcare Trans-

to determine whether caregiver FCR is conceptually similar across

formation, Faculty of Health, Queensland University of Technology, Kelvin

cancer types. This research is the first step in the development of

Grove, Queensland, Australia

interventions tailored to caregivers need.

2 Ovarian Cancer Australia, Melbourne, Victoria, Australia

Aims: Ovarian Cancer Australia established a telehealth program (Teal
436

Perceptions on diet and exercise behaviour of older

adults with haematological cancer

Support) to provide care and support to affected women. The Program
is being evaluated to assess its impact on women’s health outcomes.
This report describes symptom burden and supportive care needs of

Hattie H. Wright2,1 , Alana Colton2 , Suzanne Broadbent2 , Karina

women who attended the Program and subsequently consented to the

Rune2 , Cindy Davis2

evaluation study.

1 Sunshine Coast Health Institute, Britinya, Queensland, Australia

Methods: Using a single prospective cohort design, women completed

2 University of the Sunshine Coast, Sippy Downs, QLD, Australia

surveys assessing symptom burden (MOST v2), psychological distress
(GHQ-12), and supportive care needs (SCNS-SF34) at different time

Older adults are disproportionally impacted by cancer worldwide and it

points over 12 months.

is predicted that over 60% of cancer cases globally will be in those over

Results: One hundred and twelve of 421 women in the Program were

65 years of age. Given the complex needs of older cancer survivors it

referred to the evaluation and 86 consented between August 2020 and

is imperative to support older adults to manage their health alongside

October 2021. At baseline, 46% of participants were aged <60 years,

their caregivers and healthcare providers. Healthy lifestyle behaviour

33% were undergoing initial treatment, and 32% were dealing with

(i.e., diet and exercise) is associated with improved health outcomes

recurrence. The most frequently reported symptoms that caused mod-

and health-related quality of life (HRQOL) in cancer survivors. Adher-

erate or severe problems were fatigue (68%), anxiety (52%), trouble

ence to diet and exercise guidelines, however, remains low and there

sleeping (52%), numbness/tingling (47%), sore hands and feet (40%),

is a need for tailored self-management interventions for older cancer

depression (35%) and abdominal pain (35%). 41% reported high level

survivors.

distress and more than one third had moderate or high unmet needs

Aim: To explore the perceptions of older haematological cancer sur-

for psychological needs (e.g., uncertainty about future, fears about can-

vivors (HCS) on the role of diet and exercise in navigating daily

cer spreading, learning to feel in control of the situation, anxiety, worry

tasks.

about the results of treatment being beyond their control), and physical

Methods: A qualitative descriptive research method was used. HCS

needs (e.g., lack of energy). Women aged <60 years reported signifi-

were recruited via Queensland Cancer Registry and flyers. Eligible

cantly more severe problems related to disease or treatment-related
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symptoms (p < 0.05) and higher levels of sexuality need (p < 0.01) than

the importance of exercise, how to exercise (particularly resistance

those who aged ≥60 years. Women living in major cities reported a

training) and availability of supportive exercise resources.

significantly higher level of distress (p = 0.02) than those living in the

Conclusions: Exercise behaviour in men receiving ADT was relatively

non-metropolitan areas.

consistent over 12 months, with few men achieving recommended lev-

Conclusions: Results indicate that women accessing the Program have

els of exercise. Most men had little or no experience or knowledge of

high levels of supportive care needs and are at high risk of poorer

resistance or structured exercise and did not value these forms of exer-

outcomes. Programs focused on addressing the unique needs of this

cise. Comprehensive exercise education may be a potential strategy to

population address an important gap in health service delivery.

shift perceptions and facilitate engagement with exercise.
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Exercise behaviour in men with prostate cancer receiving

Exercise motivation in men with prostate cancer

ADT: A longitudinal mixed-methods exploration

receiving ADT: A theory-driven qualitative approach

Jasmine Yee1,2 , Kristen Bartel1 , Gabrielle Blomson2 , Harriet

Jasmine Yee1,2 , Harriet Naismith1 , Gabrielle Blomson2 , Kristen

Naismith1 , Renée Bultijnck1,3 , Julia Hunter4 , Thilo Schuler4 , Gabrielle

Bartel1 , Renée Bultijnck1,3 , Julia Hunter4 , Thilo Schuler4 , Gabrielle

Metz4 , Patrick Horsley4 , Lisa Parker4 , Claire King4 , George Hruby4 ,

Metz4 , Patrick Horsley4 , Lisa Parker4 , Claire King4 , George Hruby4 ,

Thomas Eade4 , Rachel Campbell1 , Andrew Kneebone4 , Haryana

Thomas Eade4 , Andrew Kneebone4 , Haryana Dhillon1,5 , Rachel

Dhillon1,5

Campbell1

1 CeMPED,

1 CeMPED,

School of Psychology, The University of Sydney, Campderdown,

School of Psychology, The University of Sydney, Campderdown,

NSW, Australia

NSW, Australia

2 Sydney School of Health Sciences, The University of Sydney, Camperdown,

2 Sydney School of Health Sciences, The University of Sydney, Camperdown,

NSW, Australia

NSW, Australia

3 Department of Human Structure and Repair, Ghent University, Ghent, East

3 Department of Human Structure and Repair, Ghent University, Ghent, East

Flanders, Belgium

Flanders, Belgium

4 Department

4 Department

of Radiation Oncology, Northern Sydney Cancer Centre, St

of Radiation Oncology, Northern Sydney Cancer Centre, St

Leonards, NSW, Australia

Leonards, NSW, Australia

5 Psycho-Oncology Cooperative Research Group (PoCoG), School of Psychol-

5 Psycho-Oncology Cooperative Research Group (PoCoG), School of Psychol-

ogy, The University of Sydney, Campderdown, NSW, Australia

ogy, The University of Sydney, Campderdown, NSW, Australia

Aims: The benefits of exercise for managing many side effects of

Aims: Androgen deprivation therapy (ADT) is associated with side

androgen deprivation therapy (ADT) are well-established. However,

effects deleterious to quality of life. Whilst exercise is an effective

most men receiving ADT for prostate cancer do not achieve recom-

strategy to improve fatigue and other treatment-related symptoms,

mended levels of exercise. The aims of this mixed-methods study were

few men with prostate cancer engage in sufficient levels of exercise.

to describe in men on ADT: (i) exercise behaviour over 12 months; and,

Lack of motivation presents a key barrier to exercise participation. Self-

(ii) barriers and facilitators to exercise engagement.

Determination Theory (SDT) specifies the quality, rather than quantity,

Methods: Men receiving ADT for prostate cancer were recruited from

of motivation as essential for optimal engagement in health behaviours.

the Radiation Oncology Clinic, Northern Sydney Cancer Centre. Men

We aimed to explore what motivates engagement with exercise in men

were offered referral to a community exercise program at enrol-

on ADT through the theoretical lens of SDT.

ment and followed up three, six and 12 months later. Motivational

Methods: We conducted a qualitative study with men receiving ADT

readiness (Motivational Readiness for Exercise) and physical activ-

for prostate cancer through the Radiation Oncology Clinic, Northern

ity levels (modified Godin Leisure-Time Exercise Questionnaire) were

Sydney Cancer Centre. Men participated in semi-structured interviews

captured quantitatively. Semi-structured interviews explored exer-

exploring topics related to exercise behaviour and perceptions. Inter-

cise behaviour. Interviews were transcribed and analysed thematically.

views were transcribed and exercise motivation themes identified and

Here we report longitudinal qualitative results contrasting levels of

analysed according to SDT concepts until data saturation.

motivational readiness at baseline.

Results: Twenty-four men, median age 74y (range 45–88y; ECOG

Results: Sixteen men (median age 72y, range 58–84y) participated in

0: 92%, metastatic: 26%) participated. Three exercise motivation

29 interviews. While 52% reported high levels of motivational readi-

themes were identified: (1) type of motivation; (2) psychological

ness for exercise at baseline, only 22% met exercise recommendations.

needs fostering motivation; and, (3) motivational strategies support-

There was with little change in motivation or exercise engagement

ing psychological needs. Types of exercise motivation varied between

over time. Four key themes were identified related to exercise engage-

men and included intrinsic motivation (for enjoyment) and external

ment: (1) education; (2) physical function; (3) physical activity mindset;

motivation (for anticipated benefits, out of guilt or to comply with

and (4) external environment. Lack of exercise education presented

other’s demands). Techniques to improve psychological need satisfac-

as a barrier to exercise engagement, with many men unclear about

tion include providing choice over exercise programming (home vs
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gym), healthcare providers communicating reasons exercise is impor-

2. Hillman, D., Mitchell, S., Streatfeild, J., Burns, C., Bruck, D., & Pez-

tant, structured and tailored guidance by exercise professionals, and

zullo, L. (2018). The economic cost of inadequate sleep. Sleep, 41(8),

support for exercise by family and friends.

zsy083.

Conclusions: Grounded in SDT, our results provide novel insights into
why men with prostate cancer are motivated to exercise and how social
and healthcare contexts influence motivation. These findings highlight
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the importance of considering exercise motivation when discussing,

bisexual men

Exploring the effects of cancer on the lives of gay and

referring, and designing tailored exercise interventions for men with
prostate cancer to facilitate psychological need-supportive strategies

Colin D. Ellis1

to optimise exercise engagement.

1 Western Sydney University, Penrith, NSW, Australia

Background: Most of the research involving gay and bisexual men
440

Cost effectiveness of a 12-week virtual care enabled

survivorship program

(GBM) and cancer focuses on prostate cancer, and predominately from
a biological perspective in response to the adverse effects of treatment
on the individual. Very little is known about the broader impacts of

Michael Marthick1 , Karen Eaton1

cancer on the individual or support structure.

1 Valion Health, Port Macquarie, NSW, Australia

Aim: The aim of this research was to look at the impact cancer has on
the lives of GBM.

For many cancer survivors, the long-term effects of cancer and its

Methodology: Participants were recruited via an online survey as part

treatment include both physical and mental effects, such as persisting

of the out with Cancer Study. They were asked to participate in two

fatigue, decreased muscle strength, reduced lean body mass, reduced

interviews, the second using a photovoice methodology. The data was

cardiorespiratory fitness, impact on mood, pain, urinary and gastroin-

entered into NVivo and coded using a coding framework.

testinal problems, and lymphoedema (Stricker and Jacobs, 2008). To

Results: It was identified that there had been an assumption of hetero-

assist with unmet survivorship needs, a 12-week, virtual care enabled

sexuality, and a lack of knowledge of the historical societal background

multidisciplinary survivorship program was developed. The program is

individuals had experienced over the years. Some participants felt

delivered by Australian based Oncology nurses, Exercise Physiologists,

HCP behaviour discouraged disclosure, and in some cases, participants

Psychologists and Dietitians.

were strategic in when to disclose their identity. Participants who had

Valion Health commissioned an Australian consulting firm to under-

experienced the adverse effects of cancer treatments identified issues

take a cost-effectiveness analysis of this program. A two arm cost

surrounding urinary and faecal elimination. Two main themes were

effectiveness model was developed based on the work of Hillman et

identified, the abject body, that focuses on the individual’s experience

al (2018). The objective was to design a clinically and economically

of losing the control of elimination, and the agentive self that high-

appropriate model that could estimate the benefits that would typically

lighted how individuals managed their situation. Participants shared

be paid by the largest five private health insurance firms (Medibank,

their experiences of how they were supported through their cancer

BUPA, HCF, NIB and HBF) to members who are cancer survivors,

journey by partners, biological and chosen family members, friends,

but receive no intervention, of the likes of the Cancer Support Pro-

colleagues, and others. Pets were identified as providing significant

gram. Then compare these costs and utilisation rates to those of past

support to a few participants.

Cancer Support Program participants who were surveyed directly.

Conclusion: GBM experience an uncertainty of disclosing their iden-

One hundred and six study participants were recruited from the

tity to HCP, fearing a possible negative response. When disclosing

records of people who had completed the 12-week program at least

their identity this does not guarantee that they are provided infor-

12 months previously. A telephone survey of their healthcare use and

mation that is specific to their cancer. There is lack of understanding

costs over the preceding twelve months. The comparator was the num-

surrounding the relational support they have during their cancer

ber of health services episodes across three twelve- month periods,

journey.

under standard care, where no intervention is provided.
Based on two analyses conducted using data generated from this study,
it is suggested that the Cancer Support Program results in fewer future
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admissions, reduced length of stay and fewer allied health professional

living intervention for post-treatment cancer survivors: Healthy

consultations over the immediate and long-term.

Living after Cancer Online

1. Stricker, C. T., & Jacobs, L. A. (2008). Physical late effects in adult

Morgan Leske1 , Bogda Koczwara3,2 , Jason Blunt4 , Elizabeth Eakin5 ,

Evaluating the feasibility of a co-designed, online healthy

cancer survivors. Oncology (Williston Park, NY), 22(8 Suppl Nurse

Camille Short6 , Anthony Daly4 , Julia Morris4 , Jon Degner7 , Lisa

Ed), 33–41.

Beatty1
1 College

of Education, Psychology and Social Work, Finders University,

Adelaide, SA, Australia
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Aims: Treatment options identified through precision medicine trials are often unapproved (i.e., ‘off-label’) for paediatric use. Access

Aim: Engaging in a healthy lifestyle following cancer treatment

pathways to these cancer medicines are generally opaque and time-

can improve quality of life of cancer survivors. This study aimed

consuming for paediatric oncology healthcare professionals (HCPs).

to examine the feasibility of delivering Healthy Living after Can-

The ALIGN study aims to support HCPs through a suite of resources,

cer Online (HLaC Online), a co-designed online physical activity,

including ProCure, a database which aims to streamline access to

nutrition, and psychosocial intervention for post-treatment cancer

novel medicines. Specifcally, this study aimed to (i) explore HCPs’ per-

survivors.

ceived role in identifying and accessing experimental medicines and

Methods: A mixed-methods design was used, including pre-post ques-

apply implementation science methods to identify barriers and facil-

tionnaires and a semi-structured telephone interview. Australian can-

itators encountered, and (ii) explore HCPs’ perceived acceptability of

cer survivors, <5 years post-diagnosis, were invited to participate in

ProCure, elicit end-user needs and facilitate co-design.

HLaC Online for 12 weeks. Feasibility of the HLaC Online was deter-

Methods: Paediatric oncology HCPs were recruited to participate in

mined by the intervention uptake, usage, usability, and satisfaction, and

semi-structured interviews, guided by The Consolidated Framework

attrition at the post-treatment questionnaire.

for Implementation Research (CFIR). Qualitative interview data were

Results: Fifteen cancer survivors enrolled in HLaC Online, 11 of whom

coded to the CFIR to identify key barriers, end-user needs, and the gaps

were eligible to participate. Five (45%) participants dropped out fol-

ProCure addresses. Beta version of ProCure was designed.

lowing the baseline questionnaire, before interacting with HLaC Online.

Results: Sixteen HCPs (10 oncologists, six nurse consultants) have

The remaining participants (n = 6, 45%) on average accessed 3.33

been interviewed to date. Interim analysis indicates that barriers

(SD = 3.01) of nine available modules and five (45%) completed

include resource-intensive applications to access medicines, time-

the post-treatment questionnaire. One participant completed all nine

sensitive decision-making, and complicated pharmaceutical infor-

modules. Perceived usability of HLaC Online was varied (cut off = 65,

mation. Key facilitators include Drug Access Navigators, precision

M = 64.17, range = 42.50–77.50). Qualitative feedback indicated that

medicine Molecular Tumour Boards, and a multi-disciplinary approach

the topics were relevant and helpful, although the program had a lot of

to care. HCP end-user needs addressed by ProCure include infor-

content and could feel overwhelming. Participants reported that it was

mation about medicines being centralised within a well-supported

difficult staying motivated due to lacking energy and intrinsic motiva-

platform. Additional features recommended by HCPs included blood-

tion. One suggestion was to involve someone to guide the user at the

brain-barrier penetrability data and examples of successful applica-

beginning of the program and assist with website orientation, setting

tions.

up goals, and holding accountability.

Conclusions: Interim data indicate that ProCure is acceptable to HCPs

Conclusions: Uptake and usage of HLaC Online were low. Barriers to

and has potential to streamline off-label medicines access. The next

uptake and usage include participant lack of energy and motivation,

phase is end-user beta-testing of the developed database, then pilot

absence of accountability, the amount of information provided, and

testing to evaluate the acceptability, feasibility, effectiveness, and

design issues with the manual data collection process and reminders

implementation of the ProCure database.

to use the website. Future research will investigate addressing these
barriers through the introduction of two brief guidance phone calls.
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Exercise during chemotherapy for recurrent ovarian

cancer (ECHO-R): A Phase II trial evaluating feasibility, safety
443

Designing for implementation: co-design of a paediatric

oncology medicines database (ProCure) to support complex care

and efficacy of an individually-tailored exercise intervention
during chemotherapy for recurrent ovarian cancer

provision for children with a hard-to-treat cancer
Carolina Sandler1,2,3 , Rosalind Spence1 , Andreas Obermair4 , Monika
Carolyn G. Mazariego1 , Mark Dobson2 , Skye McKay3 , Brittany

Janda5 , Elizabeth Eakin5 , Vanessa Beesley6 , Domitrios Vegenas5 ,

McGill4,5 , Rebecca Daly4,5 , Claire Wakefield4,5 , David Ziegler2,4 ,

Louisa Gordon6 , Penelope Webb6 , Merran Williams7 , Helene O’Neill7 ,

Natalie Taylor3

Sandi Hayes1

1 The

1 Menzies

Daffodil Centre, a joint venture with Cancer Council NSW, The

University of Sydney, Sydney, NSW, Australia

tralia

Health Institute Queensland, Griffith University, Brisbane, Aus-
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2 Western Sydney University, Sydney, NSW, Australia

findings of research into GSD women’s experiences of embodiment

3 Kirby Institute, University of New South Wales, Sydney, NSW, Australia

since cancer, as part of a broader Australian Research Council (ARC)

4 Royal Brisbane and Women’s Hospital, Brisbane, Qld, Australia

funded study titled ‘Out with Cancer’.

5 University of Queensland, Brisbane, Qld, Australia

Using a thematic decomposition analysis, this paper details the experi-

6 QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia

ences of embodiment and disembodiment amongst GSD women with

7 Consumer Representative, Australia

cancer in the context of the sexual body; the reproductive/fertile body;
and the ‘feminine’ body, unpicking the ways in which heteronormativ-

Introduction & Aims: Women with recurrent ovarian cancer (ROC)

ity and cisgenderism in health care act to invisibilise and disadvantage

have poor quality of life (QOL), physical well-being, function, and high

GSD women.

unmet supportive care needs. COSA recommends exercise for all peo-

Methods: The research takes a mixed methods approach, including

ple with cancer. However, the evidence supporting exercise as being

open-ended survey data, 39 semi-structured interviews, and 17 follow-

safe, feasible and important for people with cancers associated with

up Photovoice interviews with GSD women who have had cancer and

low survival rates and high morbidity, such as ROC, is limited.

their careers. Participants are selected across cancer type and range

Methods: ECHO-R is a national, single-arm trial evaluating the fea-

from ages 18–92.

sibility, safety, and preliminary efficacy of an exercise intervention

Results and Conclusions: Assumptions of heterosexuality, and cisgen-

during chemotherapy for ROC (n = 80). The 6-month exercise interven-

der embodiment, identity and expression have serious implications for

tion includes an individualised prescription of aerobic and resistance

GSD women’s physical and emotional wellbeing, agency and health

exercise at moderate-intensity, accumulating ≥150 min per week (in-

decision-making, and access to embodied and relational care in the

line with COSA recommendations). The intervention is delivered via

context of cancer. This paper explores these impacts to demonstrate

12 telephone/video-call sessions with a study-trained exercise profes-

the importance of taking seriously ‘embodied perspectives’ of cancer

sional, and when accessible, is supported through the provision of an

and makes suggestions for moving forward. This research will advance

additional 5 face-to-face sessions with a community-based Accredited

understanding of a large and growing population of cancer survivors in

Exercise Physiologist. Primary outcomes of interest are (i) feasibility as

Australia and will generate the evidence base to inform new resources

assessed by retention, adherence, and compliance (deemed acceptable

and best practice recommendations to improve physical and psycho-

when >75%); and (ii) safety: measured by adverse event occurrence

logical outcomes for GSD women cancer patients and their careers.

and characteristics, as reported by participants or exercise profes-

Some direct translational outcomes include: resources for patients and

sional and described by the rate of exercise-related adverse events (i.

carers; recommendations for clinicians; and an exhibition representing

≥grade 3, ii. grade 1–2 that require ≥2-week exercise modification).

LGBTQI+ cancer experience.

Secondary outcomes of interest are assessed using validated questionnaires and/or objectively-assessed at baseline (pre-intervention), and
6- and 9-months post-baseline, and include QOL, ovarian symptoms

446

and treatment concerns, fatigue, sleep, peripheral neuropathy, mood,

in a mouse model of 5-FU induced neuroinflammation

High fibre diet significantly reduces astrocyte abundance

hope, body composition, and function. Changes in secondary outcomes
will be analysed using generalised estimating equations to determine

Courtney Subramaniam1,2 , Hannah Rose Wardill1,2 , Marc Gladman1 ,

time effects and to explore the relationship between patient, treatment

Joanne Bowen1

and behavioural characteristics and time effects.

1 The University of Adelaide, Adelaide, SA, Australia

Conclusion: ECHO-R will determine whether exercise is feasible and

2 South

safe for women receiving treatment for ROC and will use effect

laide, SA, Australia

Australian Health and Medical Research Institute (SAHMRI), Ade-

findings to explore whether the COSA exercise and cancer position
statement is applicable to this under-studied cancer group.

Background: The neurological complications of cancer therapy remain
a significant supportive care challenge with limited understanding of pathobiology, however, recent studies have suggested that
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Gender and sexuality diverse (GSD) women’s experiences

of cancer and cancer care

the microbiota-gut-brain axis may play a role. This study therefore
aimed to investigate the effect of a high fibre diet in a model of
chemotherapy-induced neuroinflammation. We hypothesised that the

Sam Sperring1

high fibre diet would support gut microbial resistance and mitigate

1 Translational Health Research Institute, Western Sydney University, Camp-

neuroinflammation.

belltown, Sydney, NSW, Australia

Methods: Female C57Bl/6 mice (N = 24) were treated with 5fluorouracil (400 mg/per kg) or vehicle control with or without a

Background and Aims: Non-normative relationships with femininity

high fibre diet (high amylose starch) intervention. The high fibre diet

and categories of womanhood and gender performance have been

was given for 1 week prior to 5-FU and until completion of the

shown to significantly affect how gender and sexuality diverse (GSD)

study. All mice were terminated 16 days after 5-FU. Immunofluo-

women experience and make sense of cancer. This paper presents the

rescence staining for glial acidic fibrillary protein (GFAP) was per-
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formed on brain tissue to evaluate astrocyte abundance (previously

uPAR and E-cadherin immunohistochemistry. We used Pearson corre-

identified as a hallmark of 5-FU-induced neuroinflammation). RT-

lation coefficient, Kaplan Meier method and log-rank test for statistical

PCR was also performed for Il-1β on brain homogenates. Faecal

analysis.

samples were collected longitudinally for microbiota analysis using

Results: TB was assessable by H&E for 65 patients, with uPAR in 57

16S. Short chain fatty acids (SCFAs) were also quantified using

cases and E-cadherin in 45 cases. TB was not predictive of long-term

GC-MS.

overall survival (OS), the best cut off value being four TBs (p = 0.2).

Results: A profound decrease in GFAP expression was observed in the

There was excellent correlation of H&E stained and counted TBs and

CA1 region (p < 0.0001) and dentate gyrus (p = 0.0359) of the hip-

uPAR+ TBs (R2 = 88%). More than eight uPAR+ TBs was significantly

pocampus as well as the midbrain (p = 0.0215), in 5-FU treated animals

associated with worse OS (median 24 vs 42 months; p = 0.01). Strong

receiving high fibre diet when compared to 5-FU treated controls. A

E-cadherin expression showed a non-significant trend to improved OS

significant decrease in IL-1β expression was also observed between

(median 47 vs 29 months; p = 0.3). A combined high uPAR and low

in animals on the high-fibre diet compared to controls following 5-FU

E-cadherin score (i.e., mesenchymal-like cells), tended for shorter OS

(p = 0.0410). Propionic acid concentrations of caecal contents were

(median 18.5 vs 47 months; p = 0.3).

increased in animals treated with the high fibre diet and shared a neg-

Conclusions: Despite standard TB reporting not showing OS

ative correlation with GFAP expression in CA1 of the hippocampus

discrimination, uPAR shows excellent potential as a predic-

(p = 0.0252).

tive biomarker. In this pilot cohort, combination of uPAR and

Discussion: These data strongly suggest that fibre supplementa-

E-cadherin

tion reduces neuroinflammation via the production of propionic

patients.

showed

potential

to

determine

poor

prognostic

acid, warranting further investigation into how these findings can
be translated to improve neurological outcomes for people with
448

cancer.

Neoadjuvant and adjuvant pembrolizumab plus standard

of care (SOC) for the treatment of resectable locally advanced
(LA) head and neck squamous cell carcinoma (HNSCC): Phase 3
447

Urokinase plasminogen activator receptor and E-cadherin

KEYNOTE-689

expression on tumour budding in gastroesophageal
adenocarcinomas

Arkadiy Klochikhin1 , Robert I. Haddad2 , Amichay Meirovitz3 , Sufia
Safina4 , Irene Brana5 , Christophe Le Tourneau6 , Ravindra Uppaluri7 ,

Gary Tincknell3,1,2 , Asma Naveed2,4,5 , Ayesha Mukhtiar4 , Daniel

Nancy Y. Lee8 , Ezra E. W. Cohen9 , Rebecca Chernock10 , William

Brungs2,6 , Marie Ranson2

Westra11 , Hong Liu12 , Burak Gumuscu12 , Kimberly Benjamin12 ,

1 School of Chemistry and Molecular Biosciences, University of Wollongong,

Douglas Adkins10 , Elani Bowers13

Wollongong, NSW, Australia

1 Yaroslavl Regional Clinical Oncology, Yaroslavl, Russia

2 Illawarra

2 Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Health and Medical Research Institute, Wollongong, NSW, Aus-

tralia

3 Hadassah University Medical Center, Jerusalem, Israel

3 Shoalhaven Cancer Care Centre, Nowra, NSW, Australia

4 Republican Dispensary of Tatarstan MoH, Kazan, Russia

4 NSW Health Pathology, Wollongong, NSW, Australia

5 Vall d’Hebron Institute of Oncology, Barcelona, Spain

5 Southern IML, Wollongong, NSW, Australia

6 Institut Curie, Paris, France

6 Illawarra Cancer Care Centre, Wollongong, NSW, Australia

7 Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston,

MA, USA
Aims: Tumour budding (TB), groups of up to four cells beyond the inva-

8 Memorial Sloan Kettering Cancer Center, New York, NY, USA

sion zone, is a prognostic biomarker in various cancers. Their role in

9 UC San Diego, La Jolla, CA, USA

gastric, oesophageal and gastroesophageal junction (GOC) is poorly

10 Washington University School of Medicine, St Louis, MO, USA

understood. The urokinase plasminogen activator system (uPAS) and

11 Icahn School of Medicine, New York, NY, USA

epithelial to mesenchymal transition (EMT) assist tumour invasion and

12 Merck & Co., Inc., Rahway, NJ, USA

formation of distant metastasis. The uPAS membrane receptor, uPAR,

13 MSD, Melbourne, VIC, Australia

is strongly associated with the mesenchymal phenotype of EMT and
may be an EMT driver. E-cadherin is a classical marker of the epithe-

Aims: The randomized, open-label, phase 3 KEYNOTE-689 trial

lial phenotype of EMT. We aimed to assess the expression of uPAR and

(NCT03765918) is designed to evaluate neoadjuvant pembrolizumab

E-cadherin in GOC TB.

and adjuvant pembrolizumab plus SOC in previously untreated LA

Methods: Patients underwent GOC surgery between 2013 and 2021

HNSCC.

at the Illawarra Shoalhaven Local Health District, NSW. Assessment

Methods: Approximately, 704 patients with newly diagnosed,

of TB was conducted using Haematoxylin and Eosin (H&E) staining

resectable, LA HNSCC (stage III oropharyngeal p16-positive dis-

and were scored as per the international tumour budding cancer con-

ease [T4 (N0-N2), M0]; stage III/IVA oropharyngeal p16-negative; or

sensus guidelines. Areas showing the highest TB were sectioned for

stage III/IVA laryngeal or hypopharyngeal disease or disease of the
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oral cavity, independent of p16 status) will be randomly assigned 1:1

representation of an intervention’, describes an interventions com-

to arm A (200 mg Q3W neoadjuvant pembrolizumab [two cycles],

ponents, delivery mechanisms, mechanisms of impact, and intended

surgical resection, then 200 mg Q3W adjuvant pembrolizumab [15

outcomes.4 The aim of our study will be to create a logic model for

cycles] plus SOC) or arm B (surgical resection then adjuvant SOC).

‘Engage’ to better understand these inter-related factors and how they

SOC for low-risk disease is adjuvant radiotherapy, 60 Gy total, 30

contribute to this program’s effectiveness.5,6

fractions; SOC for high-risk disease is adjuvant chemoradiation, three

Methods: Study investigator (JE) developed a logic model for

cycles of 100

mg/m2

Q3W cisplatin plus 66 Gy total, 33 fractions;

‘Engage’ by retrospectively reviewing outcomes from the pilot

SOC for gross residual disease is adjuvant radiation, 70 Gy total, 35

study as well as the revised trial protocol. A participatory approach

fractions. Randomization will be stratified by primary tumour site

was then undertaken with input received from the initial pro-

(oropharynx/oral cavity vs larynx vs hypopharynx), tumour stage

gram developers (trial team) and implementers (implementation

(III vs IVA), and PD-L1 status (tumour proportion score ≥50% vs

team).

<50%). Patients must have evaluable disease and ECOG PS 0/1 for

Results: The logic model described the following outputs and cor-

eligibility. Postoperative imaging will occur Q12W after completion

responding clinical outcomes (in brackets), which include: the provi-

of SOC treatment, every 3 months until year 3, then every 6 months

sion of (a) consolidated and up-to-date health information to sur-

until year 5. Primary end points: major pathologic response and

vivors/GPs (to decrease unmet health-related information needs), (b)

event-free survival per RECIST v1.1. Secondary end points: overall

personalised treatment recommendations (to decrease unmet health-

survival, pathologic complete response, health-related quality of

related information needs and increase satisfaction with survivorship

life, and safety. End points except safety will be evaluated in PD-

care), and (c) distance-delivered consultations (to increase participa-

L1 combined positive score ≥1 tumours and regardless of PD-L1

tion and satisfaction with survivorship care). The results from the

status.

‘Engage’ evaluation study were then mapped to these outputs and

Results: KEYNOTE-689 is enrolling patients in North America,

outcomes.

South America, Europe, Asia, and Australia. Recruitment is ongoing

Conclusions: The development of this logic model now provides

globally.

‘Engage’ investigators with an explicit theoretical basis, which can

Conclusion: Results of KEYNOTE-689 will provide clarity on safety and

be tested and refined during subsequent effectiveness evaluations.

efficacy of pembrolizumab for patients with resectable LA HNSCC in

Ultimately, this process has helped clarify the active ingredients and

the neoadjuvant and adjuvant setting.

intended mechanisms of ’Engage’, and will further inform its implemen-

Clinical trial registration: NCT03765918

tation across different settings.
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Aims: Many survivors of childhood brain cancer are left to endure

Petticrew, M., Rycroft-Malone, J., White, M., & Moore, L. (2021). A

the long-term health problems caused by cancer and its treatments,

new framework for developing and evaluating complex interven-

necessitating lifelong survivorship care.1 Despite this, there are few

tions: Update of Medical Research Council guidance. BMJ, 374,

long-term survivorship services available in Australia for survivors to

n2061.

access.2

‘Engage’ is a new program that aims to overcome these bar-

6. De Silva, M. J., Breuer, E., Lee, L., Asher, L., Chowdhary, N., Lund,

riers by providing survivors with distance-delivered, multi-disciplinary

C., & Patel, V. (2014). Theory of Change: A theory-driven approach

care.3 This complex intervention has many dynamic components,

to enhance the Medical Research Council’s framework for complex

resources, and underlying mechanisms of change. A logic model,

interventions. Trials, 15(1), 1–13.

which is defined by the Medical Research Council as a ‘diagrammatic
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Physical activity patterns during immunotherapy for stage
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Phase 3, randomized, double-blind, placebo-controlled

III and IV melanoma – Trial in progress

study of pembrolizumab + chemotherapy in patients with

Sarah Marvin1 , Jasmine Yee1,2 , Jia (Jenny) Liu3,4 , Haryana Dhillon2 ,

cancer (mBC): KEYNOTE-B49

HR+/HER2− locally recurrent inoperable or metastatic breast
Kate Edwards1,5
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Peter Schmid1 , Joo Hyuk Sohn2 , Yolanda Jerez Gilarranz3 , Lucia
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2 CeMPED,

Ernesto Korbenfeld7 , Daniel Egle8 , Brigitte Poirier9 , Flora Zagouri10 ,

School of Psychology, The University of Sydney, Camperdown,

NSW, Australia
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Vincent’s Clinical School, University of NSW, Darlinghurst, NSW, Aus-
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Cancer Institute, Centre for Experimental Cancer Medicine, Queen

Mary University of London, Charterhouse Sq., London EC1M 6BQ, UK
Perkins Centre, The University of Sydney, Camperdown, NSW,
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2 Division

of Medical Oncology, Department of Internal Medicine, Yonsei

University College of Medicine, Seoul, Korea
3 Instituto

de Investigación Sanitaria Gregorio Marañón (IiSGM); Medical

Background: Physical activity (PA) is associated with physical and

Oncology Department, Hospital General Universitario Gregorio Marañón;

psychological benefits for people with cancer. Exercise is also an

Universidad Complutense de Madrid and CiberOnc, Madrid, Spain

important adjuvant to the immune system, inducing many immune-

4 Medical

modulating effects which may improve efficacy of immunotherapy

Madrid, Spain

treatment. Studies among other cancer treatments show reductions

5 Oncology

in PA with increase in symptom burden and poorer quality of life as

of Medicine, Tel Aviv University, Tel Aviv, Israel

patients progress through treatment. However, the role of exercise

6 Faculty

has not been extensively studied in people with melanoma receiv-

Sydney, NSW, Australia

ing immunotherapy, and little is known about their PA habits during

7 Hospital Británico de Buenos Aires-Oncology, Buenos Aires, Argentina

Oncology Department, Hospital Universitario Quirónsalud,
Division, Tel Aviv Sourasky Medical Center and Sackler Faculty

of Medicine, Health and Human Sciences, Macquarie University,

treatment.

8 Landeskrankenhaus

Aims: The study aims to quantify PA levels of individuals with advanced

and Medizinische Universitaet Innsbruck, Innsbruck, Austria

melanoma for 12-months following immunotherapy initiation.

9 Hopital Du Saint-Sacrement, Quebec City, QC, Canada

Methods: We are conducting a longitudinal prospective cohort study,

10 Alexandra Hospital-ONCOLOGY DEPT, Athens, Greece

recruiting adults, ECOG 0-2 with Stage III (n = 40) and IV (n = 40) cuta-

11 Karolinska

neous melanoma commencing any immunotherapy protocol who have

Bröst-endokrina tumörer och sarkom, Stockholm, Sweden

smartphone/tablet access.

12 Hacettepe University Cancer Institute, Department of Medical Oncology,

– Universitätskliniken Innsbruck, Innsbruck, Austria

Universitetssjukhuset

Solna-Tema

Cancer

–

Participants will be followed for 12-months and receive immunother-

Ankara, Turkey

apy as per standard care. Weekly step-counts and min of moderate-

13 Memorial Ankara Hospital, Medical Oncology, Balgat, Ankara, Turkey

to-vigorous PA will be retrieved from Fitbits worn continuously by

14 Medical

ME

Oncology, INTEGRA Cancer Institute, Guatemala City,

participants for 3-months.

Guatemala

Patient-reported outcome measures (PROMS) (self-reported PA,

15 Department

fatigue, quality of life, sleep, and psychological distress) will be com-

Cancer Research Institute, Seoul National University College of Medicine,

of Internal Medicine, Seoul National University Hospital,

pleted at the first four infusions, 3-months, 6-months, and 12-months.

Seoul, Republic of Korea

PA and fatigue will also be measured 1-week following the first four

16 Breast

infusions. Motivation to exercise and clinical data (treatment-related

Lisbon, Portugal

toxicities, tumour response, adverse events, changes to treatment) will

17 Merck & Co., Inc., Rahway, NJ, USA

be collected every 3-months.

18 Division

Progress: Ethical approval has been obtained, with recruitment antic-

Francisco Comprehensive Cancer Center, San Francisco, CA, USA

Unit, Champalimaud Clinical Centre/Champalimaud Foundation,

of Hematology and Oncology, University of California San

ipated to commence in early September 2022. Recruitment will occur
at three Sydney metropolitan cancer centres.

Aims: The phase 1b KEYNOTE-028 trial showed durable activ-

Significance: Understanding the relationship between PA, PROMs and

ity

clinical data may reinforce the importance of PA for those receiv-

HR+/HER2−, PD-L1–positive (combined positive score [CPS]

ing immunotherapy, whilst also suggesting mediating factors that

≥1) advanced breast cancer. KEYNOTE-B49 (NCT04895358) is a

with

pembrolizumab

monotherapy

in

previously

treated

influence the extent of PA. Findings will provide a framework for

phase 3, double-blind study of pembrolizumab+chemotherapy vs

future research to inform targeted health promotion and intervention

placebo+chemotherapy in PD-L1–positive, HR+/HER2− locally

strategies to facilitate greater PA engagement.

recurrent inoperable or mBC after progression on prior endocrine
therapy.
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Methods:~800 patients with HR+/HER2− locally recurrent inoperable

more actionable genomic alterations, enabling more patients to receive

or mBC who are candidates for chemotherapy (no prior chemother-

timely targeted treatment. The study investigates the clinical impact of

apy for metastatic disease) with PD-L1 CPS ≥1 and documented PD

CGP on the management of mNSCLC and assess feasibility of upfront

on prior endocrine therapy will be enrolled. Prior endocrine therapy

CGP implementation nationally.

comprises ≥2 lines (≥1 in combination with a CDK4/6 inhibitor) in the

Methods: Australia-wide multi-centre prospective observational

metastatic setting (group 1); or one line with CDK4/6 inhibitor treat-

cohort study involving 17 participating hospitals, recruiting 1000

ment for mBC in patients with relapse ≤24 months of primary surgery

newly diagnosed mNSCLC patients with adequate tumour tissue for

while on adjuvant endocrine therapy (group 2a); or PD ≤12 months of

CGP and SoC testing. Two cycles of standard treatment are allowed

starting endocrine therapy with CDK4/6 inhibitor for metastatic dis-

while awaiting CGP results. Patients with targetable alterations may

ease (group 2b). Patients without prior CDK4/6 inhibitor treatment

be eligible for associated substudies, clinical trials or access programs.

may enroll if they had PD ≤6-months of starting endocrine therapy

Primary Outcomes: impact of CGP (% patients with actionable

for metastatic disease and previously relapsed ≤24-months of pri-

genomic alterations with CGP vs SoC testing; % patients receiving

mary tumour surgery while on adjuvant endocrine therapy (group 3).

targeted therapy; and feasibility of CGP (time to results; % patients

Patients are randomized 1:1 to pembrolizumab 200 mg IV or placebo

requiring treatment prior to results; % patients requiring repeat biopsy

Q3W, each in combination with investigator’s choice of chemother-

for CGP).

apy: paclitaxel 90 mg/m2 IV on days (D) 1/8/15 Q4W; nab-paclitaxel

Secondary Outcomes: Percent patients with change in treatment

100 mg/m2 IV on D1/8/15 Q4W; liposomal doxorubicin 50 mg/m2 IV

recommendation; % patients participating in clinical trials; clinical

on D1 Q4W; or capecitabine 1000 mg/m2 PO BID on D1–14 Q3W.

outcomes; healthcare resource use and costs; health-related qual-

Treatment continues until PD, unacceptable toxicity, withdrawal, or, for

ity of life; and cost-effectiveness of CGP. Correlative studies will

pembrolizumab/placebo, completion of 35 cycles (∼2y); chemotherapy

explore potential prognostic biomarkers of clinical benefit of targeted

can continue per investigator discretion. Radiologic assessments are

therapies.

performed Q9W for 54 weeks and Q12W thereafter. Primary end-

ASPiRATION is a collaboration between TOGA, NHMRC Clinical Tri-

points are PFS per RECIST v1.1 by BICR and OS in patients with PD-L1

als Centre, University of Sydney, Omico and Garvan Institute of

CPS ≥10 and ≥1 tumours, separately. Enrollment is ongoing at 204

Medical Research. Support is from Australian government Medical

international sites.

Research Future Fund (MRFF application EPCD000005) and Roche
Products Pty Limited (Australia). ANZ Clinical Trials Registry: ANZCTRN12621000221853.
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ASPiRATION: An Australian observational cohort study to

Interim Results: At 31 July 2022, 534 participants had been enrolled.

assess the clinical impact of comprehensive genomic profiling in

The number of genomic alterations of interest identified to date will be

metastatic lung cancer patients. Protocol number TOGA 19/003

presented.
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Background: Non-squamous metastatic non-small cell lung cancer

5 Olso University Hospital, Olso, Norway

(mNSCLC) is a heterogeneous disease with a wide diversity of muta-

6 Yaroslavl Regional SBIH Clinical Oncology Hospital, Yaroslavl, Russia

tions, alterations or abnormal gene expression responsible for cell

7 Oncocentro Ceara, Fortalez, Brazil

growth and metastasis. Targeted treatments can improve clinical out-

8 Oncological

comes, however these are not adequately identified by standard of

Sochi, Russia

care (SoC) testing, which commonly use single gene assays or ‘hot-

9 Oncologos del Occidente S.A.S, Pereira, Colombia

spot’ panels. Comprehensive genomic profiling (CGP) can identify

10 Alfred Health, Melbourne, VIC, Australia
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5 Australian
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6 Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Aims: Treatment options are needed for patients with high-risk, LA

7 Royal Marsden Hospital, London, UK

cSCC who experience recurrence after surgery. Durable antitumour

8 University Hospital Southampton, Southampton, UK

activity has been observed with cemiplimab and pembrolizumab in

9 Princess Alexandra Hospital, Brisbane, QLD, Australia

advanced metastatic cSCC. The double-blind, phase 3 KEYNOTE-

10 St James’s University Hospital, Leeds, UK

630 study (NCT03833167) is designed to evaluate adjuvant pem-

11 Memorial Sloan Kettering Cancer Centre, New York, USA

brolizumab in resectable, high-risk, LA cSCC.

12 Royal Preston Hospital, Preston, UK

Methods: Eligibility criteria include LA cSCC with ≥1 high-risk feature:

13 Nepean Cancer Care Centre, Kingswood, NSW, Australia

histologically involved nodal disease with extracapsular extension, with

14 Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia

≥1 lymph node >2 cm in diameter or ≥2 lymph nodes involved;

15 Auckland City Hospital, Auckland, New Zealand

any index tumour with ≥2 of the following: tumour ≥4 cm with >6mm depth or invasion beyond subcutaneous fat, multifocal perineural

Background: Bleomycin, etoposide, and cisplatin (BEP) given 3-weekly

invasion for nerves <0.1 mm in diameter (≥3 foci) or any involved

× 4 remains standard 1st line chemotherapy for intermediate or poor

nerve ≥0.1 mm in diameter, poor differentiation and/or sarcomatoid

risk metastatic GCT (1). Accelerating standard regimens by shortening

and/or spindle cell histology, recurrent disease, satellite lesions and/or

the cycle length to 2-weekly improved cure rates in other cancers (2–

in-transit metastases, lymphatic or vascular involvement; any gross

4). P3BEP will determine effects of accelerated versus standard BEP in

cortical bone, skull base, and/or skull base foramen invasion. Patients

this setting. This is a first international, randomised trial of chemother-

must have undergone complete macroscopic resection, have ECOG

apy for intermediate and poor-risk metastatic GCT to include adults

PS 0/1, received adequate postoperative dose of hypofractionated or

and children of both sexes.

conventional RT, including BED EQD2 >48 Gy, and completed adju-

Methods: This open label, randomised, phase 3 trial is conducted seam-

vant RT ≥4 and ≤16 weeks from randomization. Approximately 570

lessly in 2-stages. The primary endpoint for stage I (n = 150) was

patients will be randomly assigned 1:1 to pembrolizumab 400 mg IV

complete response (CR); and for stage 2 (n = 500) is progression

Q6W or placebo for ≤9 cycles (1 year) and stratified by extracapsu-

free survival at 2 years (PFS2y). These sample sizes provide >80%

lar extension, cortical bone invasion, and prior systemic therapy (all,

power with a two-sided type I error rate of 5% to detect an abso-

yes vs no). Patients receiving placebo may be eligible to cross over

lute improvement of 25% in the CR rate (stage 1) and of 7% in the

to receive pembrolizumab (≤18 cycles) if first biopsy-proven recur-

PFS2y (stage 2). The target population is males and females aged 11–

rence occurs ≤5 years. In the pembrolizumab arm, eligible patients may

45 with intermediate-or poor-risk metastatic GCT of the testis, ovary,

receive pembrolizumab retreatment (≤18 cycles). Primary end point:

retroperitoneum, or mediastinum. Participants are randomised (1:1) to

RFS. Secondary end points include OS, HRQoL, and safety.

four cycles of standard BEP (q3w) or accelerated-BEP (q2w) with cis-

Results: Enrolment is ongoing at sites in Asia, Australia, Europe, and

platin 20 mg/m2 D1–5, etoposide 100 mg/m2 D1–5, bleomycin 30 KIU

North and South America.

weekly × 12, and pegylated G-CSF D6 or filgrastim daily. Study assess-

Conclusions: Results will provide clarity on efficacy and safety of

ments occur at 30 days after completing chemotherapy, 6 months from

adjuvant pembrolizumab in patients with high-risk, LA cSCC.

randomisation, and after completion of all post-chemotherapy treat-

Clinical Trial Registration: NCT03833167

ments (e.g. surgery). Tumour and baseline blood samples are collected
for translational substudies.
Progress: As of June 2022, 211 participants have been recruited from

455

P3BEP (ANZUP 1302): An international randomised phase

23 ANZ sites, 17 UK sites (led by Cambridge Clinical Trials Unit), and

3 trial of accelerated versus standard BEP chemotherapy for

149 USA sites (led by Children’s Oncology Group). The first planned

male and female adults and children with intermediate and

interim analysis for safety (n = 76) identified no safety concerns. Stage I

poor-risk metastatic germ cell tumours (GCTs)

analysis (n = 150) showed sufficiently favourable results with no futility
concerns, supporting ongoing trial recruitment.
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